Modulators of foxp3 expression

ABSTRACT

The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which may be useful for treating, preventing, or ameliorating cancer.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0344USSEQ_ST25.txt created Nov. 14, 2019, which is 698 kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

FIELD

The present embodiments provide methods, compounds, and compositions useful for inhibiting FOXP3 expression, which can be useful for treating, preventing, or ameliorating cancer.

BACKGROUND

Foxp3 is a lineage-defining transcription factor for regulatory T cells (Tregs) that controls a restricted set of genes associated with immunosuppression. Tregs suppress immunity (including anti-tumor immunity) via multiple effector mechanisms. The presence of Tregs within the tumor has poor prognostic outcome in multiple types of cancer. Tregs do not possess a known unique surface marker or signalling protein which could enable targeting with biologics. FOXP3 cannot be targeted by monoclonal antibodies or with conventional small molecules.

SUMMARY

Certain embodiments provided herein are directed to potent and tolerable compounds and compositions useful for inhibiting FOXP3 expression, which can be useful for treating, preventing, ameliorating, or slowing progression of cancer. In certain embodiments, the cancer is associated with an immunosuppressive microenvironment or stroma. Certain embodiments are directed to compounds and compositions useful for inhibiting FOXP3 expression in Tregs, which can be useful for treating, preventing, ameliorating, or slowing progression of cancer associated with immunosuppresive Tregs.

DETAILED DESCRIPTION

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the embodiments, as claimed. Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including” as well as other forms, such as “includes” and “included”, is not limiting.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, and GenBank and NCBI reference sequence records are hereby expressly incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

It is understood that the sequence set forth in each SEQ ID NO in the examples contained herein is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Compounds described by ION number indicate a combination of nucleobase sequence, chemical modification, and motif.

Unless otherwise indicated, the following terms have the following meanings:

“2′-deoxynucleoside” means a nucleoside comprising 2′-H(H) furanosyl sugar moiety, as found in naturally occurring deoxyribonucleic acids (DNA). In certain embodiments, a 2′-deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (uracil).

“2′-O-methoxyethyl” (also 2′-MOE and 2′-O(CH₂)₂—OCH₃) refers to an O-methoxy-ethyl modification at the 2′ position of a furanosyl ring. A 2′-O-methoxyethyl modified sugar is a modified sugar.

“2′-MOE nucleoside” (also 2′-O-methoxyethyl nucleoside) means a nucleoside comprising a 2′-MOE modified sugar moiety.

“2′-substituted nucleoside” or “2-modified nucleoside” means a nucleoside comprising a 2′-substituted or 2′-modified sugar moiety. As used herein, “2′-substituted” or “2-modified” in reference to a sugar moiety means a sugar moiety comprising at least one 2′-substituent group other than H or OH.

“3′ target site” refers to the nucleotide of a target nucleic acid which is complementary to the 3′-most nucleotide of a particular compound.

“5′ target site” refers to the nucleotide of a target nucleic acid which is complementary to the 5′-most nucleotide of a particular compound.

“5-methylcytosine” means a cytosine with a methyl group attached to the 5 position.

“About” means within +10% of a value. For example, if it is stated, “the compounds affected about 70% inhibition of FOXP3”, it is implied that FOXP3 levels are inhibited within a range of 60% and 80%.

“Administration” or “administering” refers to routes of introducing a compound or composition provided herein to an individual to perform its intended function. An example of a route of administration that can be used includes, but is not limited to parenteral administration, such as subcutaneous, intravenous, or intramuscular injection or infusion.

“Administered concomitantly” or “co-administration” means administration of two or more compounds in any manner in which the pharmacological effects of both are manifest in the patient. Concomitant administration does not require that both compounds be administered in a single pharmaceutical composition, in the same dosage form, by the same route of administration, or at the same time. The effects of both compounds need not manifest themselves at the same time. The effects need only be overlapping for a period of time and need not be coextensive. Concomitant administration or co-administration encompasses administration in parallel or sequentially.

“Amelioration” refers to an improvement or lessening of at least one indicator, sign, or symptom of an associated disease, disorder, or condition. In certain embodiments, amelioration includes a delay or slowing in the progression or severity of one or more indicators of a condition or disease. The progression or severity of indicators may be determined by subjective or objective measures, which are known to those skilled in the art.

“Animal” refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.

“Antibody,” as used in this disclosure, refers to an immunoglobulin or a fragment or a derivative thereof, and encompasses any polypeptide comprising an antigen-binding site, regardless of whether it is produced in vitro or in vivo. The term includes, but is not limited to, polyclonal, monoclonal, monospecific, polyspecific, non-specific, humanized, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, and grafted antibodies. Unless otherwise modified by the term “intact,” as in “intact antibodies,” for the purposes of this disclosure, the term “antibody” also includes antibody fragments such as Fab, F(ab′)2, Fv, scFv, Fd, dAb, and other antibody fragments that retain antigen-binding function, i.e., the ability to bind, for example, CTLA-4 or PD-L 1 specifically. Typically, such fragments would comprise an antigen-binding domain.

“Anti-CTLA-4 antibody” refers to an antibody or antigen binding fragment thereof that specifically binds a CTLA-4 polypeptide. Exemplary anti-CTLA-4 antibodies are described for example at U.S. Pat. Nos. 6,682,736; 7,109,003; 7,123,281; 7,411,057; 7,824,679; 8,143,379; 7,807,797; and 8,491,895 (Tremelimumab is 11.2.1, therein), which are herein incorporated by reference. Tremelimumab (U.S. Pat. No. 6,682,736) is an exemplary anti-CTLA-4 antibody.

“Anti-OX40 antibody” refers to an antibody or antigen binding fragment thereof that specifically binds OX40. OX40 antibodies include monoclonal and polyclonal antibodies that are specific for OX40 and antigen-binding fragments thereof. In certain aspects, anti-OX40 antibodies as described herein are monoclonal antibodies (or antigen-binding fragments thereof), e.g., murine, humanized, or fully human monoclonal antibodies. In one particular embodiment, the OX40 antibody is an OX40 receptor agonist, such as the mouse anti-human OX40 monoclonal antibody (9B12) described by Weinberg et al., J Immunother 29, 575-585 (2006). In another embodiment, an OX40 antibody is MEDI0562 as described in US 2016/0137740, incorporated herein by reference. In other embodiments, the antibody which specifically binds to OX40, or an antigen-binding fragment thereof, binds to the same OX40 epitope as mAb 9B12.

“Anti-PD-L 1 antibody” refers to an antibody or antigen binding fragment thereof that specifically binds a PD-L1 polypeptide. Exemplary anti-PD-L1 antibodies are described for example at US2013/0034559, U.S. Pat. Nos. 8,779,108 and 9,493,565 which are herein incorporated by reference. Durvalumab (MEDI4736) is an exemplary anti-PD-L 1 antibody. Other anti-PD-L 1 antibodies include BMS-936559 (Bristol-Myers Squibb) and MPDL3280A (atezolizumab) (Roche).

“Anti-PD-1 antibody” refers to an antibody or antigen binding fragment thereof that specifically binds a PD-1 polypeptide. Exemplary anti-PD-1 antibodies are described for example at U.S. Pat. Nos. 7,521,051; 8,008,449; 8,354,509; 9,073,994; 9,393,301; 9,402,899; and 9,439,962, which are herein incorporated by reference. Exemplary anti-PD-1 antibodies include, without limitation, nivolumab, pembrolizumab, pidilizumab, and AMP-514.

“Antigen-binding domain,” “antigen-binding fragment,” and “binding fragment” refer to a part of an antibody molecule that comprises amino acids responsible for the specific binding between the antibody and the antigen. In instances, where an antigen is large, the antigen-binding domain may only bind to a part of the antigen. A portion of the antigen molecule that is responsible for specific interactions with the antigen-binding domain is referred to as “epitope” or “antigenic determinant.” An antigen-binding domain typically comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH), however, it does not necessarily have to comprise both. For example, a so-called Fd antibody fragment consists only of a VH domain, but still retains some antigen-binding function of the intact antibody. Binding fragments of an antibody are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Binding fragments include Fab, Fab′, F(ab′)2, Fv, and single-chain antibodies. An antibody other than a “bispecific” or “bifunctional” antibody is understood to have each of its binding sites identical. Digestion of antibodies with the enzyme, papain, results in two identical antigen-binding fragments, known also as “Fab” fragments, and a “Fc” fragment, having no antigen-binding activity but having the ability to crystallize. Digestion of antibodies with the enzyme, pepsin, results in the a F(ab′)2 fragment in which the two arms of the antibody molecule remain linked and comprise two-antigen binding sites. The F(ab′)2 fragment has the ability to crosslink antigen. “Fv” when used herein refers to the minimum fragment of an antibody that retains both antigen-recognition and antigen-binding sites. “Fab” when used herein refers to a fragment of an antibody that comprises the constant domain of the light chain and the CH1 domain of the heavy chain.

“mAb” refers to monoclonal antibody. Antibodies of the present disclosure comprise without limitation whole native antibodies, bispecific antibodies; chimeric antibodies; Fab, Fab′, single chain V region fragments (scFv), fusion polypeptides, and unconventional antibodies.

“Antisense activity” means any detectable and/or measurable activity attributable to the hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid compared to target nucleic acid levels or target protein levels in the absence of the antisense compound to the target.

“Antisense compound” means a compound comprising an oligonucleotide and optionally one or more additional features, such as a conjugate group or terminal group. Examples of antisense compounds include single-stranded and double-stranded compounds, such as, oligonucleotides, ribozymes, siRNAs, shRNAs, ssRNAs, and occupancy-based compounds.

“Antisense inhibition” means reduction of target nucleic acid levels in the presence of an antisense compound complementary to a target nucleic acid compared to target nucleic acid levels in the absence of the antisense compound.

“Antisense mechanisms” are all those mechanisms involving hybridization of a compound with target nucleic acid, wherein the outcome or effect of the hybridization is either target degradation or target occupancy with concomitant stalling of the cellular machinery involving, for example, transcription or splicing.

“Antisense oligonucleotide” means an oligonucleotide having a nucleobase sequence that is complementary to a target nucleic acid or region or segment thereof. In certain embodiments, an antisense oligonucleotide is specifically hybridizable to a target nucleic acid or region or segment thereof.

“Bicyclic nucleoside” or “BNA” means a nucleoside comprising a bicyclic sugar moiety. “Bicyclic sugar” or “bicyclic sugar moiety” means a modified sugar moiety comprising two rings, wherein the second ring is formed via a bridge connecting two of the atoms in the first ring thereby forming a bicyclic structure. In certain embodiments, the first ring of the bicyclic sugar moiety is a furanosyl moiety. In certain embodiments, the bicyclic sugar moiety does not comprise a furanosyl moiety.

“Branching group” means a group of atoms having at least 3 positions that are capable of forming covalent linkages to at least 3 groups. In certain embodiments, a branching group provides a plurality of reactive sites for connecting tethered ligands to an oligonucleotide via a conjugate linker and/or a cleavable moiety.

“Cell-targeting moiety” means a conjugate group or portion of a conjugate group that is capable of binding to a particular cell type or particular cell types.

“cEt” or “constrained ethyl” means a bicyclic furanosyl sugar moiety comprising a bridge connecting the 4′-carbon and the 2′-carbon, wherein the bridge has the formula: 4′-CH(CH₃)—O-2′.

“cEt nucleoside” means a nucleoside comprising a cEt modified sugar moiety.

“Chemical modification” in a compound describes the substitutions or changes through chemical reaction, of any of the units in the compound relative to the original state of such unit. “Modified nucleoside” means a nucleoside having, independently, a modified sugar moiety and/or modified nucleobase. “Modified oligonucleotide” means an oligonucleotide comprising at least one modified internucleoside linkage, a modified sugar, and/or a modified nucleobase.

“Chemically distinct region” refers to a region of a compound that is in some way chemically different than another region of the same compound. For example, a region having 2′-O-methoxyethyl nucleotides is chemically distinct from a region having nucleotides without 2′-O-methoxyethyl modifications.

“Chimeric antisense compounds” means antisense compounds that have at least 2 chemically distinct regions, each position having a plurality of subunits.

“Chirally enriched population” means a plurality of molecules of identical molecular formula, wherein the number or percentage of molecules within the population that contain a particular stereochemical configuration at a particular chiral center is greater than the number or percentage of molecules expected to contain the same particular stereochemical configuration at the same particular chiral center within the population if the particular chiral center were stereorandom. Chirally enriched populations of molecules having multiple chiral centers within each molecule may contain one or more stereorandom chiral centers. In certain embodiments, the molecules are modified oligonucleotides. In certain embodiments, the molecules are compounds comprising modified oligonucleotides.

“Cleavable bond” means any chemical bond capable of being split. In certain embodiments, a cleavable bond is selected from among: an amide, a polyamide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, a di-sulfide, or a peptide.

“Cleavable moiety” means a bond or group of atoms that is cleaved under physiological conditions, for example, inside a cell, an animal, or a human.

“Complementary” in reference to an oligonucleotide means the nucleobase sequence of such oligonucleotide or one or more regions thereof matches the nucleobase sequence of another oligonucleotide or nucleic acid or one or more regions thereof when the two nucleobase sequences are aligned in opposing directions. Nucleobase matches or complementary nucleobases, as described herein, are limited to the following pairs: adenine (A) and thymine (T), adenine (A) and uracil (U), cytosine (C) and guanine (G), and 5-methyl cytosine (^(m)C) and guanine (G) unless otherwise specified. Complementary oligonucleotides and/or nucleic acids need not have nucleobase complementarity at each nucleoside and may include one or more nucleobase mismatches. By contrast, “fully complementary” or “100% complementary” in reference to oligonucleotides means that such oligonucleotides have nucleobase matches at each nucleoside without any nucleobase mismatches.

“Conjugate group” means a group of atoms that is attached to an oligonucleotide. Conjugate groups include a conjugate moiety and a conjugate linker that attaches the conjugate moiety to the oligonucleotide.

“Conjugate linker” means a group of atoms comprising at least one bond that connects a conjugate moiety to an oligonucleotide.

“Conjugate moiety” means a group of atoms that is attached to an oligonucleotide via a conjugate linker.

“Contiguous” in the context of an oligonucleotide refers to nucleosides, nucleobases, sugar moieties, or internucleoside linkages that are immediately adjacent to each other. For example, “contiguous nucleobases” means nucleobases that are immediately adjacent to each other in a sequence.

“Designing” or “Designed to” refer to the process of designing a compound that specifically hybridizes with a selected nucleic acid molecule.

“Diluent” means an ingredient in a composition that lacks pharmacological activity, but is pharmaceutically necessary or desirable. For example, the diluent in an injected composition can be a liquid, e.g. saline solution.

“Differently modified” means chemical modifications or chemical substituents that are different from one another, including absence of modifications. Thus, for example, a MOE nucleoside and an unmodified DNA nucleoside are “differently modified,” even though the DNA nucleoside is unmodified. Likewise, DNA and RNA are “differently modified,” even though both are naturally-occurring unmodified nucleosides. Nucleosides that are the same but for comprising different nucleobases are not differently modified. For example, a nucleoside comprising a 2′-OMe modified sugar and an unmodified adenine nucleobase and a nucleoside comprising a 2′-OMe modified sugar and an unmodified thymine nucleobase are not differently modified.

“Dose” means a specified quantity of a compound or pharmaceutical agent provided in a single administration, or in a specified time period. In certain embodiments, a dose may be administered in two or more boluses, tablets, or injections. For example, in certain embodiments, where subcutaneous administration is desired, the desired dose may require a volume not easily accommodated by a single injection. In such embodiments, two or more injections may be used to achieve the desired dose. In certain embodiments, a dose may be administered in two or more injections to minimize injection site reaction in an individual. In other embodiments, the compound or pharmaceutical agent is administered by infusion over an extended period of time or continuously. Doses may be stated as the amount of pharmaceutical agent per hour, day, week or month.

“Dosing regimen” is a combination of doses designed to achieve one or more desired effects.

“Double-stranded antisense compound” means an antisense compound comprising two oligomeric compounds that are complementary to each other and form a duplex, and wherein one of the two said oligomeric compounds comprises an oligonucleotide.

“Effective amount” means the amount of compound sufficient to effectuate a desired physiological outcome in an individual in need of the compound. The effective amount may vary among individuals depending on the health and physical condition of the individual to be treated, the taxonomic group of the individuals to be treated, the formulation of the composition, assessment of the individual's medical condition, and other relevant factors.

“Efficacy” means the ability to produce a desired effect.

“Expression” includes all the functions by which a gene's coded information is converted into structures present and operating in a cell. Such structures include, but are not limited to, the products of transcription and translation.

“Gapmer” means an oligonucleotide comprising an internal region having a plurality of nucleosides that support RNase H cleavage positioned between external regions having one or more nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the nucleoside or nucleosides comprising the external regions. The internal region may be referred to as the “gap” and the external regions may be referred to as the “wings.”

“Hybridization” means the annealing of oligonucleotides and/or nucleic acids. While not limited to a particular mechanism, the most common mechanism of hybridization involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases. In certain embodiments, complementary nucleic acid molecules include, but are not limited to, an antisense compound and a nucleic acid target. In certain embodiments, complementary nucleic acid molecules include, but are not limited to, an oligonucleotide and a nucleic acid target.

“Immediately adjacent” means there are no intervening elements between the immediately adjacent elements of the same kind (e.g. no intervening nucleobases between the immediately adjacent nucleobases).

“Immune checkpoint inhibitor” means an agent that inhibits the expression or activity of a protein that inhibits an immune response. In one embodiment, an immune checkpoint inhibitor is an agent that inhibits the CTLA-4 or PD-1 pathways. Particular checkpoint inhibitors include antibodies that inhibit PD-1, PD-L1 or CTLA-4.

“Immunomodulatory agent” means an agent that enhances an immune response (e.g., anti-tumor immune response). Exemplary immunomodulatory agents of the present disclosure include antibodies, such as an anti-CTLA-4 antibody, an anti-PD-L 1 antibody, an anti-PD-1 antibody and antigenic fragments of any of these, and OX40 agonists, including proteins, such as OX40 ligand fusion protein, OX40 antibody, or fragments thereof. In one embodiment, the immunomodulatory agent is an immune checkpoint inhibitor.

“Individual” means a human or non-human animal selected for treatment or therapy.

“Inhibiting the expression or activity” refers to a reduction or blockade of the expression or activity relative to the expression of activity in an untreated or control sample and does not necessarily indicate a total elimination of expression or activity.

“Internucleoside linkage” means a group or bond that forms a covalent linkage between adjacent nucleosides in an oligonucleotide. “Modified internucleoside linkage” means any internucleoside linkage other than a naturally occurring, phosphate internucleoside linkage. Non-phosphate linkages are referred to herein as modified internucleoside linkages.

“Lengthened oligonucleotides” are those that have one or more additional nucleosides relative to an oligonucleotide disclosed herein, e.g. a parent oligonucleotide.

“Linked nucleosides” means adjacent nucleosides linked together by an internucleoside linkage.

“Linker-nucleoside” means a nucleoside that links an oligonucleotide to a conjugate moiety. Linker-nucleosides are located within the conjugate linker of a compound. Linker-nucleosides are not considered part of the oligonucleotide portion of a compound even if they are contiguous with the oligonucleotide.

“Mismatch” or “non-complementary” means a nucleobase of a first oligonucleotide that is not complementary to the corresponding nucleobase of a second oligonucleotide or target nucleic acid when the first and second oligonucleotides are aligned. For example, nucleobases including but not limited to a universal nucleobase, inosine, and hypoxanthine, are capable of hybridizing with at least one nucleobase but are still mismatched or non-complementary with respect to nucleobase to which it hybridized. As another example, a nucleobase of a first oligonucleotide that is not capable of hybridizing to the corresponding nucleobase of a second oligonucleotide or target nucleic acid when the first and second oligonucleotides are aligned is a mismatch or non-complementary nucleobase.

“Modulating” refers to changing or adjusting a feature in a cell, tissue, organ or organism. For example, modulating FOXP3 RNA can mean to increase or decrease the level of FOXP3 RNA and/or FOXP3 protein in a cell, tissue, organ or organism. A “modulator” effects the change in the cell, tissue, organ or organism. For example, a FOXP3 compound can be a modulator that decreases the amount of FOXP3 RNA and/or FOXP3 protein in a cell, tissue, organ or organism.

“MOE” means methoxyethyl.

“Monomer” refers to a single unit of an oligomer. Monomers include, but are not limited to, nucleosides and nucleotides.

“Motif” means the pattern of unmodified and/or modified sugar moieties, nucleobases, and/or internucleoside linkages, in an oligonucleotide.

“Natural” or “naturally occurring” means found in nature.

“Non-bicyclic modified sugar” or “non-bicyclic modified sugar moiety” means a modified sugar moiety that comprises a modification, such as a substituent, that does not form a bridge between two atoms of the sugar to form a second ring.

“Nucleic acid” refers to molecules composed of monomeric nucleotides. A nucleic acid includes, but is not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, and double-stranded nucleic acids.

“Nucleobase” means a heterocyclic moiety capable of pairing with a base of another nucleic acid. As used herein a “naturally occurring nucleobase” is adenine (A), thymine (T), cytosine (C), uracil (U), and guanine (G). A “modified nucleobase” is a naturally occurring nucleobase that is chemically modified. A “universal base” or “universal nucleobase” is a nucleobase other than a naturally occurring nucleobase and modified nucleobase, and is capable of pairing with any nucleobase.

“Nucleobase sequence” means the order of contiguous nucleobases in a nucleic acid or oligonucleotide independent of any sugar or internucleoside linkage.

“Nucleoside” means a compound comprising a nucleobase and a sugar moiety. The nucleobase and sugar moiety are each, independently, unmodified or modified. “Modified nucleoside” means a nucleoside comprising a modified nucleobase and/or a modified sugar moiety. Modified nucleosides include abasic nucleosides, which lack a nucleobase.

“Oligomeric compound” means a compound comprising a single oligonucleotide and optionally one or more additional features, such as a conjugate group or terminal group.

“Oligonucleotide” means a polymer of linked nucleosides each of which can be modified or unmodified, independent one from another. Unless otherwise indicated, oligonucleotides consist of 8-80 linked nucleosides. “Modified oligonucleotide” means an oligonucleotide, wherein at least one sugar, nucleobase, or internucleoside linkage is modified. “Unmodified oligonucleotide” means an oligonucleotide that does not comprise any sugar, nucleobase, or internucleoside modification.

“Parent oligonucleotide” means an oligonucleotide whose sequence is used as the basis of design for more oligonucleotides of similar sequence but with different lengths, motifs, and/or chemistries. The newly designed oligonucleotides may have the same or overlapping sequence as the parent oligonucleotide.

“Parenteral administration” means administration through injection or infusion. Parenteral administration includes subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial administration, e.g. intrathecal or intracerebroventricular administration.

“Pharmaceutically acceptable carrier or diluent” means any substance suitable for use in administering to an individual. For example, a pharmaceutically acceptable carrier can be a sterile aqueous solution, such as PBS or water-for-injection.

“Pharmaceutically acceptable salts” means physiologically and pharmaceutically acceptable salts of compounds, such as oligomeric compounds or oligonucleotides, i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

“Pharmaceutical agent” means a compound that provides a therapeutic benefit when administered to an individual.

“Pharmaceutical composition” means a mixture of substances suitable for administering to an individual. For example, a pharmaceutical composition may comprise one or more compounds or salt thereof and a sterile aqueous solution.

“Phosphorothioate linkage” means a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced with a sulfur atom. A phosphorothioate internucleoside linkage is a modified internucleoside linkage.

“Phosphorus moiety” means a group of atoms comprising a phosphorus atom. In certain embodiments, a phosphorus moiety comprises a mono-, di-, or tri-phosphate, or phosphorothioate.

“Portion” means a defined number of contiguous (i.e., linked) nucleobases of a nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of a target nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of an oligomeric compound.

“Prevent” refers to delaying or forestalling the onset, development or progression of a disease, disorder, or condition for a period of time from minutes to indefinitely.

“Prodrug” means a compound in a form outside the body which, when administered to an individual, is metabolized to another form within the body or cells thereof. In certain embodiments, the metabolized form is the active, or more active, form of the compound (e.g., drug). Typically conversion of a prodrug within the body is facilitated by the action of an enzyme(s) (e.g., endogenous or viral enzyme) or chemical(s) present in cells or tissues, and/or by physiologic conditions.

“Reduce” means to bring down to a smaller extent, size, amount, or number.

“RefSeq No.” is a unique combination of letters and numbers assigned to a sequence to indicate the sequence is for a particular target transcript (e.g., target gene). Such sequence and information about the target gene (collectively, the gene record) can be found in a genetic sequence database. Genetic sequence databases include the NCBI Reference Sequence database, GenBank, the European Nucleotide Archive, and the DNA Data Bank of Japan (the latter three forming the International Nucleotide Sequence Database Collaboration or INSDC).

“Region” is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic.

“RNAi compound” means an antisense compound that acts, at least in part, through RISC or Ago2, but not through RNase H, to modulate a target nucleic acid and/or protein encoded by a target nucleic acid. RNAi compounds include, but are not limited to double-stranded siRNA, single-stranded RNA (ssRNA), and microRNA, including microRNA mimics.

“Segments” are defined as smaller or sub-portions of regions within a nucleic acid.

“Side effects” means physiological disease and/or conditions attributable to a treatment other than the desired effects. In certain embodiments, side effects include injection site reactions, liver function test abnormalities, renal function abnormalities, liver toxicity, renal toxicity, central nervous system abnormalities, myopathies, and malaise. For example, increased aminotransferase levels in serum may indicate liver toxicity or liver function abnormality. For example, increased bilirubin may indicate liver toxicity or liver function abnormality.

“Single-stranded” in reference to a compound means the compound has only one oligonucleotide.

“Self-complementary” means an oligonucleotide that at least partially hybridizes to itself. A compound consisting of one oligonucleotide, wherein the oligonucleotide of the compound is self-complementary, is a single-stranded compound. A single-stranded compound may be capable of binding to a complementary compound to form a duplex.

“Sites” are defined as unique nucleobase positions within a target nucleic acid.

“Specifically hybridizable” refers to an oligonucleotide having a sufficient degree of complementarity between the oligonucleotide and a target nucleic acid to induce a desired effect, while exhibiting minimal or no effects on non-target nucleic acids. In certain embodiments, specific hybridization occurs under physiological conditions.

“Specifically inhibit” with reference to a target nucleic acid means to reduce or block expression of the target nucleic acid while exhibiting fewer, minimal, or no effects on non-target nucleic acids. Reduction does not necessarily indicate a total elimination of the target nucleic acid's expression.

“Standard cell assay” means assay(s) described in the Examples and reasonable variations thereof.

“Standard in vivo experiment” means the procedure(s) described in the Example(s) and reasonable variations thereof.

“Stereorandom chiral center” in the context of a population of molecules of identical molecular formula means a chiral center having a random stereochemical configuration. For example, in a population of molecules comprising a stereorandom chiral center, the number of molecules having the (S) configuration of the stereorandom chiral center may be but is not necessarily the same as the number of molecules having the (R) configuration of the stereorandom chiral center. The stereochemical configuration of a chiral center is considered random when it is the result of a synthetic method that is not designed to control the stereochemical configuration. In certain embodiments, a stereorandom chiral center is a stereorandom phosphorothioate internucleoside linkage.

“Sugar moiety” means an unmodified sugar moiety or a modified sugar moiety. “Unmodified sugar moiety” or “unmodified sugar” means a 2′-OH(H) furanosyl moiety, as found in RNA (an “unmodified RNA sugar moiety”), or a 2′-H(H) moiety, as found in DNA (an “unmodified DNA sugar moiety”). Unmodified sugar moieties have one hydrogen at each of the 1′, 3′, and 4′ positions, an oxygen at the 3′ position, and two hydrogens at the 5′ position. “Modified sugar moiety” or “modified sugar” means a modified furanosyl sugar moiety or a sugar surrogate. “Modified furanosyl sugar moiety” means a furanosyl sugar comprising a non-hydrogen substituent in place of at least one hydrogen of an unmodified sugar moiety. In certain embodiments, a modified furanosyl sugar moiety is a 2′-substituted sugar moiety. Such modified furanosyl sugar moieties include bicyclic sugars and non-bicyclic sugars.

“Sugar surrogate” means a modified sugar moiety having other than a furanosyl moiety that can link a nucleobase to another group, such as an internucleoside linkage, conjugate group, or terminal group in an oligonucleotide. Modified nucleosides comprising sugar surrogates can be incorporated into one or more positions within an oligonucleotide and such oligonucleotides are capable of hybridizing to complementary compounds or nucleic acids.

“Synergy” or “synergize” refers to an effect of a combination that is greater than additive of the effects of each component alone at the same doses.

“FOXP3” means any nucleic acid or protein of FOXP3. “FOXP3 nucleic acid” means any nucleic acid encoding FOXP3. For example, in certain embodiments, a FOXP3 nucleic acid includes a DNA sequence encoding FOXP3, an RNA sequence transcribed from DNA encoding FOXP3 (including genomic DNA comprising introns and exons), and an mRNA sequence encoding FOXP3. “FOXP3 mRNA” means an mRNA encoding a FOXP3 protein. The target may be referred to in either upper or lower case.

“FOXP3 specific inhibitor” refers to any agent capable of specifically inhibiting FOXP3 RNA and/or FOXP3 protein expression or activity at the molecular level. For example, FOXP3 specific inhibitors include nucleic acids (including antisense compounds), peptides, antibodies, small molecules, and other agents capable of inhibiting the expression of FOXP3 RNA and/or FOXP3 protein.

“Target gene” refers to a gene encoding a target.

“Targeting” means the specific hybridization of a compound to a target nucleic acid in order to induce a desired effect.

“Target nucleic acid,” “target RNA,” “target RNA transcript” and “nucleic acid target” all mean a nucleic acid capable of being targeted by compounds described herein.

“Target region” means a portion of a target nucleic acid to which one or more compounds is targeted.

“Target segment” means the sequence of nucleotides of a target nucleic acid to which a compound is targeted. “5′ target site” refers to the 5′-most nucleotide of a target segment. “3′ target site” refers to the 3′-most nucleotide of a target segment.

“Terminal group” means a chemical group or group of atoms that is covalently linked to a terminus of an oligonucleotide.

“Therapeutically effective amount” means an amount of a compound, pharmaceutical agent, or composition that provides a therapeutic benefit to an individual.

“Treat” refers to administering a compound or pharmaceutical composition to an animal in order to effect an alteration or improvement of a disease, disorder, or condition in the animal.

CERTAIN EMBODIMENTS

Certain embodiments provide methods, compounds and compositions for inhibiting FOXP3 expression.

Certain embodiments provide compounds targeted to a FOXP3 nucleic acid. In certain embodiments, the FOXP3 nucleic acid has the sequence set forth in RefSeq or GENBANK Accession No. NM_014009.3 (SEQ ID NO: 1); NT_011568.12_TRUNC_11907130_11921808_COMP (SEQ ID NO: 2); NM_001114377.1 (SEQ ID NO: 3); NC_000023.11_TRUNC_49247001_49273000_COMP (SEQ ID NO: 4); or UCSC Accession No. UC064ZFP.1 corresponding to genomic co-ordinates chrX:49,251,334-49,259,240 on assembly GRCh38/hg38 (SEQ ID NO: 5); each of which is incorporated by reference in its entirety. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded.

Certain embodiments provide a compound comprising a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide 9 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 9 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide 10 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 10 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide 11 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 11 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 11 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide 12 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 12 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 12 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion within nucleotides 2269-2284 of SEQ ID NO: 1. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion within nucleotides 1233-1248, 2156-2171, 2735-2750, 4661-4676, 7307-7322, 7331-7346, 7980-7995, 11581-11596, or 12396-12411 of SEQ ID NO: 2. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and complementary within nucleotides 2269-2284 of SEQ ID NO: 1. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and complementary within nucleotides 1233-1248, 2156-2171, 2735-2750, 4661-4676, 7307-7322, 7331-7346, 7980-7995, 11581-11596, or 12396-12411 of SEQ ID NO: 2. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises a modified oligonucleotide 16 linked nucleosides in length having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575.

In certain embodiments, a compound targeted to FOXP3 is ION 1063734. Out of over 3,000 compounds that were screened as described in the Examples section below, ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313 emerged as the top lead compounds.

In certain embodiments, any of the foregoing modified oligonucleotides comprises at least one modified internucleoside linkage, at least one modified sugar, and/or at least one modified nucleobase.

In certain embodiments, any of the foregoing modified oligonucleotides comprises at least one modified sugar. In certain embodiments, at least one modified sugar comprises a 2′-O-methoxyethyl group. In certain embodiments, at least one modified sugar is a bicyclic sugar, such as a 4′-CH(CH₃)—O-2′ group, a 4′-CH₂—O-2′ group, or a 4′-(CH₂)₂—O-2′ group.

In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage, such as a phosphorothioate internucleoside linkage.

In certain embodiments, any of the foregoing modified oligonucleotides comprises at least one modified nucleobase, such as 5-methylcytosine.

In certain embodiments, any of the foregoing modified oligonucleotides comprises:

-   -   a gap segment consisting of linked deoxynucleosides;     -   a 5′ wing segment consisting of linked nucleosides; and     -   a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar. In certain embodiments, the modified oligonucleotide is 16 to 80 linked nucleosides in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length having a nucleobase sequence consisting of the sequence recited in any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide 16-80 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 9-3246, wherein the modified oligonucleotide comprises:

-   -   a gap segment consisting of linked deoxynucleosides;     -   a 5′ wing segment consisting of linked nucleosides; and     -   a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide 16-80 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575, wherein the modified oligonucleotide comprises:

-   -   a gap segment consisting of linked deoxynucleosides;     -   a 5′ wing segment consisting of linked nucleosides; and     -   a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide 16-80 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575, wherein the modified oligonucleotide comprises:

a gap segment consisting often linked deoxynucleosides;

a 5′ wing segment consisting of three linked nucleosides; and

a 3′ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein each nucleoside of each wing segment comprises a cEt nucleoside; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide 16-80 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in SEQ ID NO: 449, wherein the modified oligonucleotide comprises:

a gap segment consisting often linked deoxynucleosides;

a 5′ wing segment consisting of three linked nucleosides; and

a 3′ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein each nucleoside of each wing segment comprises a cEt nucleoside; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In certain embodiments, a compound comprises or consists of ION 1063734 or salt thereof, having the following chemical structure:

In certain embodiments, a compound comprises or consists of the sodium salt of ION 1063734, having the following chemical structure:

In any of the foregoing embodiments, the compound or oligonucleotide can be at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% complementary to a nucleic acid encoding FOXP3.

In any of the foregoing embodiments, the compound can be single-stranded. In certain embodiments, the compound comprises deoxyribonucleotides. In certain embodiments, the compound is double-stranded. In certain embodiments, the compound is double-stranded and comprises ribonucleotides. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

In any of the foregoing embodiments, the compound can be 8 to 80, 10 to 30, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 22, 18 to 24, 18 to 30, 18 to 50, 19 to 22, 19 to 30, 19 to 50, or 20 to 30 linked nucleosides in length. In certain embodiments, the compound comprises or consists of an oligonucleotide.

In certain embodiments, compounds or compositions provided herein comprise a salt of the modified oligonucleotide. In certain embodiments, the salt is a sodium salt. In certain embodiments, the salt is a potassium salt.

In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by having at least one of an increase an alanine transaminase (ALT) or aspartate transaminase (AST) value of no more than 4 fold, 3 fold, or 2 fold over saline treated animals or an increase in liver, spleen, or kidney weight of no more than 30%, 20%, 15%, 1²%, 10%, 5%, or 2% compared to control treated animals.

In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by having no increase of ALT or AST over control treated animals. In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by having no increase in liver, spleen, or kidney weight over control animals.

Certain embodiments provide a composition comprising the compound of any of the aforementioned embodiments or salt thereof and at least one of a pharmaceutically acceptable carrier or diluent. In certain embodiments, the composition has a viscosity less than about 40 centipoise (cP), less than about 30 centipose (cP), less than about 20 centipose (cP), less than about 15 centipose (cP), or less than about 10 centipose (cP).

In certain embodiments, the composition having any of the aforementioned viscosities comprises a compound provided herein at a concentration of about 100 mg/mL, about 125 mg/mL, about 150 mg/mL, about 175 mg/mL, about 200 mg/mL, about 225 mg/mL, about 250 mg/mL, about 275 mg/mL, or about 300 mg/mL. In certain embodiments, the composition having any of the aforementioned viscosities and/or compound concentrations has a temperature of room temperature or about 20° C., about 21° C., about 22° C., about 23° C., about 24° C., about 25° C., about 26° C., about 27° C., about 28° C., about 29° C., or about 30° C.

Certain Indications

Certain embodiments provided herein relate to methods of inhibiting FOXP3 expression, which can be useful for treating, preventing, or ameliorating cancer in an individual, by administration of a compound that targets FOXP3. In certain embodiments, the compound can be a FOXP3 specific inhibitor. In certain embodiments, the compound can be an antisense compound, oligomeric compound, or oligonucleotide targeted to FOXP3.

Examples of cancers treatable, preventable, and/or ameliorable with the compounds and methods provided herein include cancers with FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL).

In certain embodiments, the B-cell lymphoma is a non-Hodgkin's B-cell lymphoma. Examples of non-Hodgkin's B-cell lymphoma of certain embodiments that can be treated with compounds provided herein include, but are not limited to, diffuse large B cell lymphoma (DLBCL), activated B-cell lymphoma (ABC-DLBCL), germinal center B-cell lymphoma (GCB DLBCL), follicular lymphoma, mucosa-associated lymphatic tissue lymphoma (MALT), small cell lymphocytic lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma (MCL), Burkitt lymphoma, mediastinal large B cell lymphoma, Waldenström macroglobulinemia, nodal marginal zone B cell lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), intravascular large B-cell lymphoma, primary effusion lymphoma, and lymphomatoid granulomatosis.

In certain embodiments, the T-cell lymphoma that can be treated with compounds provided herein include, but are not limited to, peripheral T-cell lymphoma, and anaplastic large cell lymphoma (ALCL).

In certain embodiments, the leukemia that can be treated with compounds provided herein includes, but is not limited to, acute lymphocytic leukemia (ALL).

In certain embodiments, the breast cancer has one or more of the following characteristics: Androgen Receptor positive, dependent on androgen for growth; Estrogen Receptor (ER) negative, independent of estrogen for growth; Progesterone Receptor (PR) negative, independent of progesterone for growth; or Her2/neu negative. In certain embodiments, the breast cancer is ER, PR, and HER2 triple negative (ER−, PR−, HER2−). In certain embodiments, the breast cancer is triple negative and AR positive (ER−, PR−, HER2−, AR+). In certain embodiments, the breast cancer is ER negative and AR positive (ER−, AR+). In certain embodiments, the breast cancer is ER positive and AR positive (ER+, AR+). In certain embodiments, the breast cancer is apocrine. Apocrine breast cancers are often “triple negative”, meaning that the cells do not express ER, PR, or HER2 receptors, and usually, but not necessarily, AR positive. In certain embodiments, an apocrine breast cancer is ER, PR, and HER2 triple negative and AR positive (ER−, PR−, HER2−, AR+). In certain embodiments, an apocrine breast cancer is ER negative and AR positive (ER−, AR+). In certain embodiments, an apocrine breast cancer originates from the sweat gland of the breast. In certain embodiments, an apocrine breast cancer is a ductal cancer or cancer cell of the breast. In certain embodiments, an apocrine breast cancer can have any one or more of the following features: a large amount of eosinophilic granular cytoplasm, well-defined margins, large vesicular nuclei, a nuclear to cytoplasmic ratio of about 1:2, and/or accumulations of secreted granules in the apical cytoplasm known as apical snouts. In certain embodiments, the breast cancer is an ER negative and AR positive (ER−, AR+) molecular apocrine breast cancer. In certain aspects, an ER negative and AR positive (ER−, AR+) molecular apocrine breast cancer can further be PR positive, PR negative, HER2 negative, or HER2 positive. In certain embodiments, the breast cancer is HER2 positive. In certain embodiments, the breast cancer is PR positive. In certain embodiments, the breast cancer is ER positive. Breast cancer can be identified as positive or negative with respect to hormone receptors, such as ER, PR, or HER2 by standard histological techniques. For example, in some embodiments histological breast cancer samples can be classified as “triple negative” (ER−, PR−, HER2−) when less than 1% of cells demonstrate nuclear staining for estrogen and progesterone receptors, and immunohistochemical staining for HER2 shows a 0, 1-fold, or a 2-fold positive score and a FISH ratio (HER2 gene signals to chromosome 17 signals) of less than 1.8 according to the relevant ASCO and CAP guidelines. (Meyer, P. et al., PLoS ONE 7(5): e38361 (2012)).

In certain embodiments, a method of treating, preventing, or ameliorating cancer in an individual comprises administering to the individual a compound comprising a FOXP3 specific inhibitor, thereby treating, preventing, or ameliorating the cancer. In certain embodiments, the compound comprises an antisense compound targeted to FOXP3. In certain embodiments, the compound comprises an oligonucleotide targeted to FOXP3. In certain embodiments, a compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, a compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, a compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, a compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound. In certain embodiments, the compound is administered to the individual parenterally. In certain embodiments, administering the compound inhibits or reduces immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis. In certain embodiments, administering the compound induces or activates anticancer or antitumor immunity; anticancer or antitumor immune response; immune cell activation or infiltration; inflammatory cell activation or infiltration; effector immune cell activation or infiltration; T cell activation or infiltration; CD8 T cell activation or infiltration; NK cell activation or infiltration; macrophage and dendritic cell activation or infiltration; inflammation; or inflammatory cytokine or chemokine expression.

In certain embodiments, a method of inhibiting expression of FOXP3 in an individual having, or at risk of having, cancer comprises administering to the individual a compound comprising a FOXP3 specific inhibitor, thereby inhibiting expression of FOXP3 in the individual. In certain embodiments, administering the compound inhibits expression of FOXP3 in the Treg cells, tumor microenvironment, tumor stroma, Treg infiltrated tumors, immune cells, lymphoid tissue, lymph nodes, or intra-tumoral Foxp3+ cells. In certain embodiments, the individual has, or is at risk of having a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL). In certain embodiments, the compound comprises an antisense compound targeted to FOXP3. In certain embodiments, the compound comprises an oligonucleotide targeted to FOXP3.

In certain embodiments, the compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide of 16 to 80 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound. In certain embodiments, the compound is administered to the individual parenterally. In certain embodiments, administering the compound inhibits or reduces immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis. In certain embodiments, administering the compound induces or activates anticancer or antitumor immunity; anticancer or antitumor immune response; immune cell activation or infiltration; inflammatory cell activation or infiltration; effector immune cell activation or infiltration; T cell activation or infiltration; CD8 T cell activation or infiltration; NK cell activation or infiltration; macrophage and dendritic cell activation or infiltration; inflammation; or inflammatory cytokine or chemokine expression. In certain embodiments, the individual is identified as having or at risk of having cancer.

In certain embodiments, a method of inhibiting expression of FOXP3 in a cell comprises contacting the cell with a compound comprising a FOXP3 specific inhibitor, thereby inhibiting expression of FOXP3 in the cell. In certain embodiments, the cell is a cancer cell. In certain embodiments, the cell is a Treg cell, tumor microenvironment cell, tumor stroma cell, Treg cell infiltrated in a tumor, immune cell, lymphoid cell, lymph node cell, or intra-tumoral Foxp3+ cell. In certain embodiments, the cell is in the tumor microenvironment, tumor stroma, or lymph node of an individual who has, or is at risk of having cancer. In certain embodiments, the cancer is a cancer that has FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL). In certain embodiments, the compound comprises an antisense compound targeted to FOXP3. In certain embodiments, the compound comprises an oligonucleotide targeted to FOXP3. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide of 16 to 80 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

In certain embodiments, a method of reducing or inhibiting immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis of an individual having, or at risk of having, cancer comprises administering to the individual a compound comprising a FOXP3 specific inhibitor, thereby reducing or inhibiting immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis in the individual. In certain embodiments, a method of inducing or activating anticancer or antitumor immunity; anticancer or antitumor immune response; immune cell activation or infiltration; inflammatory cell activation or infiltration; effector immune cell activation or infiltration; T cell activation or infiltration; CD8 T cell activation or infiltration; NK cell activation or infiltration; macrophage and dendritic cell activation or infiltration; inflammation; or inflammatory cytokine or chemokine expression in an individual having, or at risk of having, cancer comprises administering to the individual a compound comprising a FOXP3 specific inhibitor. In certain embodiments, the individual has, or is at risk of having, a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL). In certain embodiments, the compound comprises an antisense compound targeted to FOXP3. In certain embodiments, the compound comprises an oligonucleotide targeted to FOXP3. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide of 16 to 80 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound. In certain embodiments, the compound is administered to the individual parenterally. In certain embodiments, the individual is identified as having or at risk of having cancer.

Certain embodiments are drawn to a compound comprising a FOXP3 specific inhibitor for use in treating cancer. In certain embodiments, the cancer is a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL). In certain embodiments, the compound comprises an antisense compound targeted to FOXP3. In certain embodiments, the compound comprises an oligonucleotide targeted to FOXP3.

In certain embodiments, the compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide of 16 to 80 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

Certain embodiments are drawn to a compound comprising a FOXP3 specific inhibitor for use in reducing or inhibiting immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis in an individual having cancer. Certain embodiments are drawn to a compound comprising a FOXP3 specific inhibitor for use in inducing or activating anticancer or antitumor immunity; anticancer or antitumor immune response; immune cell activation or infiltration; inflammatory cell activation or infiltration; effector immune cell activation or infiltration; T cell activation or infiltration; CD8 T cell activation or infiltration; NK cell activation or infiltration; macrophage and dendritic cell activation or infiltration; inflammation; or inflammatory cytokine or chemokine expression in an individual having cancer.

In certain embodiments, the cancer is a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL). In certain embodiments, the compound comprises an antisense compound targeted to FOXP3. In certain embodiments, the compound comprises an oligonucleotide targeted to FOXP3.

In certain embodiments, the compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide of 16 to 80 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

Certain embodiments are drawn to use of a compound comprising a FOXP3 specific inhibitor for the manufacture or preparation of a medicament for treating cancer. Certain embodiments are drawn to use of a compound comprising a FOXP3 specific inhibitor for the preparation of a medicament for treating cancer. In certain embodiments, the cancer is a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL). In certain embodiments, the compound comprises an antisense compound targeted to FOXP3. In certain embodiments, the compound comprises an oligonucleotide targeted to FOXP3. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide of 16 to 80 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

Certain embodiments are drawn to use of a compound comprising a FOXP3 specific inhibitor for the manufacture or preparation of a medicament for reducing or inhibiting immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis in an individual having cancer. Certain embodiments are drawn to use of a compound comprising a FOXP3 specific inhibitor for the manufacture or preparation of a medicament for inducing or activating anticancer or antitumor immunity; anticancer or antitumor immune response; immune cell activation or infiltration; inflammatory cell activation or infiltration; effector immune cell activation or infiltration; T cell activation or infiltration; CD8 T cell activation or infiltration; NK cell activation or infiltration; macrophage and dendritic cell activation or infiltration; inflammation; or inflammatory cytokine or chemokine expression in an individual having cancer.

In certain embodiments, the cancer is a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL). In certain embodiments, the compound comprises an antisense compound targeted to FOXP3. In certain embodiments, the compound comprises an oligonucleotide targeted to FOXP3.

In certain embodiments, the compound comprises a modified oligonucleotide 8 to 80 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a modified oligonucleotide of 16 to 80 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

In any of the foregoing methods or uses, the compound can be targeted to FOXP3. In certain embodiments, the compound comprises or consists of a modified oligonucleotide, for example a modified oligonucleotide 8 to 80 linked nucleosides in length, 10 to 30 linked nucleosides in length, 12 to 30 linked nucleosides in length, or 20 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of the nucleobase sequences recited in SEQ ID NOs: 1-5. In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar and/or at least one modified nucleobase. In certain embodiments, the modified internucleoside linkage is a phosphorothioate internucleoside linkage, the modified sugar is a bicyclic sugar or a 2′-O-methoxyethyl, and the modified nucleobase is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide comprises a gap segment consisting of linked deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides, wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

In any of the foregoing embodiments, the modified oligonucleotide can be 12 to 30, 15 to 30, 15 to 25, 15 to 24, 16 to 24, 17 to 24, 18 to 24, 19 to 24, 20 to 24, 19 to 22, 20 to 22, 16 to 20, or 17 or 20 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of the nucleobase sequences recited in SEQ ID NOs: 1-5. In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar and/or at least one modified nucleobase. In certain embodiments, the modified internucleoside linkage is a phosphorothioate internucleoside linkage, the modified sugar is a bicyclic sugar or a 2′-O-methoxyethyl, and the modified nucleobase is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide comprises a gap segment consisting of linked 2′-deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides, wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

In any of the foregoing methods or uses, the compound can comprise or consist of a modified oligonucleotide 16 to 80 linked nucleosides in length and having a nucleobase sequence comprising any one of SEQ ID NOs: 9-3246, wherein the modified oligonucleotide comprises:

-   -   a gap segment consisting of linked 2′-deoxynucleosides;     -   a 5′ wing segment consisting of linked nucleosides; and     -   a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In any of the foregoing methods or uses, the compound can comprise or consist of a modified oligonucleotide 16-80 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575, wherein the modified oligonucleotide comprises:

-   -   a gap segment consisting of linked deoxynucleosides;     -   a 5′ wing segment consisting of linked nucleosides; and     -   a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In any of the foregoing methods or uses, the compound can comprise or consist of a modified oligonucleotide 16-80 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, or 2575, wherein the modified oligonucleotide comprises:

a gap segment consisting often linked deoxynucleosides;

a 5′ wing segment consisting of three linked nucleosides; and

a 3′ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein each nucleoside of each wing segment comprises a cEt nucleoside; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide 16-80 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in SEQ ID NO: 449, wherein the modified oligonucleotide comprises:

a gap segment consisting often linked deoxynucleosides;

a 5′ wing segment consisting of three linked nucleosides; and

a 3′ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein each nucleoside of each wing segment comprises a cEt nucleoside; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In any of the foregoing methods or uses, the compound can comprise or consist of ION 1063734 or salt thereof, having the following chemical structure:

In any of the foregoing methods or uses, the compound can comprise or consist of ION 1063734, having the following chemical structure:

In any of the foregoing methods or uses, the compound can be administered parenterally. For example, in certain embodiments the compound can be administered through injection or infusion. Parenteral administration includes subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial administration, e.g. intrathecal or intracerebroventricular administration.

Certain Combinations and Combination Therapies

In certain embodiments, a first agent comprising a compound described herein is co-administered with one or more secondary agents. In certain embodiments, such second agents are designed to treat the same disease, disorder, or condition as the first agent described herein. In certain embodiments, such second agents are designed to treat a different disease, disorder, or condition as the first agent described herein. In certain embodiments, a first agent is designed to treat an undesired side effect of a second agent. In certain embodiments, second agents are co-administered with the first agent to treat an undesired effect of the first agent. In certain embodiments, such second agents are designed to treat an undesired side effect of one or more pharmaceutical compositions as described herein. In certain embodiments, second agents are co-administered with the first agent to produce a combinational effect. In certain embodiments, second agents are co-administered with the first agent to produce a synergistic effect. In certain embodiments, the co-administration of the first and second agents permits use of lower dosages than would be required to achieve a therapeutic or prophylactic effect if the agents were administered as independent therapy.

In certain embodiments, one or more compounds or compositions provided herein are co-administered with one or more secondary agents. In certain embodiments, one or more compounds or compositions provided herein and one or more secondary agents, are administered at different times. In certain embodiments, one or more compounds or compositions provided herein and one or more secondary agents, are prepared together in a single formulation. In certain embodiments, one or more compounds or compositions provided herein and one or more secondary agents, are prepared separately.

In certain embodiments, a secondary agent is selected from: innate immune cell activators including but not limited to TLR agonists (e.g. MEDI9197) and STING agonists (e.g. MK-1454); inhibitors of immunoinhibitory mediators including but not limited to CD39 and CD73 inhibitors (e.g. oleclumab), IDOl inhibitors (e.g. epacadostat), and arginase inhibitors (e.g. INCB001158); activators of T cell costimulatory receptors including but not limited to CD137 agonists (e.g. urelumab, utomilumab), CD27 agonists (e.g. varlimumab), and CD40 agonists (e.g. MEDI5083); inhibitors of T cell inhibitory receptors including but not limited to LAG3 inhibitors (e.g. relatlimab), TIM3 inhibitors (e.g. LY3321367), and TIGIT inhibitors (e.g. tiragolumab); activators of Treg inhibitory receptors including but not limited to GITR agonists (e.g. MEDI1873); NK cell activation strategies including but not limited to NKG2a (e.g. monalizumab); cancer vaccines (e.g. Sipuleucel-T); and immunogenic killing of the tumor including but not limited to oncolytic viruses, radiation, photodynamic therapy, and chemotherapy (e.g. anthracyclines, oxaliplatin etc).

In certain embodiments, a secondary agent is selected from: immuno-oncology (10) agents; immune checkpoint inhibitors; immunomodulatory agents; PDI-PDL1/2 pathway inhibitors; PD-L1 inhibitors including but not limited to durvalumab, avelumab, and atezolizumab; PD-1 inhibitors including but not limited to nivolumab and pembrolizumab; CTLA-4 inhibitors including but not limited to ipilimumab and tremelimumab; STAT3 inhibitors including but not limited to STAT3 siRNA, STAT3 antisense oligonucleotides, and danvatirsen (AZD9150); and adenosine 2A receptor (A2AR) antagonists including but not limited to AZD4635.

Certain embodiments are directed to the use of a compound targeted to FOXP3 as described herein in combination with a secondary agent. In particular embodiments such use is in a method of treating a patient suffering from cancer including, but not limited to, a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas (e.g. epitheloid, rhabdoid and synovial), chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL). In certain embodiments, a secondary agent is selected from: immuno-oncology (10) agents; immune checkpoint inhibitors; immunomodulatory agents; PDI-PDL1/2 pathway inhibitors; PD-L1 inhibitors including but not limited to durvalumab, avelumab, and atezolizumab; PD-1 inhibitors including but not limited to nivolumab and pembrolizumab; CTLA-4 inhibitors including but not limited to ipilimumab and tremelimumab; STAT3 inhibitors including but not limited to STAT3 siRNA, STAT3 antisense oligonucleotides, and danvatirsen (AZD9150).

Certain embodiments are drawn to a combination of a compound targeted to FOXP3 as described herein and a secondary agent, such as a secondary agent selected from: immuno-oncology (10) agents; immune checkpoint inhibitors; immunomodulatory agents; PDI-PDL1/2 pathway inhibitors; PD-L1 inhibitors including but not limited to durvalumab, avelumab, and atezolizumab; PD-1 inhibitors including but not limited to nivolumab and pembrolizumab; CTLA-4 inhibitors including but not limited to ipilimumab and tremelimumab; STAT3 inhibitors including but not limited to STAT3 siRNA, STAT3 antisense oligonucleotides, and danvatirsen (AZD9150).

In certain embodiments the compound targeted to FOXP3 as described herein and the secondary agent are used in combination treatment by administering the two agents simultaneously, separately or sequentially. In certain embodiments the two agents are formulated as a fixed dose combination product. In other embodiments the two agents are provided to the patient as separate units which can then either be taken simultaneously or serially (sequentially).

In certain embodiments, a compound targeted to FOXP3 as described herein is used in combination with an immunomodulatory agent such as an anti-PD-L 1 antibody (or an antigen-binding fragment thereof), an anti-PD-1 antibody (or an antigen-binding fragment thereof), an anti-CTLA-4 antibody (or an antigen-binding fragment thereof) or an OX40 agonist ((e.g., an OX40 ligand fusion protein, or an OX40 agonist antibody or antigen-binding fragment thereof).

In certain embodiments, a compound targeted to FOXP3 as described herein is used in combination with an immune checkpoint inhibitor such as an anti-PD-L 1 antibody (or an antigen-binding fragment thereof), an anti-PD-1 antibody (or an antigen-binding fragment thereof), or an anti-CTLA-4 antibody (or an antigen-binding fragment thereof).

Anti-PD-L1 antibodies are known in the art. Exemplary anti-PD-L1 antibodies include: MEDI4736 (durvalumab), MPDL3280A, BMS936559, 2.7A4, AMP-714, MDX-1105 and MPDL3280A (atezolizumab).

Anti-PD-1 antibodies are known in the art. Exemplary anti-PD-1 antibodies include: nivolumab, pembrolizumab, pidilizumab, and AMP-514

Anti-CTLA-4 antibodies are known in the art. Exemplary anti-CTLA-4 antibodies include: tremelimumab and ipilimumab, also termed MDX-010 (or BMS-734016).

OX40 agonists and antibodies are known in the art. Exemplary OX40 agonists and/or antibodies include: MEDI6383, 9B12 and MEDI0562.

In one embodiment, the combination includes the antisense oligonucleotide Ionis 651987 or a salt thereof, and at least one immunomodulator selected from the group consisting of: MEDI4736, MPDL3280A, BMS936559, 2.7A4, AMP-714, MDX-1105, nivolumab, pembrolizumab, pidilizumab, MPDL3280A, tremelimumab, ipilimumab, MEDI0562 and MEDI0562.

In one embodiment, the combination includes the anti-PD-L1 antibody MEDI4736 (duvalumab) and ION 1063734.

In one embodiment, the combination includes ION 1063734, the anti-PD-L1 antibody MEDI4736 (durvalumab) and the anti-CTLA-4 antibody tremelimumab.

Certain Anti-PD-L1 Antibodies

Antibodies that specifically bind and inhibit PD-L1 are included in the present disclosure.

Durvalumab (MEDI4736) is an exemplary anti-PD-L1 antibody that is selective for a PD-L1 polypeptide and blocks the binding of PD-L1 to the PD-1 and CD80 receptors. Durvalumab can relieve PD-L 1-mediated suppression of human T-cell activation in vitro and inhibits tumor growth in a xenograft model via a T-cell dependent mechanism.

Information regarding durvalumab (or fragments thereof) for use in the methods provided herein can be found in U.S. Pat. No. 8,779,108, the disclosure of which is incorporated herein by reference in its entirety. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fcγ receptors responsible for mediating antibody-dependent cell-mediated cytotoxicity (ADCC). In certain embodiments, MEDI4736 or an antigen-binding fragment thereof for use in the methods provided herein comprises the variable heavy chain and variable light chain CDR sequences of the 2.14H9OPT antibody as disclosed in U.S. Pat. Nos. 8,779,108 and 9,493,565, which is herein incorporated by reference in its entirety.

There are numerous anti-PD-L1 antibodies in the published literature that could feature in the present disclosure, including compounds in development and/or in clinical trials such as: durvalumab (MEDI4736), MPDL3280A, BMS936559, 2.7A4, AMP-714 and MDX-1105. Patent specifications disclosing anti-PD-L1 antibodies that may be useful in the present disclosure include: U.S. Pat. Nos. 7,943,743; 8,383,796; 9,102,725; 9,273,135 (BMS/Medarex), US2006/0153841 (Dana Farber), US2011/0271358 (Dana Farber), U.S. Pat. Nos. 8,552,154 and 9,102,727 (Dana Farber), U.S. Pat. No. 8,217,149 (Genentech), including issued U.S. Pat. No. 8,217,149, US2012/0039906 (INSERM), US2016/0031990 (Amplimmune), U.S. Pat. No. 8,779,108 (MedImmune—for durvalumab/MEDI4726 and 2.7A4), US2014/0044738 (Amplimmune—for AMP-714) and US2010/0285039 (John's Hopkins University). Each of these disclosures is herein incorporated by reference in its entirety.

Certain Anti-CTLA-4 Antibodies

Antibodies that specifically bind CTLA-4 and inhibit CTLA-4 activity are useful for enhancing an anti-tumor immune response. Information regarding tremelimumab (or antigen-binding fragments thereof) for use in the methods provided herein can be found in U.S. Pat. No. 6,682,736 (where it is referred to as 11.2.1), the disclosure of which is incorporated herein by reference in its entirety. Tremelimumab (also known as CP-675,206, CP-675, CP-675206, and ticilimumab) is a human IgG2 monoclonal antibody that is highly selective for CTLA-4 and blocks binding of CTLA-4 to CD80 (B7.1) and CD86 (B7.2). It has been shown to result in immune activation in vitro and some patients treated with tremelimumab have shown tumor regression. In certain embodiments, tremelimumab or an antigen-binding fragment thereof for use in the methods provided herein comprises the variable heavy chain and variable light chain CDR sequences of the 11.2.1 antibody as disclosed in U.S. Pat. No. 6,682,736, which is herein incorporated by reference in its entirety.

Other anti-CTLA-4 antibodies are described, for example, in US 20070243184. In one embodiment, the anti-CTLA-4 antibody is Ipilimumab, also termed MDX-010; BMS-734016.

Certain OX40 Agonists

OX40 agonists interact with the OX40 receptor on CD4+ T-cells during, or shortly after, priming by an antigen resulting in an increased response of the CD4+ T-cells to the antigen. An OX40 agonist interacting with the OX40 receptor on antigen specific CD4+ T-cells can increase T cell proliferation as compared to the response to antigen alone. The elevated response to the antigen can be maintained for a period of time substantially longer than in the absence of an OX40 agonist. Thus, stimulation via an OX40 agonist enhances the antigen specific immune response by boosting T-cell recognition of antigens, e.g., tumor cells. OX40 agonists are described, for example, in U.S. Pat. Nos. 6,312,700, 7,504,101, 7,622,444, and 7,959,925, which are incorporated herein by reference in their entireties. Methods of using such agonists in cancer treatment are described, for example, in US2015/0098942 and in US2015/0157710, each of which are incorporated herein by reference in its entirety.

OX40 agonists include, but are not limited to OX40 binding molecules, e.g., binding polypeptides, e.g., OX40 ligand (“OX40L”) or an OX40-binding fragment, variant, or derivative thereof, such as soluble extracellular ligand domains and OX40L fusion proteins, and anti-OX40 antibodies (for example, monoclonal antibodies such as humanized monoclonal antibodies), or an antigen-binding fragment, variant or derivative thereof. Examples of anti-OX40 monoclonal antibodies are described, for example, in U.S. Pat. Nos. 5,821,332 and 6,156,878, the disclosures of which are incorporated herein by reference in their entireties. In certain embodiments, the anti-OX40 monoclonal antibody is 9B 12, or an antigen-binding fragment, variant, or derivative thereof, as described in Weinberg, A. D., et al. J Immunother 29, 575-585 (2006), which is incorporated herein by reference in its entirety. In another embodiment, an OX40 antibody is MEDI0562 as described in US 2016/0137740.

In other embodiments, the antibody which specifically binds to OX40, or an antigen-binding fragment thereof binds to the same OX40 epitope as mAb 9B12. An exemplary humanized OX40 antibody is described by Morris et al., Mol Immunol. May 2007; 44(12): 3112-3121. 9B12 is a murine IgG, anti-OX40 mAb directed against the extracellular domain of human OX40 (CD 134) (Weinberg, A. D., et al. J Immunother 29, 575-585 (2006)). It was selected from a panel of anti-OX40 monoclonal antibodies because of its ability to elicit an agonist response for OX40 signaling, stability, and for its high level of production by the hybridoma. For use in clinical applications, 9B12 mAb is equilibrated with phosphate buffered saline, pH 7.0, and its concentration is adjusted to 5.0 mg/ml by diafiltration.

“OX40 ligand” (“OX40L”) (also variously termed tumor necrosis factor ligand superfamily member 4, gp34, TAX transcriptionally-activated glycoprotein-1, and CD252) is found largely on antigen presenting cells (APCs), and can be induced on activated B cells, dendritic cells (DCs), Langerhans cells, plamacytoid DCs, and macrophages (Croft, M., (2010) Ann Rev Immunol 28:57-78). Other cells, including activated T cells, NK cells, mast cells, endothelial cells, and smooth muscle cells can express OX40L in response to inflammatory cytokines (Id.). OX40L specifically binds to the OX40 receptor. The human protein is described in U.S. Pat. No. 6,156,878. The mouse OX40L is described in U.S. Pat. No. 5,457,035. OX40L is expressed on the surface of cells and includes an intracellular, a transmembrane and an extracellular receptor-binding domain. A functionally active soluble form of OX40L can be produced by deleting the intracellular and transmembrane domains as described, e.g., in U.S. Pat. Nos. 5,457,035; 6,312,700; 6,156,878; 6,242,566; 6,528,055; 6,528,623; 7,098,184; and 7,125,670, the disclosures of which are incorporated herein for all purposes. A functionally active form of OX40L is a form that retains the capacity to bind specifically to OX40, that is, that possesses an OX40 “receptor binding domain.” An example is amino acids 51 to 183 of human OX40L. Methods of determining the ability of an OX40L molecule or derivative to bind specifically to OX40 are discussed below. Methods of making and using OX40L and its derivatives (such as derivatives that include an OX40 binding domain) are described in U.S. Pat. Nos. 6,156,878; 6,242,566; 6,528,055; 6,528,623; 7,098,184; and 7,125,670, which also describe proteins comprising the soluble form of OX40L linked to other peptides, such as human immunoglobulin (“Ig”) Fc regions, that can be produced to facilitate purification of OX40 ligand from cultured cells, or to enhance the stability of the molecule after in vivo administration to a mammal (see also, U.S. Pat. Nos. 5,457,035 and 7,959,925, both of which are incorporated by reference herein in their entireties).

Also included within the definition of OX40L are OX40 ligand variants which vary in amino acid sequence from naturally occurring OX40 ligand molecules but which retain the ability to specifically bind to an OX40 receptor. Such variants are described in U.S. Pat. Nos. 5,457,035; 6,156,878; 6,242,566; 6,528,055; 6,528,623; 7,098,184; and 7,125,670. In a related embodiment, a mutant of OX40L which has lost the ability to specifically bind to OX40, for example amino acids 51 to 183, in which the phenylalanine at position 180 of the receptor-binding domain of human OX40L has been replaced with alanine (F180A) is used.

OX40 agonists include a fusion protein in which one or more domains of OX40L is covalently linked to one or more additional protein domains. Exemplary OX40L fusion proteins that can be used as OX40 agonists are described in U.S. Pat. No. 6,312,700, the disclosure of which is incorporated herein by reference in its entirety. In one embodiment, an OX40 agonist includes an OX40L fusion polypeptide that self-assembles into a multimeric (e.g., trimeric or hexameric) OX40L fusion protein. Such fusion proteins are described, e.g., in U.S. Pat. No. 7,959,925, which is incorporated by reference herein in its entirety. The multimeric OX40L fusion protein exhibits increased efficacy in enhancing antigen specific immune response in a subject, particularly a human subject, due to its ability to spontaneously assemble into highly stable trimers and hexamers.

In another embodiment, an OX40 agonist capable of assembling into a multimeric form includes a fusion polypeptide comprising in an N-terminal to C-terminal direction: an immunoglobulin domain, wherein the immunoglobulin domain includes an Fc domain, a trimerization domain, wherein the trimerization domain includes a coiled coil trimerization domain, and a receptor binding domain, wherein the receptor binding domain is an OX40 receptor binding domain, e.g., an OX40L or an OX40-binding fragment, variant, or derivative thereof, where the fusion polypeptide can self-assemble into a trimeric fusion protein. In one aspect, an OX40 agonist capable of assembling into a multimeric form is capable of binding to the OX40 receptor and stimulating at least one OX40 mediated activity. In certain aspects, the OX40 agonist includes an extracellular domain of OX40 ligand.

The trimerization domain of an OX40 agonist capable of assembling into a multimeric form serves to promote self-assembly of individual OX40L fusion polypeptide molecules into a trimeric protein. Thus, an OX40L fusion polypeptide with a trimerization domain self-assembles into a trimeric OX40L fusion protein. In one aspect, the trimerization domain is an isoleucine zipper domain or other coiled coli polypeptide structure. Exemplary coiled coil trimerization domains include: TRAF2 (GENBANK® Accession No. Q12933, amino acids 299-348; Thrombospondin 1 (Accession No. P07996, amino acids 291-314; Matrilin-4 (Accession No. 095460, amino acids 594-618; CMP (matrilin-1) (Accession No. NP-002370, amino acids 463-496; HSF1 (Accession No. AAX42211, amino acids 165-191; and Cubilin (Accession No. NP-001072, amino acids 104-138. In certain specific aspects, the trimerization domain includes a TRAF2 trimerization domain, a Matrilin-4 trimerization domain, or a combination thereof.

OX40L FP is a human OX40 ligand IgG4P fusion protein that specifically binds to, and triggers signaling by, the human OX40 receptor, a member of the TNFR superfamily. OX40L FP is also disclosed in US2016/0024176, incorporated herein by reference in its entirety. OX40L FP is composed of three distinct domains: (1) human OX40 ligand extracellular receptor binding domains (RBDs) that form homotrimers and bind the OX40 receptor; (2) isoleucine zipper trimerization domains derived from TNFR-associated factor 2 that stabilize the homotrimeric structure of the OX40 ligand RBDs; and (3) human IgG4 fragment crystallizable gamma (Fcγ) domains that facilitate Fcγ receptor clustering of the fusion protein when bound to OX40 receptors, and contain a serine to proline substitution at position 228 (according to EU numbering) in the hinge regions (IgG4P) to promote stability of two sets of OX40 ligand RBD homotrimers. The IgG4P Fc domain is fused directly to an isoleucine zipper trimerization domain derived from amino acid residues 310-349 of human tumor necrosis factor 2 (TRAF2). Fused to the c-terminus of the TRAF2 domain are amino acid residues 51-183 of the extracellular receptor binding domain (RBD) of human OX40L (gene name TNFSF4). The TRAF2 domain stabilizes the homotrimeric structure of OX40L RBDs to enable OX40 binding and activation, while the IgG4P Fc domain confers serum stability, dimerization of OX40L trimers, and facilitates Fcγ receptor clustering of the hexameric fusion protein. One OX40L FP variant possesses a phenylalanine (F) to alanine (A) mutation at the amino acid corresponding to position 180 in OX40L. Another OX40L FP variant has the IgG4P Fc domain replaced with a human IgG1 Fc domain. In particular embodiments, the OX40 agonist for use in the present disclosure is one of the OX40L FP variants.

In particular embodiments, the OX40 agonist for use in the present disclosure has been modified to increase its serum half-life. For example, the serum half-life of an OX40 agonist can be increased by conjugation to a heterologous molecule such as serum albumin, an antibody Fc region, or PEG. In certain embodiments, OX40 agonists can be conjugated to other therapeutic agents or toxins to form immunoconjugates and/or fusion proteins. In certain embodiments, the OX40 agonist can be formulated so as to facilitate administration and promote stability of the active agent.

Antibody Derivatives

Antibodies for use in the present disclosure (e.g., anti-CTLA-4, anti-PD-L1, anti-PD-1, anti-OX40) may include variants of these sequences that retain the ability to specifically bind their targets. Such variants may be derived from the sequence of these antibodies by a skilled artisan using techniques well known in the art. For example, amino acid substitutions, deletions, or additions, can be made in the FRs and/or in the CDRs. While changes in the FRs are usually designed to improve stability and immunogenicity of the antibody, changes in the CDRs are typically designed to increase affinity of the antibody for its target. Variants of FRs also include naturally occurring immunoglobulin allotypes. Such affinity-increasing changes may be determined empirically by routine techniques that involve altering the CDR and testing the affinity antibody for its target. For example, conservative amino acid substitutions can be made within any one of the disclosed CDRs. Various alterations can be made according to the methods described in Antibody Engineering, 2nd ed., Oxford University Press, ed. Borrebaeck, 1995. These include but are not limited to nucleotide sequences that are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a “silent” change. For example, the nonpolar amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine, and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Derivatives and analogs of antibodies of the present disclosure can be produced by various techniques well known in the art, including recombinant and synthetic methods (Maniatis (1990) Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., and Bodansky et al. (1995) The Practice of Peptide Synthesis, 2nd ed., Spring Verlag, Berlin, Germany). Analogous shuffling or combinatorial techniques are also disclosed by Stemmer (Nature (1994) 370: 389-391), who describes the technique in relation to a β-lactamase gene but observes that the approach may be used for the generation of antibodies.

One may generate novel VH or VL regions carrying one or more sequences derived from the sequences disclosed herein using random mutagenesis of one or more selected VH and/or VL genes. One such technique, error-prone PCR, is described by Gram et al. (Proc. Nat. Acad. Sci. U.S.A. (1992) 89: 3576-3580). Another method that may be used is to direct mutagenesis to CDRs of VH or VL genes. Such techniques are disclosed by Barbas et al. (Proc. Nat. Acad. Sci. U.S.A. (1994) 91: 3809-3813) and Schier et al. (J. Mol. Biol. (1996) 263: 551-567).

Similarly, one or more, or all three CDRs may be grafted into a repertoire of VH or VL domains, which are then screened for an antigen-binding fragment specific for CTLA-4 or PD-L 1.

A portion of an immunoglobulin variable domain will comprise at least one of the CDRs substantially as set out herein and, optionally, intervening framework regions from the scFv fragments as set out herein. The portion may include at least about 50% of either or both of FR1 and FR4, the 50% being the C-terminal 50% of FR1 and the N-terminal 50% of FR4. Additional residues at the N-terminal or C-terminal end of the substantial part of the variable domain may be those not normally associated with naturally occurring variable domain regions. For example, construction of antibodies by recombinant DNA techniques may result in the introduction of N- or C-terminal residues encoded by linkers introduced to facilitate cloning or other manipulation steps. Other manipulation steps include the introduction of linkers to join variable domains to further protein sequences including immunoglobulin heavy chain constant regions, other variable domains (for example, in the production of diabodies), or proteinaceous labels as discussed in further detail below.

A skilled artisan will recognize that antibodies for use in the present disclosure may comprise antigen-binding fragments containing only a single CDR from either VL or VH domain. Either one of the single chain specific binding domains can be used to screen for complementary domains capable of forming a two-domain specific antigen-binding fragment capable of, for example, binding to CTLA-4 and PD-L 1.

Antibodies for use in the present disclosure described herein can be linked to another functional molecule, e.g., another peptide or protein (albumin, another antibody, etc.). For example, the antibodies can be linked by chemical cross-linking or by recombinant methods. The antibodies may also be linked to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337. The antibodies can be chemically modified by covalent conjugation to a polymer, for example, to increase their circulating half-life. Exemplary polymers and methods to attach them are also shown in U.S. Pat. Nos. 4,766,106; 4,179,337; 4,495,285, and 4,609,546.

The antibodies may also be altered to have a glycosylation pattern that differs from the native pattern. For example, one or more carbohydrate moieties can be deleted and/or one or more glycosylation sites added to the original antibody. Addition of glycosylation sites to the presently disclosed antibodies may be accomplished by altering the amino acid sequence to contain glycosylation site consensus sequences known in the art. Another means of increasing the number of carbohydrate moieties on the antibodies is by chemical or enzymatic coupling of glycosides to the amino acid residues of the antibody. Such methods are described in WO 87/05330, and in Aplin et al. (1981) CRC Crit. Rev. Biochem., 22: 259-306. Removal of any carbohydrate moieties from the antibodies may be accomplished chemically or enzymatically, for example, as described by Hakimuddin et al. (1987) Arch. Biochem. Biophys., 259: 52; and Edge et al. (1981) Anal. Biochem., 118: 131 and by Thotakura et al. (1987) Meth. Enzymol., 138: 350. The antibodies may also be tagged with a detectable, or functional, label. Detectable labels include radiolabels such as 1311 or 99Tc, which may also be attached to antibodies using conventional chemistry. Detectable labels also include enzyme labels such as horseradish peroxidase or alkaline phosphatase. Detectable labels further include chemical moieties such as biotin, which may be detected via binding to a specific cognate detectable moiety, e.g., labeled avidin.

Antibodies, in which CDR sequences differ only insubstantially from those set forth herein are encompassed within the scope of this present disclosure. Typically, an amino acid is substituted by a related amino acid having similar charge, hydrophobic, or stereochemical characteristics. Such substitutions would be within the ordinary skills of an artisan. Unlike in CDRs, more substantial changes can be made in FRs without adversely affecting the binding properties of an antibody. Changes to FRs include, but are not limited to, humanizing a non-human derived or engineering certain framework residues that are important for antigen contact or for stabilizing the binding site, e.g., changing the class or subclass of the constant region, changing specific amino acid residues which might alter the effector function such as Fc receptor binding, e.g., as described in U.S. Pat. Nos. 5,624,821 and 5,648,260 and Lund et al. (1991) J. Immun. 147: 2657-2662 and Morgan et al. (1995) Immunology 86: 319-324, or changing the species from which the constant region is derived.

One of skill in the art will appreciate that the modifications described above are not all-exhaustive, and that many other modifications would be obvious to a skilled artisan in light of the teachings of the present disclosure.

Certain Compounds

In certain embodiments, compounds described herein can be antisense compounds. In certain embodiments, the antisense compound comprises or consists of an oligomeric compound. In certain embodiments, the oligomeric compound comprises a modified oligonucleotide. In certain embodiments, the modified oligonucleotide has a nucleobase sequence complementary to that of a target nucleic acid.

In certain embodiments, a compound described herein comprises or consists of a modified oligonucleotide. In certain embodiments, the modified oligonucleotide has a nucleobase sequence complementary to that of a target nucleic acid.

In certain embodiments, a compound or antisense compound is single-stranded. Such a single-stranded compound or antisense compound comprises or consists of an oligomeric compound. In certain embodiments, such an oligomeric compound comprises or consists of an oligonucleotide and optionally a conjugate group. In certain embodiments, the oligonucleotide is an antisense oligonucleotide. In certain embodiments, the oligonucleotide is modified. In certain embodiments, the oligonucleotide of a single-stranded antisense compound or oligomeric compound comprises a self-complementary nucleobase sequence.

In certain embodiments, compounds are double-stranded. Such double-stranded compounds comprise a first modified oligonucleotide having a region complementary to a target nucleic acid and a second modified oligonucleotide having a region complementary to the first modified oligonucleotide. In certain embodiments, the modified oligonucleotide is an RNA oligonucleotide. In such embodiments, the thymine nucleobase in the modified oligonucleotide is replaced by a uracil nucleobase. In certain embodiments, compound comprises a conjugate group. In certain embodiments, one of the modified oligonucleotides is conjugated. In certain embodiments, both the modified oligonucleotides are conjugated. In certain embodiments, the first modified oligonucleotide is conjugated. In certain embodiments, the second modified oligonucleotide is conjugated. In certain embodiments, the first modified oligonucleotide is 12-30 linked nucleosides in length and the second modified oligonucleotide is 12-30 linked nucleosides in length. In certain embodiments, one of the modified oligonucleotides has a nucleobase sequence comprising at least 8 contiguous nucleobases of any of SEQ ID NOs: 9-3246.

In certain embodiments, antisense compounds are double-stranded. Such double-stranded antisense compounds comprise a first oligomeric compound having a region complementary to a target nucleic acid and a second oligomeric compound having a region complementary to the first oligomeric compound. The first oligomeric compound of such double stranded antisense compounds typically comprises or consists of a modified oligonucleotide and optionally a conjugate group. The oligonucleotide of the second oligomeric compound of such double-stranded antisense compound may be modified or unmodified. Either or both oligomeric compounds of a double-stranded antisense compound may comprise a conjugate group. The oligomeric compounds of double-stranded antisense compounds may include non-complementary overhanging nucleosides.

Examples of single-stranded and double-stranded compounds include but are not limited to oligonucleotides, siRNAs, microRNA targeting oligonucleotides, and single-stranded RNAi compounds, such as small hairpin RNAs (shRNAs), single-stranded siRNAs (ssRNAs), and microRNA mimics.

In certain embodiments, a compound described herein has a nucleobase sequence that, when written in the 5′ to 3′ direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.

In certain embodiments, a compound described herein comprises an oligonucleotide 10 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 12 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 12 to 22 linked subunits in length. In certain embodiments, compound described herein comprises an oligonucleotide 14 to 30 linked subunits in length. In certain embodiments, compound described herein comprises an oligonucleotide 14 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 15 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 15 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 16 to 30 linked subunits in length.

In certain embodiments, a compound described herein comprises an oligonucleotide 16 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 17 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 17 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 to 21 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 20 to 30 linked subunits in length. In other words, such oligonucleotides are 12 to 30 linked subunits, 14 to 30 linked subunits, 14 to 20 subunits, 15 to 30 subunits, 15 to 20 subunits, 16 to 30 subunits, 16 to 20 subunits, 17 to 30 subunits, 17 to 20 subunits, 18 to 30 subunits, 18 to 20 subunits, 18 to 21 subunits, 20 to 30 subunits, or 12 to 22 linked subunits in length, respectively. In certain embodiments, a compound described herein comprises an oligonucleotide 14 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 16 linked subunits in length.

In certain embodiments, a compound described herein comprises an oligonucleotide 17 linked subunits in length. In certain embodiments, compound described herein comprises an oligonucleotide 18 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 19 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 20 linked subunits in length. In other embodiments, a compound described herein comprises an oligonucleotide 8 to 80, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 22, 18 to 24, 18 to 30, 18 to 50, 19 to 22, 19 to 30, 19 to 50, or 20 to 30 linked subunits. In certain such embodiments, the compound described herein comprises an oligonucleotide 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 linked subunits in length, or a range defined by any two of the above values. In some embodiments the linked subunits are nucleotides, nucleosides, or nucleobases.

In certain embodiments, the compound may further comprise additional features or elements, such as a conjugate group, that are attached to the oligonucleotide. In certain embodiments, such compounds are antisense compounds. In certain embodiments, such compounds are oligomeric compounds. In embodiments where a conjugate group comprises a nucleoside (i.e. a nucleoside that links the conjugate group to the oligonucleotide), the nucleoside of the conjugate group is not counted in the length of the oligonucleotide.

In certain embodiments, compounds may be shortened or truncated. For example, a single subunit may be deleted from the 5′ end (5′ truncation), or alternatively from the 3′ end (3′ truncation). A shortened or truncated compound targeted to an FOXP3 nucleic acid may have two subunits deleted from the 5′ end, or alternatively may have two subunits deleted from the 3′ end, of the compound. Alternatively, the deleted nucleosides may be dispersed throughout the compound.

When a single additional subunit is present in a lengthened compound, the additional subunit may be located at the 5′ or 3′ end of the compound. When two or more additional subunits are present, the added subunits may be adjacent to each other, for example, in a compound having two subunits added to the 5′ end (5′ addition), or alternatively to the 3′ end (3′ addition), of the compound. Alternatively, the added subunits may be dispersed throughout the compound.

It is possible to increase or decrease the length of a compound, such as an oligonucleotide, and/or introduce mismatch bases without eliminating activity (Woolf et al. Proc. Natl. Acad. Sci. USA 1992, 89:7305-7309; Gautschi et al. J. Natl. Cancer Inst. March 2001, 93:463-471; Maher and Dolnick Nuc. Acid. Res. 1998, 16:3341-3358). However, seemingly small changes in oligonucleotide sequence, chemistry and motif can make large differences in one or more of the many properties required for clinical development (Seth et al. J. Med. Chem. 2009, 52, 10; Egli et al. J. Am. Chem. Soc. 2011, 133, 16642).

In certain embodiments, compounds described herein are interfering RNA compounds (RNAi), which include double-stranded RNA compounds (also referred to as short-interfering RNA or siRNA) and single-stranded RNAi compounds (or ssRNA). Such compounds work at least in part through the RISC pathway to degrade and/or sequester a target nucleic acid (thus, include microRNA/microRNA-mimic compounds). As used herein, the term siRNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term “RNAi” is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics.

In certain embodiments, a compound described herein can comprise any of the oligonucleotide sequences targeted to FOXP3 described herein. In certain embodiments, the compound can be double-stranded. In certain embodiments, the compound comprises a first strand comprising at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobase portion of any one of SEQ ID NOs: 9-3246 and a second strand. In certain embodiments, the compound comprises a first strand comprising the nucleobase sequence of any one of SEQ ID NOs: 9-3246 and a second strand. In certain embodiments, the compound comprises ribonucleotides in which the first strand has uracil (U) in place of thymine (T) in any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises (i) a first strand comprising a nucleobase sequence complementary to the site on FOXP3 to which any of SEQ ID NOs: 9-3246 is targeted, and (ii) a second strand. In certain embodiments, the compound comprises one or more modified nucleotides in which the 2′ position in the sugar contains a halogen (such as fluorine group; 2′-F) or contains an alkoxy group (such as a methoxy group; 2′-OMe). In certain embodiments, the compound comprises at least one 2′-F sugar modification and at least one 2′-OMe sugar modification. In certain embodiments, the at least one 2′-F sugar modification and at least one 2′-OMe sugar modification are arranged in an alternating pattern for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases along a strand of the dsRNA compound. In certain embodiments, the compound comprises one or more linkages between adjacent nucleotides other than a naturally-occurring phosphodiester linkage. Examples of such linkages include phosphoramide, phosphorothioate, and phosphorodithioate linkages. The compounds may also be chemically modified nucleic acid molecules as taught in U.S. Pat. No. 6,673,661. In other embodiments, the compound contains one or two capped strands, as disclosed, for example, by WO 00/63364, filed Apr. 19, 2000.

In certain embodiments, the first strand of the compound is an siRNA guide strand and the second strand of the compound is an siRNA passenger strand. In certain embodiments, the second strand of the compound is complementary to the first strand. In certain embodiments, each strand of the compound is 16, 17, 18, 19, 20, 21, 22, or 23 linked nucleosides in length. In certain embodiments, the first or second strand of the compound can comprise a conjugate group.

In certain embodiments, a compound described herein can comprise any of the oligonucleotide sequences targeted to FOXP3 described herein. In certain embodiments, the compound is single stranded. In certain embodiments, such a compound is a single-stranded RNAi (ssRNAi) compound. In certain embodiments, the compound comprises at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobase portion of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises the nucleobase sequence of any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises ribonucleotides in which uracil (U) is in place of thymine (T) in any one of SEQ ID NOs: 9-3246. In certain embodiments, the compound comprises a nucleobase sequence complementary to the site on FOXP3 to which any of SEQ ID NOs: 9-3246 is targeted. In certain embodiments, the compound comprises one or more modified nucleotides in which the 2′ position in the sugar contains a halogen (such as fluorine group; 2′-F) or contains an alkoxy group (such as a methoxy group; 2′-OMe). In certain embodiments, the compound comprises at least one 2′-F sugar modification and at least one 2′-OMe sugar modification. In certain embodiments, the at least one 2′-F sugar modification and at least one 2′-OMe sugar modification are arranged in an alternating pattern for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases along a strand of the compound. In certain embodiments, the compound comprises one or more linkages between adjacent nucleotides other than a naturally-occurring phosphodiester linkage. Examples of such linkages include phosphoramide, phosphorothioate, and phosphorodithioate linkages. The compounds may also be chemically modified nucleic acid molecules as taught in U.S. Pat. No. 6,673,661. In other embodiments, the compound contains a capped strand, as disclosed, for example, by WO 00/63364, filed Apr. 19, 2000. In certain embodiments, the compound consists of 16, 17, 18, 19, 20, 21, 22, or 23 linked nucleosides. In certain embodiments, the compound can comprise a conjugate group.

In certain embodiments, compounds described herein comprise modified oligonucleotides. Certain modified oligonucleotides have one or more asymmetric center and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), as a or β such as for sugar anomers, or as (D) or (L) such as for amino acids etc. Included in the modified oligonucleotides provided herein are all such possible isomers, including their racemic and optically pure forms, unless specified otherwise. Likewise, all cis- and trans-isomers and tautomeric forms are also included.

The compounds described herein include variations in which one or more atoms are replaced with a non-radioactive isotope or radioactive isotope of the indicated element. For example, compounds herein that comprise hydrogen atoms encompass all possible deuterium substitutions for each of the ¹H hydrogen atoms. Isotopic substitutions encompassed by the compounds herein include but are not limited to: ²H or ³H in place of ¹H, ¹³C or ¹⁴C in place of ¹²C, ¹⁵N in place of ¹⁴N, ¹⁷O or ¹⁸O in place of ¹⁶O, and ³³S, ³⁴S, ³⁵S, or ³⁶S in place of ³²S. In certain embodiments, non-radioactive isotopic substitutions may impart new properties on the compound that are beneficial for use as a therapeutic or research tool. In certain embodiments, radioactive isotopic substitutions may make the compound suitable for research or diagnostic purposes, such as an imaging assay.

Certain Mechanisms

In certain embodiments, compounds described herein comprise or consist of modified oligonucleotides. In certain embodiments, compounds described herein are antisense compounds. In certain embodiments, compounds comprise oligomeric compounds. In certain embodiments, compounds described herein are capable of hybridizing to a target nucleic acid, resulting in at least one antisense activity. In certain embodiments, compounds described herein selectively affect one or more target nucleic acid. Such compounds comprise a nucleobase sequence that hybridizes to one or more target nucleic acid, resulting in one or more desired antisense activity and does not hybridize to one or more non-target nucleic acid or does not hybridize to one or more non-target nucleic acid in such a way that results in a significant undesired antisense activity. In certain antisense activities, hybridization of a compound described herein to a target nucleic acid results in recruitment of a protein that cleaves the target nucleic acid. For example, certain compounds described herein result in RNase H mediated cleavage of the target nucleic acid. RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. The DNA in such an RNA:DNA duplex need not be unmodified DNA. In certain embodiments, compounds described herein are sufficiently “DNA-like” to elicit RNase H activity. Further, in certain embodiments, one or more non-DNA-like nucleoside in the gap of a gapmer is tolerated.

In certain antisense activities, compounds described herein or a portion of the compound is loaded into an RNA-induced silencing complex (RISC), ultimately resulting in cleavage of the target nucleic acid. For example, certain compounds described herein result in cleavage of the target nucleic acid by Argonaute. Compounds that are loaded into RISC are RNAi compounds. RNAi compounds may be double-stranded (siRNA) or single-stranded (ssRNA).

In certain embodiments, hybridization of compounds described herein to a target nucleic acid does not result in recruitment of a protein that cleaves that target nucleic acid. In certain such embodiments, hybridization of the compound to the target nucleic acid results in alteration of splicing of the target nucleic acid. In certain embodiments, hybridization of the compound to a target nucleic acid results in inhibition of a binding interaction between the target nucleic acid and a protein or other nucleic acid. In certain such embodiments, hybridization of the compound to a target nucleic acid results in alteration of translation of the target nucleic acid.

Antisense activities may be observed directly or indirectly. In certain embodiments, observation or detection of an antisense activity involves observation or detection of a change in an amount of a target nucleic acid or protein encoded by such target nucleic acid, a change in the ratio of splice variants of a nucleic acid or protein, and/or a phenotypic change in a cell or animal.

Target Nucleic Acids, Target Regions and Nucleotide Sequences

In certain embodiments, compounds described herein comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid encodes a protein. In certain such embodiments, the target nucleic acid is selected from: an mRNA and a pre-mRNA, including intronic, exonic and untranslated regions. In certain embodiments, the target RNA is an mRNA. In certain embodiments, the target nucleic acid is a pre-mRNA. In certain such embodiments, the target region is entirely within an intron. In certain embodiments, the target region spans an intron/exon junction. In certain embodiments, the target region is at least 50% within an intron.

Nucleotide sequences that encode FOXP3 include, without limitation, the following: RefSEQ No. NM_014009.3 (SEQ ID NO: 1); NT_011568.12_TRUNC_11907130_11921808_COMP (SEQ ID NO: 2); NM_001114377.1 (SEQ ID NO: 3); NC_000023.11_TRUNC_49247001_49273000_COMP (SEQ ID NO: 4); or UCSC Accession No. UC064ZFP.1 corresponding to genomic co-ordinates chrX:49,251,334-49,259,240 on assembly GRCh38/hg38 (SEQ ID NO: 5); each of which is incorporated by reference in its entirety.

Hybridization

In some embodiments, hybridization occurs between a compound disclosed herein and a FOXP3 nucleic acid. The most common mechanism of hybridization involves hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary nucleobases of the nucleic acid molecules.

Hybridization can occur under varying conditions. Hybridization conditions are sequence-dependent and are determined by the nature and composition of the nucleic acid molecules to be hybridized.

Methods of determining whether a sequence is specifically hybridizable to a target nucleic acid are well known in the art. In certain embodiments, the compounds provided herein are specifically hybridizable with a FOXP3 nucleic acid.

Complementarity

An oligonucleotide is said to be complementary to another nucleic acid when the nucleobase sequence of such oligonucleotide or one or more regions thereof matches the nucleobase sequence of another oligonucleotide or nucleic acid or one or more regions thereof when the two nucleobase sequences are aligned in opposing directions. Nucleobase matches or complementary nucleobases, as described herein, are limited to the following pairs: adenine (A) and thymine (T), adenine (A) and uracil (U), cytosine (C) and guanine (G), and 5-methyl cytosine (mC) and guanine (G) unless otherwise specified. Complementary oligonucleotides and/or nucleic acids need not have nucleobase complementarity at each nucleoside and may include one or more nucleobase mismatches. An oligonucleotide is fully complementary or 100% complementary when such oligonucleotides have nucleobase matches at each nucleoside without any nucleobase mismatches.

In certain embodiments, compounds described herein comprise or consist of modified oligonucleotides. In certain embodiments, compounds described herein are antisense compounds. In certain embodiments, compounds comprise oligomeric compounds. Non-complementary nucleobases between a compound and a FOXP3 nucleic acid may be tolerated provided that the compound remains able to specifically hybridize to a target nucleic acid. Moreover, a compound may hybridize over one or more segments of a FOXP3 nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure).

In certain embodiments, the compounds provided herein, or a specified portion thereof, are, are at least, or are up to 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to a FOXP3 nucleic acid, a target region, target segment, or specified portion thereof. In certain embodiments, the compounds provided herein, or a specified portion thereof, are 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, 95% to 100%, or any number in between these ranges, complementary to a FOXP3 nucleic acid, a target region, target segment, or specified portion thereof. Percent complementarity of a compound with a target nucleic acid can be determined using routine methods.

For example, a compound in which 18 of 20 nucleobases of the compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining non-complementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, a compound which is 18 nucleobases in length having four non-complementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid. Percent complementarity of a compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403 410; Zhang and Madden, Genome Res., 1997, 7, 649 656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482 489).

In certain embodiments, compounds described herein, or specified portions thereof, are fully complementary (i.e. 100% complementary) to a target nucleic acid, or specified portion thereof. For example, a compound may be fully complementary to a FOXP3 nucleic acid, or a target region, or a target segment or target sequence thereof. As used herein, “fully complementary” means each nucleobase of a compound is complementary to the corresponding nucleobase of a target nucleic acid. For example, a 20 nucleobase compound is fully complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20 nucleobase portion of the target nucleic acid that is fully complementary to the compound. Fully complementary can also be used in reference to a specified portion of the first and/or the second nucleic acid. For example, a 20 nucleobase portion of a 30 nucleobase compound can be “fully complementary” to a target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30 nucleobase compound is fully complementary to the target sequence if the target sequence has a corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase portion of the compound. At the same time, the entire 30 nucleobase compound may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the compound are also complementary to the target sequence.

In certain embodiments, compounds described herein comprise one or more mismatched nucleobases relative to the target nucleic acid. In certain such embodiments, antisense activity against the target is reduced by such mismatch, but activity against a non-target is reduced by a greater amount. Thus, in certain such embodiments selectivity of the compound is improved. In certain embodiments, the mismatch is specifically positioned within an oligonucleotide having a gapmer motif. In certain such embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, or 8 from the 5′-end of the gap region. In certain such embodiments, the mismatch is at position 9, 8, 7, 6, 5, 4, 3, 2, 1 from the 3′-end of the gap region. In certain such embodiments, the mismatch is at position 1, 2, 3, or 4 from the 5′-end of the wing region. In certain such embodiments, the mismatch is at position 4, 3, 2, or 1 from the 3′-end of the wing region. In certain embodiments, the mismatch is specifically positioned within an oligonucleotide not having a gapmer motif. In certain such embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 from the 5′-end of the oligonucleotide. In certain such embodiments, the mismatch is at position, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 from the 3′-end of the oligonucleotide.

The location of a non-complementary nucleobase may be at the 5′ end or 3′ end of the compound. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal position of the compound. When two or more non-complementary nucleobases are present, they may be contiguous (i.e. linked) or non-contiguous. In one embodiment, a non-complementary nucleobase is located in the wing segment of a gapmer oligonucleotide.

In certain embodiments, compounds described herein that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleobases in length comprise no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a FOXP3 nucleic acid, or specified portion thereof.

In certain embodiments, compounds described herein that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a FOXP3 nucleic acid, or specified portion thereof.

In certain embodiments, compounds described herein also include those which are complementary to a portion of a target nucleic acid. As used herein, “portion” refers to a defined number of contiguous (i.e. linked) nucleobases within a region or segment of a target nucleic acid. A “portion” can also refer to a defined number of contiguous nucleobases of a compound. In certain embodiments, the—compounds, are complementary to at least an 8 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 9 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 10 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least an 11 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 12 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 13 nucleobase portion of a target segment.

In certain embodiments, the compounds are complementary to at least a 14 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 15 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 16 nucleobase portion of a target segment. Also contemplated are compounds that are complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleobase portion of a target segment, or a range defined by any two of these values.

Identity

The compounds provided herein may also have a defined percent identity to a particular nucleotide sequence, SEQ ID NO, or compound represented by a specific ION number, or portion thereof. In certain embodiments, compounds described herein are antisense compounds or oligomeric compounds. In certain embodiments, compounds described herein are modified oligonucleotides. As used herein, a compound is identical to the sequence disclosed herein if it has the same nucleobase pairing ability. For example, a RNA which contains uracil in place of thymidine in a disclosed DNA sequence would be considered identical to the DNA sequence since both uracil and thymidine pair with adenine. Shortened and lengthened versions of the compounds described herein as well as compounds having non-identical bases relative to the compounds provided herein also are contemplated. The non-identical bases may be adjacent to each other or dispersed throughout the compound. Percent identity of an compound is calculated according to the number of bases that have identical base pairing relative to the sequence to which it is being compared.

In certain embodiments, compounds described herein, or portions thereof, are, or are at least, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more of the compounds or SEQ ID NOs, or a portion thereof, disclosed herein. In certain embodiments, compounds described herein are about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, or any percentage between such values, to a particular nucleotide sequence, SEQ ID NO, or compound represented by a specific ION number, or portion thereof, in which the compounds comprise an oligonucleotide having one or more mismatched nucleobases. In certain such embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 from the 5′-end of the oligonucleotide. In certain such embodiments, the mismatch is at position, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 from the 3′-end of the oligonucleotide.

In certain embodiments, compounds described herein comprise or consist of antisense compounds. In certain embodiments, a portion of the antisense compound is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid.

In certain embodiments, compounds described herein comprise or consist of oligonucleotides. In certain embodiments, a portion of the oligonucleotide is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid.

Certain Modified Compounds

In certain embodiments, compounds described herein comprise or consist of oligonucleotides consisting of linked nucleosides. Oligonucleotides may be unmodified oligonucleotides (RNA or DNA) or may be modified oligonucleotides. Modified oligonucleotides comprise at least one modification relative to unmodified RNA or DNA (i.e., comprise at least one modified nucleoside (comprising a modified sugar moiety and/or a modified nucleobase) and/or at least one modified internucleoside linkage).

A. Modified Nucleosides

Modified nucleosides comprise a modified sugar moiety or a modified nucleobase or both a modifed sugar moiety and a modified nucleobase.

1. Modified Sugar Moieties

In certain embodiments, sugar moieties are non-bicyclic modified sugar moieties. In certain embodiments, modified sugar moieties are bicyclic or tricyclic sugar moieties. In certain embodiments, modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of other types of modified sugar moieties.

In certain embodiments, modified sugar moieties are non-bicyclic modified sugar moieties comprising a furanosyl ring with one or more acyclic substituent, including but not limited to substituents at the 2′, 4′, and/or 5′ positions. In certain embodiments one or more acyclic substituent of non-bicyclic modified sugar moieties is branched. Examples of 2′-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 2′-F, 2′-OCH₃ (“OMe” or “O-methyl”), and 2′-O(CH₂)₂OCH₃ (“MOE”). In certain embodiments, 2′-substituent groups are selected from among: halo, allyl, amino, azido, SH, CN, OCN, CF₃, OCF₃, O—C₁-C₁₀ alkoxy, O—C₁-C₁₀ substituted alkoxy, O—C₁-C₁₀ alkyl, O—C₁-C₁₀ substituted alkyl, S-alkyl, N(R_(m))-alkyl, O-alkenyl, S-alkenyl, N(R_(m))-alkenyl, O-alkynyl, S-alkynyl, N(R_(m))-alkynyl, O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH₂)₂SCH₃, O(CH₂)₂ON(R_(m))(R) or OCH₂C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is, independently, H, an amino protecting group, or substituted or unsubstituted C₁-C₁₀ alkyl, and the 2′-substituent groups described in Cook et al., U.S. Pat. No. 6,531,584; Cook et al., U.S. Pat. No. 5,859,221; and Cook et al., U.S. Pat. No. 6,005,087. Certain embodiments of these 2′-substituent groups can be further substituted with one or more substituent groups independently selected from among: hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl and alkynyl. Examples of 4′-substituent groups suitable for linearly non-bicyclic modified sugar moieties include but are not limited to alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015/106128. Examples of 5′-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 5′-methyl (R or S), 5′-vinyl, and 5′-methoxy. In certain embodiments, non-bicyclic modified sugars comprise more than one non-bridging sugar substituent, for example, 2′-F-5′-methyl sugar moieties and the modified sugar moieties and modified nucleosides described in Migawa et al., US2010/190837 and Rajeev et al., US2013/0203836.

In certain embodiments, a 2′-substituted nucleoside or 2′-non-bicyclic modified nucleoside comprises a sugar moiety comprising a linear 2′-substituent group selected from: F, NH₂, N₃, OCF₃, OCH₃, O(CH₂)₃NH₂, CH₂CH═CH₂, OCH₂CH═CH₂, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O(CH₂)₂ON(R_(m))(R_(n)), O(CH₂)₂O(CH₂)₂N(CH₃)₂, and N-substituted acetamide (OCH₂C(═O)—N(R_(m))(R_(n))), where each R_(m) and R_(n) is, independently, H, an amino protecting group, or substituted or unsubstituted C₁-C₁₀ alkyl.

In certain embodiments, a 2′-substituted nucleoside or 2′-non-bicyclic modified nucleoside comprises a sugar moiety comprising a linear 2′-substituent group selected from: F, OCF₃, OCH₃, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O(CH₂)₂ON(CH₃)₂, O(CH₂)₂O(CH₂)₂N(CH₃)₂, and OCH₂C(═O)—N(H)CH₃ (“NMA”).

In certain embodiments, a 2′-substituted nucleoside or 2′-non-bicyclic modified nucleoside comprises a sugar moiety comprising a linear 2′-substituent group selected from: F, OCH₃, and OCH₂CH₂OCH₃.

Nucleosides comprising modified sugar moieties, such as non-bicyclic modified sugar moieties, are referred to by the position(s) of the substitution(s) on the sugar moiety of the nucleoside. For example, nucleosides comprising 2′-substituted or 2-modified sugar moieties are referred to as 2′-substituted nucleosides or 2-modified nucleosides.

Certain modified sugar moieties comprise a bridging sugar substituent that forms a second ring resulting in a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety comprises a bridge between the 4′ and the 2′ furanose ring atoms. Examples of such 4′ to 2′ bridging sugar substituents include but are not limited to: 4′-CH₂-2′, 4′-(CH₂)₂-2′, 4′-(CH₂)₃-2′, 4′-CH₂—O-2′ (“LNA”), 4′-CH₂—S-2′, 4′-(CH₂)₂—O-2′ (“ENA”), 4′-CH(CH₃)—O-2′ (referred to as “constrained ethyl” or “cEt” when in the S configuration), 4′-CH₂—O—CH₂-2′, 4′-CH₂—N(R)-2′, 4′-CH(CH₂OCH₃)—O-2′ (“constrained MOE” or “cMOE”) and analogs thereof (see. e.g., Seth et al., U.S. Pat. No. 7,399,845, Bhat et al., U.S. Pat. No. 7,569,686, Swayze et al., U.S. Pat. No. 7,741,457, and Swayze et al., U.S. Pat. No. 8,022,193), 4′-C(CH₃)(CH₃)—O-2′ and analogs thereof (see. e.g., Seth et al., U.S. Pat. No. 8,278,283), 4′-CH₂—N(OCH₃)-2′ and analogs thereof (see. e.g., Prakash et al., U.S. Pat. No. 8,278,425), 4′-CH₂—O—N(CH₃)-2′ (see. e.g., Allerson et al., U.S. Pat. No. 7,696,345 and Allerson et al., U.S. Pat. No. 8,124,745), 4′-CH₂—C(H)(CH₃)-2′ (see, e.g., Zhou, et al., J. Org. Chem., 2009, 74, 118-134), 4′-CH₂—C(═CH₂)-2′ and analogs thereof (see e.g., Seth et al., U.S. Pat. No. 8,278,426), 4′-C(R_(a)R_(b))—N(R)—O-2′, 4′-C(R_(a)R_(b))—O—N(R)-2′, 4′-CH₂—O—N(R)-2′, and 4′-CH₂—N(R)—O-2′, wherein each R, R_(a), and R_(b) is, independently, H, a protecting group, or C₁-C₁₂ alkyl (see, e.g. Imanishi et al., U.S. Pat. No. 7,427,672).

In certain embodiments, such 4′ to 2′ bridges independently comprise from 1 to 4 linked groups independently selected from: —[C(R_(a))(R_(b))]—, —[C(R_(a))(R_(b))]—O—, —C(R_(a))═C(R_(b))—, —C(R_(a))═N—, —C(═NR_(a))—, —C(═O)—, —C(═S)—, —O—, —Si(R_(a))₂—, —S(═O)_(x)—, and —N(R_(b))—;

wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_(a) and R_(b) is, independently, H, a protecting group, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇ alicyclic radical, halogen, OJ, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(═O)—H), substituted acyl, CN, sulfonyl (S(═O)₂-J₁), or sulfoxyl (S(═O)-J₁); and each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl (C(═O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl, or a protecting group.

Additional bicyclic sugar moieties are known in the art, see, for example: Freier et al., Nucleic Acids Research, 1997, 25(22), 4429-4443, Albaek et al., J. Org. Chem., 2006, 71, 7731-7740, Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S.A, 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc., 2007, 129. 8362-8379; Elayadi et al., Curr. Opinion Invens. Drugs. 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; Wengel et al., U.S. Pat. No. 7,053,207, Imanishi et al., U.S. Pat. No. 6,268,490, Imanishi et al. U.S. Pat. No. 6,770,748, Imanishi et al., U.S. RE44,779; Wengel et al., U.S. Pat. No. 6,794,499, Wengel et al., U.S. Pat. No. 6,670,461; Wengel et al., U.S. Pat. No. 7,034,133, Wengel et al., U.S. Pat. No. 8,080,644; Wengel et al., U.S. Pat. No. 8,034,909; Wengel et al., U.S. Pat. No. 8,153,365; Wengel et al., U.S. Pat. No. 7,572,582; and Ramasamy et al., U.S. Pat. No. 6,525,191, Torsten et al., WO 2004/106356, Wengel et al., WO 1999/014226; Seth et al., WO 2007/134181; Seth et al., U.S. Pat. No. 7,547,684; Seth et al., U.S. Pat. No. 7,666,854; Seth et al., U.S. Pat. No. 8,088,746; Seth et al., U.S. Pat. No. 7,750,131; Seth et al., U.S. Pat. No. 8,030,467; Seth et al., U.S. Pat. No. 8,268,980; Seth et al., U.S. Pat. No. 8,546,556; Seth et al., U.S. Pat. No. 8,530,640; Migawa et al., U.S. Pat. No. 9,012,421; Seth et al., U.S. Pat. No. 8,501,805; Allerson et al., US2008/0039618; and Migawa et al., US2015/0191727.

In certain embodiments, bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by isomeric configuration. For example, an LNA nucleoside (described herein) may be in the α-L configuration or in the β-D configuration.

α-L-methyleneoxy (4′-CH₂—O-2′) or α-L-LNA bicyclic nucleosides have been incorporated into oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research. 2003, 21, 6365-6372). Herein, general descriptions of bicyclic nucleosides include both isomeric configurations. When the positions of specific bicyclic nucleosides (e.g., LNA or cEt) are identified in exemplified embodiments herein, they are in the β-D configuration, unless otherwise specified.

In certain embodiments, modified sugar moieties comprise one or more non-bridging sugar substituent and one or more bridging sugar substituent (e.g., 5′-substituted and 4′-2′ bridged sugars).

In certain embodiments, modified sugar moieties are sugar surrogates. In certain such embodiments, the oxygen atom of the sugar moiety is replaced, e.g., with a sulfur, carbon or nitrogen atom. In certain such embodiments, such modified sugar moieties also comprise bridging and/or non-bridging substituents as described herein. For example, certain sugar surrogates comprise a 4′-sulfur atom and a substitution at the 2′-position (see, e.g., Bhat et al., U.S. Pat. No. 7,875,733 and Bhat et al., U.S. Pat. No. 7,939,677) and/or the 5′ position.

In certain embodiments, sugar surrogates comprise rings having other than 5 atoms. For example, in certain embodiments, a sugar surrogate comprises a six-membered tetrahydropyran (“THP”). Such tetrahydropyrans may be further modified or substituted. Nucleosides comprising such modified tetrahydropyrans include but are not limited to hexitol nucleic acid (“HNA”), anitol nucleic acid (“ANA”), manitol nucleic acid (“MNA”) (see e.g., Leumann, C J. Bioorg. & Med. Chem. 2002, 10, 841-854), fluoro HNA:

(“F-HNA”, see e.g., Swayze et al., U.S. Pat. No. 8,088,904; Swayze et al., U.S. Pat. No. 8,440,803; and Swayze et al., U.S. Pat. No. 9,005,906, F-HNA can also be referred to as a F-THP or 3′-fluoro tetrahydropyran), and nucleosides comprising additional modified THP compounds having the formula:

wherein, independently, for each of said modified THP nucleoside:

Bx is a nucleobase moiety;

T₃ and T₄ are each, independently, an internucleoside linking group linking the modified THP nucleoside to the remainder of an oligonucleotide or one of T₃ and T₄ is an internucleoside linking group linking the modified THP nucleoside to the remainder of an oligonucleotide and the other of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugate group, or a 5′ or 3′-terminal group; q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each, independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl; and each of R, and R₂ is independently selected from among: hydrogen, halogen, substituted or unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(═X)J₁, OC(═X)NJ₁J₂, NJ₃C(═X)NJ₁J₂, and CN, wherein X is O, S or NJ₁, and each J₁, J₂, and J₃ is, independently, H or C₁-C₆ alkyl.

In certain embodiments, modified THP nucleosides are provided wherein q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is other than H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is methyl. In certain embodiments, modified THP nucleosides are provided wherein one of R₁ and R₂ is F. In certain embodiments, R, is F and R₂ is H, in certain embodiments, R, is methoxy and R₂ is H, and in certain embodiments, R, is methoxyethoxy and R₂ is H.

In certain embodiments, sugar surrogates comprise rings having more than 5 atoms and more than one heteroatom. For example, nucleosides comprising morpholino sugar moieties and their use in oligonucleotides have been reported (see, e.g., Braasch et al., Biochemistry, 2002, 41, 4503-4510 and Summerton et al., U.S. Pat. No. 5,698,685; Summerton et al., U.S. Pat. No. 5,166,315; Summerton et al., U.S. Pat. No. 5,185,444; and Summerton et al., U.S. Pat. No. 5,034,506). As used here, the term “morpholino” means a sugar surrogate having the following structure:

In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are referred to herein as “modified morpholinos.”

In certain embodiments, sugar surrogates comprise acyclic moieties. Examples of nucleosides and oligonucleotides comprising such acyclic sugar surrogates include but are not limited to: peptide nucleic acid (“PNA”), acyclic butyl nucleic acid (see, e.g., Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., US2013/130378.

Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can be used in modified nucleosides.

2. Modified Nucleobases

Nucleobase (or base) modifications or substitutions are structurally distinguishable from, yet functionally interchangeable with, naturally occurring or synthetic unmodified nucleobases. Both natural and modified nucleobases are capable of participating in hydrogen bonding. Such nucleobase modifications can impart nuclease stability, binding affinity or some other beneficial biological property to antisense compounds.

In certain embodiments, compounds described herein comprise modified oligonucleotides. In certain embodiments, modified oligonucleotides comprise one or more nucleoside comprising an unmodified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more nucleoside comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more nucleoside that does not comprise a nucleobase, referred to as an abasic nucleoside.

In certain embodiments, modified nucleobases are selected from: 5-substituted pyrimidines, 6-azapyrimi-dines, alkyl or alkynyl substituted pyrimidines, alkyl substituted purines, and N-2, N-6 and 0-6 substituted purines. In certain embodiments, modified nucleobases are selected from: 2-aminopropyladenine, 5-hydroxymethyl cytosine, 5-methylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyladenine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl (C═C—CH3) uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, 8-aza and other 8-substituted purines, 5-halo, particularly 5-bromo, 5-trifluoromethyl, 5-halouracil, and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, 6-N-benzoyladenine, 2-N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl 4-N-benzoylcytosine, 5-methyl 4-N-benzoyluracil, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazine-2-one, 1,3-diazaphenothiazine-2-one and 9-(2-aminoethoxy)-1,3-diazaphenoxazine-2-one (G-clamp). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in Merigan et al., U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, Crooke, S. T. and Lebleu, B., Eds., CRC Press, 1993, 273-288; and those disclosed in Chapters 6 and 15, Antisense Drug Technology, Crooke S. T., Ed., CRC Press, 2008, 163-166 and 442-443.

Publications that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, Manoharan et al., US2003/0158403, Manoharan et al., US2003/0175906; Dinh et al., U.S. Pat. No. 4,845,205; Spielvogel et al., U.S. Pat. No. 5,130,302; Rogers et al., U.S. Pat. No. 5,134,066; Bischofberger et al., U.S. Pat. No. 5,175,273; Urdea et al., U.S. Pat. No. 5,367,066; Benner et al., U.S. Pat. No. 5,432,272; Matteucci et al., U.S. Pat. No. 5,434,257; Gmeiner et al., U.S. Pat. No. 5,457,187; Cook et al., U.S. Pat. No. 5,459,255; Froehler et al., U.S. Pat. No. 5,484,908; Matteucci et al., U.S. Pat. No. 5,502,177; Hawkins et al., U.S. Pat. No. 5,525,711; Haralambidis et al., U.S. Pat. No. 5,552,540; Cook et al., U.S. Pat. No. 5,587,469; Froehler et al., U.S. Pat. No. 5,594,121; Switzer et al., U.S. Pat. No. 5,596,091; Cook et al., U.S. Pat. No. 5,614,617; Froehler et al., U.S. Pat. No. 5,645,985; Cook et al., U.S. Pat. No. 5,681,941; Cook et al., U.S. Pat. No. 5,811,534; Cook et al., U.S. Pat. No. 5,750,692; Cook et al., U.S. Pat. No. 5,948,903; Cook et al., U.S. Pat. No. 5,587,470; Cook et al., U.S. Pat. No. 5,457,191; Matteucci et al., U.S. Pat. No. 5,763,588; Froehler et al., U.S. Pat. No. 5,830,653; Cook et al., U.S. Pat. No. 5,808,027; Cook et al., U.S. Pat. No. 6,166,199; and Matteucci et al., U.S. Pat. No. 6,005,096.

In certain embodiments, compounds targeted to a FOXP3 nucleic acid comprise one or more modified nucleobases. In certain embodiments, the modified nucleobase is 5-methylcytosine. In certain embodiments, each cytosine is a 5-methylcytosine.

3. Modified Internucleoside Linkages

The naturally occurring internucleoside linkage of RNA and DNA is a 3′ to 5′ phosphodiester linkage In certain embodiments, compounds described herein having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over compounds having naturally occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

Representative internucleoside linkages having a chiral center include but are not limited to alkylphosphonates and phosphorothioates. Modified oligonucleotides comprising internucleoside linkages having a chiral center can be prepared as populations of modified oligonucleotides comprising stereorandom internucleoside linkages, or as populations of modified oligonucleotides comprising phosphorothioate linkages in particular stereochemical configurations. In certain embodiments, populations of modified oligonucleotides comprise phosphorothioate internucleoside linkages wherein all of the phosphorothioate internucleoside linkages are stereorandom. Such modified oligonucleotides can be generated using synthetic methods that result in random selection of the stereochemical configuration of each phosphorothioate linkage. Nonetheless, as is well understood by those of skill in the art, each individual phosphorothioate of each individual oligonucleotide molecule has a defined stereoconfiguration. In certain embodiments, populations of modified oligonucleotides are enriched for modified oligonucleotides comprising one or more particular phosphorothioate internucleoside linkages in a particular, independently selected stereochemical configuration.

In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 65% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 70% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 80% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 90% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 99% of the molecules in the population. Such chirally enriched populations of modified oligonucleotides can be generated using synthetic methods known in the art, e.g., methods described in Oka et al., JACS 125, 8307 (2003), Wan et al. Nuc. Acid. Res. 42, 13456 (2014), and WO 2017/015555. In certain embodiments, a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one indicated phosphorothioate in the (Sp) configuration. In certain embodiments, a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one phosphorothioate in the (Rp) configuration. In certain embodiments, modified oligonucleotides comprising (Rp) and/or (Sp) phosphorothioates comprise one or more of the following formulas, respectively, wherein “B” indicates a nucleobase:

Unless otherwise indicated, chiral internucleoside linkages of modified oligonucleotides described herein can be stereorandom or in a particular stereochemical configuration.

In certain embodiments, compounds targeted to an FOXP3 nucleic acid comprise one or more modified internucleoside linkages. In certain embodiments, the modified internucleoside linkages are phosphorothioate linkages. In certain embodiments, each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage.

In certain embodiments, compounds described herein comprise oligonucleotides. Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom as well as internucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well known.

In certain embodiments, nucleosides of modified oligonucleotides may be linked together using any internucleoside linkage. The two main classes of internucleoside linking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus-containing internucleoside linkages include but are not limited to phosphates, which contain a phosphodiester bond (“P═O”) (also referred to as unmodified or naturally occurring linkages), phosphotriesters, methylphosphonates, phosphoramidates, and phosphorothioates (“P═S”), and phosphorodithioates (“HS-P═S”). Representative non-phosphorus containing internucleoside linking groups include but are not limited to methylenemethylimino (—CH2-N(CH3)-O-CH2-), thiodiester, thionocarbamate (—O—C(═O)(NH)—S—); siloxane (—O—SiH2-O—); and N,N′-dimethylhydrazine (—CH2-N(CH3)-N(CH3)-). Modified internucleoside linkages, compared to naturally occurring phosphate linkages, can be used to alter, typically increase, nuclease resistance of the oligonucleotide. In certain embodiments, internucleoside linkages having a chiral atom can be prepared as a racemic mixture, or as separate enantiomers. Representative chiral internucleoside linkages include but are not limited to alkylphosphonates and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing internucleoside linkages are well known to those skilled in the art.

Neutral internucleoside linkages include, without limitation, phosphotriesters, methylphosphonates, MMI (3′-CH2-N(CH3)-O-5′), amide-3 (3′-CH2-C(═O)—N(H)-5′), amide-4 (3′-CH2-N(H)—C(═O)-5′), formacetal (3′-O-CH2-O-5′), methoxypropyl, and thioformacetal (3′-S-CH2-O-5′). Further neutral internucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See for example: Carbohydrate Modifications in Antisense Research; Y. S. Sanghvi and P. D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral internucleoside linkages include nonionic linkages comprising mixed N, O, S and CH2 component parts.

In certain embodiments, oligonucleotides comprise modified internucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or modified internucleoside linkage motif. In certain embodiments, internucleoside linkages are arranged in a gapped motif. In such embodiments, the internucleoside linkages in each of two wing regions are different from the internucleoside linkages in the gap region. In certain embodiments the internucleoside linkages in the wings are phosphodiester and the internucleoside linkages in the gap are phosphorothioate. The nucleoside motif is independently selected, so such oligonucleotides having a gapped internucleoside linkage motif may or may not have a gapped nucleoside motif and if it does have a gapped nucleoside motif, the wing and gap lengths may or may not be the same.

In certain embodiments, oligonucleotides comprise a region having an alternating internucleoside linkage motif. In certain embodiments, oligonucleotides comprise a region of uniformly modified internucleoside linkages. In certain such embodiments, the oligonucleotide comprises a region that is uniformly linked by phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide is uniformly linked by phosphorothioate. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate and at least one internucleoside linkage is phosphorothioate.

In certain embodiments, the oligonucleotide comprises at least 6 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 8 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 10 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 6 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 8 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 10 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least block of at least one 12 consecutive phosphorothioate internucleoside linkages. In certain such embodiments, at least one such block is located at the 3′ end of the oligonucleotide. In certain such embodiments, at least one such block is located within 3 nucleosides of the 3′ end of the oligonucleotide.

In certain embodiments, oligonucleotides comprise one or more methylphosponate linkages. In certain embodiments, oligonucleotides having a gapmer nucleoside motif comprise a linkage motif comprising all phosphorothioate linkages except for one or two methylphosponate linkages. In certain embodiments, one methylphosponate linkage is in the central gap of an oligonucleotide having a gapmer nucleoside motif.

In certain embodiments, it is desirable to arrange the number of phosphorothioate internucleoside linkages and phosphodiester internucleoside linkages to maintain nuclease resistance. In certain embodiments, it is desirable to arrange the number and position of phosphorothioate internucleoside linkages and the number and position of phosphodiester internucleoside linkages to maintain nuclease resistance. In certain embodiments, the number of phosphorothioate internucleoside linkages may be decreased and the number of phosphodiester internucleoside linkages may be increased. In certain embodiments, the number of phosphorothioate internucleoside linkages may be decreased and the number of phosphodiester internucleoside linkages may be increased while still maintaining nuclease resistance. In certain embodiments it is desirable to decrease the number of phosphorothioate internucleoside linkages while retaining nuclease resistance. In certain embodiments it is desirable to increase the number of phosphodiester internucleoside linkages while retaining nuclease resistance.

Certain Motifs

In certain embodiments, compounds described herein comprise oligonucleotides. Oligonucleotides can have a motif, e.g. a pattern of unmodified and/or modified sugar moieties, nucleobases, and/or internucleoside linkages. In certain embodiments, modified oligonucleotides comprise one or more modified nucleoside comprising a modified sugar. In certain embodiments, modified oligonucleotides comprise one or more modified nucleosides comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more modified internucleoside linkage. In such embodiments, the modified, unmodified, and differently modified sugar moieties, nucleobases, and/or internucleoside linkages of a modified oligonucleotide define a pattern or motif. In certain embodiments, the patterns of sugar moieties, nucleobases, and internucleoside linkages are each independent of one another. Thus, a modified oligonucleotide may be described by its sugar motif, nucleobase motif and/or internucleoside linkage motif (as used herein, nucleobase motif describes the modifications to the nucleobases independent of the sequence of nucleobases).

a. Certain Sugar Motifs

In certain embodiments, compounds described herein comprise oligonucleotides. In certain embodiments, oligonucleotides comprise one or more type of modified sugar and/or unmodified sugar moiety arranged along the oligonucleotide or region thereof in a defined pattern or sugar motif. In certain instances, such sugar motifs include but are not limited to any of the sugar modifications discussed herein.

In certain embodiments, modified oligonucleotides comprise or consist of a region having a gapmer motif, which comprises two external regions or “wings” and a central or internal region or “gap.” The three regions of a gapmer motif (the 5′-wing, the gap, and the 3′-wing) form a contiguous sequence of nucleosides wherein at least some of the sugar moieties of the nucleosides of each of the wings differ from at least some of the sugar moieties of the nucleosides of the gap. Specifically, at least the sugar moieties of the nucleosides of each wing that are closest to the gap (the 3′-most nucleoside of the 5′-wing and the 5′-most nucleoside of the 3′-wing) differ from the sugar moiety of the neighboring gap nucleosides, thus defining the boundary between the wings and the gap (i.e., the wing/gap junction). In certain embodiments, the sugar moieties within the gap are the same as one another. In certain embodiments, the gap includes one or more nucleoside having a sugar moiety that differs from the sugar moiety of one or more other nucleosides of the gap. In certain embodiments, the sugar motifs of the two wings are the same as one another (symmetric gapmer). In certain embodiments, the sugar motif of the 5′-wing differs from the sugar motif of the 3′-wing (asymmetric gapmer).

In certain embodiments, the wings of a gapmer comprise 1-5 nucleosides. In certain embodiments, the wings of a gapmer comprise 2-5 nucleosides. In certain embodiments, the wings of a gapmer comprise 3-5 nucleosides. In certain embodiments, the nucleosides of a gapmer are all modified nucleosides.

In certain embodiments, the gap of a gapmer comprises 7-12 nucleosides. In certain embodiments, the gap of a gapmer comprises 7-10 nucleosides. In certain embodiments, the gap of a gapmer comprises 8-10 nucleosides. In certain embodiments, the gap of a gapmer comprises 10 nucleosides. In certain embodiment, each nucleoside of the gap of a gapmer is an unmodified 2′-deoxy nucleoside.

In certain embodiments, the gapmer is a deoxy gapmer. In such embodiments, the nucleosides on the gap side of each wing/gap junction are unmodified 2′-deoxy nucleosides and the nucleosides on the wing sides of each wing/gap junction are modified nucleosides. In certain such embodiments, each nucleoside of the gap is an unmodified 2′-deoxy nucleoside. In certain such embodiments, each nucleoside of each wing is a modified nucleoside.

In certain embodiments, a modified oligonucleotide has a fully modified sugar motif wherein each nucleoside of the modified oligonucleotide comprises a modified sugar moiety. In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif wherein each nucleoside of the region comprises a modified sugar moiety. In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif, wherein each nucleoside within the fully modified region comprises the same modified sugar moiety, referred to herein as a uniformly modified sugar motif. In certain embodiments, a fully modified oligonucleotide is a uniformly modified oligonucleotide. In certain embodiments, each nucleoside of a uniformly modified comprises the same 2′-modification.

In certain embodiments, a modified oligonucleotide can comprise a sugar motif described in Swayze et al., US2010/0197762; Freier et al., US2014/0107330; Freier et al., US2015/0184153; and Seth et al., US2015/0267195, each of which is incorporated by reference in its entirety herein.

Certain embodiments provided herein are directed to modified oligomeric compounds useful for inhibiting target nucleic acid expression, which can be useful for treating, preventing, ameliorating, or slowing progression of a disease associated with such a target nucleic acid. In certain embodiments, the modified oligomeric compounds comprise antisense oligonucleotides that are gapmers having certain sugar motifs. In certain embodiments, the gapmer sugar motifs provided herein can be combined with any nucleobase sequence and any internucleoside linkage motif to form potent antisense oligonucleotides.

In certain embodiments, a method comprises contacting a cell or administering to a subject a compound comprising a modified oligonucleotide 16 linked nucleosides in length having the motif: ekk-d9-kkee, wherein ‘d’ represents a 2′-deoxyribose sugar, ‘k’ represents a cEt nucleoside, and ‘e’ represents a 2′-MOE nucleoside. In certain embodiments, the cell is a cancer cell. In certain embodiments, the subject has cancer. In certain embodiments, administering the compound to the subject treats the subject's cancer.

In certain embodiments, a method comprises contacting a cell or administering to a subject a compound comprising a modified oligonucleotide 16 linked nucleosides in length having the motif: k-d9-kekeke, wherein ‘d’ represents a 2′-deoxyribose sugar, ‘k’ represents a cEt nucleoside, and ‘e’ represents a 2′-MOE nucleoside.

In certain embodiments, the cell is a cancer cell. In certain embodiments, the subject has cancer. In certain embodiments, administering the compound to the subject treats the subject's cancer.

In certain embodiments, a method comprises contacting a cell or administering to a subject a compound comprising a modified oligonucleotide 16 linked nucleosides in length having the motif: kkk-d8-kekek, wherein ‘d’ represents a 2′-deoxyribose sugar, ‘k’ represents a cEt nucleoside, and ‘e’ represents a 2′-MOE nucleoside. In certain embodiments, the cell is a cancer cell. In certain embodiments, the subject has cancer.

In certain embodiments, administering the compound to the subject treats the subject's cancer.

In certain embodiments, a method comprises contacting a cell or administering to a subject a compound comprising a modified oligonucleotide 16 linked nucleosides in length having the motif: kkk-d9-keke, wherein ‘d’ represents a 2′-deoxyribose sugar, ‘k’ represents a cEt nucleoside, and ‘e’ represents a 2′-MOE nucleoside.

In certain embodiments, the cell is a cancer cell. In certain embodiments, the subject has cancer. In certain embodiments, administering the compound to the subject treats the subject's cancer.

In certain embodiments, a method comprises contacting a cell or administering to a subject a compound comprising a modified oligonucleotide 16 linked nucleosides in length having the motif: kk-d9-kdkdk, wherein ‘d’ represents a 2′-deoxyribose sugar, ‘k’ represents a cEt nucleoside, and ‘e’ represents a 2′-MOE nucleoside.

In certain embodiments, the cell is a cancer cell. In certain embodiments, the subject has cancer. In certain embodiments, administering the compound to the subject treats the subject's cancer.

In certain embodiments, a compound comprises a modified oligonucleotide 16 linked nucleosides in length having the motif: kk-d9-eeekk, wherein ‘d’ represents a 2′-deoxyribose sugar, ‘k’ represents a cEt nucleoside, and ‘e’ represents a 2′-MOE nucleoside. In certain embodiments, a method comprises contacting a cell or administering to a subject a compound comprising a modified oligonucleotide 16 linked nucleosides in length having the motif: kk-d9-eeekk, wherein ‘d’ represents a 2′-deoxyribose sugar, ‘k’ represents a cEt nucleoside, and ‘e’ represents a 2′-MOE nucleoside. In certain embodiments, the cell is a cancer cell. In certain embodiments, the subject has cancer. In certain embodiments, administering the compound to the subject treats the subject's cancer.

In certain embodiments, a method comprises contacting a cell or administering to a subject a compound comprising a modified oligonucleotide 16 linked nucleosides in length having the motif: kk-d9-ekeke, wherein ‘d’ represents a 2′-deoxyribose sugar, ‘k’ represents a cEt nucleoside, and ‘e’ represents a 2′-MOE nucleoside.

In certain embodiments, the cell is a cancer cell. In certain embodiments, the subject has cancer. In certain embodiments, administering the compound to the subject treats the subject's cancer.

b. Certain Nucleobase Motifs

In certain embodiments, compounds described herein comprise oligonucleotides. In certain embodiments, oligonucleotides comprise modified and/or unmodified nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases are modified. In certain embodiments, each purine or each pyrimidine is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each uracil is modified. In certain embodiments, each cytosine is modified. In certain embodiments, some or all of the cytosine nucleobases in a modified oligonucleotide are 5-methylcytosines.

In certain embodiments, modified oligonucleotides comprise a block of modified nucleobases. In certain such embodiments, the block is at the 3′-end of the oligonucleotide. In certain embodiments the block is within 3 nucleosides of the 3′-end of the oligonucleotide. In certain embodiments, the block is at the 5′-end of the oligonucleotide. In certain embodiments the block is within 3 nucleosides of the 5′-end of the oligonucleotide.

In certain embodiments, oligonucleotides having a gapmer motif comprise a nucleoside comprising a modified nucleobase. In certain such embodiments, one nucleoside comprising a modified nucleobase is in the central gap of an oligonucleotide having a gapmer motif. In certain such embodiments, the sugar moiety of said nucleoside is a 2′-deoxyribosyl moiety. In certain embodiments, the modified nucleobase is selected from: a 2-thiopyrimidine and a 5-propynepyrimidine.

c. Certain Internucleoside Linkage Motifs

In certain embodiments, compounds described herein comprise oligonucleotides. In certain embodiments, oligonucleotides comprise modified and/or unmodified internucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, essentially each internucleoside linking group is a phosphate internucleoside linkage (P═O). In certain embodiments, each internucleoside linking group of a modified oligonucleotide is a phosphorothioate (P═S). In certain embodiments, each internucleoside linking group of a modified oligonucleotide is independently selected from a phosphorothioate and phosphate internucleoside linkage. In certain embodiments, the sugar motif of a modified oligonucleotide is a gapmer and the internucleoside linkages within the gap are all modified. In certain such embodiments, some or all of the internucleoside linkages in the wings are unmodified phosphate linkages.

In certain embodiments, the terminal internucleoside linkages are modified.

4. Certain Modified Oligonucleotides

In certain embodiments, compounds described herein comprise modified oligonucleotides. In certain embodiments, the above modifications (sugar, nucleobase, internucleoside linkage) are incorporated into a modified oligonucleotide. In certain embodiments, modified oligonucleotides are characterized by their modification, motifs, and overall lengths. In certain embodiments, such parameters are each independent of one another. Thus, unless otherwise indicated, each internucleoside linkage of an oligonucleotide having a gapmer sugar motif may be modified or unmodified and may or may not follow the gapmer modification pattern of the sugar modifications. For example, the internucleoside linkages within the wing regions of a sugar gapmer may be the same or different from one another and may be the same or different from the internucleoside linkages of the gap region of the sugar motif. Likewise, such gapmer oligonucleotides may comprise one or more modified nucleobase independent of the gapmer pattern of the sugar modifications. Furthermore, in certain instances, an oligonucleotide is described by an overall length or range and by lengths or length ranges of two or more regions (e.g., a regions of nucleosides having specified sugar modifications), in such circumstances it may be possible to select numbers for each range that result in an oligonucleotide having an overall length falling outside the specified range. In such circumstances, both elements must be satisfied. For example, in certain embodiments, a modified oligonucleotide consists of 15-20 linked nucleosides and has a sugar motif consisting of three regions, A, B, and C, wherein region A consists of 2-6 linked nucleosides having a specified sugar motif, region B consists of 6-10 linked nucleosides having a specified sugar motif, and region C consists of 2-6 linked nucleosides having a specified sugar motif. Such embodiments do not include modified oligonucleotides where A and C each consist of 6 linked nucleosides and B consists of 10 linked nucleosides (even though those numbers of nucleosides are permitted within the requirements for A, B, and C) because the overall length of such oligonucleotide is 22, which exceeds the upper limit of the overall length of the modified oligonucleotide (20). Herein, if a description of an oligonucleotide is silent with respect to one or more parameter, such parameter is not limited. Thus, a modified oligonucleotide described only as having a gapmer sugar motif without further description may have any length, internucleoside linkage motif, and nucleobase motif. Unless otherwise indicated, all modifications are independent of nucleobase sequence.

Certain Conjugated Compounds

In certain embodiments, the compounds described herein comprise or consist of an oligonucleotide (modified or unmodified) and optionally one or more conjugate groups and/or terminal groups. Conjugate groups consist of one or more conjugate moiety and a conjugate linker which links the conjugate moiety to the oligonucleotide. Conjugate groups may be attached to either or both ends of an oligonucleotide and/or at any internal position. In certain embodiments, conjugate groups are attached to the 2′-position of a nucleoside of a modified oligonucleotide. In certain embodiments, conjugate groups that are attached to either or both ends of an oligonucleotide are terminal groups. In certain such embodiments, conjugate groups or terminal groups are attached at the 3′ and/or 5′-end of oligonucleotides. In certain such embodiments, conjugate groups (or terminal groups) are attached at the 3′-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 3′-end of oligonucleotides. In certain embodiments, conjugate groups (or terminal groups) are attached at the 5′-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 5′-end of oligonucleotides.

In certain embodiments, the oligonucleotide is modified. In certain embodiments, the oligonucleotide of a compound has a nucleobase sequence that is complementary to a target nucleic acid. In certain embodiments, oligonucleotides are complementary to a messenger RNA (mRNA). In certain embodiments, oligonucleotides are complementary to a sense transcript.

Examples of terminal groups include but are not limited to conjugate groups, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified.

A. Certain Conjugate Groups

In certain embodiments, oligonucleotides are covalently attached to one or more conjugate groups. In certain embodiments, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge and clearance In certain embodiments, conjugate groups impart a new property on the attached oligonucleotide, e.g., fluorophores or reporter groups that enable detection of the oligonucleotide.

Certain conjugate groups and conjugate moieties have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic, a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264. 229-237), an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, i, 923-937), a tocopherol group (Nishina et al., Molecular Therapy Nucleic Acids, 2015, 4, e220; doi: 10.1038/mtna.2014.72 and Nishina et al., Molecular Therapy. 2008, 16, 734-740), or a GalNAc cluster (e.g., WO2014/179620).

1. Conjugate Moieties

Conjugate moieties include, without limitation, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates (e.g., GalNAc), vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, and dyes.

In certain embodiments, a conjugate moiety comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

2 Conjugate Linkers

Conjugate moieties are attached to oligonucleotides through conjugate linkers. In certain compounds, a conjugate group is a single chemical bond (i.e. conjugate moiety is attached to an oligonucleotide via a conjugate linker through a single bond). In certain embodiments, the conjugate linker comprises a chain structure, such as a hydrocarbyl chain, or an oligomer of repeating units such as ethylene glycol, nucleosides, or amino acid units.

In certain embodiments, a conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker includes at least one neutral linking group.

In certain embodiments, conjugate linkers, including the conjugate linkers described above, are bifunctional linking moieties, e.g., those known in the art to be useful for attaching conjugate groups to parent compounds, such as the oligonucleotides provided herein. In general, a bifunctional linking moiety comprises at least two functional groups. One of the functional groups is selected to bind to a particular site on a compound and the other is selected to bind to a conjugate group. Examples of functional groups used in a bifunctional linking moiety include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In certain embodiments, bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.

Examples of conjugate linkers include but are not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other conjugate linkers include but are not limited to substituted or unsubstituted C₁-C₁₀ alkyl, substituted or unsubstituted C₂-C₁₀ alkenyl or substituted or unsubstituted C₂-C₁₀ alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

In certain embodiments, conjugate linkers comprise 1-10 linker-nucleosides. In certain embodiments, such linker-nucleosides are modified nucleosides. In certain embodiments such linker-nucleosides comprise a modified sugar moiety. In certain embodiments, linker-nucleosides are unmodified. In certain embodiments, linker-nucleosides comprise an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain embodiments, a cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine and 2-N-isobutyrylguanine. It is typically desirable for linker-nucleosides to be cleaved from the compound after it reaches a target tissue. Accordingly, linker-nucleosides are typically linked to one another and to the remainder of the compound through cleavable bonds.

In certain embodiments, such cleavable bonds are phosphodiester bonds.

Herein, linker-nucleosides are not considered to be part of the oligonucleotide. Accordingly, in embodiments in which a compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and/or a specified percent complementarity to a reference nucleic acid and the compound also comprises a conjugate group comprising a conjugate linker comprising linker-nucleosides, those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid. For example, a compound may comprise (1) a modified oligonucleotide consisting of 8-30 nucleosides and (2) a conjugate group comprising 1-10 linker-nucleosides that are contiguous with the nucleosides of the modified oligonucleotide. The total number of contiguous linked nucleosides in such a compound is more than 30. Alternatively, an compound may comprise a modified oligonucleotide consisting of 8-30 nucleosides and no conjugate group. The total number of contiguous linked nucleosides in such a compound is no more than 30. Unless otherwise indicated conjugate linkers comprise no more than 10 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 5 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 3 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 2 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 1 linker-nucleoside.

In certain embodiments, it is desirable for a conjugate group to be cleaved from the oligonucleotide. For example, in certain circumstances compounds comprising a particular conjugate moiety are better taken up by a particular cell type, but once the compound has been taken up, it is desirable that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Thus, certain conjugate may comprise one or more cleavable moieties, typically within the conjugate linker. In certain embodiments, a cleavable moiety is a cleavable bond. In certain embodiments, a cleavable moiety is a group of atoms comprising at least one cleavable bond. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds. In certain embodiments, a cleavable moiety is selectively cleaved inside a cell or subcellular compartment, such as a lysosome. In certain embodiments, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases.

In certain embodiments, a cleavable bond is selected from among: an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide. In certain embodiments, a cleavable bond is one or both of the esters of a phosphodiester. In certain embodiments, a cleavable moiety comprises a phosphate or phosphodiester. In certain embodiments, the cleavable moiety is a phosphate linkage between an oligonucleotide and a conjugate moiety or conjugate group.

In certain embodiments, a cleavable moiety comprises or consists of one or more linker-nucleosides. In certain such embodiments, one or more linker-nucleosides are linked to one another and/or to the remainder of the compound through cleavable bonds. In certain embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain embodiments, a cleavable moiety is 2′-deoxy nucleoside that is attached to either the 3′ or 5′-terminal nucleoside of an oligonucleotide by a phosphate internucleoside linkage and covalently attached to the remainder of the conjugate linker or conjugate moiety by a phosphate or phosphorothioate linkage. In certain such embodiments, the cleavable moiety is 2′-deoxyadenosine.

Compositions and Methods for Formulating Pharmaceutical Compositions

Compounds described herein may be admixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

Certain embodiments provide pharmaceutical compositions comprising one or more compounds or a salt thereof. In certain embodiments, the compounds are antisense compounds or oligomeric compounds. In certain embodiments, the compounds comprise or consist of a modified oligonucleotide. In certain such embodiments, the pharmaceutical composition comprises a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutical composition comprises a sterile saline solution and one or more compound. In certain embodiments, such pharmaceutical composition consists of a sterile saline solution and one or more compound. In certain embodiments, the sterile saline is pharmaceutical grade saline. In certain embodiments, a pharmaceutical composition comprises one or more compound and sterile water. In certain embodiments, a pharmaceutical composition consists of one compound and sterile water. In certain embodiments, the sterile water is pharmaceutical grade water. In certain embodiments, a pharmaceutical composition comprises one or more compound and phosphate-buffered saline (PBS). In certain embodiments, a pharmaceutical composition consists of one or more compound and sterile PBS. In certain embodiments, the sterile PBS is pharmaceutical grade PBS. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

A compound described herein targeted to FOXP3 nucleic acid can be utilized in pharmaceutical compositions by combining the compound with a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutically acceptable diluent is water, such as sterile water suitable for injection. Accordingly, in one embodiment, employed in the methods described herein is a pharmaceutical composition comprising a compound targeted to FOXP3 nucleic acid and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is water. In certain embodiments, the compound comprises or consists of a modified oligonucleotide provided herein.

Pharmaceutical compositions comprising compounds provided herein encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. In certain embodiments, the compounds are antisense compounds or oligomeric compounds. In certain embodiments, the compound comprises or consists of a modified oligonucleotide. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

A prodrug can include the incorporation of additional nucleosides at one or both ends of a compound which are cleaved by endogenous nucleases within the body, to form the active compound.

In certain embodiments, the compounds or compositions further comprise a pharmaceutically acceptable carrier or diluent.

EXAMPLES

The Examples below describe the screening process to identify lead compounds targeted to FOXP3. Out of over 3,000 oligonucleotides that were screened, ION 1062428, 1062641, 1062835, 1062937, 1063268, 1063649, 1063655, 1063734, 1064096, or 1064313 emerged as the top lead compounds.

Non-Limiting Disclosure and Incorporation by Reference

Although the sequence listing accompanying this filing identifies each sequence as either “RNA” or “DNA” as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as “RNA” or “DNA” to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2′-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2′-OH for the natural 2′-H of DNA) or as an RNA having a modified base (thymine (methylated uracil) for natural uracil of RNA).

Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and/or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further example and without limitation, an oligonucleotide having the nucleobase sequence “ATCGATCG” encompasses any oligonucleotides having such nucleobase sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG” and those having some DNA bases and some RNA bases such as “AUCGATCG” and compounds having other modified nucleobases, such as “AT^(m)CGAUCG,” wherein ^(m)C indicates a cytosine base comprising a methyl group at the 5-position.

While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references recited in the present application is incorporated herein by reference in its entirety.

Example 1: Antisense Inhibition of Human Foxp3 in LNCaP Cells by cEt Gapmers

Modified oligonucleotides were designed to target a Foxp3 nucleic acid and were tested for their effect on Foxp3 mRNA level in vitro. The modified oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below. Cultured LNCaP cells at a density of 30,000 cells per well were transfected using electroporation with 3,000 nM of modified oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and Foxp3 mRNA levels were measured by quantitative real-time RTPCR. Human primer probe set RTS35925 (forward sequence CTACTTCAAGTTCCACAACATGC, designated herein as SEQ ID NO.: 6; reverse sequence CCAGTGGTAGATCTCATTGAGTG; designated herein as SEQ ID NO.: 7; probe sequence CCTITCACCTACGCCACGCTCAT, designated herein as SEQ ID NO.: 8) was used to measure mRNA levels. Foxp3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to untreated control cells (% UTC). The modified oligonucleotides with percent control values marked with an asterisk (*) target the amplicon region of the primer probe set. Additional assays may be used to measure the potency and efficacy of the modified oligonucleotides targeting the amplicon region.

The newly designed modified oligonucleotides in the Tables below were designed as 3-10-3 cEt gapmers. The gapmers are 16 nucleosides in length, wherein the central gap segment comprises of ten 2′-deoxynucleosides and is flanked by wing segments on the 5′ direction and the 3′ direction comprising three nucleosides each. Each nucleoside in the 5′ wing segment and each nucleoside in the 3′ wing segment has a cEt sugar modification. The internucleoside linkages throughout each gapmer are phosphorothioate (P═S) linkages. All cytosine residues throughout each gapmer are 5-methylcytosines.

“Start site” indicates the 5′-most nucleoside to which the gapmer is targeted in the human gene sequence. “Stop site” indicates the 3′-most nucleoside to which the gapmer is targeted human gene sequence. Each gapmer listed in the Tables below is targeted to either SEQ ID NO.: 1 (GENBANK Accession No. NM_014009.3), or SEQ ID NO.: 2 (the complement of GENBANK Accession No. NT_011568.12 truncated from nucleotides 11907130 to Ser. No. 11/921,808), or SEQ ID No.: 3 (GENBANK Accession No. NM_001114377.1), or SEQ ID No.: 4 (the complement of GENBANK Accession No. NC_000023.11 truncated from nucleotides 49247001 to 49273000), or SEQ ID No. 5 (UCSC Accession No. UC064ZFP.1 corresponding to genomic co-ordinates chrX:49,251,334-49,259,240 on assembly GRCh38/hg38). ‘N/A’ indicates that the modified oligonucleotide does not target that particular gene sequence with 100% complementarity. ‘N.D.’ indicates that the % UTC is not defined for that particular modified oligonucleotide in that particular experiment. Activity of that modified oligonucleotide may be defined in a different experiment.

TABLE 1 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1 and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO 895287 1168 1183 12038 12053 TTGAAGTAGTCCATGT  58*  9 910921 7 22 407 422 ATTTTTTTCGATGAGT 49 10 910925 77 92 477 492 TTTTATACCGAGAAGA 45 11 910929 376 391 6914 6929 TGCGATGGTGGCATGG 44 12 910933 564 579 7727 7742 GGCTGATCATGGCTGG 35 13 910937 765 780 8411 8426 CACCATTTGCCAGCAG 50 14 910941 1000 1015 N/A N/A TCGGATGATGCCACAG 42 15 910945 1144 1159 N/A N/A AACTCTGGGAATGTGC 72 16 910949 1416 1431 13826 13841 TGCGGAACTCCAGCTC 127  17 910953 1591 1606 14001 14016 GTGGAAACCTCACTTC 62 18 910957 1802 1817 14212 14227 GAAGTAATCTGTGCGA 37 19 910961 2114 2129 14524 14539 GAATTCTAACAGGCCG 36 20 910965 2216 2231 14626 14641 GGTATTTTTGGCAAGG 23 21 910969 2336 2351 N/A N/A CGGTACTGTGGGTTGG 19 22 910973 1851 1866 14261 14276 AGGGACAGGATTGTGA 54 23 910977 726 741 N/A N/A CCGAAAGGGTGCTGTC 81 24 910981 164 179 N/A N/A GTCCAAGGGCAGGCTT 44 25 910985 618 633 7781 7796 GGCCAGGCCGGGCCTT 88 26 910989 63 78 463 478 GAAAAACCACGCTGTA 65 27 910993 772 787 8418 8433 TTGCAGACACCATTTG 88 28 911000 1267 1282 13497 13512 TGGTAGATCTCATTGA  69* 29 911004 2108 2123 14518 14533 TAACAGGCCGTGTGTG 72 30 911008 1859 1874 14269 14284 GTTGAGTGAGGGACAG 54 31 911012 2272 2287 N/A N/A AGGCATGGATCAGGGC 32 32 911016 57 72 457 472 CCACGCTGTACGGTGT 39 33 911020 1257 1272 13487 13502 CATTGAGTGTCCGCTG  65* 34 911024 382 397 6920 6935 TGCAGCTGCGATGGTG 59 35 911028 1741 1756 14151 14166 GGCTGCAGGGCTCGAC 25 36 911032 55 70 455 470 ACGCTGTACGGTGTGG 17 37 911036 898 913 9488 9503 AGAGACTGTACCATCT 121  38 911040 2112 2127 14522 14537 ATTCTAACAGGCCGTG 55 39 911044 2110 2125 14520 14535 TCTAACAGGCCGTGTG 56 40 911048 770 785 8416 8431 GCAGACACCATTTGCC 95 41 911052 163 178 N/A N/A TCCAAGGGCAGGCTTG 76 42 911056 2282 2297 N/A N/A GTCTAAGCTGAGGCAT 51 43 911060 133 148 533 548 CAGAAAAGGATCAGCC 63 44 911064 900 915 9490 9505 CCAGAGACTGTACCAT 90 45 911068 N/A N/A 8373 8388 GCCGAAAGGGTGCTGG 73 46 911072 N/A N/A 13638 13653 TGCCTATGAGCCCAGA 106  47 911076 N/A N/A 13697 13712 CGTCAACCTCTGAGGC 111  48 911080 N/A N/A 658 673 GTACATCCCACTGTAC 90 49 911084 N/A N/A 1386 1401 GACAATGGTGTGAAGT 36 50 911088 N/A N/A 1569 1584 CTAATTTGGTTACAGA 39 51 911092 N/A N/A 2137 2152 GTTAATAACCATTCCA 50 52 911096 N/A N/A 2390 2405 CTCTATAGTAAATGGA 78 53 911100 N/A N/A 2663 2678 TAAAATGCCCAGATCC 54 54 911104 N/A N/A 3219 3234 TGACAATTGCCCCTCT 115  55 911108 N/A N/A 3358 3373 TGCATTTCGGTGAGGC 44 56 911112 N/A N/A 4082 4097 AGATTTAAAGGATCCT 60 57 911116 N/A N/A 4291 4306 TGACATGGGTGCTGGT 45 58 911120 N/A N/A 5167 5182 GGTATTAAGTTCTTAG 21 59 911124 N/A N/A 5704 5719 GCTCATGCTACACCCC 37 60 911128 N/A N/A 5966 5981 TGGATTGGGTGCAAAA 60 61 911132 N/A N/A 6111 6126 GACTTAATCTGAAGCT 50 62 911136 N/A N/A 6376 6391 CACTTGAGAGCTGTTT 70 63 911140 N/A N/A 6642 6657 TGAGATACTCGACCAC 95 64 911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 24 65 911148 N/A N/A 7644 7659 GCACATGTGGGCTGTG 69 66 911152 N/A N/A 7964 7979 ATCTTTAAGGTTCTGC 23 67 911156 N/A N/A 8561 8576 CTACTTATTGGGATGA 50 68 911160 N/A N/A 8686 8701 CTTATTATACATACGA 77 69 911164 N/A N/A 8824 8839 GATTCTAGAGCCTGGC 39 70 911168 N/A N/A 9505 9520 GCATTACCTGCTGCTC 85 71 911172 N/A N/A 9603 9618 CTTTATACCAGCCCTC 68 72 911176 N/A N/A 9878 9893 CCTGAATGTGAGGTTA 51 73 911180 N/A N/A 10317 10332 TGCTTTAACAACTCAG 16 74 911184 N/A N/A 10546 10561 TACATTCGCATCATGA 33 75 911188 N/A N/A 10690 10705 GTATTTATTAGAGCAC 59 76 911192 N/A N/A 11343 11358 AGGATTAGGAGCTTGG 33 77 911196 N/A N/A 11615 11630 GAATTACTTAGCAGGG 47 78 911200 N/A N/A 11825 11840 CCAAAATAGTTCTCCC 49 79 911204 N/A N/A 11885 11900 AGGTACTGTTTGCTGA 65 80 911208 N/A N/A 12242 12257 CACATTTGAGGCACGG 42 81 911212 N/A N/A 12289 12304 AGGTTTGGATTTGCGG 45 82 911216 N/A N/A 12398 12413 GGCTATTTTATGGGTC 64 83 911220 N/A N/A 12706 12721 GGGAATATCTGGTATC 62 84 911224 N/A N/A 12812 12827 GATCAGTTTGGATTCA 63 85 911228 N/A N/A 12898 12913 GGACATGGTTAGGTGG 61 86

TABLE 2 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO 910922 11 26 411 426 CCAAATTTTTTTCGAT 61  87 910926 80 95 480 495 TGCTTTTATACCGAGA 11  88 910930 485 500 7550 7565 GTGCATGAAATGTGGC 25  89 910934 694 709 8271 8286 GGATTTGGGAAGGTGC 59  90 910938 873 888 9463 9478 GGAGACATTGTGCCCT 45  91 910942 1022 1037 11178 11193 TACGATGCAGCAGGAG 59  92 910946 1174 1189 12044 12059 TGGAACTTGAAGTAGT  24*  93 910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT 126   94 910954 1656 1671 14066 14081 CAAAGGATATGATGGG 76  95 910958 1896 1911 14306 14321 GTGTACTGAGGCAGGC 13  96 910962 2116 2131 14526 14541 GTGAATTCTAACAGGC 25  97 910966 2217 2232 14627 14642 GGGTATTTTTGGCAAG 46  98 910970 2360 2375 N/A N/A AGCTCGGCTGCAGTTT 41  99 910974 434 449 7499 7514 GCCCAGCCGTGCCCCG 64 100 910978 69 84 469 484 CGAGAAGAAAAACCAC 30 101 910982 1464 1479 13874 13889 GGCCAGGTGTAGGGTT 75 102 910986 1310 1325 13540 13555 GGCAGGATGGTTTCTG 99 103 910990 500 515 7663 7678 CACCGTTGAGAGCTGG 39 104 910994 768 783 8414 8429 AGACACCATTTGCCAG 62 105 910997 148 163 548 563 GGTGAAGTGGACTGAC 25 106 911001 1400 1415 13810 13825 ATCCACGGTCCACACA 96 107 911005 1219 1234 N/A N/A GCCCAGCGGATGAGCG  33* 108 911009 1657 1672 14067 14082 GCAAAGGATATGATGG 59 109 911013 2277 2292 N/A N/A AGCTGAGGCATGGATC 62 110 911017 1739 1754 14149 14164 CTGCAGGGCTCGACTG 50 111 911021 902 917 9492 9507 CTCCAGAGACTGTACC 82 112 911025 38 53 438 453 AGCCGCAGACCTCTCT 39 113 911029 65 80 465 480 AAGAAAAACCACGCTG 70 114 911033 2111 2126 14521 14536 TTCTAACAGGCCGTGT 57 115 911037 818 833 8464 8479 GAGGAAGTCCTCTGGC 43 116 911041 875 890 9465 9480 GAGGAGACATTGTGCC 43 117 911045 879 894 9469 9484 TCTGGAGGAGACATTG 62 118 911049 327 342 6865 6880 CTCGAAGATCTCGGCC 69 119 911053 64 79 464 479 AGAAAAACCACGCTGT 46 120 911057 2109 2124 14519 14534 CTAACAGGCCGTGTGT 49 121 911061 1850 1865 14260 14275 GGGACAGGATTGTGAC 53 122 911065 1598 1613 14008 14023 CAAGACAGTGGAAACC 45 123 911069 N/A N/A 13585 13600 GGCCATCCCAGTCACC 72 124 911073 N/A N/A 13670 13685 ACCAACAACCCACATC 107  125 911077 N/A N/A 13663 13678 ACCCACATCCCGTTCC 55 126 911081 N/A N/A 745 760 ATTAAGTACTTCACCT 75 127 911085 N/A N/A 1447 1462 ATATGGACTCTGGTCA 34 128 911089 N/A N/A 1828 1843 AAAAATGCACGCCCCC 62 129 911093 N/A N/A 2163 2178 GCTATATATGTAATGG 16 130 911097 N/A N/A 2522 2537 ATAACCATTGCAGTAC 33 131 911101 N/A N/A 2734 2749 GTGAATAGTCAGTCCA 21 132 911105 N/A N/A 3246 3261 TCATTAGGTGTCTGCA 17 133 911109 N/A N/A 3711 3726 CAATCAAGGTTTTCGG 35 134 911113 N/A N/A 4083 4098 TAGATTTAAAGGATCC 45 135 911117 N/A N/A 4442 4457 CCAGATTTTTCCGCCA 48 136 911121 N/A N/A 5275 5290 AGTATAGAAGGGTTCT 38 137 911125 N/A N/A 5819 5834 CAGCATGGCAAGTGAC 66 138 911129 N/A N/A 6042 6057 AGTGACATGGGTTTTA 34 139 911133 N/A N/A 6197 6212 GCTATTGTAACAGTCC 20 140 911137 N/A N/A 6497 6512 GTACATGTACATACCC 59 141 911141 N/A N/A 6992 7007 ACAGTAAAGGTCGGCA 49 142 911145 N/A N/A 7422 7437 GGCCATCCTGATCCTC 59 143 911149 N/A N/A 7866 7881 GCCTACACTGCTCACA 44 144 911153 N/A N/A 8186 8201 CACCTATGGAGGCTGT 86 145 911157 N/A N/A 8565 8580 CTTACTACTTATTGGG 78 146 911161 N/A N/A 8687 8702 TCTTATTATACATACG 61 147 911165 N/A N/A 8859 8874 TGGCATGAGGAGTAGC 57 148 911169 N/A N/A 9506 9521 GGCATTACCTGCTGCT 78 149 911173 N/A N/A 9604 9619 CCTTTATACCAGCCCT 59 150 911177 N/A N/A 9921 9936 GGGCATGTTTGGAGCT 58 151 911181 N/A N/A 10330 10345 GGCTATTTGCATTTGC 28 152 911185 N/A N/A 10551 10566 ATCTGTACATTCGCAT 28 153 911189 N/A N/A 10691 10706 CGTATTTATTAGAGCA 41 154 911193 N/A N/A 11446 11461 GCGGATGCATTTTCCC 32 155 911197 N/A N/A 11617 11632 TGGAATTACTTAGCAG 47 156 911201 N/A N/A 11826 11841 GCCAAAATAGTTCTCC 42 157 911205 N/A N/A 11909 11924 GTCAACACCCGTGTCC 57 158 911209 N/A N/A 12243 12258 TCACATTTGAGGCACG 38 159 911213 N/A N/A 12295 12310 TGGTTTAGGTTTGGAT 68 160 911217 N/A N/A 12406 12421 TAGCTTTAGGCTATTT 72 161 911221 N/A N/A 12771 12786 GATGATTGCAGTGAGG 40 162 911225 N/A N/A 12820 12835 GGGAATTTGATCAGTT 79 163 911229 N/A N/A 12928 12943 GTTTGAATTATCGAGT 59 164

TABLE 3 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO 910923 12 27 412 427 TCCAAATTTTTTTCGA 52 165 910927 178 193 6716 6731 GGCATCGGGTCCTTGT 51 166 910931 507 522 7670 7685 GGGCATCCACCGTTGA 57 167 910935 709 724 8286 8301 TTCCTGGGTGCACTGG 56 168 910939 944 959 9739 9754 CTGCATGGCACTCAGC 33 169 910943 1024 1039 11180 11195 GCTACGATGCAGCAGG 29 170 910947 1260 1275 13490 13505 TCTCATTGAGTGTCCG  27* 171 910951 1552 1567 13962 13977 GGCCTATCATCCCTGC 96 172 910955 1799 1814 14209 14224 GTAATCTGTGCGAGCA 19 173 910959 1922 1937 14332 14347 GATGATGCAGCTTTGA 19 174 910963 2117 2132 14527 14542 GGTGAATTCTAACAGG 26 175 910967 2303 2318 N/A N/A TAAATGAGTAGTTCCT 37 176 910971 992 1007 N/A N/A TGCCACAGATGAAGCC 63 177 910975 72 87 472 487 TACCGAGAAGAAAAAC 56 178 910979 1855 1870 14265 14280 AGTGAGGGACAGGATT 36 179 910983 2072 2087 14482 14497 CCTCAGATCCTGAGGG 81 180 910987 421 436 7486 7501 CCGGAGGGTGCCACCA 52 181 910991 1092 1107 11248 11263 CAAACAGGCTGTCAGG 65 182 910995 78 93 478 493 CTTTTATACCGAGAAG 38 183 910998 1374 1389 13784 13799 CGCTCTCCACCCGCAC 41 184 911002 42 57 442 457 TGGAAGCCGCAGACCT 28 185 911006 2287 2302 N/A N/A CTGCAGTCTAAGCTGA 63 186 911010 423 438 7488 7503 CCCCGGAGGGTGCCAC 62 187 911014 1892 1907 14302 14317 ACTGAGGCAGGCTCTC 16 188 911018 1458 1473 13868 13883 GTGTAGGGTTGGAACA 84 189 911022 599 614 7762 7777 GGAGAAGACCCCAGTG 55 190 911026 66 81 466 481 GAAGAAAAACCACGCT 56 191 911030 2355 2370 N/A N/A GGCTGCAGTTTATTGG 36 192 911034 132 147 532 547 AGAAAAGGATCAGCCT 65 193 911038 1459 1474 13869 13884 GGTGTAGGGTTGGAAC 70 194 911042 59 74 459 474 AACCACGCTGTACGGT 44 195 911046 131 146 531 546 GAAAAGGATCAGCCTG 52 196 911050 326 341 6864 6879 TCGAAGATCTCGGCCC 94 197 911054 1517 1532 13927 13942 CACCAGTTTGGCCCCT 39 198 911058 52 67 452 467 CTGTACGGTGTGGAAG 51 199 911062 76 91 476 491 TTTATACCGAGAAGAA 38 200 911070 N/A N/A 13594 13609 GGCACTTGAGGCCATC 74 201 911074 N/A N/A 13661 13676 CCACATCCCGTTCCTC 62 202 911078 N/A N/A 13570 13585 CGCCACCTCAGAGGAG 104  203 911082 N/A N/A 1258 1273 AACTGATGCTCACTCT 66 204 911086 N/A N/A 1495 1510 TGCAGAATCGAGCTCA 27 205 911090 N/A N/A 1923 1938 CATAATAATACTCACC 63 206 911094 N/A N/A 2189 2204 CAAATGATGAATTGGG 23 207 911098 N/A N/A 2610 2625 GGGTTTATTGTGTGTC 13 208 911102 N/A N/A 2766 2781 TGAGATAATTAGGGAG 25 209 911106 N/A N/A 3269 3284 CCCTTCTACGCTGTCT 39 210 911110 N/A N/A 3753 3768 GCCAATACAGAGCCCA  9 211 911114 N/A N/A 4155 4170 ACAGATACTGGGACCC 34 212 911118 N/A N/A 4660 4675 GCATAGATACATTCTC 15 213 911122 N/A N/A 5541 5556 GGCTTTTCAGGATCCT 57 214 911126 N/A N/A 5937 5952 TAGACATGAAGAGTCT 69 215 911130 N/A N/A 6108 6123 TTAATCTGAAGCTGGA 64 216 911134 N/A N/A 6271 6286 TCCTATTTTGCCCCAG 48 217 911138 N/A N/A 6498 6513 GGTACATGTACATACC 59 218 911142 N/A N/A 7068 7083 TGCATAAGTCACAGAC 45 219 911146 N/A N/A 7561 7576 GTCCATACCTGGTGCA 51 220 911150 N/A N/A 7886 7901 GAGTACTGCAATTCAG 45 221 911154 N/A N/A 8495 8510 GTAGACTGGCACAGGC 72 222 911158 N/A N/A 8581 8596 AGTTTAGCTCTTGCAT 36 223 911162 N/A N/A 8710 8725 GGGTAAATAACAGCAC 17 224 911166 N/A N/A 9385 9400 GGTGACCACGACAGGC 62 225 911170 N/A N/A 9538 9553 CACTATCCCTATCCCT 50 226 911174 N/A N/A 9646 9661 CCAGGCTACGGTCTTC 64 227 911178 N/A N/A 10311 10326 AACAACTCAGGATCAC 28 228 911182 N/A N/A 10378 10393 GGTTACATAGCTGGTC 19 229 911186 N/A N/A 10625 10640 TTGAATAGGGCTCTTT 51 230 911190 N/A N/A 10692 10707 CCGTATTTATTAGAGC 49 231 911194 N/A N/A 11447 11462 AGCGGATGCATTTTCC 21 232 911198 N/A N/A 11683 11698 TGGATAGGTGAGCTCG 34 233 911202 N/A N/A 11846 11861 TTATTCTTTGCACCAC 33 234 911206 N/A N/A 11921 11936 TGAGATCTCACCGTCA 83 235 911210 N/A N/A 12245 12260 GGTCACATTTGAGGCA 49 236 911214 N/A N/A 12303 12318 CTGGATGGTGGTTTAG 82 237 911218 N/A N/A 12528 12543 GTATTGACATACTGGG 35 238 911222 N/A N/A 12777 12792 AGCGATGATGATTGCA 64 239 911226 N/A N/A 12821 12836 AGGGAATTTGATCAGT 43 240 911230 N/A N/A 13042 13057 CCAACTTAAGGGTCAG 42 241

TABLE 4 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO 910924 54 69 454 469 CGCTGTACGGTGTGGA 13 242 910928 269 284 6807 6822 GGCTTTGGGTGCAGCC 96 243 910932 560 575 7723 7738 GATCATGGCTGGGCTC 28 244 910936 749 764 8395 8410 TGGGTAGGAGCTCTGG 27 245 910940 946 961 9741 9756 GCCTGCATGGCACTCA 43 246 910944 1028 1043 11184 11199 AGCAGCTACGATGCAG 53 247 910948 1309 1324 13539 13554 GCAGGATGGTTTCTGA 99 248 910952 1562 1577 13972 13987 GCACATCCAGGGCCTA 25 249 910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC 10 250 910960 2113 2128 14523 14538 AATTCTAACAGGCCGT 25 251 910964 2180 2195 14590 14605 GTCTGCACGGGACTCA 33 252 910968 2304 2319 N/A N/A ATAAATGAGTAGTTCC 28 253 910972 324 339 6862 6877 GAAGATCTCGGCCCTG 47 254 910976 2301 2316 N/A N/A AATGAGTAGTTCCTCT 35 255 910980 71 86 471 486 ACCGAGAAGAAAAACC 18 256 910984 385 400 N/A N/A AGCTGCAGCTGCGATG 44 257 910988 75 90 475 490 TTATACCGAGAAGAAA 68 258 910992 1893 1908 14303 14318 TACTGAGGCAGGCTCT 27 259 910996 36 51 436 451 CCGCAGACCTCTCTCT 36 260 910999 2302 2317 N/A N/A AAATGAGTAGTTCCTC 50 261 911003 413 428 7478 7493 TGCCACCATGACTAGG 62 262 911007 985 1000 9780 9795 GATGAAGCCTTGGTCA 50 263 911011 1901 1916 14311 14326 TTTGAGTGTACTGAGG 12 264 911015 1849 1864 14259 14274 GGACAGGATTGTGACA 56 265 911019 1792 1807 14202 14217 GTGCGAGCAGCTGAGG 13 266 911023 79 94 479 494 GCTTTTATACCGAGAA  5 267 911027 725 740 N/A N/A CGAAAGGGTGCTGTCC 78 268 911031 727 742 N/A N/A GCCGAAAGGGTGCTGT 48 269 911035 147 162 547 562 GTGAAGTGGACTGACA 43 270 911039 62 77 462 477 AAAAACCACGCTGTAC 61 271 911043 2280 2295 N/A N/A CTAAGCTGAGGCATGG 35 272 911047 659 674 8236 8251 GGACACCCATTCCAGG 59 273 911051 116 131 516 531 GGCTTGTGGGAAACTG 17 274 911055 158 173 N/A N/A GGGCAGGCTTGGTGAA 82 275 911059 43 58 443 458 GTGGAAGCCGCAGACC 23 276 911063 1169 1184 12039 12054 CTTGAAGTAGTCCATG  49* 277 911067 N/A N/A 8302 8317 GTCCACTGACCTGTCC 111  278 911071 N/A N/A 13600 13615 TGCGATGGCACTTGAG 51 279 911075 N/A N/A 13564 13579 CTCAGAGGAGCTCACC 87 280 911079 N/A N/A 13595 13610 TGGCACTTGAGGCCAT 119  281 911083 N/A N/A 1275 1290 GCTACTAGGGTGAACA 22 282 911087 N/A N/A 1547 1562 AATAGCTAACACTTCG 32 283 911091 N/A N/A 2068 2083 GGAGTAAGGACATGAC 27 284 911095 N/A N/A 2233 2248 ATCATAAGCATCACAA 49 285 911099 N/A N/A 2639 2654 TATAAGTTTTAACACC 62 286 911103 N/A N/A 2941 2956 TGTATTGCAAAGCAAC 38 287 911107 N/A N/A 3357 3372 GCATTTCGGTGAGGCC 39 288 911111 N/A N/A 3802 3817 TGCCTTTGGTCTGGGC 56 289 911115 N/A N/A 4248 4263 CACTATGACAAGCCCC 29 290 911119 N/A N/A 4945 4960 TCCCTTATGGCCCCCA 25 291 911123 N/A N/A 5629 5644 TTCTATTGTCCTCACC 68 292 911127 N/A N/A 5938 5953 ATAGACATGAAGAGTC 50 293 911131 N/A N/A 6109 6124 CTTAATCTGAAGCTGG 22 294 911135 N/A N/A 6309 6324 CATCTTGCCGGAGCTG 26 295 911139 N/A N/A 6564 6579 CCCATAGTTGCACCCC 44 296 911143 N/A N/A 7174 7189 ACTACAATACGGCCTC 44 297 911147 N/A N/A 7572 7587 GCCCATTCACCGTCCA 48 298 911151 N/A N/A 7963 7978 TCTTTAAGGTTCTGCA 40 299 911155 N/A N/A 8496 8511 GGTAGACTGGCACAGG 33 300 911159 N/A N/A 8684 8699 TATTATACATACGAGA 81 301 911163 N/A N/A 8767 8782 AGATTTTGATCAAGAC 25 302 911167 N/A N/A 9399 9414 GAAGATTCCATGCAGG 75 303 911171 N/A N/A 9540 9555 CGCACTATCCCTATCC 12 304 911175 N/A N/A 9868 9883 AGGTTAGGTTCCCTGC 34 305 911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG 10 306 911183 N/A N/A 10451 10466 GGTTATGTGGCACCCT 21 307 911187 N/A N/A 10686 10701 TTATTAGAGCACAGGT 72 308 911191 N/A N/A 10716 10731 TGGAATCCCACAAAAC 61 309 911195 N/A N/A 11611 11626 TACTTAGCAGGGTCCC 37 310 911199 N/A N/A 11684 11699 GTGGATAGGTGAGCTC 29 311 911203 N/A N/A 11864 11879 TGACATAAGTTGTATC 46 312 911207 N/A N/A 11994 12009 ATGAATCAAGCCCCAT 95 313 911211 N/A N/A 12284 12299 TGGATTTGCGGACAGG 33 314 911215 N/A N/A 12324 12339 CAGAATTTGGCATGCT 51 315 911219 N/A N/A 12530 12545 GTGTATTGACATACTG 67 316 911223 N/A N/A 12790 12805 GGATTACAGAGTCAGC 36 317 911227 N/A N/A 12893 12908 TGGTTAGGTGGTTAGG 59 318 911231 N/A N/A 13242 13257 GGGTATGGTTGTTCTG 38 319

TABLE 5 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 32  65 1062005 1 16 401 416 TTCGATGAGTGTGTGC 43 320 1062037 118 133 518 533 CTGGCTTGTGGGAAAC 30 321 1062069 310 325 6848 6863 TGGAAGGTTCCCCCTG 110  322 1062101 422 437 7487 7502 CCCGGAGGGTGCCACC 212  323 1062133 594 609 7757 7772 AGACCCCAGTGGCGGT 69 324 1062165 752 767 8398 8413 CAGTGGGTAGGAGCTC 150  325 1062197 869 884 9459 9474 ACATTGTGCCCTGCCC 24 326 1062229 1049 1064 11205 11220 GACGACAGGGCCTTGG 53 327 1062261 1181 1196 12051 12066 CATGTTGTGGAACTTG  65* 328 1062293 1423 1438 13833 13848 CGTTTCTTGCGGAACT 105  329 1062325 1592 1607 14002 14017 AGTGGAAACCTCACTT 86 330 1062357 1848 1863 14258 14273 GACAGGATTGTGACAT 43 331 1062389 2026 2041 14436 14451 GCACACCCCTGTGTTG 61 332 1062421 2208 2223 14618 14633 TGGCAAGGCAGTGTGT 68 333 1062453 N/A N/A 8298 8313 ACTGACCTGTCCTTCC 318  334 1062485 N/A N/A 13599 13614 GCGATGGCACTTGAGG 143  335 1062549 N/A N/A 684 699 TACCTGGCTGGAATCA 64 336 1062581 N/A N/A 866 881 ACAGCATTTCAAGTTG 113  337 1062613 N/A N/A 1108 1123 GATCGATGGAGTGTGG 104  338 1062645 N/A N/A 1237 1252 AATGTAAAGGTCCTCG 23 339 1062678 N/A N/A 1337 1352 AAAGCGATACAAGCAA 30 340 1062710 N/A N/A 1475 1490 AGCCCTGAACAACCTG 67 341 1062742 N/A N/A 1721 1736 CGGCACTTGGTCAAAT 102  342 1062774 N/A N/A 1877 1892 ATAGGACAACCTTTTG 40 343 1062806 N/A N/A 2074 2089 CTATTAGGAGTAAGGA 172  344 1062838 N/A N/A 2159 2174 TATATGTAATGGCTGA 11 345 1062870 N/A N/A 2391 2406 CCTCTATAGTAAATGG 62 346 1062902 N/A N/A 2585 2600 GCTAAGTATTTACTGT 68 347 1062934 N/A N/A 2731 2746 AATAGTCAGTCCATTA 46 348 1062966 N/A N/A 2866 2881 GAAAGCTTGGACATGG 34 349 1062998 N/A N/A 3067 3082 GCGAGAGGAGGATTGC 65 350 1063030 N/A N/A 3244 3259 ATTAGGTGTCTGCAGG 74 351 1063062 N/A N/A 3389 3404 GAGATCTAGGCTTGGA 21 352 1063094 N/A N/A 3641 3656 ATCACCACGCTCTGGC 31 353 1063126 N/A N/A 3863 3878 CCAAATACATGGCCAC 133  354 1063158 N/A N/A 4102 4117 ATCATAGAACAGCATT 19 355 1063190 N/A N/A 4223 4238 AGACCTGGCCCTTCTT 122  356 1063222 N/A N/A 4402 4417 CCGGGCTTCATCGACA 99 357 1063253 N/A N/A 4555 4570 TCCCTTTCTGACTGGG 198  358 1063285 N/A N/A 4710 4725 AGAGCTAAGAATTCTC 65 359 1063317 N/A N/A 5080 5095 CTGGGAGAGCACTGGT 62 360 1063349 N/A N/A 5274 5289 GTATAGAAGGGTTCTG 43 361 1063381 N/A N/A 5482 5497 CAGCCAACCCCATTAT 134  362 1063413 N/A N/A 5655 5670 CTGTCCAAGCCACGCA 96 363 1063445 N/A N/A 5855 5870 AGGAGGCGAGTCCAGG 65 364 1063477 N/A N/A 6012 6027 AAGGACCGAGCTGACA 39 365 1063509 N/A N/A 6133 6148 GCGAGAAGTGGGTAGA 47 366 1063541 N/A N/A 6280 6295 TCCTCGGAGTCCTATT 163  367 1063573 N/A N/A 6449 6464 GGCTTGCCTGCCCACG 65 368 1063605 N/A N/A 6969 6984 GTCCAGGTACCCCACC 100  369 1063637 N/A N/A 7171 7186 ACAATACGGCCTCCTC 127  370 1063669 N/A N/A 7376 7391 ACTGCAAGCCCACATG 84 371 1063701 N/A N/A 7802 7817 CTGAGGTGTTACCAGG 35 372 1063733 N/A N/A 7968 7983 CTGCATCTTTAAGGTT 60 373 1063765 N/A N/A 8045 8060 GCTTAAAGACGGCCAT 88 374 1063796 N/A N/A 8559 8574 ACTTATTGGGATGAAG 92 375 1063828 N/A N/A 8848 8863 GTAGCAGGGCAAAGCA 69 376 1063860 N/A N/A 9051 9066 TAAGGGTTGTGTGTAG 318  377 1063892 N/A N/A 9413 9428 TGCCTAAGTAGGGAGA 78 378 1063924 N/A N/A 9644 9659 AGGCTACGGTCTTCCC 68 379 1063956 N/A N/A 9960 9975 AGAGGGTTTGTAAGTA 155  380 1063988 N/A N/A 10527 10542 ATAAATTACCACCAGC 55 381 1064020 N/A N/A 10757 10772 TTTCAAAGCAAGGACG 113  382 1064052 N/A N/A 11379 11394 ATGGAGCTCCTTTGCA 219  383 1064084 N/A N/A 11550 11565 AGGCATGGCCCCAATC 109  384 1064118 N/A N/A 11622 11637 GCTCCTGGAATTACTT 38 385 1064150 N/A N/A 11717 11732 GCTAAGCCCACAGGCC 215  386 1064182 N/A N/A 11803 11818 TGAAAAGAAGCGGAGT 98 387 1064214 N/A N/A 11910 11925 CGTCAACACCCGTGTC 93 388 1064246 N/A N/A 11978 11993 GCAGGACCTCCTAGCT 203  389 1064278 N/A N/A 12199 12214 GGAATGGAGGAACCCA 256  390 1064310 N/A N/A 12384 12399 TCCAGGAGAGGGTTAG 123  391 1064342 N/A N/A 12578 12593 ATCAAATGGGTGTTAC 102  392 1064374 N/A N/A 12781 12796 AGTCAGCGATGATGAT 64 393 1064406 N/A N/A 12924 12939 GAATTATCGAGTATCT 57 394 1064438 N/A N/A 13217 13232 AAGGGATCAGGACTGA 188  395

TABLE 6 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 60  65 1062006 2 17 402 417 TTTCGATGAGTGTGTG 38 396 1062038 119 134 519 534 CCTGGCTTGTGGGAAA 67 397 1062070 311 326 6849 6864 CTGGAAGGTTCCCCCT 109  398 1062102 424 439 7489 7504 GCCCCGGAGGGTGCCA 202  399 1062134 595 610 7758 7773 AAGACCCCAGTGGCGG 47 400 1062166 754 769 8400 8415 AGCAGTGGGTAGGAGC 77 401 1062198 876 891 9466 9481 GGAGGAGACATTGTGC 119  402 1062230 1050 1065 11206 11221 GGACGACAGGGCCTTG 164  403 1062262 1183 1198 12053 12068 CGCATGTTGTGGAACT  27* 404 1062294 1426 1441 13836 13851 CTCCGTTTCTTGCGGA 136  405 1062326 1593 1608 14003 14018 CAGTGGAAACCTCACT 117  406 1062358 1852 1867 14262 14277 GAGGGACAGGATTGTG 134  407 1062390 2028 2043 14438 14453 GGGCACACCCCTGTGT 194  408 1062422 2209 2224 14619 14634 TTGGCAAGGCAGTGTG 20 409 1062454 N/A N/A 8299 8314 CACTGACCTGTCCTTC 117  410 1062486 N/A N/A 13601 13616 CTGCGATGGCACTTGA 115  411 1062550 N/A N/A 685 700 TTACCTGGCTGGAATC 91 412 1062582 N/A N/A 867 882 GACAGCATTTCAAGTT 139  413 1062614 N/A N/A 1109 1124 AGATCGATGGAGTGTG 107  414 1062646 N/A N/A 1238 1253 AAATGTAAAGGTCCTC 28 415 1062679 N/A N/A 1338 1353 TAAAGCGATACAAGCA 100  416 1062711 N/A N/A 1476 1491 CAGCCCTGAACAACCT 83 417 1062743 N/A N/A 1723 1738 ATCGGCACTTGGTCAA 63 418 1062775 N/A N/A 1878 1893 AATAGGACAACCTTTT 143  419 1062807 N/A N/A 2075 2090 CCTATTAGGAGTAAGG 140  420 1062839 N/A N/A 2160 2175 ATATATGTAATGGCTG 31 421 1062871 N/A N/A 2392 2407 ACCTCTATAGTAAATG 67 422 1062903 N/A N/A 2609 2624 GGTTTATTGTGTGTCA 14 423 1062935 N/A N/A 2732 2747 GAATAGTCAGTCCATT 54 424 1062967 N/A N/A 2868 2883 TAGAAAGCTTGGACAT 156  425 1062999 N/A N/A 3069 3084 GTGCGAGAGGAGGATT 111  426 1063031 N/A N/A 3245 3260 CATTAGGTGTCTGCAG 37 427 1063063 N/A N/A 3390 3405 TGAGATCTAGGCTTGG 41 428 1063095 N/A N/A 3642 3657 CATCACCACGCTCTGG 110  429 1063127 N/A N/A 3864 3879 CCCAAATACATGGCCA 77 430 1063159 N/A N/A 4104 4119 GAATCATAGAACAGCA 20 431 1063191 N/A N/A 4228 4243 TCTGAAGACCTGGCCC 90 432 1063223 N/A N/A 4406 4421 TGCGCCGGGCTTCATC 87 433 1063254 N/A N/A 4575 4590 CTGCACTGTCTGTTGG 176  434 1063286 N/A N/A 4712 4727 CCAGAGCTAAGAATTC 81 435 1063318 N/A N/A 5083 5098 GGCCTGGGAGAGCACT 153  436 1063350 N/A N/A 5276 5291 GAGTATAGAAGGGTTC 68 437 1063382 N/A N/A 5496 5511 TGGAAGGGACTGCCCA 145  438 1063414 N/A N/A 5656 5671 CCTGTCCAAGCCACGC 19 439 1063446 N/A N/A 5856 5871 AAGGAGGCGAGTCCAG 103  440 1063478 N/A N/A 6013 6028 GAAGGACCGAGCTGAC 163  441 1063510 N/A N/A 6135 6150 AGGCGAGAAGTGGGTA 53 442 1063542 N/A N/A 6281 6296 CTCCTCGGAGTCCTAT 95 443 1063574 N/A N/A 6455 6470 GCACCTGGCTTGCCTG 67 444 1063606 N/A N/A 6981 6996 CGGCACCTGTAGGTCC 141  445 1063638 N/A N/A 7172 7187 TACAATACGGCCTCCT 86 446 1063670 N/A N/A 7377 7392 CACTGCAAGCCCACAT 66 447 1063702 N/A N/A 7803 7818 GCTGAGGTGTTACCAG 109  448 1063734 N/A N/A 7980 7995 GATTTTGACATTCTGC 11 449 1063766 N/A N/A 8046 8061 AGCTTAAAGACGGCCA 147  450 1063797 N/A N/A 8560 8575 TACTTATTGGGATGAA 75 451 1063829 N/A N/A 8850 8865 GAGTAGCAGGGCAAAG 183  452 1063861 N/A N/A 9052 9067 CTAAGGGTTGTGTGTA 235  453 1063893 N/A N/A 9414 9429 GTGCCTAAGTAGGGAG 105  454 1063925 N/A N/A 9645 9660 CAGGCTACGGTCTTCC 62 455 1063957 N/A N/A 9961 9976 CAGAGGGTTTGTAAGT 102  456 1063989 N/A N/A 10541 10556 TCGCATCATGAGAAAT 82 457 1064021 N/A N/A 11113 11128 GCTTAAACTTCCCACT 106  458 1064053 N/A N/A 11380 11395 CATGGAGCTCCTTTGC 182  459 1064085 N/A N/A 11551 11566 GAGGCATGGCCCCAAT 211  460 1064119 N/A N/A 11633 11648 GGAAAGGAGGTGCTCC 92 461 1064151 N/A N/A 11719 11734 CTGCTAAGCCCACAGG 140  462 1064183 N/A N/A 11804 11819 TTGAAAAGAAGCGGAG 141  463 1064215 N/A N/A 11913 11928 CACCGTCAACACCCGT 63 464 1064247 N/A N/A 11980 11995 ATGCAGGACCTCCTAG 244  465 1064279 N/A N/A 12200 12215 GGGAATGGAGGAACCC 112  466 1064311 N/A N/A 12385 12400 GTCCAGGAGAGGGTTA 241  467 1064343 N/A N/A 12579 12594 GATCAAATGGGTGTTA 84 468 1064375 N/A N/A 12784 12799 CAGAGTCAGCGATGAT 77 469 1064407 N/A N/A 12925 12940 TGAATTATCGAGTATC 53 470 1064439 N/A N/A 13219 13234 GTAAGGGATCAGGACT 136  471

TABLE 7 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 20  65 1062008 4 19 404 419 TTTTTCGATGAGTGTG  9 472 1062040 128 143 528 543 AAGGATCAGCCTGGCT 67 473 1062072 313 328 6851 6866 CCCTGGAAGGTTCCCC 49 474 1062104 459 474 7524 7539 GGAGTGCCTGTAAGTG 13 475 1062136 597 612 7760 7775 AGAAGACCCCAGTGGC 47 476 1062168 766 781 8412 8427 ACACCATTTGCCAGCA 59 477 1062200 878 893 9468 9483 CTGGAGGAGACATTGT 62 478 1062232 1091 1106 11247 11262 AAACAGGCTGTCAGGG 101  479 1062264 1185 1200 12055 12070 GTCGCATGTTGTGGAA  10* 480 1062296 1430 1445 13840 13855 CTGGCTCCGTTTCTTG 130  481 1062328 1595 1610 14005 14020 GACAGTGGAAACCTCA 15 482 1062360 1854 1869 14264 14279 GTGAGGGACAGGATTG 58 483 1062392 2040 2055 14450 14465 GTGTAGGCCTCTGGGC 45 484 1062424 2212 2227 14622 14637 TTTTTGGCAAGGCAGT 61 485 1062456 N/A N/A 8301 8316 TCCACTGACCTGTCCT 73 486 1062488 N/A N/A 13603 13618 AGCTGCGATGGCACTT 116  487 1062520 N/A N/A 553 568 ACCTTGGTGAAGTGGA 63 488 1062552 N/A N/A 687 702 CCTTACCTGGCTGGAA 187  489 1062584 N/A N/A 879 894 CAGTTGCACCTGGACA 111  490 1062616 N/A N/A 1111 1126 GGAGATCGATGGAGTG 37 491 1062648 N/A N/A 1259 1274 GAACTGATGCTCACTC 26 492 1062681 N/A N/A 1340 1355 TCTAAAGCGATACAAG 97 493 1062713 N/A N/A 1490 1505 AATCGAGCTCACCCCA 76 494 1062745 N/A N/A 1726 1741 ACAATCGGCACTTGGT 34 495 1062777 N/A N/A 1886 1901 GAGCATAAAATAGGAC 57 496 1062809 N/A N/A 2077 2092 ACCCTATTAGGAGTAA 144  497 1062841 N/A N/A 2234 2249 CATCATAAGCATCACA 19 498 1062873 N/A N/A 2396 2411 CTTAACCTCTATAGTA 51 499 1062905 N/A N/A 2616 2631 GATCTTGGGTTTATTG 81 500 1062937 N/A N/A 2735 2750 AGTGAATAGTCAGTCC 17 501 1062969 N/A N/A 2905 2920 CCTGGTATAAGAACAG 23 502 1063001 N/A N/A 3100 3115 GGACACATGCATGGAG 73 503 1063033 N/A N/A 3248 3263 AGTCATTAGGTGTCTG 23 504 1063065 N/A N/A 3392 3407 CCTGAGATCTAGGCTT 48 505 1063097 N/A N/A 3658 3673 ACTGACATGCCTCCAT 54 506 1063129 N/A N/A 3884 3899 GTCCACTCTGGAACAA 91 507 1063161 N/A N/A 4123 4138 GTATAACACCAGGACC 63 508 1063193 N/A N/A 4236 4251 CCCCTAGCTCTGAAGA 69 509 1063225 N/A N/A 4414 4429 CGGCCGGATGCGCCGG 120  510 1063256 N/A N/A 4584 4599 GCCGGCTTCCTGCACT 100  511 1063288 N/A N/A 4714 4729 GGCCAGAGCTAAGAAT 71 512 1063320 N/A N/A 5094 5109 CTCCGAACAAGGGCCT 30 513 1063352 N/A N/A 5313 5328 CTGAGTTGGGCACACA 58 514 1063384 N/A N/A 5521 5536 TCCTGGTCTGAGAGGA 76 515 1063416 N/A N/A 5686 5701 GCCTCAAATGCCCACT 61 516 1063448 N/A N/A 5858 5873 GCAAGGAGGCGAGTCC 55 517 1063480 N/A N/A 6015 6030 TGGAAGGACCGAGCTG 101  518 1063512 N/A N/A 6139 6154 GAGAAGGCGAGAAGTG 150  519 1063544 N/A N/A 6293 6308 GTCTCGGACTTTCTCC 57 520 1063576 N/A N/A 6483 6498 CCACACATGCCCCACG 102  521 1063608 N/A N/A 6983 6998 GTCGGCACCTGTAGGT 50 522 1063640 N/A N/A 7175 7190 GACTACAATACGGCCT 52 523 1063672 N/A N/A 7382 7397 CTCTGCACTGCAAGCC 30 524 1063704 N/A N/A 7867 7882 AGCCTACACTGCTCAC 60 525 1063736 N/A N/A 8001 8016 TGTAAAGCTCTGTGGT 43 526 1063768 N/A N/A 8048 8063 GAAGCTTAAAGACGGC 42 527 1063799 N/A N/A 8563 8578 TACTACTTATTGGGAT 52 528 1063831 N/A N/A 8852 8867 AGGAGTAGCAGGGCAA 60 529 1063863 N/A N/A 9054 9069 TGCTAAGGGTTGTGTG 37 530 1063895 N/A N/A 9425 9440 TCCGCCTGGCAGTGCC 40 531 1063927 N/A N/A 9687 9702 ACATGAGGCCTCAGCC 91 532 1063959 N/A N/A 9963 9978 GTCAGAGGGTTTGTAA 64 533 1063991 N/A N/A 10543 10558 ATTCGCATCATGAGAA 33 534 1064023 N/A N/A 11115 11130 AGGCTTAAACTTCCCA 60 535 1064055 N/A N/A 11383 11398 CAGCATGGAGCTCCTT 27 536 1064087 N/A N/A 11554 11569 GGTGAGGCATGGCCCC 57 537 1064121 N/A N/A 11653 11668 GATTTTCCTTGGTCAG 119  538 1064153 N/A N/A 11728 11743 CTCTGATCCCTGCTAA 84 539 1064185 N/A N/A 11810 11825 CCGAGGTTGAAAAGAA 87 540 1064217 N/A N/A 11919 11934 AGATCTCACCGTCAAC 107  541 1064249 N/A N/A 11984 11999 CCCCATGCAGGACCTC 129  542 1064281 N/A N/A 12202 12217 TTGGGAATGGAGGAAC 106  543 1064313 N/A N/A 12396 12411 CTATTTTATGGGTCCA 14 544 1064345 N/A N/A 12584 12599 TTAAGGATCAAATGGG 74 545 1064377 N/A N/A 12786 12801 TACAGAGTCAGCGATG 60 546 1064409 N/A N/A 12927 12942 TTTGAATTATCGAGTA 66 547 1064441 N/A N/A 13221 13236 AGGTAAGGGATCAGGA 83 548

TABLE 8 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 24  65 1062009 5 20 405 420 TTTTTTCGATGAGTGT 29 549 1062041 143 158 543 558 AGTGGACTGACAGAAA 39 550 1062073 314 329 6852 6867 GCCCTGGAAGGTTCCC 114  551 1062105 461 476 7526 7541 GAGGAGTGCCTGTAAG 61 552 1062137 600 615 7763 7778 GGGAGAAGACCCCAGT 86 553 1062169 771 786 8417 8432 TGCAGACACCATTTGC 75 554 1062201 895 910 9485 9500 GACTGTACCATCTCTC 87 555 1062233 1098 1113 11254 11269 GGACAGCAAACAGGCT 87 556 1062265 1186 1201 12056 12071 GGTCGCATGTTGTGGA  10* 557 1062297 1433 1448 13843 13858 CCTCTGGCTCCGTTTC 95 558 1062329 1596 1611 14006 14021 AGACAGTGGAAACCTC 85 559 1062361 1856 1871 14266 14281 GAGTGAGGGACAGGAT 16 560 1062393 2041 2056 14451 14466 TGTGTAGGCCTCTGGG 23 561 1062425 2215 2230 14625 14640 GTATTTTTGGCAAGGC 19 562 1062457 N/A N/A 8304 8319 CTGTCCACTGACCTGT 39 563 1062489 N/A N/A 13609 13624 ACTTTGAGCTGCGATG 64 564 1062521 N/A N/A 554 569 CACCTTGGTGAAGTGG 70 565 1062553 N/A N/A 688 703 ACCTTACCTGGCTGGA 58 566 1062585 N/A N/A 880 895 TCAGTTGCACCTGGAC 48 567 1062617 N/A N/A 1112 1127 AGGAGATCGATGGAGT 67 568 1062649 N/A N/A 1260 1275 AGAACTGATGCTCACT 41 569 1062682 N/A N/A 1341 1356 CTCTAAAGCGATACAA 94 570 1062714 N/A N/A 1491 1506 GAATCGAGCTCACCCC 56 571 1062746 N/A N/A 1727 1742 AACAATCGGCACTTGG 31 572 1062778 N/A N/A 1887 1902 GGAGCATAAAATAGGA 116  573 1062810 N/A N/A 2078 2093 CACCCTATTAGGAGTA 94 574 1062842 N/A N/A 2235 2250 CCATCATAAGCATCAC 24 575 1062874 N/A N/A 2397 2412 TCTTAACCTCTATAGT 46 576 1062906 N/A N/A 2618 2633 CTGATCTTGGGTTTAT 63 577 1062938 N/A N/A 2736 2751 GAGTGAATAGTCAGTC 10 578 1062970 N/A N/A 2920 2935 GCAAAACAGTGTGGCC 65 579 1063002 N/A N/A 3125 3140 GATAGTGAGAGACATT 98 580 1063034 N/A N/A 3249 3264 AAGTCATTAGGTGTCT 28 581 1063066 N/A N/A 3393 3408 TCCTGAGATCTAGGCT 83 582 1063098 N/A N/A 3666 3681 CCTGACTGACTGACAT 113  583 1063130 N/A N/A 3886 3901 CTGTCCACTCTGGAAC 69 584 1063162 N/A N/A 4124 4139 AGTATAACACCAGGAC 36 585 1063194 N/A N/A 4243 4258 TGACAAGCCCCTAGCT 112  586 1063226 N/A N/A 4418 4433 ATGGCGGCCGGATGCG 147  587 1063257 N/A N/A 4586 4601 CAGCCGGCTTCCTGCA 122  588 1063289 N/A N/A 4719 4734 CACTTGGCCAGAGCTA 29 589 1063321 N/A N/A 5095 5110 GCTCCGAACAAGGGCC 59 590 1063353 N/A N/A 5314 5329 ACTGAGTTGGGCACAC 63 591 1063385 N/A N/A 5522 5537 ATCCTGGTCTGAGAGG 52 592 1063417 N/A N/A 5727 5742 CCAATTTCTGGCCCTC 51 593 1063449 N/A N/A 5859 5874 GGCAAGGAGGCGAGTC 29 594 1063481 N/A N/A 6016 6031 CTGGAAGGACCGAGCT 80 595 1063513 N/A N/A 6140 6155 GGAGAAGGCGAGAAGT 46 596 1063545 N/A N/A 6303 6318 GCCGGAGCTGGTCTCG 85 597 1063577 N/A N/A 6563 6578 CCATAGTTGCACCCCA 37 598 1063609 N/A N/A 6985 7000 AGGTCGGCACCTGTAG 56 599 1063641 N/A N/A 7176 7191 GGACTACAATACGGCC 47 600 1063673 N/A N/A 7387 7402 AAATACTCTGCACTGC 101  601 1063705 N/A N/A 7868 7883 TAGCCTACACTGCTCA 72 602 1063737 N/A N/A 8006 8021 AGCTTTGTAAAGCTCT 30 603 1063769 N/A N/A 8049 8064 AGAAGCTTAAAGACGG 68 604 1063800 N/A N/A 8564 8579 TTACTACTTATTGGGA 124  605 1063832 N/A N/A 8854 8869 TGAGGAGTAGCAGGGC 47 606 1063864 N/A N/A 9055 9070 CTGCTAAGGGTTGTGT 88 607 1063896 N/A N/A 9503 9518 ATTACCTGCTGCTCCA 72 608 1063928 N/A N/A 9688 9703 AACATGAGGCCTCAGC 80 609 1063960 N/A N/A 10283 10298 TCTTAGAGTCAGAGGG 30 610 1063992 N/A N/A 10545 10560 ACATTCGCATCATGAG 60 611 1064024 N/A N/A 11116 11131 GAGGCTTAAACTTCCC 34 612 1064056 N/A N/A 11386 11401 GGGCAGCATGGAGCTC 83 613 1064088 N/A N/A 11560 11575 AGAGTGGGTGAGGCAT 94 614 1064122 N/A N/A 11654 11669 CGATTTTCCTTGGTCA 26 615 1064154 N/A N/A 11729 11744 TCTCTGATCCCTGCTA 94 616 1064186 N/A N/A 11811 11826 CCCGAGGTTGAAAAGA 63 617 1064218 N/A N/A 11920 11935 GAGATCTCACCGTCAA 69 618 1064250 N/A N/A 11987 12002 AAGCCCCATGCAGGAC 80 619 1064282 N/A N/A 12240 12255 CATTTGAGGCACGGCT 105  620 1064314 N/A N/A 12399 12414 AGGCTATTTTATGGGT 70 621 1064346 N/A N/A 12585 12600 GTTAAGGATCAAATGG 78 622 1064378 N/A N/A 12787 12802 TTACAGAGTCAGCGAT 105  623 1064410 N/A N/A 12936 12951 CAGAGATGGTTTGAAT 75 624 1064442 N/A N/A 13222 13237 TAGGTAAGGGATCAGG 76 625

Example 2: Antisense Inhibition of Human Foxp3 in SUP-M2 Cells by cEt Gapmers

Modified oligonucleotides were designed to target a Foxp3 nucleic acid and were tested for their effect on Foxp3 mRNA level in vitro. The modified oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below. Cultured SUP-M2 cells at a density of 60,000 cells per well were treated using free uptake with 3,000 nM of modified oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and Foxp3 mRNA levels were measured by quantitative real-time RTPCR. Human primer probe set RTS35925 was used to measure mRNA levels. Foxp3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to untreated control cells (% UTC). The modified oligonucleotides with percent control values marked with an asterisk (*) target the amplicon region of the primer probe set. Additional assays may be used to measure the potency and efficacy of the modified oligonucleotides targeting the amplicon region.

The newly designed modified oligonucleotides in the Tables below were designed as 3-10-3 cEt gapmers. The gapmers are 16 nucleosides in length, wherein the central gap segment comprises of ten 2′-deoxynucleosides and is flanked by wing segments on the 5′ direction and the 3′ direction comprising three nucleosides each. Each nucleoside in the 5′ wing segment and each nucleoside in the 3′ wing segment has a cEt sugar modification. The internucleoside linkages throughout each gapmer are phosphorothioate (P═S) linkages. All cytosine residues throughout each gapmer are 5-methylcytosines. “Start site” indicates the 5′-most nucleoside to which the gapmer is targeted in the human gene sequence. “Stop site” indicates the 3′-most nucleoside to which the gapmer is targeted human gene sequence. Each gapmer listed in the Tables below is targeted to either SEQ ID NO.: 1 or SEQ ID NO.: 2. ‘N/A’ indicates that the modified oligonucleotide does not target that particular gene sequence with 100% complementarity. ‘N.D.’ indicates that the % UTC is not defined for that specific modified oligonucleotide in that specific experiment. Activity of that modified oligonucleotide may be defined in a different experiment.

TABLE 9 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC 21 250  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 37  65 1062005 1 16 401 416 TTCGATGAGTGTGTGC 20 320 1062037 118 133 518 533 CTGGCTTGTGGGAAAC 63 321 1062069 310 325 6848 6863 TGGAAGGTTCCCCCTG 142  322 1062101 422 437 7487 7502 CCCGGAGGGTGCCACC 135  323 1062133 594 609 7757 7772 AGACCCCAGTGGCGGT 85 324 1062165 752 767 8398 8413 CAGTGGGTAGGAGCTC 66 325 1062197 869 884 9459 9474 ACATTGTGCCCTGCCC 101  326 1062229 1049 1064 11205 11220 GACGACAGGGCCTTGG 78 327 1062261 1181 1196 12051 12066 CATGTTGTGGAACTTG 111* 328 1062293 1423 1438 13833 13848 CGTTTCTTGCGGAACT 105 329 1062325 1592 1607 14002 14017 AGTGGAAACCTCACTT 67 330 1062357 1848 1863 14258 14273 GACAGGATTGTGACAT 101  331 1062389 2026 2041 14436 14451 GCACACCCCTGTGTTG 84 332 1062421 2208 2223 14618 14633 TGGCAAGGCAGTGTGT 66 333 1062453 N/A N/A 8298 8313 ACTGACCTGTCCTTCC 133  334 1062485 N/A N/A 13599 13614 GCGATGGCACTTGAGG 68 335 1062517 N/A N/A N/A N/A GGCGAGGCTCCTGAGA 92 626 1062549 N/A N/A 684 699 TACCTGGCTGGAATCA 101  336 1062581 N/A N/A 866 881 ACAGCATTTCAAGTTG 132  337 1062613 N/A N/A 1108 1123 GATCGATGGAGTGTGG 65 338 1062645 N/A N/A 1237 1252 AATGTAAAGGTCCTCG 27 339 1062678 N/A N/A 1337 1352 AAAGCGATACAAGCAA 87 340 1062710 N/A N/A 1475 1490 AGCCCTGAACAACCTG 85 341 1062742 N/A N/A 1721 1736 CGGCACTTGGTCAAAT 96 342 1062774 N/A N/A 1877 1892 ATAGGACAACCTTTTG 113  343 1062806 N/A N/A 2074 2089 CTATTAGGAGTAAGGA 70 344 1062838 N/A N/A 2159 2174 TATATGTAATGGCTGA 25 345 1062870 N/A N/A 2391 2406 CCTCTATAGTAAATGG 108  346 1062902 N/A N/A 2585 2600 GCTAAGTATTTACTGT 52 347 1062934 N/A N/A 2731 2746 AATAGTCAGTCCATTA 78 348 1062966 N/A N/A 2866 2881 GAAAGCTTGGACATGG 47 349 1062998 N/A N/A 3067 3082 GCGAGAGGAGGATTGC 103  350 1063030 N/A N/A 3244 3259 ATTAGGTGTCTGCAGG 45 351 1063062 N/A N/A 3389 3404 GAGATCTAGGCTTGGA 26 352 1063094 N/A N/A 3641 3656 ATCACCACGCTCTGGC 38 353 1063126 N/A N/A 3863 3878 CCAAATACATGGCCAC 73 354 1063158 N/A N/A 4102 4117 ATCATAGAACAGCATT 26 355 1063190 N/A N/A 4223 4238 AGACCTGGCCCTTCTT 125  356 1063222 N/A N/A 4402 4417 CCGGGCTTCATCGACA 108  357 1063253 N/A N/A 4555 4570 TCCCTTTCTGACTGGG 108  358 1063285 N/A N/A 4710 4725 AGAGCTAAGAATTCTC 108  359 1063317 N/A N/A 5080 5095 CTGGGAGAGCACTGGT 111  360 1063349 N/A N/A 5274 5289 GTATAGAAGGGTTCTG 64 361 1063381 N/A N/A 5482 5497 CAGCCAACCCCATTAT 139  362 1063413 N/A N/A 5655 5670 CTGTCCAAGCCACGCA 79 363 1063445 N/A N/A 5855 5870 AGGAGGCGAGTCCAGG 92 364 1063477 N/A N/A 6012 6027 AAGGACCGAGCTGACA 53 365 1063509 N/A N/A 6133 6148 GCGAGAAGTGGGTAGA 47 366 1063541 N/A N/A 6280 6295 TCCTCGGAGTCCTATT 116  367 1063573 N/A N/A 6449 6464 GGCTTGCCTGCCCACG 134  368 1063605 N/A N/A 6969 6984 GTCCAGGTACCCCACC 65 369 1063637 N/A N/A 7171 7186 ACAATACGGCCTCCTC 92 370 1063669 N/A N/A 7376 7391 ACTGCAAGCCCACATG 56 371 1063701 N/A N/A 7802 7817 CTGAGGTGTTACCAGG 78 372 1063733 N/A N/A 7968 7983 CTGCATCTTTAAGGTT 56 373 1063765 N/A N/A 8045 8060 GCTTAAAGACGGCCAT 96 374 1063796 N/A N/A 8559 8574 ACTTATTGGGATGAAG 70 375 1063828 N/A N/A 8848 8863 GTAGCAGGGCAAAGCA 156  376 1063860 N/A N/A 9051 9066 TAAGGGTTGTGTGTAG 136  377 1063892 N/A N/A 9413 9428 TGCCTAAGTAGGGAGA 103  378 1063924 N/A N/A 9644 9659 AGGCTACGGTCTTCCC 67 379 1063956 N/A N/A 9960 9975 AGAGGGTTTGTAAGTA 78 380 1063988 N/A N/A 10527 10542 ATAAATTACCACCAGC 41 381 1064020 N/A N/A 10757 10772 TTTCAAAGCAAGGACG 81 382 1064052 N/A N/A 11379 11394 ATGGAGCTCCTTTGCA 89 383 1064084 N/A N/A 11550 11565 AGGCATGGCCCCAATC 168  384 1064118 N/A N/A 11622 11637 GCTCCTGGAATTACTT 91 385 1064150 N/A N/A 11717 11732 GCTAAGCCCACAGGCC 81 386 1064182 N/A N/A 11803 11818 TGAAAAGAAGCGGAGT 80 387 1064214 N/A N/A 11910 11925 CGTCAACACCCGTGTC 114  388 1064246 N/A N/A 11978 11993 GCAGGACCTCCTAGCT 104  389 1064278 N/A N/A 12199 12214 GGAATGGAGGAACCCA 133  390 1064310 N/A N/A 12384 12399 TCCAGGAGAGGGTTAG 45 391 1064342 N/A N/A 12578 12593 ATCAAATGGGTGTTAC 89 392 1064374 N/A N/A 12781 12796 AGTCAGCGATGATGAT 64 393 1064406 N/A N/A 12924 12939 GAATTATCGAGTATCT 99 394 1064438 N/A N/A 13217 13232 AAGGGATCAGGACTGA 112  395

TABLE 10 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC 19 250  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 41  65 1062006 2 17 402 417 TTTCGATGAGTGTGTG 31 396 1062038 119 134 519 534 CCTGGCTTGTGGGAAA 86 397 1062070 311 326 6849 6864 CTGGAAGGTTCCCCCT 131  398 1062102 424 439 7489 7504 GCCCCGGAGGGTGCCA 99 399 1062134 595 610 7758 7773 AAGACCCCAGTGGCGG 57 400 1062166 754 769 8400 8415 AGCAGTGGGTAGGAGC 37 401 1062198 876 891 9466 9481 GGAGGAGACATTGTGC 107  402 1062230 1050 1065 11206 11221 GGACGACAGGGCCTTG 81 403 1062262 1183 1198 12053 12068 CGCATGTTGTGGAACT  66* 404 1062294 1426 1441 13836 13851 CTCCGTTTCTTGCGGA 115  405 1062326 1593 1608 14003 14018 CAGTGGAAACCTCACT 118  406 1062358 1852 1867 14262 14277 GAGGGACAGGATTGTG 68 407 1062390 2028 2043 14438 14453 GGGCACACCCCTGTGT 128  408 1062422 2209 2224 14619 14634 TTGGCAAGGCAGTGTG 19 409 1062454 N/A N/A 8299 8314 CACTGACCTGTCCTTC 70 410 1062486 N/A N/A 13601 13616 CTGCGATGGCACTTGA 114  411 1062550 N/A N/A 685 700 TTACCTGGCTGGAATC 129  412 1062582 N/A N/A 867 882 GACAGCATTTCAAGTT 42 413 1062614 N/A N/A 1109 1124 AGATCGATGGAGTGTG 59 414 1062646 N/A N/A 1238 1253 AAATGTAAAGGTCCTC 40 415 1062679 N/A N/A 1338 1353 TAAAGCGATACAAGCA 82 416 1062711 N/A N/A 1476 1491 CAGCCCTGAACAACCT 123  417 1062743 N/A N/A 1723 1738 ATCGGCACTTGGTCAA 44 418 1062775 N/A N/A 1878 1893 AATAGGACAACCTTTT 74 419 1062807 N/A N/A 2075 2090 CCTATTAGGAGTAAGG 127  420 1062839 N/A N/A 2160 2175 ATATATGTAATGGCTG 24 421 1062871 N/A N/A 2392 2407 ACCTCTATAGTAAATG 103  422 1062903 N/A N/A 2609 2624 GGTTTATTGTGTGTCA  5 423 1062935 N/A N/A 2732 2747 GAATAGTCAGTCCATT 64 424 1062967 N/A N/A 2868 2883 TAGAAAGCTTGGACAT 100  425 1062999 N/A N/A 3069 3084 GTGCGAGAGGAGGATT 71 426 1063031 N/A N/A 3245 3260 CATTAGGTGTCTGCAG 59 427 1063063 N/A N/A 3390 3405 TGAGATCTAGGCTTGG 23 428 1063095 N/A N/A 3642 3657 CATCACCACGCTCTGG 117  429 1063127 N/A N/A 3864 3879 CCCAAATACATGGCCA 40 430 1063159 N/A N/A 4104 4119 GAATCATAGAACAGCA 39 431 1063191 N/A N/A 4228 4243 TCTGAAGACCTGGCCC 61 432 1063223 N/A N/A 4406 4421 TGCGCCGGGCTTCATC 78 433 1063254 N/A N/A 4575 4590 CTGCACTGTCTGTTGG 93 434 1063286 N/A N/A 4712 4727 CCAGAGCTAAGAATTC 69 435 1063318 N/A N/A 5083 5098 GGCCTGGGAGAGCACT 71 436 1063350 N/A N/A 5276 5291 GAGTATAGAAGGGTTC 70 437 1063382 N/A N/A 5496 5511 TGGAAGGGACTGCCCA 119  438 1063414 N/A N/A 5656 5671 CCTGTCCAAGCCACGC 51 439 1063446 N/A N/A 5856 5871 AAGGAGGCGAGTCCAG 127  440 1063478 N/A N/A 6013 6028 GAAGGACCGAGCTGAC 104  441 1063510 N/A N/A 6135 6150 AGGCGAGAAGTGGGTA 43 442 1063542 N/A N/A 6281 6296 CTCCTCGGAGTCCTAT 33 443 1063574 N/A N/A 6455 6470 GCACCTGGCTTGCCTG 59 444 1063606 N/A N/A 6981 6996 CGGCACCTGTAGGTCC 113  445 1063638 N/A N/A 7172 7187 TACAATACGGCCTCCT 54 446 1063670 N/A N/A 7377 7392 CACTGCAAGCCCACAT 48 447 1063702 N/A N/A 7803 7818 GCTGAGGTGTTACCAG 76 448 1063734 N/A N/A 7980 7995 GATTTTGACATTCTGC  3 449 1063766 N/A N/A 8046 8061 AGCTTAAAGACGGCCA 116  450 1063797 N/A N/A 8560 8575 TACTTATTGGGATGAA 42 451 1063829 N/A N/A 8850 8865 GAGTAGCAGGGCAAAG 112  452 1063861 N/A N/A 9052 9067 CTAAGGGTTGTGTGTA 69 453 1063893 N/A N/A 9414 9429 GTGCCTAAGTAGGGAG 48 454 1063925 N/A N/A 9645 9660 CAGGCTACGGTCTTCC 113  455 1063957 N/A N/A 9961 9976 CAGAGGGTTTGTAAGT 75 456 1063989 N/A N/A 10541 10556 TCGCATCATGAGAAAT 58 457 1064021 N/A N/A 11113 11128 GCTTAAACTTCCCACT 118  458 1064053 N/A N/A 11380 11395 CATGGAGCTCCTTTGC 122  459 1064085 N/A N/A 11551 11566 GAGGCATGGCCCCAAT 143  460 1064119 N/A N/A 11633 11648 GGAAAGGAGGTGCTCC 125  461 1064151 N/A N/A 11719 11734 CTGCTAAGCCCACAGG 86 462 1064183 N/A N/A 11804 11819 TTGAAAAGAAGCGGAG 55 463 1064215 N/A N/A 11913 11928 CACCGTCAACACCCGT 58 464 1064247 N/A N/A 11980 11995 ATGCAGGACCTCCTAG 131  465 1064279 N/A N/A 12200 12215 GGGAATGGAGGAACCC 113  466 1064311 N/A N/A 12385 12400 GTCCAGGAGAGGGTTA 88 467 1064343 N/A N/A 12579 12594 GATCAAATGGGTGTTA 81 468 1064375 N/A N/A 12784 12799 CAGAGTCAGCGATGAT 98 469 1064407 N/A N/A 12925 12940 TGAATTATCGAGTATC 86 470 1064439 N/A N/A 13219 13234 GTAAGGGATCAGGACT 66 471

TABLE 11 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC 18 250  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 36  65 1062008 4 19 404 419 TTTTTCGATGAGTGTG 13 472 1062040 128 143 528 543 AAGGATCAGCCTGGCT 111  473 1062072 313 328 6851 6866 CCCTGGAAGGTTCCCC 92 474 1062104 459 474 7524 7539 GGAGTGCCTGTAAGTG 78 475 1062136 597 612 7760 7775 AGAAGACCCCAGTGGC 98 476 1062168 766 781 8412 8427 ACACCATTTGCCAGCA 119  477 1062200 878 893 9468 9483 CTGGAGGAGACATTGT 64 478 1062232 1091 1106 11247 11262 AAACAGGCTGTCAGGG 129  479 1062264 1185 1200 12055 12070 GTCGCATGTTGTGGAA   5* 480 1062296 1430 1445 13840 13855 CTGGCTCCGTTTCTTG 91 481 1062328 1595 1610 14005 14020 GACAGTGGAAACCTCA 71 482 1062360 1854 1869 14264 14279 GTGAGGGACAGGATTG 76 483 1062392 2040 2055 14450 14465 GTGTAGGCCTCTGGGC 201  484 1062424 2212 2227 14622 14637 TTTTTGGCAAGGCAGT 154  485 1062456 N/A N/A 8301 8316 TCCACTGACCTGTCCT 74 486 1062488 N/A N/A 13603 13618 AGCTGCGATGGCACTT 123  487 1062520 N/A N/A 553 568 ACCTTGGTGAAGTGGA 60 488 1062552 N/A N/A 687 702 CCTTACCTGGCTGGAA 130  489 1062584 N/A N/A 879 894 CAGTTGCACCTGGACA 81 490 1062616 N/A N/A 1111 1126 GGAGATCGATGGAGTG 93 491 1062648 N/A N/A 1259 1274 GAACTGATGCTCACTC 78 492 1062681 N/A N/A 1340 1355 TCTAAAGCGATACAAG 104  493 1062713 N/A N/A 1490 1505 AATCGAGCTCACCCCA 208  494 1062745 N/A N/A 1726 1741 ACAATCGGCACTTGGT 84 495 1062777 N/A N/A 1886 1901 GAGCATAAAATAGGAC 93 496 1062809 N/A N/A 2077 2092 ACCCTATTAGGAGTAA 133  497 1062841 N/A N/A 2234 2249 CATCATAAGCATCACA 101  498 1062873 N/A N/A 2396 2411 CTTAACCTCTATAGTA 106  499 1062905 N/A N/A 2616 2631 GATCTTGGGTTTATTG 207  500 1062937 N/A N/A 2735 2750 AGTGAATAGTCAGTCC 76 501 1062969 N/A N/A 2905 2920 CCTGGTATAAGAACAG 86 502 1063001 N/A N/A 3100 3115 GGACACATGCATGGAG 95 503 1063033 N/A N/A 3248 3263 AGTCATTAGGTGTCTG 49 504 1063065 N/A N/A 3392 3407 CCTGAGATCTAGGCTT 77 505 1063097 N/A N/A 3658 3673 ACTGACATGCCTCCAT 32 506 1063129 N/A N/A 3884 3899 GTCCACTCTGGAACAA 123  507 1063161 N/A N/A 4123 4138 GTATAACACCAGGACC 135  508 1063193 N/A N/A 4236 4251 CCCCTAGCTCTGAAGA 106  509 1063225 N/A N/A 4414 4429 CGGCCGGATGCGCCGG 158  510 1063256 N/A N/A 4584 4599 GCCGGCTTCCTGCACT 145  511 1063288 N/A N/A 4714 4729 GGCCAGAGCTAAGAAT 52 512 1063320 N/A N/A 5094 5109 CTCCGAACAAGGGCCT 41 513 1063352 N/A N/A 5313 5328 CTGAGTTGGGCACACA 93 514 1063384 N/A N/A 5521 5536 TCCTGGTCTGAGAGGA 170  515 1063416 N/A N/A 5686 5701 GCCTCAAATGCCCACT 91 516 1063448 N/A N/A 5858 5873 GCAAGGAGGCGAGTCC 57 517 1063480 N/A N/A 6015 6030 TGGAAGGACCGAGCTG 101  518 1063512 N/A N/A 6139 6154 GAGAAGGCGAGAAGTG 109  519 1063544 N/A N/A 6293 6308 GTCTCGGACTTTCTCC 217  520 1063576 N/A N/A 6483 6498 CCACACATGCCCCACG 95 521 1063608 N/A N/A 6983 6998 GTCGGCACCTGTAGGT 122  522 1063640 N/A N/A 7175 7190 GACTACAATACGGCCT 83 523 1063672 N/A N/A 7382 7397 CTCTGCACTGCAAGCC 91 524 1063704 N/A N/A 7867 7882 AGCCTACACTGCTCAC 69 525 1063736 N/A N/A 8001 8016 TGTAAAGCTCTGTGGT 61 526 1063768 N/A N/A 8048 8063 GAAGCTTAAAGACGGC 34 527 1063799 N/A N/A 8563 8578 TACTACTTATTGGGAT 158  528 1063831 N/A N/A 8852 8867 AGGAGTAGCAGGGCAA 76 529 1063863 N/A N/A 9054 9069 TGCTAAGGGTTGTGTG 108  530 1063895 N/A N/A 9425 9440 TCCGCCTGGCAGTGCC 25 531 1063927 N/A N/A 9687 9702 ACATGAGGCCTCAGCC 111  532 1063959 N/A N/A 9963 9978 GTCAGAGGGTTTGTAA 63 533 1063991 N/A N/A 10543 10558 ATTCGCATCATGAGAA 188  534 1064023 N/A N/A 11115 11130 AGGCTTAAACTTCCCA 119  535 1064055 N/A N/A 11383 11398 CAGCATGGAGCTCCTT 98 536 1064087 N/A N/A 11554 11569 GGTGAGGCATGGCCCC 86 537 1064121 N/A N/A 11653 11668 GATTTTCCTTGGTCAG 51 538 1064153 N/A N/A 11728 11743 CTCTGATCCCTGCTAA 139  539 1064185 N/A N/A 11810 11825 CCGAGGTTGAAAAGAA 150  540 1064217 N/A N/A 11919 11934 AGATCTCACCGTCAAC 142  541 1064249 N/A N/A 11984 11999 CCCCATGCAGGACCTC 96 542 1064281 N/A N/A 12202 12217 TTGGGAATGGAGGAAC 151  543 1064313 N/A N/A 12396 12411 CTATTTTATGGGTCCA 13 544 1064345 N/A N/A 12584 12599 TTAAGGATCAAATGGG 65 545 1064377 N/A N/A 12786 12801 TACAGAGTCAGCGATG 82 546 1064409 N/A N/A 12927 12942 TTTGAATTATCGAGTA 83 547 1064441 N/A N/A 13221 13236 AGGTAAGGGATCAGGA 150  548

TABLE 12 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC  17 250  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  53  65 1062009    5   20   405   420 TTTTTTCGATGAGTGT  35 549 1062041  143  158   543   558 AGTGGACTGACAGAAA 117 550 1062073  314  329  6852  6867 GCCCTGGAAGGTTCCC  94 551 1062105  461  476  7526  7541 GAGGAGTGCCTGTAAG 103 552 1062137  600  615  7763  7778 GGGAGAAGACCCCAGT 107 553 1062169  771  786  8417  8432 TGCAGACACCATTTGC 159 554 1062201  895  910  9485  9500 GACTGTACCATCTCTC 126 555 1062233 1098 1113 11254 11269 GGACAGCAAACAGGCT 122 556 1062265 1186 1201 12056 12071 GGTCGCATGTTGTGGA    1* 557 1062297 1433 1448 13843 13858 CCTCTGGCTCCGTTTC 110 558 1062329 1596 1611 14006 14021 AGACAGTGGAAACCTC 117 559 1062361 1856 1871 14266 14281 GAGTGAGGGACAGGAT  95 560 1062393 2041 2056 14451 14466 TGTGTAGGCCTCTGGG  32 561 1062425 2215 2230 14625 14640 GTATTTTTGGCAAGGC  14 562 1062457 N/A N/A  8304  8319 CTGTCCACTGACCTGT 160 563 1062489 N/A N/A 13609 13624 ACTTTGAGCTGCGATG  63 564 1062521 N/A N/A   554   569 CACCTTGGTGAAGTGG 144 565 1062553 N/A N/A   688   703 ACCTTACCTGGCTGGA 141 566 1062585 N/A N/A   880   895 TCAGTTGCACCTGGAC 118 567 1062617 N/A N/A  1112  1127 AGGAGATCGATGGAGT 100 568 1062649 N/A N/A  1260  1275 AGAACTGATGCTCACT  82 569 1062682 N/A N/A  1341  1356 CTCTAAAGCGATACAA 125 570 1062714 N/A N/A  1491  1506 GAATCGAGCTCACCCC 112 571 1062746 N/A N/A  1727  1742 AACAATCGGCACTTGG  56 572 1062778 N/A N/A  1887  1902 GGAGCATAAAATAGGA  97 573 1062810 N/A N/A  2078  2093 CACCCTATTAGGAGTA  95 574 1062842 N/A N/A  2235  2250 CCATCATAAGCATCAC  76 575 1062874 N/A N/A  2397  2412 TCTTAACCTCTATAGT 105 576 1062906 N/A N/A  2618  2633 CTGATCTTGGGTTTAT  63 577 1062938 N/A N/A  2736  2751 GAGTGAATAGTCAGTC  21 578 1062970 N/A N/A  2920  2935 GCAAAACAGTGTGGCC 112 579 1063002 N/A N/A  3125  3140 GATAGTGAGAGACATT  73 580 1063034 N/A N/A  3249  3264 AAGTCATTAGGTGTCT  77 581 1063066 N/A N/A  3393  3408 TCCTGAGATCTAGGCT 101 582 1063098 N/A N/A  3666  3681 CCTGACTGACTGACAT 148 583 1063130 N/A N/A  3886  3901 CTGTCCACTCTGGAAC 121 584 1063162 N/A N/A  4124  4139 AGTATAACACCAGGAC  54 585 1063194 N/A N/A  4243  4258 TGACAAGCCCCTAGCT 121 586 1063226 N/A N/A  4418  4433 ATGGCGGCCGGATGCG 103 587 1063257 N/A N/A  4586  4601 CAGCCGGCTTCCTGCA 124 588 1063289 N/A N/A  4719  4734 CACTTGGCCAGAGCTA  88 589 1063321 N/A N/A  5095  5110 GCTCCGAACAAGGGCC 177 590 1063353 N/A N/A  5314  5329 ACTGAGTTGGGCACAC  62 591 1063385 N/A N/A  5522  5537 ATCCTGGTCTGAGAGG 138 592 1063417 N/A N/A  5727  5742 CCAATTTCTGGCCCTC 115 593 1063449 N/A N/A  5859  5874 GGCAAGGAGGCGAGTC  65 594 1063481 N/A N/A  6016  6031 CTGGAAGGACCGAGCT  75 595 1063513 N/A N/A  6140  6155 GGAGAAGGCGAGAAGT  95 596 1063545 N/A N/A  6303  6318 GCCGGAGCTGGTCTCG 108 597 1063577 N/A N/A  6563  6578 CCATAGTTGCACCCCA 135 598 1063609 N/A N/A  6985  7000 AGGTCGGCACCTGTAG 126 599 1063641 N/A N/A  7176  7191 GGACTACAATACGGCC 118 600 1063673 N/A N/A  7387  7402 AAATACTCTGCACTGC 105 601 1063705 N/A N/A  7868  7883 TAGCCTACACTGCTCA 118 602 1063737 N/A N/A  8006  8021 AGCTTTGTAAAGCTCT 117 603 1063769 N/A N/A  8049  8064 AGAAGCTTAAAGACGG  11 604 1063800 N/A N/A  8564  8579 TTACTACTTATTGGGA 103 605 1063832 N/A N/A  8854  8869 TGAGGAGTAGCAGGGC  72 606 1063864 N/A N/A  9055  9070 CTGCTAAGGGTTGTGT 104 607 1063896 N/A N/A  9503  9518 ATTACCTGCTGCTCCA 142 608 1063928 N/A N/A  9688  9703 AACATGAGGCCTCAGC  80 609 1063960 N/A N/A 10283 10298 TCTTAGAGTCAGAGGG  45 610 1063992 N/A N/A 10545 10560 ACATTCGCATCATGAG  57 611 1064024 N/A N/A 11116 11131 GAGGCTTAAACTTCCC 104 612 1064056 N/A N/A 11386 11401 GGGCAGCATGGAGCTC 157 613 1064088 N/A N/A 11560 11575 AGAGTGGGTGAGGCAT 133 614 1064122 N/A N/A 11654 11669 CGATTTTCCTTGGTCA  42 615 1064154 N/A N/A 11729 11744 TCTCTGATCCCTGCTA  71 616 1064186 N/A N/A 11811 11826 CCCGAGGTTGAAAAGA 118 617 1064218 N/A N/A 11920 11935 GAGATCTCACCGTCAA  71 618 1064250 N/A N/A 11987 12002 AAGCCCCATGCAGGAC 154 619 1064282 N/A N/A 12240 12255 CATTTGAGGCACGGCT 140 620 1064314 N/A N/A 12399 12414 AGGCTATTTTATGGGT 102 621 1064346 N/A N/A 12585 12600 GTTAAGGATCAAATGG 117 622 1064378 N/A N/A 12787 12802 TTACAGAGTCAGCGAT 125 623 1064410 N/A N/A 12936 12951 CAGAGATGGTTTGAAT  67 624 1064442 N/A N/A 13222 13237 TAGGTAAGGGATCAGG  79 625

TABLE 13 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC  40 250  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  28  65 1062010    6   21   406   421 TTTTTTTCGATGAGTG  22 627 1062042  145  160   545   560 GAAGTGGACTGACAGA  58 628 1062074  316  331  6854  6869 CGGCCCTGGAAGGTTC 149 629 1062106  462  477  7527  7542 GGAGGAGTGCCTGTAA  89 630 1062138  614  629  7777  7792 AGGCCGGGCCTTGAGG 138 631 1062170  793  808  8439  8454 ACCTTCTCACATCCGG  61 632 1062202  896  911  9486  9501 AGACTGTACCATCTCT 135 633 1062234 1100 1115 11256 11271 CCGGACAGCAAACAGG 105 634 1062266 1248 1263 13478 13493 TCCGCTGCTTCTCTGG    7* 635 1062298 1449 1464 13859 13874 TGGAACACCTGCTGGG 231 636 1062330 1599 1614 14009 14024 GCAAGACAGTGGAAAC  88 637 1062362 1887 1902 14297 14312 GGCAGGCTCTCTGTGT  84 638 1062394 2042 2057 14452 14467 CTGTGTAGGCCTCTGG  50 639 1062426 2245 2260 14655 14670 GAGTGAGGTGAGTGGC  43 640 1062458 N/A N/A  8321  8336 GAGGATCCTTCCCAGC 156 641 1062490 N/A N/A 13610 13625 CACTTTGAGCTGCGAT 185 642 1062522 N/A N/A   555   570 TCACCTTGGTGAAGTG 137 643 1062554 N/A N/A   689   704 GACCTTACCTGGCTGG 105 644 1062586 N/A N/A   884   899 ATTTTCAGTTGCACCT 123 645 1062618 N/A N/A  1113  1128 AAGGAGATCGATGGAG 140 646 1062650 N/A N/A  1261  1276 CAGAACTGATGCTCAC  53 647 1062683 N/A N/A  1342  1357 CCTCTAAAGCGATACA  70 648 1062715 N/A N/A  1492  1507 AGAATCGAGCTCACCC  67 649 1062747 N/A N/A  1728  1743 CAACAATCGGCACTTG 117 650 1062779 N/A N/A  1889  1904 AGGGAGCATAAAATAG 135 651 1062811 N/A N/A  2079  2094 ACACCCTATTAGGAGT 101 652 1062843 N/A N/A  2237  2252 AACCATCATAAGCATC  78 653 1062875 N/A N/A  2398  2413 CTCTTAACCTCTATAG 133 654 1062907 N/A N/A  2619  2634 GCTGATCTTGGGTTTA  38 655 1062939 N/A N/A  2737  2752 TGAGTGAATAGTCAGT  59 656 1062971 N/A N/A  2940  2955 GTATTGCAAAGCAACA 217 657 1063003 N/A N/A  3133  3148 GAACAAGAGATAGTGA 118 658 1063035 N/A N/A  3251  3266 TTAAGTCATTAGGTGT  56 659 1063067 N/A N/A  3395  3410 AGTCCTGAGATCTAGG  55 660 1063099 N/A N/A  3668  3683 AGCCTGACTGACTGAC  52 661 1063131 N/A N/A  3905  3920 CCCTAGGGCCTCAGTC 144 662 1063163 N/A N/A  4125  4140 TAGTATAACACCAGGA  44 663 1063195 N/A N/A  4245  4260 TATGACAAGCCCCTAG 156 664 1063227 N/A N/A  4421  4436 GTCATGGCGGCCGGAT 121 665 1063258 N/A N/A  4589  4604 GGGCAGCCGGCTTCCT 209 666 1063290 N/A N/A  4720  4735 ACACTTGGCCAGAGCT 102 667 1063322 N/A N/A  5117  5132 ACAGGAGTGTGGGTCT 164 668 1063354 N/A N/A  5318  5333 CAGCACTGAGTTGGGC 106 669 1063386 N/A N/A  5524  5539 TAATCCTGGTCTGAGA 113 670 1063418 N/A N/A  5728  5743 CCCAATTTCTGGCCCT  95 671 1063450 N/A N/A  5860  5875 GGGCAAGGAGGCGAGT  76 672 1063482 N/A N/A  6017  6032 GCTGGAAGGACCGAGC 199 673 1063514 N/A N/A  6158  6173 GAATGGGCTGGTGGCA 103 674 1063546 N/A N/A  6363  6378 TTTCAAGCCTCAGGCC 169 675 1063578 N/A N/A  6565  6580 CCCCATAGTTGCACCC  48 676 1063610 N/A N/A  6986  7001 AAGGTCGGCACCTGTA 162 677 1063642 N/A N/A  7195  7210 ACACATAGCTATGCTC 125 678 1063674 N/A N/A  7388  7403 CAAATACTCTGCACTG 104 679 1063706 N/A N/A  7869  7884 ATAGCCTACACTGCTC 219 680 1063738 N/A N/A  8009  8024 ACTAGCTTTGTAAAGC 150 681 1063770 N/A N/A  8056  8071 CTGGCAGAGAAGCTTA 207 682 1063801 N/A N/A  8566  8581 TCTTACTACTTATTGG  88 683 1063833 N/A N/A  8856  8871 CATGAGGAGTAGCAGG 291 684 1063865 N/A N/A  9056  9071 GCTGCTAAGGGTTGTG 176 685 1063897 N/A N/A  9504  9519 CATTACCTGCTGCTCC 120 686 1063929 N/A N/A  9689  9704 AAACATGAGGCCTCAG 214 687 1063961 N/A N/A 10285 10300 GATCTTAGAGTCAGAG 111 688 1063993 N/A N/A 10547 10562 GTACATTCGCATCATG  80 689 1064025 N/A N/A 11117 11132 AGAGGCTTAAACTTCC 131 690 1064057 N/A N/A 11445 11460 CGGATGCATTTTCCCA 250 691 1064089 N/A N/A 11564 11579 GTCCAGAGTGGGTGAG  78 692 1064123 N/A N/A 11655 11670 CCGATTTTCCTTGGTC 111 693 1064155 N/A N/A 11735 11750 TCAAGGTCTCTGATCC  96 694 1064187 N/A N/A 11813 11828 TCCCCGAGGTTGAAAA 173 695 1064219 N/A N/A 11922 11937 CTGAGATCTCACCGTC 121 696 1064251 N/A N/A 11990 12005 ATCAAGCCCCATGCAG 144 697 1064283 N/A N/A 12241 12256 ACATTTGAGGCACGGC  86 698 1064315 N/A N/A 12430 12445 TAGGGCAAGGTGCAGA  86 699 1064347 N/A N/A 12586 12601 AGTTAAGGATCAAATG 172 700 1064379 N/A N/A 12788 12803 ATTACAGAGTCAGCGA 105 701 1064411 N/A N/A 12937 12952 CCAGAGATGGTTTGAA 186 702 1064443 N/A N/A 13223 13238 TTAGGTAAGGGATCAG 113 703

TABLE 14 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  895475 N/A N/A  4422  4437 CGTCATGGCGGCCGGA  96 704  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC  27 250  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  42  65 1062011    8   23   408   423 AATTTTTTTCGATGAG  80 705 1062043  146  161   546   561 TGAAGTGGACTGACAG  83 706 1062075  318  333  6856  6871 CTCGGCCCTGGAAGGT 106 707 1062107  463  478  7528  7543 TGGAGGAGTGCCTGTA  64 708 1062139  615  630  7778  7793 CAGGCCGGGCCTTGAG  95 709 1062171  796  811  8442  8457 AAGACCTTCTCACATC  80 710 1062203  897  912  9487  9502 GAGACTGTACCATCTC 145 711 1062235 1101 1116 11257 11272 TCCGGACAGCAAACAG 120 712 1062267 1251 1266 13481 13496 GTGTCCGCTGCTTCTC    3* 713 1062299 1450 1465 13860 13875 TTGGAACACCTGCTGG  48 714 1062331 1738 1753 14148 14163 TGCAGGGCTCGACTGG  42 715 1062363 1894 1909 14304 14319 GTACTGAGGCAGGCTC  57 716 1062395 2043 2058 14453 14468 TCTGTGTAGGCCTCTG  11 717 1062427 2268 2283 N/A N/A ATGGATCAGGGCTCAG  28 718 1062459 N/A N/A  8322  8337 CGAGGATCCTTCCCAG 144 719 1062491 N/A N/A 13611 13626 CCACTTTGAGCTGCGA  98 720 1062523 N/A N/A   556   571 CTCACCTTGGTGAAGT 131 721 1062555 N/A N/A   690   705 AGACCTTACCTGGCTG 108 722 1062587 N/A N/A   885   900 AATTTTCAGTTGCACC  96 723 1062619 N/A N/A  1114  1129 AAAGGAGATCGATGGA  80 724 1062651 N/A N/A  1263  1278 AACAGAACTGATGCTC  77 725 1062684 N/A N/A  1343  1358 TCCTCTAAAGCGATAC  99 726 1062716 N/A N/A  1493  1508 CAGAATCGAGCTCACC  58 727 1062748 N/A N/A  1730  1745 TCCAACAATCGGCACT  78 728 1062780 N/A N/A  1894  1909 AGTAGAGGGAGCATAA 100 729 1062812 N/A N/A  2080  2095 AACACCCTATTAGGAG  77 730 1062844 N/A N/A  2253  2268 CTATTTGACTGTATAA 134 731 1062876 N/A N/A  2407  2422 GTACCCACACTCTTAA 100 732 1062908 N/A N/A  2623  2638 TAATGCTGATCTTGGG  36 733 1062940 N/A N/A  2739  2754 ATTGAGTGAATAGTCA  69 734 1062972 N/A N/A  2943  2958 ATTGTATTGCAAAGCA  62 735 1063004 N/A N/A  3144  3159 CGAGCAAGAGAGAACA 126 736 1063036 N/A N/A  3252  3267 GTTAAGTCATTAGGTG  27 737 1063068 N/A N/A  3396  3411 GAGTCCTGAGATCTAG  62 738 1063100 N/A N/A  3710  3725 AATCAAGGTTTTCGGG  69 739 1063132 N/A N/A  3906  3921 TCCCTAGGGCCTCAGT  81 740 1063164 N/A N/A  4126  4141 ATAGTATAACACCAGG  31 741 1063196 N/A N/A  4246  4261 CTATGACAAGCCCCTA  96 742 1063259 N/A N/A  4591  4606 CTGGGCAGCCGGCTTC 104 743 1063291 N/A N/A  4721  4736 GACACTTGGCCAGAGC 100 744 1063323 N/A N/A  5118  5133 AACAGGAGTGTGGGTC  61 745 1063355 N/A N/A  5321  5336 TCACAGCACTGAGTTG  82 746 1063387 N/A N/A  5526  5541 TATAATCCTGGTCTGA 100 747 1063419 N/A N/A  5729  5744 CCCCAATTTCTGGCCC  54 748 1063451 N/A N/A  5862  5877 CAGGGCAAGGAGGCGA  77 749 1063483 N/A N/A  6018  6033 AGCTGGAAGGACCGAG  79 750 1063515 N/A N/A  6161  6176 ACAGAATGGGCTGGTG 118 751 1063547 N/A N/A  6367  6382 GCTGTTTCAAGCCTCA  67 752 1063579 N/A N/A  6582  6597 GGACATGTCCCGAGGG  51 753 1063611 N/A N/A  6987  7002 AAAGGTCGGCACCTGT 190 754 1063643 N/A N/A  7196  7211 GACACATAGCTATGCT 116 755 1063675 N/A N/A  7390  7405 TTCAAATACTCTGCAC 107 756 1063707 N/A N/A  7870  7885 AATAGCCTACACTGCT 205 757 1063739 N/A N/A  8010  8025 GACTAGCTTTGTAAAG  94 758 1063771 N/A N/A  8106  8121 CGAAAACCCTGACTCC 147 759 1063802 N/A N/A  8567  8582 ATCTTACTACTTATTG  93 760 1063834 N/A N/A  8857  8872 GCATGAGGAGTAGCAG  85 761 1063866 N/A N/A  9098  9113 GTGCAAAGGCCTGGCT 167 762 1063898 N/A N/A  9507  9522 TGGCATTACCTGCTGC 128 763 1063930 N/A N/A  9690  9705 CAAACATGAGGCCTCA 127 764 1063962 N/A N/A 10301 10316 GATCACAGTGTTTGGG  30 765 1063994 N/A N/A 10578 10593 TAAACCCCCCTGGCCT  65 766 1064026 N/A N/A 11119 11134 CCAGAGGCTTAAACTT 120 767 1064058 N/A N/A 11448 11463 GAGCGGATGCATTTTC  69 768 1064090 N/A N/A 11573 11588 GTAGCTGGAGTCCAGA  61 769 1064124 N/A N/A 11656 11671 CCCGATTTTCCTTGGT 154 770 1064156 N/A N/A 11736 11751 GTCAAGGTCTCTGATC 100 771 1064188 N/A N/A 11821 11836 AATAGTTCTCCCCGAG  95 772 1064220 N/A N/A 11923 11938 CCTGAGATCTCACCGT 153 773 1064252 N/A N/A 11991 12006 AATCAAGCCCCATGCA 133 774 1064284 N/A N/A 12278 12293 TGCGGACAGGTTTGGG  30 775 1064316 N/A N/A 12432 12447 TTTAGGGCAAGGTGCA  85 776 1064348 N/A N/A 12587 12602 AAGTTAAGGATCAAAT 122 777 1064380 N/A N/A 12789 12804 GATTACAGAGTCAGCG 102 778 1064412 N/A N/A 12950 12965 TTTAGGTCAGAAGCCA 171 779 1064444 N/A N/A 13224 13239 ATTAGGTAAGGGATCA 122 780

TABLE 15 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC   9  65 1062012   10   25   410   425 CAAATTTTTTTCGATG  65 781 1062044  149  164   549   564 TGGTGAAGTGGACTGA  25 782 1062076  319  334  6857  6872 TCTCGGCCCTGGAAGG  89 783 1062108  464  479  7529  7544 CTGGAGGAGTGCCTGT  74 784 1062140  633  648 N/A N/A TGATCCCAGGTGGGAG  92 785 1062172  798  813  8444  8459 CGAAGACCTTCTCACA 106 786 1062204  901  916  9491  9506 TCCAGAGACTGTACCA  76 787 1062236 1102 1117 11258 11273 CTCCGGACAGCAAACA  92 788 1062268 1253 1268 13483 13498 GAGTGTCCGCTGCTTC    5* 789 1062300 1453 1468 13863 13878 GGGTTGGAACACCTGC  85 790 1062332 1740 1755 14150 14165 GCTGCAGGGCTCGACT  60 791 1062364 1895 1910 14305 14320 TGTACTGAGGCAGGCT  42 792 1062396 2050 2065 14460 14475 CGCTGCTTCTGTGTAG  31 793 1062428 2269 2284 N/A N/A CATGGATCAGGGCTCA  28 794 1062460 N/A N/A  8323  8338 GCGAGGATCCTTCCCA  73 795 1062492 N/A N/A 13612 13627 CCCACTTTGAGCTGCG  55 796 1062524 N/A N/A   557   572 ACTCACCTTGGTGAAG 112 797 1062556 N/A N/A   691   706 AAGACCTTACCTGGCT  72 798 1062588 N/A N/A   928   943 CATCAAGAGCTAAGAG  96 799 1062620 N/A N/A  1115  1130 GAAAGGAGATCGATGG  72 800 1062652 N/A N/A  1265  1280 TGAACAGAACTGATGC  36 801 1062685 N/A N/A  1350  1365 AAGGGTCTCCTCTAAA  62 802 1062717 N/A N/A  1494  1509 GCAGAATCGAGCTCAC  53 803 1062749 N/A N/A  1731  1746 GTCCAACAATCGGCAC  57 804 1062781 N/A N/A  1895  1910 AAGTAGAGGGAGCATA  41 805 1062813 N/A N/A  2081  2096 GAACACCCTATTAGGA  63 806 1062845 N/A N/A  2255  2270 ACCTATTTGACTGTAT  56 807 1062877 N/A N/A  2408  2423 AGTACCCACACTCTTA  52 808 1062909 N/A N/A  2624  2639 CTAATGCTGATCTTGG  22 809 1062941 N/A N/A  2741  2756 TTATTGAGTGAATAGT  54 810 1062973 N/A N/A  2945  2960 GAATTGTATTGCAAAG  45 811 1063005 N/A N/A  3145  3160 GCGAGCAAGAGAGAAC  58 812 1063037 N/A N/A  3253  3268 GGTTAAGTCATTAGGT  19 813 1063069 N/A N/A  3398  3413 TAGAGTCCTGAGATCT  95 814 1063101 N/A N/A  3713  3728 CACAATCAAGGTTTTC  21 815 1063133 N/A N/A  3946  3961 TAGGGCCTCTTGCCTA 110 816 1063165 N/A N/A  4127  4142 AATAGTATAACACCAG  35 817 1063197 N/A N/A  4249  4264 CCACTATGACAAGCCC  29 818 1063228 N/A N/A  4438  4453 ATTTTTCCGCCATTGA  76 819 1063260 N/A N/A  4608  4623 GGACCTAGAGGGCCGG  69 820 1063292 N/A N/A  4722  4737 GGACACTTGGCCAGAG  53 821 1063324 N/A N/A  5125  5140 CGTGAGAAACAGGAGT  20 822 1063356 N/A N/A  5331  5346 CCGTTCCACCTCACAG  38 823 1063388 N/A N/A  5527  5542 CTATAATCCTGGTCTG  64 824 1063420 N/A N/A  5739  5754 TCAGAGTTCACCCCAA  48 825 1063452 N/A N/A  5863  5878 TCAGGGCAAGGAGGCG  61 826 1063484 N/A N/A  6019  6034 CAGCTGGAAGGACCGA  87 827 1063516 N/A N/A  6162  6177 CACAGAATGGGCTGGT  46 828 1063548 N/A N/A  6374  6389 CTTGAGAGCTGTTTCA  59 829 1063580 N/A N/A  6584  6599 TGGGACATGTCCCGAG  59 830 1063612 N/A N/A  6988  7003 TAAAGGTCGGCACCTG  84 831 1063644 N/A N/A  7197  7212 GGACACATAGCTATGC  43 832 1063676 N/A N/A  7424  7439 GAGGCCATCCTGATCC  52 833 1063708 N/A N/A  7871  7886 GAATAGCCTACACTGC  75 834 1063740 N/A N/A  8012  8027 TTGACTAGCTTTGTAA  34 835 1063772 N/A N/A  8107  8122 TCGAAAACCCTGACTC  75 836 1063803 N/A N/A  8580  8595 GTTTAGCTCTTGCATC  41 837 1063835 N/A N/A  8860  8875 TTGGCATGAGGAGTAG  61 838 1063867 N/A N/A  9107  9122 GGACGGCCTGTGCAAA  81 839 1063899 N/A N/A  9508  9523 CTGGCATTACCTGCTG  91 840 1063931 N/A N/A  9691  9706 ACAAACATGAGGCCTC  74 841 1063963 N/A N/A 10305 10320 TCAGGATCACAGTGTT  19 842 1063995 N/A N/A 10579 10594 CTAAACCCCCCTGGCC  71 843 1064027 N/A N/A 11120 11135 CCCAGAGGCTTAAACT  87 844 1064059 N/A N/A 11449 11464 TGAGCGGATGCATTTT  59 845 1064091 N/A N/A 11575 11590 TAGTAGCTGGAGTCCA  16 846 1064125 N/A N/A 11657 11672 CCCCGATTTTCCTTGG  32 847 1064157 N/A N/A 11737 11752 AGTCAAGGTCTCTGAT  75 848 1064189 N/A N/A 11822 11837 AAATAGTTCTCCCCGA  42 849 1064221 N/A N/A 11924 11939 GCCTGAGATCTCACCG  42 850 1064253 N/A N/A 11992 12007 GAATCAAGCCCCATGC  75 851 1064285 N/A N/A 12282 12297 GATTTGCGGACAGGTT  67 852 1064317 N/A N/A 12433 12448 GTTTAGGGCAAGGTGC  77 853 1064349 N/A N/A 12589 12604 TGAAGTTAAGGATCAA  69 854 1064381 N/A N/A 12793 12808 ATGGGATTACAGAGTC  40 855 1064413 N/A N/A 12951 12966 CTTTAGGTCAGAAGCC  72 856 1064445 N/A N/A 13225 13240 GATTAGGTAAGGGATC 104 857

TABLE 16 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  29  65 1062007    3   18   403   418 TTTTCGATGAGTGTGT  12 858 1062039  121  136   521   536 AGCCTGGCTTGTGGGA  68 859 1062071  312  327  6850  6865 CCTGGAAGGTTCCCCC  65 860 1062103  425  440  7490  7505 TGCCCCGGAGGGTGCC  87 861 1062135  596  611  7759  7774 GAAGACCCCAGTGGCG  47 862 1062167  762  777  8408  8423 CATTTGCCAGCAGTGG  76 863 1062199  877  892  9467  9482 TGGAGGAGACATTGTG  63 864 1062231 1060 1075 11216 11231 GACCAGGCTGGGACGA  42 865 1062263 1184 1199 12054 12069 TCGCATGTTGTGGAAC    2* 866 1062295 1428 1443 13838 13853 GGCTCCGTTTCTTGCG 214 867 1062327 1594 1609 14004 14019 ACAGTGGAAACCTCAC  48 868 1062359 1853 1868 14263 14278 TGAGGGACAGGATTGT  75 869 1062391 2037 2052 14447 14462 TAGGCCTCTGGGCACA  67 870 1062423 2211 2226 14621 14636 TTTTGGCAAGGCAGTG  54 871 1062455 N/A N/A  8300  8315 CCACTGACCTGTCCTT 114 872 1062487 N/A N/A 13602 13617 GCTGCGATGGCACTTG  74 873 1062551 N/A N/A   686   701 CTTACCTGGCTGGAAT  78 874 1062583 N/A N/A   868   883 GGACAGCATTTCAAGT  60 875 1062615 N/A N/A  1110  1125 GAGATCGATGGAGTGT  61 876 1062647 N/A N/A  1251  1266 GCTCACTCTCATAAAA  67 877 1062680 N/A N/A  1339  1354 CTAAAGCGATACAAGC  43 878 1062712 N/A N/A  1489  1504 ATCGAGCTCACCCCAG  11 879 1062744 N/A N/A  1725  1740 CAATCGGCACTTGGTC  46 880 1062776 N/A N/A  1879  1894 AAATAGGACAACCTTT  74 881 1062808 N/A N/A  2076  2091 CCCTATTAGGAGTAAG  58 882 1062840 N/A N/A  2162  2177 CTATATATGTAATGGC  14 883 1062872 N/A N/A  2395  2410 TTAACCTCTATAGTAA  58 884 1062904 N/A N/A  2615  2630 ATCTTGGGTTTATTGT  21 885 1062936 N/A N/A  2733  2748 TGAATAGTCAGTCCAT  34 886 1062968 N/A N/A  2873  2888 CAGAATAGAAAGCTTG  60 887 1063000 N/A N/A  3088  3103 GGAGAGCCAGAGTGCA  81 888 1063032 N/A N/A  3247  3262 GTCATTAGGTGTCTGC   3 889 1063064 N/A N/A  3391  3406 CTGAGATCTAGGCTTG  46 890 1063096 N/A N/A  3645  3660 CATCATCACCACGCTC  60 891 1063128 N/A N/A  3865  3880 TCCCAAATACATGGCC  70 892 1063160 N/A N/A  4122  4137 TATAACACCAGGACCT  66 893 1063192 N/A N/A  4235  4250 CCCTAGCTCTGAAGAC  71 894 1063224 N/A N/A  4412  4427 GCCGGATGCGCCGGGC  84 895 1063255 N/A N/A  4582  4597 CGGCTTCCTGCACTGT  85 896 1063287 N/A N/A  4713  4728 GCCAGAGCTAAGAATT  64 897 1063319 N/A N/A  5093  5108 TCCGAACAAGGGCCTG  25 898 1063351 N/A N/A  5277  5292 GGAGTATAGAAGGGTT  35 899 1063383 N/A N/A  5497  5512 CTGGAAGGGACTGCCC  67 900 1063415 N/A N/A  5685  5700 CCTCAAATGCCCACTC  65 901 1063447 N/A N/A  5857  5872 CAAGGAGGCGAGTCCA  74 902 1063479 N/A N/A  6014  6029 GGAAGGACCGAGCTGA  40 903 1063511 N/A N/A  6136  6151 AAGGCGAGAAGTGGGT  24 904 1063543 N/A N/A  6290  6305 TCGGACTTTCTCCTCG  45 905 1063575 N/A N/A  6466  6481 GCAGAGGTCCAGCACC  70 906 1063607 N/A N/A  6982  6997 TCGGCACCTGTAGGTC  87 907 1063639 N/A N/A  7173  7188 CTACAATACGGCCTCC  62 908 1063671 N/A N/A  7378  7393 GCACTGCAAGCCCACA  40 909 1063703 N/A N/A  7804  7819 GGCTGAGGTGTTACCA  46 910 1063735 N/A N/A  8000  8015 GTAAAGCTCTGTGGTT  19 911 1063767 N/A N/A  8047  8062 AAGCTTAAAGACGGCC  59 912 1063798 N/A N/A  8562  8577 ACTACTTATTGGGATG  90 913 1063830 N/A N/A  8851  8866 GGAGTAGCAGGGCAAA  50 914 1063862 N/A N/A  9053  9068 GCTAAGGGTTGTGTGT  58 915 1063894 N/A N/A  9417  9432 GCAGTGCCTAAGTAGG  87 916 1063926 N/A N/A  9685  9700 ATGAGGCCTCAGCCTG 100 917 1063958 N/A N/A  9962  9977 TCAGAGGGTTTGTAAG  49 918 1063990 N/A N/A 10542 10557 TTCGCATCATGAGAAA 101 919 1064022 N/A N/A 11114 11129 GGCTTAAACTTCCCAC  91 920 1064054 N/A N/A 11382 11397 AGCATGGAGCTCCTTT  38 921 1064086 N/A N/A 11552 11567 TGAGGCATGGCCCCAA 106 922 1064120 N/A N/A 11652 11667 ATTTTCCTTGGTCAGG  30 923 1064152 N/A N/A 11727 11742 TCTGATCCCTGCTAAG  74 924 1064184 N/A N/A 11805 11820 GTTGAAAAGAAGCGGA  30 925 1064216 N/A N/A 11916 11931 TCTCACCGTCAACACC  81 926 1064248 N/A N/A 11981 11996 CATGCAGGACCTCCTA  59 927 1064280 N/A N/A 12201 12216 TGGGAATGGAGGAACC  68 928 1064312 N/A N/A 12394 12409 ATTTTATGGGTCCAGG  27 929 1064344 N/A N/A 12582 12597 AAGGATCAAATGGGTG  70 930 1064376 N/A N/A 12785 12800 ACAGAGTCAGCGATGA  75 931 1064408 N/A N/A 12926 12941 TTGAATTATCGAGTAT  83 932 1064440 N/A N/A 13220 13235 GGTAAGGGATCAGGAC  70 933

TABLE 17 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC  18 250  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  35  65 1062013   13   28   413   428 ATCCAAATTTTTTTCG  83 934 1062045  150  165   550   565 TTGGTGAAGTGGACTG  84 935 1062077  320  335  6858  6873 ATCTCGGCCCTGGAAG 114 936 1062109  466  481  7531  7546 TCCTGGAGGAGTGCCT  91 937 1062141  635  650 N/A N/A GTTGATCCCAGGTGGG  45 938 1062173  799  814  8445  8460 TCGAAGACCTTCTCAC 105 939 1062205  945  960  9740  9755 CCTGCATGGCACTCAG 104 940 1062237 1103 1118 11259 11274 CCTCCGGACAGCAAAC 133 941 1062269 1256 1271 13486 13501 ATTGAGTGTCCGCTGC   34* 942 1062301 1454 1469 13864 13879 AGGGTTGGAACACCTG 160 943 1062333 1742 1757 14152 14167 TGGCTGCAGGGCTCGA  57 944 1062365 1897 1912 14307 14322 AGTGTACTGAGGCAGG  25 945 1062397 2063 2078 14473 14488 CTGAGGGTACTGACGC  13 946 1062429 2270 2285 N/A N/A GCATGGATCAGGGCTC  69 947 1062461 N/A N/A  8324  8339 GGCGAGGATCCTTCCC 117 948 1062493 N/A N/A 13613 13628 GCCCACTTTGAGCTGC 122 949 1062525 N/A N/A   559   574 ACACTCACCTTGGTGA 152 950 1062557 N/A N/A   692   707 AAAGACCTTACCTGGC  41 951 1062589 N/A N/A   929   944 GCATCAAGAGCTAAGA 109 952 1062621 N/A N/A  1116  1131 GGAAAGGAGATCGATG 120 953 1062653 N/A N/A  1267  1282 GGTGAACAGAACTGAT  77 954 1062686 N/A N/A  1351  1366 CAAGGGTCTCCTCTAA 114 955 1062718 N/A N/A  1496  1511 CTGCAGAATCGAGCTC  54 956 1062750 N/A N/A  1747  1762 GAGAAACAACCGGAAT  91 957 1062782 N/A N/A  1896  1911 TAAGTAGAGGGAGCAT  39 958 1062814 N/A N/A  2083  2098 ATGAACACCCTATTAG  96 959 1062846 N/A N/A  2256  2271 AACCTATTTGACTGTA  93 960 1062878 N/A N/A  2409  2424 CAGTACCCACACTCTT 100 961 1062910 N/A N/A  2625  2640 CCTAATGCTGATCTTG  72 962 1062942 N/A N/A  2742  2757 GTTATTGAGTGAATAG  74 963 1062974 N/A N/A  2952  2967 GGGTATTGAATTGTAT  69 964 1063006 N/A N/A  3151  3166 CAAAGAGCGAGCAAGA  85 965 1063038 N/A N/A  3254  3269 TGGTTAAGTCATTAGG   6 966 1063070 N/A N/A  3399  3414 CTAGAGTCCTGAGATC  82 967 1063102 N/A N/A  3714  3729 CCACAATCAAGGTTTT  47 968 1063134 N/A N/A  3947  3962 ATAGGGCCTCTTGCCT 117 969 1063166 N/A N/A  4129  4144 CAAATAGTATAACACC 101 970 1063198 N/A N/A  4338  4353 CCGAGAACTGGCTGCC  51 971 1063229 N/A N/A  4439  4454 GATTTTTCCGCCATTG 120 972 1063261 N/A N/A  4610  4625 GAGGACCTAGAGGGCC 100 973 1063293 N/A N/A  4725  4740 CCTGGACACTTGGCCA 142 974 1063325 N/A N/A  5139  5154 TTAGAACATTACTGCG  46 975 1063357 N/A N/A  5370  5385 TAAACTCTCTGGTGTG  88 976 1063389 N/A N/A  5528  5543 CCTATAATCCTGGTCT  43 977 1063421 N/A N/A  5744  5759 CCCCATCAGAGTTCAC  59 978 1063453 N/A N/A  5870  5885 CTGGATCTCAGGGCAA  93 979 1063485 N/A N/A  6020  6035 GCAGCTGGAAGGACCG  78 980 1063517 N/A N/A  6192  6207 TGTAACAGTCCTGGCA 118 981 1063549 N/A N/A  6377  6392 CCACTTGAGAGCTGTT  46 982 1063581 N/A N/A  6585  6600 CTGGGACATGTCCCGA 159 983 1063613 N/A N/A  6989  7004 GTAAAGGTCGGCACCT 113 984 1063645 N/A N/A  7240  7255 ACCTACTTGGCCCCAG  67 985 1063677 N/A N/A  7427  7442 TGAGAGGCCATCCTGA  93 986 1063709 N/A N/A  7872  7887 AGAATAGCCTACACTG  88 987 1063741 N/A N/A  8013  8028 TTTGACTAGCTTTGTA  65 988 1063773 N/A N/A  8109  8124 CCTCGAAAACCCTGAC  39 989 1063804 N/A N/A  8582  8597 GAGTTTAGCTCTTGCA  20 990 1063836 N/A N/A  8863  8878 ATGTTGGCATGAGGAG  70 991 1063868 N/A N/A  9108  9123 GGGACGGCCTGTGCAA 104 992 1063900 N/A N/A  9524  9539 CTTACCCTCCACCGCC  83 993 1063932 N/A N/A  9692  9707 CACAAACATGAGGCCT  45 994 1063964 N/A N/A 10306 10321 CTCAGGATCACAGTGT  47 995 1063996 N/A N/A 10580 10595 CCTAAACCCCCCTGGC 124 996 1064028 N/A N/A 11121 11136 ACCCAGAGGCTTAAAC 111 997 1064060 N/A N/A 11450 11465 GTGAGCGGATGCATTT  60 998 1064092 N/A N/A 11577 11592 TATAGTAGCTGGAGTC  65 999 1064126 N/A N/A 11658 11673 ACCCCGATTTTCCTTG  74 1000 1064158 N/A N/A 11741 11756 TGACAGTCAAGGTCTC 113 1001 1064190 N/A N/A 11823 11838 AAAATAGTTCTCCCCG  41 1002 1064222 N/A N/A 11926 11941 AGGCCTGAGATCTCAC  70 1003 1064254 N/A N/A 11993 12008 TGAATCAAGCCCCATG 125 1004 1064286 N/A N/A 12283 12298 GGATTTGCGGACAGGT  16 1005 1064318 N/A N/A 12434 12449 CGTTTAGGGCAAGGTG  97 1006 1064350 N/A N/A 12616 12631 TGAGATGAAGGAGTTG 142 1007 1064382 N/A N/A 12795 12810 GAATGGGATTACAGAG  92 1008 1064414 N/A N/A 12952 12967 GCTTTAGGTCAGAAGC 105 1009 1064446 N/A N/A 13226 13241 GGATTAGGTAAGGGAT 105 1010

TABLE 18 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC  18  250  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  42   65 1062014   35   50   435   450 CGCAGACCTCTCTCTT  57 1011 1062046  151  166   551   566 CTTGGTGAAGTGGACT  67 1012 1062078  321  336  6859  6874 GATCTCGGCCCTGGAA  33 1013 1062110  467  482  7532  7547 GTCCTGGAGGAGTGCC  69 1014 1062142  658  673  8235  8250 GACACCCATTCCAGGC  78 1015 1062174  800  815  8446  8461 TTCGAAGACCTTCTCA 131 1016 1062206  979  994  9774  9789 GCCTTGGTCAGTGCCA  36 1017 1062238 1104 1119 11260 11275 GCCTCCGGACAGCAAA  98 1018 1062270 1258 1273 13488 13503 TCATTGAGTGTCCGCT   75* 1019 1062302 1455 1470 13865 13880 TAGGGTTGGAACACCT  82 1020 1062334 1743 1758 14153 14168 TTGGCTGCAGGGCTCG  30 1021 1062366 1898 1913 14308 14323 GAGTGTACTGAGGCAG  12 1022 1062398 2064 2079 14474 14489 CCTGAGGGTACTGACG  49 1023 1062430 2271 2286 N/A N/A GGCATGGATCAGGGCT  75 1024 1062462 N/A N/A  8325  8340 GGGCGAGGATCCTTCC  53 1025 1062494 N/A N/A 13634 13649 TATGAGCCCAGACCCA  95 1026 1062526 N/A N/A   560   575 GACACTCACCTTGGTG  96 1027 1062558 N/A N/A   693   708 TAAAGACCTTACCTGG  87 1028 1062590 N/A N/A   931   946 AGGCATCAAGAGCTAA 107 1029 1062622 N/A N/A  1117  1132 AGGAAAGGAGATCGAT 107 1030 1062654 N/A N/A  1268  1283 GGGTGAACAGAACTGA  56 1031 1062687 N/A N/A  1352  1367 CCAAGGGTCTCCTCTA  95 1032 1062719 N/A N/A  1497  1512 CCTGCAGAATCGAGCT  68 1033 1062751 N/A N/A  1748  1763 CGAGAAACAACCGGAA  69 1034 1062783 N/A N/A  1897  1912 TTAAGTAGAGGGAGCA  25 1035 1062815 N/A N/A  2084  2099 GATGAACACCCTATTA 126 1036 1062847 N/A N/A  2258  2273 CTAACCTATTTGACTG  70 1037 1062879 N/A N/A  2410  2425 CCAGTACCCACACTCT  85 1038 1062911 N/A N/A  2626  2641 ACCTAATGCTGATCTT  72 1039 1062943 N/A N/A  2748  2763 GATAAAGTTATTGAGT  79 1040 1062975 N/A N/A  2953  2968 TGGGTATTGAATTGTA  43 1041 1063007 N/A N/A  3152  3167 ACAAAGAGCGAGCAAG 136 1042 1063039 N/A N/A  3255  3270 CTGGTTAAGTCATTAG  26 1043 1063071 N/A N/A  3401  3416 ACCTAGAGTCCTGAGA 132 1044 1063103 N/A N/A  3716  3731 CCCCACAATCAAGGTT  78 1045 1063135 N/A N/A  3949  3964 TCATAGGGCCTCTTGC  92 1046 1063167 N/A N/A  4132  4147 CTTCAAATAGTATAAC 101 1047 1063199 N/A N/A  4339  4354 TCCGAGAACTGGCTGC  62 1048 1063230 N/A N/A  4440  4455 AGATTTTTCCGCCATT 102 1049 1063262 N/A N/A  4611  4626 AGAGGACCTAGAGGGC  66 1050 1063294 N/A N/A  4726  4741 GCCTGGACACTTGGCC  41 1051 1063326 N/A N/A  5140  5155 CTTAGAACATTACTGC  33 1052 1063358 N/A N/A  5398  5413 TAGGAAGTGTTTCCGT  82 1053 1063390 N/A N/A  5529  5544 TCCTATAATCCTGGTC 103 1054 1063422 N/A N/A  5765  5780 GTAGAAGCTTCTCTAC 100 1055 1063454 N/A N/A  5923  5938 CTGGCATTAAATATGT  94 1056 1063486 N/A N/A  6030  6045 TTTAGCTTGAGCAGCT 100 1057 1063518 N/A N/A  6193  6208 TTGTAACAGTCCTGGC  44 1058 1063550 N/A N/A  6378  6393 TCCACTTGAGAGCTGT  52 1059 1063582 N/A N/A  6586  6601 GCTGGGACATGTCCCG  84 1060 1063614 N/A N/A  6990  7005 AGTAAAGGTCGGCACC  98 1061 1063646 N/A N/A  7244  7259 CCTCACCTACTTGGCC  32 1062 1063678 N/A N/A  7428  7443 GTGAGAGGCCATCCTG  85 1063 1063710 N/A N/A  7873  7888 CAGAATAGCCTACACT  85 1064 1063742 N/A N/A  8015  8030 ATTTTGACTAGCTTTG  53 1065 1063774 N/A N/A  8110  8125 GCCTCGAAAACCCTGA  30 1066 1063805 N/A N/A  8587  8602 TCTCAGAGTTTAGCTC  60 1067 1063837 N/A N/A  8864  8879 CATGTTGGCATGAGGA  40 1068 1063869 N/A N/A  9110  9125 GAGGGACGGCCTGTGC 108 1069 1063901 N/A N/A  9525  9540 CCTTACCCTCCACCGC  35 1070 1063933 N/A N/A  9693  9708 GCACAAACATGAGGCC 111 1071 1063965 N/A N/A 10307 10322 ACTCAGGATCACAGTG  77 1072 1063997 N/A N/A 10581 10596 ACCTAAACCCCCCTGG  75 1073 1064029 N/A N/A 11124 11139 GTGACCCAGAGGCTTA 105 1074 1064061 N/A N/A 11451 11466 TGTGAGCGGATGCATT  80 1075 1064093 N/A N/A 11578 11593 ATATAGTAGCTGGAGT  71 1076 1064127 N/A N/A 11659 11674 CACCCCGATTTTCCTT  66 1077 1064159 N/A N/A 11743 11758 GATGACAGTCAAGGTC  70 1078 1064191 N/A N/A 11824 11839 CAAAATAGTTCTCCCC  30 1079 1064223 N/A N/A 11929 11944 TACAGGCCTGAGATCT  69 1080 1064255 N/A N/A 11995 12010 GATGAATCAAGCCCCA  55 1081 1064287 N/A N/A 12296 12311 GTGGTTTAGGTTTGGA  13 1082 1064319 N/A N/A 12453 12468 TAGAGTAAGAGCTGGG  64 1083 1064351 N/A N/A 12638 12653 TCTGAGAAGGCATTGG  73 1084 1064383 N/A N/A 12809 12824 CAGTTTGGATTCAGGA  55 1085 1064415 N/A N/A 12953 12968 GGCTTTAGGTCAGAAG 133 1086 1064447 N/A N/A 13229 13244 CTGGGATTAGGTAAGG 110 1087

TABLE 19 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC  33  250  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  36   65 1062015   37   52   437   452 GCCGCAGACCTCTCTC  32 1088 1062047  153  168 N/A N/A GGCTTGGTGAAGTGGA  48 1089 1062079  322  337  6860  6875 AGATCTCGGCCCTGGA 122 1090 1062111  483  498  7548  7563 GCATGAAATGTGGCCT 120 1091 1062143  661  676  8238  8253 CTGGACACCCATTCCA 126 1092 1062175  801  816  8447  8462 CTTCGAAGACCTTCTC 103 1093 1062207  980  995  9775  9790 AGCCTTGGTCAGTGCC 125 1094 1062239 1111 1126 11267 11282 CACAGGTGCCTCCGGA 165 1095 1062271 1259 1274 13489 13504 CTCATTGAGTGTCCGC   79* 1096 1062303 1456 1471 13866 13881 GTAGGGTTGGAACACC 140 1097 1062335 1744 1759 14154 14169 TTTGGCTGCAGGGCTC  35 1098 1062367 1899 1914 14309 14324 TGAGTGTACTGAGGCA  31 1099 1062399 2065 2080 14475 14490 TCCTGAGGGTACTGAC 108 1100 1062431 2273 2288 N/A N/A GAGGCATGGATCAGGG  42 1101 1062463 N/A N/A  8326  8341 AGGGCGAGGATCCTTC 106 1102 1062495 N/A N/A 13636 13651 CCTATGAGCCCAGACC 144 1103 1062527 N/A N/A   561   576 GGACACTCACCTTGGT 113 1104 1062559 N/A N/A   694   709 TTAAAGACCTTACCTG 116 1105 1062591 N/A N/A   932   947 GAGGCATCAAGAGCTA  90 1106 1062623 N/A N/A  1119  1134 GGAGGAAAGGAGATCG 149 1107 1062655 N/A N/A  1271  1286 CTAGGGTGAACAGAAC  55 1108 1062688 N/A N/A  1358  1373 CCCGCCCCAAGGGTCT  56 1109 1062720 N/A N/A  1503  1518 GCTAAGCCTGCAGAAT  96 1110 1062752 N/A N/A  1749  1764 ACGAGAAACAACCGGA 130 1111 1062784 N/A N/A  1907  1922 TAGGGTTAGCTTAAGT  46 1112 1062816 N/A N/A  2085  2100 AGATGAACACCCTATT  72 1113 1062848 N/A N/A  2259  2274 ACTAACCTATTTGACT  89 1114 1062880 N/A N/A  2411  2426 TCCAGTACCCACACTC  83 1115 1062912 N/A N/A  2627  2642 CACCTAATGCTGATCT  63 1116 1062944 N/A N/A  2761  2776 TAATTAGGGAGAAGAT 101 1117 1062976 N/A N/A  2954  2969 CTGGGTATTGAATTGT  57 1118 1063008 N/A N/A  3153  3168 CACAAAGAGCGAGCAA 108 1119 1063040 N/A N/A  3256  3271 TCTGGTTAAGTCATTA  76 1120 1063072 N/A N/A  3402  3417 CACCTAGAGTCCTGAG 130 1121 1063104 N/A N/A  3739  3754 CATCATCAGACTCTCT 114 1122 1063136 N/A N/A  3950  3965 TTCATAGGGCCTCTTG  74 1123 1063168 N/A N/A  4151  4166 ATACTGGGACCCCTGG 123 1124 1063200 N/A N/A  4340  4355 TTCCGAGAACTGGCTG  48 1125 1063231 N/A N/A  4441  4456 CAGATTTTTCCGCCAT  84 1126 1063263 N/A N/A  4613  4628 GTAGAGGACCTAGAGG  50 1127 1063295 N/A N/A  4742  4757 GGTCACTTCTGAAGCT  71 1128 1063327 N/A N/A  5142  5157 GGCTTAGAACATTACT  98 1129 1063359 N/A N/A  5399  5414 TTAGGAAGTGTTTCCG 109 1130 1063391 N/A N/A  5530  5545 ATCCTATAATCCTGGT 128 1131 1063423 N/A N/A  5768  5783 CCTGTAGAAGCTTCTC  82 1132 1063455 N/A N/A  5930  5945 GAAGAGTCTGGCATTA  73 1133 1063487 N/A N/A  6031  6046 TTTTAGCTTGAGCAGC 174 1134 1063519 N/A N/A  6194  6209 ATTGTAACAGTCCTGG  54 1135 1063551 N/A N/A  6379  6394 CTCCACTTGAGAGCTG  81 1136 1063583 N/A N/A  6587  6602 GGCTGGGACATGTCCC 147 1137 1063615 N/A N/A  6991  7006 CAGTAAAGGTCGGCAC 188 1138 1063647 N/A N/A  7305  7320 TCGAGTAACTTTTTAA  44 1139 1063679 N/A N/A  7429  7444 GGTGAGAGGCCATCCT 108 1140 1063711 N/A N/A  7874  7889 TCAGAATAGCCTACAC 121 1141 1063743 N/A N/A  8017  8032 ACATTTTGACTAGCTT  40 1142 1063775 N/A N/A  8111  8126 AGCCTCGAAAACCCTG 145 1143 1063806 N/A N/A  8597  8612 GAACCCACAGTCTCAG 110 1144 1063838 N/A N/A  8875  8890 AATAAGGCTGGCATGT 110 1145 1063870 N/A N/A  9113  9128 GTGGAGGGACGGCCTG  92 1146 1063902 N/A N/A  9535  9550 TATCCCTATCCCTTAC 180 1147 1063934 N/A N/A  9694  9709 GGCACAAACATGAGGC 117 1148 1063966 N/A N/A 10310 10325 ACAACTCAGGATCACA  62 1149 1063998 N/A N/A 10582 10597 CACCTAAACCCCCCTG 114 1150 1064030 N/A N/A 11157 11172 GTCGGATGATGCCTGG  81 1151 1064062 N/A N/A 11452 11467 TTGTGAGCGGATGCAT  91 1152 1064094 N/A N/A 11579 11594 AATATAGTAGCTGGAG  43 1153 1064128 N/A N/A 11660 11675 CCACCCCGATTTTCCT 125 1154 1064160 N/A N/A 11744 11759 GGATGACAGTCAAGGT  50 1155 1064192 N/A N/A 11827 11842 TGCCAAAATAGTTCTC  88 1156 1064224 N/A N/A 11930 11945 CTACAGGCCTGAGATC 114 1157 1064256 N/A N/A 11996 12011 GGATGAATCAAGCCCC  97 1158 1064288 N/A N/A 12318 12333 TTGGCATGCTCTGGCC 118 1159 1064320 N/A N/A 12455 12470 GTTAGAGTAAGAGCTG 101 1160 1064352 N/A N/A 12639 12654 TTCTGAGAAGGCATTG 118 1161 1064384 N/A N/A 12822 12837 CAGGGAATTTGATCAG  92 1162 1064416 N/A N/A 12961 12976 GATGACTTGGCTTTAG  83 1163 1064448 N/A N/A 13240 13255 GTATGGTTGTTCTGGG 101 1164

TABLE 20 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910956 1800 1815 14210 14225 AGTAATCTGTGCGAGC  23  250  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  40   65 1062016   40   55   440   455 GAAGCCGCAGACCTCT  53 1165 1062048  156  171 N/A N/A GCAGGCTTGGTGAAGT  48 1166 1062080  323  338  6861  6876 AAGATCTCGGCCCTGG 131 1167 1062112  484  499  7549  7564 TGCATGAAATGTGGCC  39 1168 1062144  662  677  8239  8254 CCTGGACACCCATTCC  42 1169 1062176  802  817  8448  8463 TCTTCGAAGACCTTCT  76 1170 1062208  981  996  9776  9791 AAGCCTTGGTCAGTGC  92 1171 1062240 1112 1127 11268 11283 CCACAGGTGCCTCCGG  49 1172 1062272 1261 1276 13491 13506 ATCTCATTGAGTGTCC   74* 1173 1062304 1460 1475 13870 13885 AGGTGTAGGGTTGGAA  41 1174 1062336 1746 1761 14156 14171 TGTTTGGCTGCAGGGC  19 1175 1062368 1900 1915 14310 14325 TTGAGTGTACTGAGGC   3 1176 1062400 2068 2083 14478 14493 AGATCCTGAGGGTACT  72 1177 1062432 2274 2289 N/A N/A TGAGGCATGGATCAGG  54 1178 1062464 N/A N/A  8327  8342 GAGGGCGAGGATCCTT  40 1179 1062496 N/A N/A 13637 13652 GCCTATGAGCCCAGAC  67 1180 1062528 N/A N/A   567   582 GAGCAGGGACACTCAC 210 1181 1062560 N/A N/A   728   743 TAAGTCTTCTGCCATT  23 1182 1062592 N/A N/A   937   952 GATGAGAGGCATCAAG 140 1183 1062624 N/A N/A  1142  1157 CAAGAAAAGAGAGCGG  39 1184 1062656 N/A N/A  1273  1288 TACTAGGGTGAACAGA  77 1185 1062689 N/A N/A  1393  1408 TACGGTTGACAATGGT  36 1186 1062721 N/A N/A  1533  1548 CGTGAGCACTTACTTT  80 1187 1062753 N/A N/A  1750  1765 AACGAGAAACAACCGG  26 1188 1062785 N/A N/A  1908  1923 CTAGGGTTAGCTTAAG  81 1189 1062817 N/A N/A  2086  2101 AAGATGAACACCCTAT  78 1190 1062849 N/A N/A  2260  2275 GACTAACCTATTTGAC  66 1191 1062881 N/A N/A  2419  2434 AGTCTGGCTCCAGTAC  89 1192 1062913 N/A N/A  2628  2643 ACACCTAATGCTGATC  95 1193 1062945 N/A N/A  2763  2778 GATAATTAGGGAGAAG  30 1194 1062977 N/A N/A  2955  2970 GCTGGGTATTGAATTG  75 1195 1063009 N/A N/A  3154  3169 ACACAAAGAGCGAGCA 119 1196 1063041 N/A N/A  3257  3272 GTCTGGTTAAGTCATT  67 1197 1063073 N/A N/A  3405  3420 TCCCACCTAGAGTCCT  78 1198 1063105 N/A N/A  3742  3757 GCCCATCATCAGACTC  34 1199 1063137 N/A N/A  3951  3966 CTTCATAGGGCCTCTT  35 1200 1063169 N/A N/A  4152  4167 GATACTGGGACCCCTG  38 1201 1063201 N/A N/A  4356  4371 CACCCCACAGGTTTCG  46 1202 1063232 N/A N/A  4443  4458 CCCAGATTTTTCCGCC  70 1203 1063264 N/A N/A  4631  4646 GAGATGATCTGTCTGG  47 1204 1063296 N/A N/A  4800  4815 ATTTCGGTGCAAATGG  54 1205 1063328 N/A N/A  5143  5158 GGGCTTAGAACATTAC  65 1206 1063360 N/A N/A  5416  5431 GAACTCCACTTCTTTC  52 1207 1063392 N/A N/A  5592  5607 TCCGGGCCCCCTGCTG  65 1208 1063424 N/A N/A  5769  5784 GCCTGTAGAAGCTTCT  97 1209 1063456 N/A N/A  5931  5946 TGAAGAGTCTGGCATT 179 1210 1063488 N/A N/A  6032  6047 GTTTTAGCTTGAGCAG  31 1211 1063520 N/A N/A  6195  6210 TATTGTAACAGTCCTG  30 1212 1063552 N/A N/A  6381  6396 CCCTCCACTTGAGAGC  33 1213 1063584 N/A N/A  6589  6604 TTGGCTGGGACATGTC  39 1214 1063616 N/A N/A  6993  7008 CACAGTAAAGGTCGGC  71 1215 1063648 N/A N/A  7306  7321 ATCGAGTAACTTTTTA  14 1216 1063680 N/A N/A  7430  7445 GGGTGAGAGGCCATCC 229 1217 1063712 N/A N/A  7876  7891 ATTCAGAATAGCCTAC 105 1218 1063744 N/A N/A  8018  8033 GACATTTTGACTAGCT   5 1219 1063776 N/A N/A  8115  8130 CCTGAGCCTCGAAAAC  72 1220 1063807 N/A N/A  8599  8614 TTGAACCCACAGTCTC  44 1221 1063839 N/A N/A  8876  8891 GAATAAGGCTGGCATG  90 1222 1063871 N/A N/A  9172  9187 TTGGAAGTGTGGTGAG  49 1223 1063903 N/A N/A  9536  9551 CTATCCCTATCCCTTA  56 1224 1063935 N/A N/A  9695  9710 TGGCACAAACATGAGG 131 1225 1063967 N/A N/A 10312 10327 TAACAACTCAGGATCA  28 1226 1063999 N/A N/A 10583 10598 TCACCTAAACCCCCCT  34 1227 1064031 N/A N/A 11159 11174 TTGTCGGATGATGCCT  33 1228 1064063 N/A N/A 11455 11470 CTTTTGTGAGCGGATG  50 1229 1064095 N/A N/A 11580 11595 GAATATAGTAGCTGGA  12 1230 1064129 N/A N/A 11661 11676 TCCACCCCGATTTTCC 177 1231 1064161 N/A N/A 11747 11762 CCAGGATGACAGTCAA  26 1232 1064193 N/A N/A 11848 11863 ATTTATTCTTTGCACC  75 1233 1064225 N/A N/A 11931 11946 TCTACAGGCCTGAGAT  77 1234 1064257 N/A N/A 12017 12032 AGGAACTCTGTCAGAG  39 1235 1064289 N/A N/A 12321 12336 AATTTGGCATGCTCTG 186 1236 1064321 N/A N/A 12456 12471 AGTTAGAGTAAGAGCT 160 1237 1064353 N/A N/A 12647 12662 GATGAAGGTTCTGAGA  39 1238 1064385 N/A N/A 12824 12839 GTCAGGGAATTTGATC  89 1239 1064417 N/A N/A 12965 12980 ATGGGATGACTTGGCT  81 1240 1064449 N/A N/A 13243 13258 TGGGTATGGTTGTTCT  42 1241

TABLE 21 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT 109   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  12   65 1062017   44   59   444   459 TGTGGAAGCCGCAGAC  32 1242 1062049  161  176 N/A N/A CAAGGGCAGGCTTGGT 120 1243 1062081  325  340  6863  6878 CGAAGATCTCGGCCCT  52 1244 1062113  486  501  7551  7566 GGTGCATGAAATGTGG  34 1245 1062145  663  678  8240  8255 CCCTGGACACCCATTC  57 1246 1062177  803  818  8449  8464 CTCTTCGAAGACCTTC 127 1247 1062209  982  997  9777  9792 GAAGCCTTGGTCAGTG  35 1248 1062241 1116 1131 11272 11287 TACCCCACAGGTGCCT  53 1249 1062273 1268 1283 13498 13513 GTGGTAGATCTCATTG   61* 1250 1062305 1461 1476 13871 13886 CAGGTGTAGGGTTGGA  18 1251 1062337 1756 1771 14166 14181 GTGAAGGCTCTGTTTG  37 1252 1062369 1902 1917 14312 14327 GTTTGAGTGTACTGAG  23 1253 1062401 2070 2085 14480 14495 TCAGATCCTGAGGGTA 123 1254 1062433 2275 2290 N/A N/A CTGAGGCATGGATCAG  36 1255 1062465 N/A N/A  8328  8343 GGAGGGCGAGGATCCT 100 1256 1062497 N/A N/A 13642 13657 AATGTGCCTATGAGCC 136 1257 1062529 N/A N/A   624   639 CCCGCCGTGCCTACCT  21 1258 1062561 N/A N/A   740   755 GTACTTCACCTTTAAG  33 1259 1062593 N/A N/A   938   953 GGATGAGAGGCATCAA  54 1260 1062625 N/A N/A  1143  1158 GCAAGAAAAGAGAGCG 127 1261 1062657 N/A N/A  1274  1289 CTACTAGGGTGAACAG  60 1262 1062690 N/A N/A  1394  1409 CTACGGTTGACAATGG  44 1263 1062722 N/A N/A  1570  1585 TCTAATTTGGTTACAG  55 1264 1062754 N/A N/A  1751  1766 AAACGAGAAACAACCG  40 1265 1062786 N/A N/A  1910  1925 ACCTAGGGTTAGCTTA  93 1266 1062818 N/A N/A  2087  2102 TAAGATGAACACCCTA 125 1267 1062850 N/A N/A  2261  2276 AGACTAACCTATTTGA  41 1268 1062882 N/A N/A  2436  2451 CTGGGTTTGTCCCAGA 119 1269 1062914 N/A N/A  2630  2645 TAACACCTAATGCTGA 128 1270 1062946 N/A N/A  2767  2782 CTGAGATAATTAGGGA  52 1271 1062978 N/A N/A  2956  2971 GGCTGGGTATTGAATT  36 1272 1063010 N/A N/A  3155  3170 CACACAAAGAGCGAGC  45 1273 1063042 N/A N/A  3267  3282 CTTCTACGCTGTCTGG  57 1274 1063074 N/A N/A  3425  3440 GGAGAGAGCCAGAACC  30 1275 1063106 N/A N/A  3748  3763 TACAGAGCCCATCATC  52 1276 1063138 N/A N/A  3968  3983 AGTCAGGCAGCTTGCT  42 1277 1063170 N/A N/A  4153  4168 AGATACTGGGACCCCT  69 1278 1063202 N/A N/A  4363  4378 GATACCCCACCCCACA 142 1279 1063233 N/A N/A  4444  4459 GCCCAGATTTTTCCGC  51 1280 1063265 N/A N/A  4632  4647 GGAGATGATCTGTCTG  72 1281 1063297 N/A N/A  4801  4816 GATTTCGGTGCAAATG  95 1282 1063329 N/A N/A  5159  5174 GTTCTTAGTCTCCTGG  20 1283 1063361 N/A N/A  5418  5433 GAGAACTCCACTTCTT 121 1284 1063393 N/A N/A  5602  5617 CCACAATGGCTCCGGG  51 1285 1063425 N/A N/A  5818  5833 AGCATGGCAAGTGACA  41 1286 1063457 N/A N/A  5932  5947 ATGAAGAGTCTGGCAT 130 1287 1063489 N/A N/A  6033  6048 GGTTTTAGCTTGAGCA  63 1288 1063521 N/A N/A  6196  6211 CTATTGTAACAGTCCT  86 1289 1063553 N/A N/A  6395  6410 CAATGGTTGTTTCCCC  33 1290 1063585 N/A N/A  6592  6607 GCATTGGCTGGGACAT  93 1291 1063617 N/A N/A  6994  7009 CCACAGTAAAGGTCGG  46 1292 1063649 N/A N/A  7307  7322 GATCGAGTAACTTTTT  16 1293 1063681 N/A N/A  7555  7570 ACCTGGTGCATGAAAT  50 1294 1063713 N/A N/A  7878  7893 CAATTCAGAATAGCCT  53 1295 1063745 N/A N/A  8019  8034 TGACATTTTGACTAGC  25 1296 1063777 N/A N/A  8134  8149 ATTTTGAGCTTCCCAC 146 1297 1063808 N/A N/A  8600  8615 TTTGAACCCACAGTCT 160 1298 1063840 N/A N/A  8877  8892 GGAATAAGGCTGGCAT  46 1299 1063872 N/A N/A  9181  9196 GAGATAATGTTGGAAG  97 1300 1063904 N/A N/A  9537  9552 ACTATCCCTATCCCTT  95 1301 1063936 N/A N/A  9787  9802 CACCACAGATGAAGCC  48 1302 1063968 N/A N/A 10313 10328 TTAACAACTCAGGATC 145 1303 1064000 N/A N/A 10585 10600 AGTCACCTAAACCCCC  87 1304 1064032 N/A N/A 11300 11315 TTACCTGGGAATGTGC  50 1305 1064064 N/A N/A 11456 11471 GCTTTTGTGAGCGGAT  27 1306 1064096 N/A N/A 11581 11596 CGAATATAGTAGCTGG  21 1307 1064130 N/A N/A 11662 11677 ATCCACCCCGATTTTC 111 1308 1064162 N/A N/A 11769 11784 TGCAAGAGGTTAAATG 129 1309 1064194 N/A N/A 11861 11876 CATAAGTTGTATCATT 116 1310 1064226 N/A N/A 11932 11947 GTCTACAGGCCTGAGA  51 1311 1064258 N/A N/A 12018 12033 GAGGAACTCTGTCAGA 122 1312 1064290 N/A N/A 12322 12337 GAATTTGGCATGCTCT  50 1313 1064322 N/A N/A 12457 12472 GAGTTAGAGTAAGAGC  51 1314 1064354 N/A N/A 12648 12663 GGATGAAGGTTCTGAG  89 1315 1064386 N/A N/A 12825 12840 GGTCAGGGAATTTGAT 134 1316 1064418 N/A N/A 13014 13029 TTAAGAGTCAGGCTGG  59 1317 1064450 N/A N/A 13244 13259 GTGGGTATGGTTGTTC  90 1318

TABLE 22 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) % UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT 109   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  21   65 1062018   46 61   446   461 GGTGTGGAAGCCGCAG  49 1319 1062050  172 187  6710  6725 GGGTCCTTGTCCAAGG  43 1320 1062082  328 343  6866  6881 CCTCGAAGATCTCGGC 112 1321 1062114  487 502  7552  7567 TGGTGCATGAAATGTG 137 1322 1062146  664 679  8241  8256 TCCCTGGACACCCATT  37 1323 1062178  804 819  8450  8465 GCTCTTCGAAGACCTT  35 1324 1062210  984 999  9779  9794 ATGAAGCCTTGGTCAG  52 1325 1062242 1117 1132 11273 11288 CTACCCCACAGGTGCC  80 1326 1062274 1293 1308 13523 13538 AGAAGGCAAACATGCG  41 1327 1062306 1463 1478 13873 13888 GCCAGGTGTAGGGTTG  35 1328 1062338 1757 1772 14167 14182 TGTGAAGGCTCTGTTT  86 1329 1062370 1903 1918 14313 14328 TGTTTGAGTGTACTGA  46 1330 1062402 2071 2086 14481 14496 CTCAGATCCTGAGGGT  88 1331 1062434 2276 2291 N/A N/A GCTGAGGCATGGATCA  41 1332 1062466 N/A N/A  8329  8344 AGGAGGGCGAGGATCC  43 1333 1062498 N/A N/A 13645 13660 CCCAATGTGCCTATGA  55 1334 1062530 N/A N/A   643   658 CCAGAGGGCCCCTGAC  52 1335 1062562 N/A N/A   741   756 AGTACTTCACCTTTAA  17 1336 1062594 N/A N/A   940   955 AAGGATGAGAGGCATC 158 1337 1062626 N/A N/A  1180  1195 TAGGCTGGATGCTGGC 167 1338 1062658 N/A N/A  1276  1291 TGCTACTAGGGTGAAC 126 1339 1062691 N/A N/A  1395  1410 ACTACGGTTGACAATG  39 1340 1062723 N/A N/A  1576  1591 CATGATTCTAATTTGG  21 1341 1062755 N/A N/A  1773  1788 AGTCAGGGATGTTTAT  50 1342 1062787 N/A N/A  1911  1926 CACCTAGGGTTAGCTT 134 1343 1062819 N/A N/A  2088  2103 ATAAGATGAACACCCT  42 1344 1062851 N/A N/A  2262  2277 AAGACTAACCTATTTG  48 1345 1062883 N/A N/A  2437  2452 GCTGGGTTTGTCCCAG  71 1346 1062915 N/A N/A  2632  2647 TTTAACACCTAATGCT  98 1347 1062947 N/A N/A  2768  2783 TCTGAGATAATTAGGG 101 1348 1062979 N/A N/A  2958  2973 ATGGCTGGGTATTGAA  24 1349 1063011 N/A N/A  3178  3193 GGATACATAGAGACAA  57 1350 1063043 N/A N/A  3276  3291 GCCAGGGCCCTTCTAC 114 1351 1063107 N/A N/A  3750  3765 AATACAGAGCCCATCA  50 1352 1063139 N/A N/A  3971  3986 GAAAGTCAGGCAGCTT  43 1353 1063171 N/A N/A  4156  4171 CACAGATACTGGGACC  60 1354 1063203 N/A N/A  4366  4381 GCAGATACCCCACCCC  24 1355 1063234 N/A N/A  4449  4464 GACTTGCCCAGATTTT  28 1356 1063266 N/A N/A  4633  4648 TGGAGATGATCTGTCT  48 1357 1063298 N/A N/A  4802  4817 CGATTTCGGTGCAAAT  37 1358 1063330 N/A N/A  5160  5175 AGTTCTTAGTCTCCTG   9 1359 1063362 N/A N/A  5420  5435 TTGAGAACTCCACTTC  70 1360 1063394 N/A N/A  5606  5621 CCCTCCACAATGGCTC  28 1361 1063426 N/A N/A  5820  5835 CCAGCATGGCAAGTGA  46 1362 1063458 N/A N/A  5933  5948 CATGAAGAGTCTGGCA  32 1363 1063490 N/A N/A  6034  6049 GGGTTTTAGCTTGAGC  35 1364 1063522 N/A N/A  6198  6213 GGCTATTGTAACAGTC 112 1365 1063554 N/A N/A  6398  6413 GGGCAATGGTTGTTTC  82 1366 1063586 N/A N/A  6593  6608 GGCATTGGCTGGGACA 110 1367 1063618 N/A N/A  6996  7011 TGCCACAGTAAAGGTC  47 1368 1063650 N/A N/A  7308  7323 AGATCGAGTAACTTTT   8 1369 1063682 N/A N/A  7556  7571 TACCTGGTGCATGAAA  58 1370 1063714 N/A N/A  7879  7894 GCAATTCAGAATAGCC  49 1371 1063746 N/A N/A  8020  8035 CTGACATTTTGACTAG  35 1372 1063778 N/A N/A  8146  8161 ACAAGGCCTCTCATTT  58 1373 1063809 N/A N/A  8623  8638 GCCAGTCAGGGATGGA  55 1374 1063841 N/A N/A  8878  8893 TGGAATAAGGCTGGCA  37 1375 1063873 N/A N/A  9203  9218 CTTGAGCCTGGCCAGA  87 1376 1063905 N/A N/A  9539  9554 GCACTATCCCTATCCC  16 1377 1063937 N/A N/A  9789  9804 CTCACCACAGATGAAG  62 1378 1063969 N/A N/A 10314 10329 TTTAACAACTCAGGAT  72 1379 1064001 N/A N/A 10588 10603 GAAAGTCACCTAAACC  35 1380 1064033 N/A N/A 11302 11317 TCTTACCTGGGAATGT 145 1381 1064065 N/A N/A 11457 11472 AGCTTTTGTGAGCGGA  54 1382 1064097 N/A N/A 11582 11597 CCGAATATAGTAGCTG  54 1383 1064131 N/A N/A 11664 11679 GAATCCACCCCGATTT  56 1384 1064163 N/A N/A 11771 11786 GATGCAAGAGGTTAAA  43 1385 1064195 N/A N/A 11863 11878 GACATAAGTTGTATCA  87 1386 1064227 N/A N/A 11934 11949 GAGTCTACAGGCCTGA  38 1387 1064259 N/A N/A 12019 12034 GGAGGAACTCTGTCAG  41 1388 1064291 N/A N/A 12323 12338 AGAATTTGGCATGCTC  43 1389 1064323 N/A N/A 12458 12473 GGAGTTAGAGTAAGAG  76 1390 1064355 N/A N/A 12649 12664 AGGATGAAGGTTCTGA  77 1391 1064387 N/A N/A 12847 12862 TTCGGTGTGGAGTGAG  82 1392 1064419 N/A N/A 13016 13031 GGTTAAGAGTCAGGCT  40 1393 1064451 N/A N/A 13245 13260 TGTGGGTATGGTTGTT  35 1394

TABLE 23 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT 200   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  14   65 1062019   49   64   449   464 TACGGTGTGGAAGCCG  65 1395 1062051  174  189  6712  6727 TCGGGTCCTTGTCCAA  38 1396 1062083  329  344  6867  6882 GCCTCGAAGATCTCGG  67 1397 1062115  488  503  7553  7568 CTGGTGCATGAAATGT  62 1398 1062147  669  684  8246  8261 CCGGCTCCCTGGACAC  61 1399 1062179  810  825  8456  8471 CCTCTGGCTCTTCGAA 148 1400 1062211  987 1002  9782  9797 CAGATGAAGCCTTGGT  39 1401 1062243 1118 1133 11274 11289 GCTACCCCACAGGTGC 108 1402 1062275 1312 1327 13542 13557 GTGGCAGGATGGTTTC  52 1403 1062307 1482 1497 13892 13907 CTTGATCTTGAGGTCA  59 1404 1062339 1764 1779 14174 14189 GGCTGGTTGTGAAGGC  40 1405 1062371 1904 1919 14314 14329 TTGTTTGAGTGTACTG  64 1406 1062403 2076 2091 14486 14501 GGGACCTCAGATCCTG  78 1407 1062435 2283 2298 N/A N/A AGTCTAAGCTGAGGCA  68 1408 1062467 N/A N/A  8330  8345 TAGGAGGGCGAGGATC  90 1409 1062499 N/A N/A 13646 13661 CCCCAATGTGCCTATG  93 1410 1062531 N/A N/A   644   659 ACCAGAGGGCCCCTGA  95 1411 1062563 N/A N/A   742   757 AAGTACTTCACCTTTA  50 1412 1062595 N/A N/A  1002  1017 CGGGAGAAAGAGAGGC  38 1413 1062627 N/A N/A  1183  1198 CTCTAGGCTGGATGCT  65 1414 1062659 N/A N/A  1287  1302 TGCAATCCTCCTGCTA 117 1415 1062692 N/A N/A  1397  1412 AAACTACGGTTGACAA  71 1416 1062724 N/A N/A  1577  1592 GCATGATTCTAATTTG   5 1417 1062756 N/A N/A  1784  1799 TCCAAGGAAGCAGTCA  78 1418 1062788 N/A N/A  1914  1929 ACTCACCTAGGGTTAG  92 1419 1062820 N/A N/A  2089  2104 AATAAGATGAACACCC  73 1420 1062852 N/A N/A  2305  2320 GGACTTTCTAAGCACA  48 1421 1062884 N/A N/A  2438  2453 CGCTGGGTTTGTCCCA  65 1422 1062916 N/A N/A  2634  2649 GTTTTAACACCTAATG  65 1423 1062948 N/A N/A  2790  2805 GGAGTATGGTTTAACA  38 1424 1062980 N/A N/A  2961  2976 CCCATGGCTGGGTATT 109 1425 1063012 N/A N/A  3179  3194 GGGATACATAGAGACA  78 1426 1063044 N/A N/A  3277  3292 GGCCAGGGCCCTTCTA 100 1427 1063076 N/A N/A  3491  3506 GAATGGTAGCCCAGGT  64 1428 1063108 N/A N/A  3751  3766 CAATACAGAGCCCATC  73 1429 1063140 N/A N/A  3972  3987 TGAAAGTCAGGCAGCT  73 1430 1063172 N/A N/A  4157  4172 CCACAGATACTGGGAC  97 1431 1063204 N/A N/A  4367  4382 GGCAGATACCCCACCC  73 1432 1063235 N/A N/A  4450  4465 CGACTTGCCCAGATTT  59 1433 1063267 N/A N/A  4659  4674 CATAGATACATTCTCA  65 1434 1063299 N/A N/A  4804  4819 ACCGATTTCGGTGCAA  65 1435 1063331 N/A N/A  5161  5176 AAGTTCTTAGTCTCCT  19 1436 1063363 N/A N/A  5421  5436 CTTGAGAACTCCACTT  69 1437 1063395 N/A N/A  5609  5624 AAGCCCTCCACAATGG  53 1438 1063427 N/A N/A  5821  5836 TCCAGCATGGCAAGTG  74 1439 1063459 N/A N/A  5934  5949 ACATGAAGAGTCTGGC  37 1440 1063491 N/A N/A  6036  6051 ATGGGTTTTAGCTTGA  21 1441 1063523 N/A N/A  6199  6214 AGGCTATTGTAACAGT  52 1442 1063555 N/A N/A  6399  6414 AGGGCAATGGTTGTTT 132 1443 1063587 N/A N/A  6603  6618 GGTCAAAGCAGGCATT  30 1444 1063619 N/A N/A  7005  7020 CCCGCCCAGTGCCACA  23 1445 1063651 N/A N/A  7309  7324 GAGATCGAGTAACTTT  27 1446 1063683 N/A N/A  7557  7572 ATACCTGGTGCATGAA  72 1447 1063715 N/A N/A  7880  7895 TGCAATTCAGAATAGC  59 1448 1063747 N/A N/A  8021  8036 GCTGACATTTTGACTA  63 1449 1063779 N/A N/A  8147  8162 CACAAGGCCTCTCATT  78 1450 1063810 N/A N/A  8658  8673 CGAGAGAAGCTAAGTA  71 1451 1063842 N/A N/A  8879  8894 GTGGAATAAGGCTGGC  50 1452 1063874 N/A N/A  9210  9225 CTCACCACTTGAGCCT  70 1453 1063906 N/A N/A  9541  9556 GCGCACTATCCCTATC  74 1454 1063938 N/A N/A  9790  9805 GCTCACCACAGATGAA  88 1455 1063970 N/A N/A 10315 10330 CTTTAACAACTCAGGA  57 1456 1064002 N/A N/A 10615 10630 CTCTTTACCACCCAAC  96 1457 1064034 N/A N/A 11304 11319 ATTCTTACCTGGGAAT 110 1458 1064066 N/A N/A 11458 11473 AAGCTTTTGTGAGCGG  79 1459 1064098 N/A N/A 11583 11598 GCCGAATATAGTAGCT  70 1460 1064132 N/A N/A 11665 11680 CGAATCCACCCCGATT 114 1461 1064164 N/A N/A 11773 11788 AGGATGCAAGAGGTTA  45 1462 1064196 N/A N/A 11865 11880 CTGACATAAGTTGTAT 117 1463 1064228 N/A N/A 11936 11951 GTGAGTCTACAGGCCT  46 1464 1064260 N/A N/A 12021 12036 GTGGAGGAACTCTGTC   78* 1465 1064292 N/A N/A 12325 12340 TCAGAATTTGGCATGC  59 1466 1064324 N/A N/A 12459 12474 AGGAGTTAGAGTAAGA  97 1467 1064356 N/A N/A 12650 12665 TAGGATGAAGGTTCTG  84 1468 1064388 N/A N/A 12848 12863 GTTCGGTGTGGAGTGA  82 1469 1064420 N/A N/A 13017 13032 GGGTTAAGAGTCAGGC  12 1470 1064452 N/A N/A 13246 13261 GTGTGGGTATGGTTGT  66 1471

TABLE 24 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT 202   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  30   65 1062020   50   65   450   465 GTACGGTGTGGAAGCC  41 1472 1062052  175  190  6713  6728 ATCGGGTCCTTGTCCA  37 1473 1062084  330  345  6868  6883 CGCCTCGAAGATCTCG  80 1474 1062116  490  505 N/A N/A AGCTGGTGCATGAAAT 104 1475 1062148  670  685  8247  8262 GCCGGCTCCCTGGACA  96 1476 1062180  811  826  8457  8472 TCCTCTGGCTCTTCGA 100 1477 1062212  999 1014 N/A N/A CGGATGATGCCACAGA 101 1478 1062244 1120 1135 11276 11291 TGGCTACCCCACAGGT  90 1479 1062276 1367 1382 13777 13792 CACCCGCACAAAGCAC 111 1480 1062308 1484 1499 13894 13909 TCCTTGATCTTGAGGT 113 1481 1062340 1790 1805 14200 14215 GCGAGCAGCTGAGGCA  70 1482 1062372 1906 1921 14316 14331 GGTTGTTTGAGTGTAC   9 1483 1062404 2077 2092 14487 14502 TGGGACCTCAGATCCT  72 1484 1062436 2284 2299 N/A N/A CAGTCTAAGCTGAGGC  42 1485 1062468 N/A N/A  8331  8346 ATAGGAGGGCGAGGAT 114 1486 1062500 N/A N/A 13647 13662 TCCCCAATGTGCCTAT 111 1487 1062532 N/A N/A   645   660 TACCAGAGGGCCCCTG  99 1488 1062564 N/A N/A   744   759 TTAAGTACTTCACCTT  56 1489 1062596 N/A N/A  1006  1021 ATGGCGGGAGAAAGAG  36 1490 1062628 N/A N/A  1184  1199 GCTCTAGGCTGGATGC 107 1491 1062660 N/A N/A  1294  1309 GGCACCTTGCAATCCT  36 1492 1062693 N/A N/A  1398  1413 TAAACTACGGTTGACA 114 1493 1062725 N/A N/A  1587  1602 CCAATATATAGCATGA  22 1494 1062757 N/A N/A  1785  1800 ATCCAAGGAAGCAGTC  88 1495 1062789 N/A N/A  1917  1932 AATACTCACCTAGGGT  79 1496 1062821 N/A N/A  2107  2122 GCAAATCAATAAGGGA  40 1497 1062853 N/A N/A  2313  2328 GTAGGAAAGGACTTTC  76 1498 1062885 N/A N/A  2459  2474 CACACATAGGGCTTGG  26 1499 1062917 N/A N/A  2638  2653 ATAAGTTTTAACACCT  56 1500 1062949 N/A N/A  2803  2818 ACTGGAGGACCATGGA 115 1501 1062981 N/A N/A  2987  3002 TAAAGAAGGGCAAGGT  81 1502 1063013 N/A N/A  3180  3195 AGGGATACATAGAGAC  88 1503 1063045 N/A N/A  3288  3303 GAGTAGACAAGGGCCA  82 1504 1063077 N/A N/A  3540  3555 GTCCAACCTGTGGGAA 118 1505 1063109 N/A N/A  3752  3767 CCAATACAGAGCCCAT  74 1506 1063141 N/A N/A  3986  4001 TCCTTGGAACCATCTG  48 1507 1063173 N/A N/A  4159  4174 CTCCACAGATACTGGG  65 1508 1063205 N/A N/A  4368  4383 GGGCAGATACCCCACC  92 1509 1063236 N/A N/A  4452  4467 CCCGACTTGCCCAGAT  67 1510 1063268 N/A N/A  4661  4676 AGCATAGATACATTCT  32 1511 1063300 N/A N/A  4805  4820 TACCGATTTCGGTGCA  71 1512 1063332 N/A N/A  5162  5177 TAAGTTCTTAGTCTCC  24 1513 1063364 N/A N/A  5422  5437 ACTTGAGAACTCCACT 100 1514 1063396 N/A N/A  5611  5626 GAAAGCCCTCCACAAT  98 1515 1063428 N/A N/A  5822  5837 ATCCAGCATGGCAAGT  79 1516 1063460 N/A N/A  5935  5950 GACATGAAGAGTCTGG  58 1517 1063492 N/A N/A  6037  6052 CATGGGTTTTAGCTTG  78 1518 1063524 N/A N/A  6200  6215 GAGGCTATTGTAACAG  53 1519 1063556 N/A N/A  6400  6415 GAGGGCAATGGTTGTT  38 1520 1063588 N/A N/A  6635  6650 CTCGACCACCTGAGCC 133 1521 1063620 N/A N/A  7036  7051 AACCACTTCCTGTGCC  85 1522 1063652 N/A N/A  7310  7325 GGAGATCGAGTAACTT  22 1523 1063684 N/A N/A  7558  7573 CATACCTGGTGCATGA  97 1524 1063716 N/A N/A  7881  7896 CTGCAATTCAGAATAG  66 1525 1063748 N/A N/A  8028  8043 CGCAGGTGCTGACATT  56 1526 1063780 N/A N/A  8148  8163 CCACAAGGCCTCTCAT 149 1527 1063811 N/A N/A  8659  8674 TCGAGAGAAGCTAAGT 112 1528 1063843 N/A N/A  8887  8902 TGGGAACAGTGGAATA  66 1529 1063875 N/A N/A  9211  9226 ACTCACCACTTGAGCC 101 1530 1063907 N/A N/A  9542  9557 TGCGCACTATCCCTAT  92 1531 1063939 N/A N/A  9793  9808 GTCGCTCACCACAGAT  66 1532 1063971 N/A N/A 10341 10356 CTGGCAAGTCTGGCTA  61 1533 1064003 N/A N/A 10616 10631 GCTCTTTACCACCCAA  63 1534 1064035 N/A N/A 11305 11320 CATTCTTACCTGGGAA  99 1535 1064067 N/A N/A 11460 11475 GGAAGCTTTTGTGAGC  56 1536 1064099 N/A N/A 11584 11599 GGCCGAATATAGTAGC  98 1537 1064133 N/A N/A 11666 11681 GCGAATCCACCCCGAT  63 1538 1064165 N/A N/A 11774 11789 AAGGATGCAAGAGGTT  78 1539 1064197 N/A N/A 11866 11881 CCTGACATAAGTTGTA  86 1540 1064229 N/A N/A 11941 11956 ACAAGGTGAGTCTACA 144 1541 1064261 N/A N/A 12089 12104 ACCCAGCGGATGAGCG   39* 1542 1064293 N/A N/A 12326 12341 GTCAGAATTTGGCATG  75 1543 1064325 N/A N/A 12460 12475 AAGGAGTTAGAGTAAG 171 1544 1064357 N/A N/A 12651 12666 CTAGGATGAAGGTTCT  55 1545 1064389 N/A N/A 12849 12864 GGTTCGGTGTGGAGTG  98 1546 1064421 N/A N/A 13018 13033 TGGGTTAAGAGTCAGG  32 1547 1064453 N/A N/A 13256 13271 GGTTAGATGGGTGTGG  82 1548

TABLE 25 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT  93   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  49   65 1062021   51   66   451   466 TGTACGGTGTGGAAGC  40 1549 1062053  176  191  6714  6729 CATCGGGTCCTTGTCC  81 1550 1062085  331  346  6869  6884 CCGCCTCGAAGATCTC  67 1551 1062117  494  509 N/A N/A TGAGAGCTGGTGCATG 129 1552 1062149  672  687  8249  8264 GTGCCGGCTCCCTGGA  83 1553 1062181  816  831  8462  8477 GGAAGTCCTCTGGCTC  98 1554 1062213 1001 1016 N/A N/A GTCGGATGATGCCACA  85 1555 1062245 1124 1139 11280 11295 TCCATGGCTACCCCAC 115 1556 1062277 1368 1383 13778 13793 CCACCCGCACAAAGCA 114 1557 1062309 1485 1500 13895 13910 TTCCTTGATCTTGAGG  89 1558 1062341 1791 1806 14201 14216 TGCGAGCAGCTGAGGC  72 1559 1062373 1907 1922 14317 14332 AGGTTGTTTGAGTGTA   8 1560 1062405 2078 2093 14488 14503 TTGGGACCTCAGATCC  72 1561 1062437 2285 2300 N/A N/A GCAGTCTAAGCTGAGG  66 1562 1062469 N/A N/A  8332  8347 GATAGGAGGGCGAGGA 128 1563 1062501 N/A N/A 13648 13663 CTCCCCAATGTGCCTA  87 1564 1062533 N/A N/A   663   678 GCTGGGTACATCCCAC 127 1565 1062565 N/A N/A   746   761 CATTAAGTACTTCACC 104 1566 1062597 N/A N/A  1007  1022 GATGGCGGGAGAAAGA  96 1567 1062629 N/A N/A  1185  1200 AGCTCTAGGCTGGATG 108 1568 1062661 N/A N/A  1297  1312 CCCGGCACCTTGCAAT  87 1569 1062694 N/A N/A  1399  1414 CTAAACTACGGTTGAC 107 1570 1062726 N/A N/A  1613  1628 GTTAATTGAATAAAGC 113 1571 1062758 N/A N/A  1797  1812 CCCTTTTCAGGAATCC  81 1572 1062790 N/A N/A  1918  1933 TAATACTCACCTAGGG  99 1573 1062822 N/A N/A  2109  2124 TGGCAAATCAATAAGG  95 1574 1062854 N/A N/A  2316  2331 CAAGTAGGAAAGGACT 101 1575 1062886 N/A N/A  2460  2475 TCACACATAGGGCTTG  59 1576 1062918 N/A N/A  2649  2664 CCATTCAAGATATAAG  50 1577 1062950 N/A N/A  2804  2819 AACTGGAGGACCATGG 115 1578 1062982 N/A N/A  3017  3032 TCAACTGATGCTGCCT  53 1579 1063014 N/A N/A  3181  3196 TAGGGATACATAGAGA 121 1580 1063046 N/A N/A  3308  3323 ACTGAGCACGGAGAGG 100 1581 1063078 N/A N/A  3562  3577 CCCCACACTGTGATCG  76 1582 1063110 N/A N/A  3754  3769 CGCCAATACAGAGCCC 109 1583 1063142 N/A N/A  3987  4002 CTCCTTGGAACCATCT  56 1584 1063174 N/A N/A  4163  4178 CAGGCTCCACAGATAC  85 1585 1063206 N/A N/A  4369  4384 AGGGCAGATACCCCAC 158 1586 1063237 N/A N/A  4454  4469 CCCCCGACTTGCCCAG  32 1587 1063269 N/A N/A  4662  4677 AAGCATAGATACATTC  69 1588 1063301 N/A N/A  4806  4821 ATACCGATTTCGGTGC 119 1589 1063333 N/A N/A  5163  5178 TTAAGTTCTTAGTCTC  39 1590 1063365 N/A N/A  5423  5438 GACTTGAGAACTCCAC 110 1591 1063397 N/A N/A  5613  5628 TTGAAAGCCCTCCACA 119 1592 1063429 N/A N/A  5826  5841 ACGGATCCAGCATGGC  35 1593 1063461 N/A N/A  5936  5951 AGACATGAAGAGTCTG 114 1594 1063493 N/A N/A  6048  6063 AGTCAAAGTGACATGG  71 1595 1063525 N/A N/A  6202  6217 AGGAGGCTATTGTAAC  85 1596 1063557 N/A N/A  6401  6416 TGAGGGCAATGGTTGT  79 1597 1063589 N/A N/A  6636  6651 ACTCGACCACCTGAGC 140 1598 1063621 N/A N/A  7043  7058 ACCCAGAAACCACTTC 112 1599 1063653 N/A N/A  7311  7326 TGGAGATCGAGTAACT  23 1600 1063685 N/A N/A  7559  7574 CCATACCTGGTGCATG 117 1601 1063717 N/A N/A  7888  7903 CAGAGTACTGCAATTC  73 1602 1063749 N/A N/A  8029  8044 TCGCAGGTGCTGACAT  97 1603 1063781 N/A N/A  8185  8200 ACCTATGGAGGCTGTG  78 1604 1063812 N/A N/A  8662  8677 AGGTCGAGAGAAGCTA 131 1605 1063844 N/A N/A  8888  8903 TTGGGAACAGTGGAAT 119 1606 1063876 N/A N/A  9228  9243 CTGCATGTCAGGCCTG  85 1607 1063908 N/A N/A  9543  9558 TTGCGCACTATCCCTA  51 1608 1063940 N/A N/A  9794  9809 GGTCGCTCACCACAGA  73 1609 1063972 N/A N/A 10373 10388 CATAGCTGGTCCTGCT  61 1610 1064004 N/A N/A 10621 10636 ATAGGGCTCTTTACCA  83 1611 1064036 N/A N/A 11306 11321 CCATTCTTACCTGGGA 110 1612 1064068 N/A N/A 11465 11480 CGAAAGGAAGCTTTTG 152 1613 1064100 N/A N/A 11585 11600 TGGCCGAATATAGTAG  90 1614 1064134 N/A N/A 11667 11682 GGCGAATCCACCCCGA  96 1615 1064166 N/A N/A 11777 11792 CCAAAGGATGCAAGAG 115 1616 1064198 N/A N/A 11867 11882 ACCTGACATAAGTTGT 119 1617 1064230 N/A N/A 11942 11957 TACAAGGTGAGTCTAC 140 1618 1064262 N/A N/A 12092 12107 CTTACCCAGCGGATGA  62 1619 1064294 N/A N/A 12330 12345 TAGGGTCAGAATTTGG  60 1620 1064326 N/A N/A 12461 12476 GAAGGAGTTAGAGTAA 140 1621 1064358 N/A N/A 12652 12667 GCTAGGATGAAGGTTC  87 1622 1064390 N/A N/A 12850 12865 GGGTTCGGTGTGGAGT  81 1623 1064422 N/A N/A 13019 13034 GTGGGTTAAGAGTCAG 127 1624 1064454 N/A N/A 13329 13344 CAGGACTAGATGTGGG 100 1625

TABLE 26 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT 179   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  51   65 1062022   53   68   453   468 GCTGTACGGTGTGGAA  59 1626 1062054  177  192  6715  6730 GCATCGGGTCCTTGTC 112 1627 1062086  332  347  6870  6885 CCCGCCTCGAAGATCT  31 1628 1062118  495  510 N/A N/A TTGAGAGCTGGTGCAT 153 1629 1062150  675  690  8252  8267 GCAGTGCCGGCTCCCT  45 1630 1062182  819  834  8465  8480 TGAGGAAGTCCTCTGG 124 1631 1062214 1002 1017 N/A N/A TGTCGGATGATGCCAC  56 1632 1062246 1141 1156 N/A N/A TCTGGGAATGTGCTGT  43 1633 1062278 1369 1384 13779 13794 TCCACCCGCACAAAGC  76 1634 1062310 1513 1528 13923 13938 AGTTTGGCCCCTGTTC  23 1635 1062342 1793 1808 14203 14218 TGTGCGAGCAGCTGAG  36 1636 1062374 1910 1925 14320 14335 TTGAGGTTGTTTGAGT  51 1637 1062406 2081 2096 14491 14506 GTGTTGGGACCTCAGA  42 1638 1062438 2296 2311 N/A N/A GTAGTTCCTCTGCAGT  59 1639 1062470 N/A N/A  8333  8348 GGATAGGAGGGCGAGG  31 1640 1062502 N/A N/A 13649 13664 CCTCCCCAATGTGCCT  56 1641 1062534 N/A N/A   664   679 AGCTGGGTACATCCCA 106 1642 1062566 N/A N/A   747   762 GCATTAAGTACTTCAC  22 1643 1062598 N/A N/A  1009  1024 CAGATGGCGGGAGAAA 165 1644 1062630 N/A N/A  1188  1203 CAAAGCTCTAGGCTGG  87 1645 1062662 N/A N/A  1299  1314 GCCCCGGCACCTTGCA  46 1646 1062695 N/A N/A  1400  1415 GCTAAACTACGGTTGA  40 1647 1062727 N/A N/A  1630  1645 GCTTCAAAAACACTAC 104 1648 1062759 N/A N/A  1803  1818 GCAACTCCCTTTTCAG  54 1649 1062791 N/A N/A  1919  1934 ATAATACTCACCTAGG  49 1650 1062823 N/A N/A  2110  2125 GTGGCAAATCAATAAG  32 1651 1062855 N/A N/A  2337  2352 GGTGAACATTTATCTC  62 1652 1062887 N/A N/A  2462  2477 AATCACACATAGGGCT 145 1653 1062919 N/A N/A  2655  2670 CCAGATCCATTCAAGA  47 1654 1062951 N/A N/A  2805  2820 AAACTGGAGGACCATG  95 1655 1062983 N/A N/A  3018  3033 TTCAACTGATGCTGCC  72 1656 1063015 N/A N/A  3182  3197 ATAGGGATACATAGAG  86 1657 1063047 N/A N/A  3316  3331 CCTTCTACACTGAGCA  40 1658 1063079 N/A N/A  3584  3599 GCCCAGCTCTTGTGAG 117 1659 1063111 N/A N/A  3755  3770 TCGCCAATACAGAGCC  90 1660 1063143 N/A N/A  3991  4006 CAAACTCCTTGGAACC  58 1661 1063175 N/A N/A  4181  4196 AGCTCTGAGAGTGCCA 125 1662 1063207 N/A N/A  4370  4385 GAGGGCAGATACCCCA  29 1663 1063238 N/A N/A  4455  4470 GCCCCCGACTTGCCCA  16 1664 1063270 N/A N/A  4665  4680 GCAAAGCATAGATACA  35 1665 1063302 N/A N/A  4807  4822 AATACCGATTTCGGTG 129 1666 1063334 N/A N/A  5164  5179 ATTAAGTTCTTAGTCT  82 1667 1063366 N/A N/A  5424  5439 TGACTTGAGAACTCCA 136 1668 1063398 N/A N/A  5614  5629 CTTGAAAGCCCTCCAC 133 1669 1063430 N/A N/A  5827  5842 CACGGATCCAGCATGG 135 1670 1063462 N/A N/A  5939  5954 GATAGACATGAAGAGT  65 1671 1063494 N/A N/A  6075  6090 AGCTTGGATGTAGTGG  88 1672 1063526 N/A N/A  6203  6218 GAGGAGGCTATTGTAA  87 1673 1063558 N/A N/A  6402  6417 ATGAGGGCAATGGTTG  42 1674 1063590 N/A N/A  6637  6652 TACTCGACCACCTGAG 101 1675 1063622 N/A N/A  7056  7071 AGACTTGCCTGGGACC 135 1676 1063654 N/A N/A  7312  7327 ATGGAGATCGAGTAAC  13 1677 1063686 N/A N/A  7560  7575 TCCATACCTGGTGCAT  73 1678 1063718 N/A N/A  7906  7921 CCTGACACCTTTGACC  49 1679 1063750 N/A N/A  8030  8045 TTCGCAGGTGCTGACA  64 1680 1063782 N/A N/A  8212  8227 GTTGATCCCTGTGGGT  54 1681 1063813 N/A N/A  8680  8695 ATACATACGAGAAAAC  59 1682 1063845 N/A N/A  8892  8907 AACTTTGGGAACAGTG  71 1683 1063877 N/A N/A  9251  9266 TAACACATGCCCCTCA  98 1684 1063909 N/A N/A  9545  9560 TTTTGCGCACTATCCC  86 1685 1063941 N/A N/A  9820  9835 TCTGAGTCTGCCACCA  35 1686 1063973 N/A N/A 10374 10389 ACATAGCTGGTCCTGC  35 1687 1064005 N/A N/A 10622 10637 AATAGGGCTCTTTACC  55 1688 1064037 N/A N/A 11308 11323 GACCATTCTTACCTGG  58 1689 1064069 N/A N/A 11466 11481 CCGAAAGGAAGCTTTT  95 1690 1064102 N/A N/A 11592 11607 CTTCTGATGGCCGAAT  86 1691 1064135 N/A N/A 11668 11683 GGGCGAATCCACCCCG  81 1692 1064167 N/A N/A 11778 11793 ACCAAAGGATGCAAGA 136 1693 1064199 N/A N/A 11868 11883 CACCTGACATAAGTTG 195 1694 1064231 N/A N/A 11943 11958 CTACAAGGTGAGTCTA  56 1695 1064263 N/A N/A 12093 12108 GCTTACCCAGCGGATG  165* 1696 1064295 N/A N/A 12331 12346 TTAGGGTCAGAATTTG 155 1697 1064327 N/A N/A 12462 12477 GGAAGGAGTTAGAGTA 129 1698 1064359 N/A N/A 12653 12668 CGCTAGGATGAAGGTT 126 1699 1064391 N/A N/A 12864 12879 TGAGGTTAGTTGTGGG  22 1700 1064423 N/A N/A 13020 13035 GGTGGGTTAAGAGTCA 141 1701 1064455 N/A N/A 13330 13345 ACAGGACTAGATGTGG  65 1702

TABLE 27 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  582998 N/A N/A  8468  8483 ACTTGAGGAAGTCCTC 105 1703  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT  90   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  28   65 1062023   56   71   456   471 CACGCTGTACGGTGTG 104 1704 1062055  204  219  6742  6757 CCGAGGGCTTGCCAGG  94 1705 1062087  333  348  6871  6886 CCCCGCCTCGAAGATC  28 1706 1062119  496  511 N/A N/A GTTGAGAGCTGGTGCA  82 1707 1062151  680  695  8257  8272 GCAGAGCAGTGCCGGC  82 1708 1062183  820  835  8466  8481 TTGAGGAAGTCCTCTG  56 1709 1062215 1003 1018 N/A N/A TTGTCGGATGATGCCA  75 1710 1062247 1151 1166 N/A N/A GTGGAGGAACTCTGGG  26 1711 1062279 1370 1385 13780 13795 CTCCACCCGCACAAAG  54 1712 1062311 1514 1529 13924 13939 CAGTTTGGCCCCTGTT  59 1713 1062343 1794 1809 14204 14219 CTGTGCGAGCAGCTGA  57 1714 1062375 1913 1928 14323 14338 GCTTTGAGGTTGTTTG  22 1715 1062407 2082 2097 14492 14507 CGTGTTGGGACCTCAG  22 1716 1062439 2298 2313 N/A N/A GAGTAGTTCCTCTGCA  32 1717 1062471 N/A N/A  8354  8369 GACAGAGGGTGTCAGG 114 1718 1062503 N/A N/A 13650 13665 TCCTCCCCAATGTGCC  57 1719 1062535 N/A N/A   666   681 GTAGCTGGGTACATCC  46 1720 1062567 N/A N/A   753   768 GCCCATGCATTAAGTA  83 1721 1062599 N/A N/A  1010  1025 ACAGATGGCGGGAGAA 123 1722 1062631 N/A N/A  1189  1204 ACAAAGCTCTAGGCTG  92 1723 1062663 N/A N/A  1312  1327 AAGTGCTCAGCTTGCC  70 1724 1062696 N/A N/A  1401  1416 AGCTAAACTACGGTTG  76 1725 1062728 N/A N/A  1683  1698 GAGGACAGTCTTGTCC  96 1726 1062760 N/A N/A  1821  1836 CACGCCCCCTTTGCCC  27 1727 1062792 N/A N/A  1920  1935 AATAATACTCACCTAG 111 1728 1062824 N/A N/A  2113  2128 GCTGTGGCAAATCAAT  59 1729 1062856 N/A N/A  2341  2356 CATAGGTGAACATTTA  47 1730 1062888 N/A N/A  2478  2493 TAAGTGCCTGGCTAAA  70 1731 1062920 N/A N/A  2656  2671 CCCAGATCCATTCAAG  48 1732 1062952 N/A N/A  2806  2821 CAAACTGGAGGACCAT 113 1733 1062984 N/A N/A  3019  3034 GTTCAACTGATGCTGC  41 1734 1063016 N/A N/A  3183  3198 GATAGGGATACATAGA  92 1735 1063048 N/A N/A  3317  3332 CCCTTCTACACTGAGC  48 1736 1063080 N/A N/A  3591  3606 TCACCTAGCCCAGCTC  75 1737 1063112 N/A N/A  3756  3771 TTCGCCAATACAGAGC  47 1738 1063144 N/A N/A  3994  4009 GTCCAAACTCCTTGGA 104 1739 1063176 N/A N/A  4189  4204 AGGTTTGAAGCTCTGA  33 1740 1063208 N/A N/A  4371  4386 AGAGGGCAGATACCCC  83 1741 1063239 N/A N/A  4456  4471 AGCCCCCGACTTGCCC  44 1742 1063271 N/A N/A  4666  4681 AGCAAAGCATAGATAC  49 1743 1063303 N/A N/A  4808  4823 TAATACCGATTTCGGT 110 1744 1063335 N/A N/A  5165  5180 TATTAAGTTCTTAGTC  47 1745 1063367 N/A N/A  5426  5441 AGTGACTTGAGAACTC  67 1746 1063399 N/A N/A  5616  5631 ACCTTGAAAGCCCTCC  28 1747 1063431 N/A N/A  5828  5843 GCACGGATCCAGCATG  85 1748 1063463 N/A N/A  5942  5957 GTAGATAGACATGAAG  59 1749 1063495 N/A N/A  6076  6091 CAGCTTGGATGTAGTG  55 1750 1063527 N/A N/A  6235  6250 AGATTCATCTGGCTGC  46 1751 1063559 N/A N/A  6403  6418 TATGAGGGCAATGGTT  77 1752 1063591 N/A N/A  6638  6653 ATACTCGACCACCTGA  76 1753 1063623 N/A N/A  7060  7075 TCACAGACTTGCCTGG  83 1754 1063655 N/A N/A  7331  7346 CGTATGGAAACTGAGG  19 1755 1063687 N/A N/A  7562  7577 CGTCCATACCTGGTGC  94 1756 1063719 N/A N/A  7907  7922 ACCTGACACCTTTGAC  89 1757 1063751 N/A N/A  8031  8046 ATTCGCAGGTGCTGAC  64 1758 1063814 N/A N/A  8682  8697 TTATACATACGAGAAA 108 1759 1063846 N/A N/A  8895  8910 TAGAACTTTGGGAACA  73 1760 1063878 N/A N/A  9253  9268 CTTAACACATGCCCCT  82 1761 1063910 N/A N/A  9551  9566 AGAAGGTTTTGCGCAC  20 1762 1063942 N/A N/A  9866  9881 GTTAGGTTCCCTGCAC  68 1763 1063974 N/A N/A 10375 10390 TACATAGCTGGTCCTG  34 1764 1064006 N/A N/A 10623 10638 GAATAGGGCTCTTTAC  87 1765 1064038 N/A N/A 11309 11324 GGACCATTCTTACCTG 104 1766 1064070 N/A N/A 11467 11482 CCCGAAAGGAAGCTTT  65 1767 1064103 N/A N/A 11594 11609 CCCTTCTGATGGCCGA  28 1768 1064136 N/A N/A 11669 11684 CGGGCGAATCCACCCC 110 1769 1064168 N/A N/A 11779 11794 CACCAAAGGATGCAAG 109 1770 1064200 N/A N/A 11869 11884 GCACCTGACATAAGTT  77 1771 1064232 N/A N/A 11944 11959 CCTACAAGGTGAGTCT 100 1772 1064264 N/A N/A 12094 12109 TGCTTACCCAGCGGAT  107* 1773 1064296 N/A N/A 12333 12348 GTTTAGGGTCAGAATT 105 1774 1064328 N/A N/A 12463 12478 GGGAAGGAGTTAGAGT 107 1775 1064360 N/A N/A 12654 12669 GCGCTAGGATGAAGGT 102 1776 1064392 N/A N/A 12866 12881 GATGAGGTTAGTTGTG  93 1777 1064424 N/A N/A 13041 13056 CAACTTAAGGGTCAGG  86 1778 1064456 N/A N/A 13331 13346 GACAGGACTAGATGTG  91 1779

TABLE 28 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT  90   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  39   65 1062024   58   73   458   473 ACCACGCTGTACGGTG  92 1780 1062056  205  220  6743  6758 GCCGAGGGCTTGCCAG 103 1781 1062088  334  349  6872  6887 GCCCCGCCTCGAAGAT  56 1782 1062120  498  513 N/A N/A CCGTTGAGAGCTGGTG  68 1783 1062152  682  697  8259  8274 GTGCAGAGCAGTGCCG  78 1784 1062184  822  837 N/A N/A GCTTGAGGAAGTCCTC  79 1785 1062216 1004 1019 11160 11175 CTTGTCGGATGATGCC  49 1786 1062248 1157 1172 12027 12042 CATGTTGTGGAGGAAC  69 1787 1062280 1372 1387 13782 13797 CTCTCCACCCGCACAA  67 1788 1062312 1515 1530 13925 13940 CCAGTTTGGCCCCTGT  88 1789 1062344 1795 1810 14205 14220 TCTGTGCGAGCAGCTG  43 1790 1062376 1915 1930 14325 14340 CAGCTTTGAGGTTGTT  30 1791 1062408 2105 2120 14515 14530 CAGGCCGTGTGTGTGA  64 1792 1062440 2299 2314 N/A N/A TGAGTAGTTCCTCTGC  56 1793 1062472 N/A N/A 13560 13575 GAGGAGCTCACCTTCC 106 1794 1062504 N/A N/A 13655 13670 CCCGTTCCTCCCCAAT  34 1795 1062536 N/A N/A   668   683 CGGTAGCTGGGTACAT  36 1796 1062568 N/A N/A   755   770 CTGCCCATGCATTAAG  70 1797 1062600 N/A N/A  1011  1026 GACAGATGGCGGGAGA  98 1798 1062632 N/A N/A  1190  1205 TACAAAGCTCTAGGCT  82 1799 1062664 N/A N/A  1314  1329 TTAAGTGCTCAGCTTG  77 1800 1062697 N/A N/A  1402  1417 CAGCTAAACTACGGTT  86 1801 1062729 N/A N/A  1684  1699 TGAGGACAGTCTTGTC  69 1802 1062761 N/A N/A  1827  1842 AAAATGCACGCCCCCT  36 1803 1062793 N/A N/A  1997  2012 GTAATCACAAGATGCA  56 1804 1062825 N/A N/A  2120  2135 ATAAAGAGCTGTGGCA  81 1805 1062857 N/A N/A  2345  2360 CCAACATAGGTGAACA   2 1806 1062889 N/A N/A  2479  2494 TTAAGTGCCTGGCTAA  73 1807 1062921 N/A N/A  2668  2683 TACCCTAAAATGCCCA  55 1808 1062953 N/A N/A  2807  2822 TCAAACTGGAGGACCA 112 1809 1062985 N/A N/A  3024  3039 GGCTGGTTCAACTGAT  50 1810 1063017 N/A N/A  3184  3199 AGATAGGGATACATAG  89 1811 1063049 N/A N/A  3318  3333 GCCCTTCTACACTGAG  32 1812 1063081 N/A N/A  3592  3607 CTCACCTAGCCCAGCT 103 1813 1063113 N/A N/A  3757  3772 CTTCGCCAATACAGAG  74 1814 1063145 N/A N/A  4023  4038 CTCAGTATGTGTAGGC  35 1815 1063177 N/A N/A  4190  4205 CAGGTTTGAAGCTCTG  73 1816 1063209 N/A N/A  4372  4387 AAGAGGGCAGATACCC  81 1817 1063240 N/A N/A  4457  4472 CAGCCCCCGACTTGCC  65 1818 1063272 N/A N/A  4668  4683 TCAGCAAAGCATAGAT  77 1819 1063304 N/A N/A  4809  4824 CTAATACCGATTTCGG  93 1820 1063336 N/A N/A  5166  5181 GTATTAAGTTCTTAGT  71 1821 1063368 N/A N/A  5428  5443 ATAGTGACTTGAGAAC 101 1822 1063400 N/A N/A  5617  5632 CACCTTGAAAGCCCTC  35 1823 1063432 N/A N/A  5829  5844 TGCACGGATCCAGCAT 123 1824 1063464 N/A N/A  5943  5958 TGTAGATAGACATGAA  67 1825 1063496 N/A N/A  6094  6109 GATCAGGAGCAGTGCT  93 1826 1063528 N/A N/A  6251  6266 TAGGCATGGACTCAAA  78 1827 1063560 N/A N/A  6404  6419 CTATGAGGGCAATGGT  82 1828 1063592 N/A N/A  6639  6654 GATACTCGACCACCTG  66 1829 1063624 N/A N/A  7066  7081 CATAAGTCACAGACTT  93 1830 1063656 N/A N/A  7352  7367 TATGATCATCCCCCTT  73 1831 1063688 N/A N/A  7563  7578 CCGTCCATACCTGGTG  89 1832 1063720 N/A N/A  7908  7923 GACCTGACACCTTTGA  60 1833 1063752 N/A N/A  8032  8047 CATTCGCAGGTGCTGA  70 1834 1063783 N/A N/A  8469  8484 CACTTGAGGAAGTCCT  92 1835 1063815 N/A N/A  8683  8698 ATTATACATACGAGAA  90 1836 1063847 N/A N/A  8899  8914 GAGCTAGAACTTTGGG  80 1837 1063879 N/A N/A  9254  9269 CCTTAACACATGCCCC  59 1838 1063911 N/A N/A  9553  9568 ACAGAAGGTTTTGCGC  57 1839 1063943 N/A N/A  9867  9882 GGTTAGGTTCCCTGCA  56 1840 1063975 N/A N/A 10376 10391 TTACATAGCTGGTCCT  36 1841 1064007 N/A N/A 10624 10639 TGAATAGGGCTCTTTA  84 1842 1064039 N/A N/A 11311 11326 AAGGACCATTCTTACC 135 1843 1064071 N/A N/A 11468 11483 TCCCGAAAGGAAGCTT  64 1844 1064105 N/A N/A 11602 11617 GGGTCCCTCCCTTCTG  69 1845 1064137 N/A N/A 11670 11685 TCGGGCGAATCCACCC  88 1846 1064169 N/A N/A 11782 11797 GCACACCAAAGGATGC 110 1847 1064201 N/A N/A 11870 11885 AGCACCTGACATAAGT  81 1848 1064233 N/A N/A 11945 11960 CCCTACAAGGTGAGTC  79 1849 1064265 N/A N/A 12095 12110 CTGCTTACCCAGCGGA   93* 1850 1064297 N/A N/A 12334 12349 GGTTTAGGGTCAGAAT  51 1851 1064329 N/A N/A 12477 12492 TGGCATAAAGGCTGGG  48 1852 1064361 N/A N/A 12682 12697 GTGAGGTTCAGGTTTG  54 1853 1064393 N/A N/A 12867 12882 GGATGAGGTTAGTTGT  98 1854 1064425 N/A N/A 13043 13058 GCCAACTTAAGGGTCA  68 1855 1064457 N/A N/A 13332 13347 GGACAGGACTAGATGT  91 1856

TABLE 29 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT 143   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  53   65 1062025   60   75   460   475 AAACCACGCTGTACGG 143 1857 1062057  206  221  6744  6759 GGCCGAGGGCTTGCCA  88 1858 1062089  337  352  6875  6890 TGGGCCCCGCCTCGAA 232 1859 1062121  499  514 N/A N/A ACCGTTGAGAGCTGGT 423 1860 1062153  693  708  8270  8285 GATTTGGGAAGGTGCA 138 1861 1062185  824  839 N/A N/A GTGCTTGAGGAAGTCC 305 1862 1062217 1006 1021 11162 11177 CCCTTGTCGGATGATG  97 1863 1062249 1159 1174 12029 12044 TCCATGTTGTGGAGGA 448* 1864 1062281 1376 1391 13786 13801 CTCGCTCTCCACCCGC 69 1865 1062313 1516 1531 13926 13941 ACCAGTTTGGCCCCTG 127 1866 1062345 1796 1811 14206 14221 ATCTGTGCGAGCAGCT  69 1867 1062377 1917 1932 14327 14342 TGCAGCTTTGAGGTTG  52 1868 1062409 2107 2122 14517 14532 AACAGGCCGTGTGTGT  67 1869 1062441 2300 2315 N/A N/A ATGAGTAGTTCCTCTG  47 1870 1062473 N/A N/A 13561 13576 AGAGGAGCTCACCTTC 139 1871 1062505 N/A N/A 13656 13671 TCCCGTTCCTCCCCAA 110 1872 1062537 N/A N/A   669   684 ACGGTAGCTGGGTACA 141 1873 1062569 N/A N/A   785   800 ATCAATTGATGAATTC  64 1874 1062601 N/A N/A  1012  1027 AGACAGATGGCGGGAG  71 1875 1062633 N/A N/A  1191  1206 GTACAAAGCTCTAGGC  40 1876 1062665 N/A N/A  1315  1330 GTTAAGTGCTCAGCTT 146 1877 1062698 N/A N/A  1409  1424 GTCCACACAGCTAAAC  75 1878 1062730 N/A N/A  1686  1701 TGTGAGGACAGTCTTG 520 1879 1062762 N/A N/A  1829  1844 TAAAAATGCACGCCCC  70 1880 1062794 N/A N/A  1998  2013 AGTAATCACAAGATGC 201 1881 1062826 N/A N/A  2121  2136 AATAAAGAGCTGTGGC 144 1882 1062858 N/A N/A  2346  2361 GCCAACATAGGTGAAC 147 1883 1062890 N/A N/A  2480  2495 GTTAAGTGCCTGGCTA  59 1884 1062922 N/A N/A  2670  2685 TATACCCTAAAATGCC  63 1885 1062954 N/A N/A  2808  2823 TTCAAACTGGAGGACC 166 1886 1062986 N/A N/A  3026  3041 CTGGCTGGTTCAACTG  65 1887 1063018 N/A N/A  3185  3200 GAGATAGGGATACATA 149 1888 1063050 N/A N/A  3323  3338 AATTTGCCCTTCTACA  98 1889 1063082 N/A N/A  3610  3625 ACCTATGGAGTCCGGG  57 1890 1063114 N/A N/A  3758  3773 CCTTCGCCAATACAGA 410 1891 1063146 N/A N/A  4024  4039 TCTCAGTATGTGTAGG  57 1892 1063178 N/A N/A  4191  4206 CCAGGTTTGAAGCTCT  33 1893 1063210 N/A N/A  4373  4388 GAAGAGGGCAGATACC 239 1894 1063241 N/A N/A  4460  4475 TCACAGCCCCCGACTT 317 1895 1063273 N/A N/A  4674  4689 CCTGACTCAGCAAAGC 238 1896 1063305 N/A N/A  4810  4825 ACTAATACCGATTTCG  97 1897 1063337 N/A N/A  5169  5184 CAGGTATTAAGTTCTT  67 1898 1063369 N/A N/A  5429  5444 CATAGTGACTTGAGAA 379 1899 1063401 N/A N/A  5618  5633 TCACCTTGAAAGCCCT  67 1900 1063433 N/A N/A  5830  5845 ATGCACGGATCCAGCA  76 1901 1063465 N/A N/A  5956  5971 GCAAAAGTGCAGGTGT 127 1902 1063497 N/A N/A  6097  6112 CTGGATCAGGAGCAGT 533 1903 1063529 N/A N/A  6254  6269 GACTAGGCATGGACTC  62 1904 1063561 N/A N/A  6405  6420 TCTATGAGGGCAATGG 283 1905 1063593 N/A N/A  6640  6655 AGATACTCGACCACCT 243 1906 1063625 N/A N/A  7067  7082 GCATAAGTCACAGACT 121 1907 1063657 N/A N/A  7354  7369 GCTATGATCATCCCCC  90 1908 1063689 N/A N/A  7565  7580 CACCGTCCATACCTGG 461 1909 1063721 N/A N/A  7909  7924 AGACCTGACACCTTTG  41 1910 1063753 N/A N/A  8033  8048 CCATTCGCAGGTGCTG 164 1911 1063784 N/A N/A  8470  8485 TCACTTGAGGAAGTCC 117 1912 1063816 N/A N/A  8685  8700 TTATTATACATACGAG 214 1913 1063848 N/A N/A  8900  8915 GGAGCTAGAACTTTGG 208 1914 1063880 N/A N/A  9361  9376 GCTCAATGCTCTGAAT  93 1915 1063912 N/A N/A  9554  9569 GACAGAAGGTTTTGCG  28 1916 1063944 N/A N/A  9869  9884 GAGGTTAGGTTCCCTG  63 1917 1063976 N/A N/A 10377 10392 GTTACATAGCTGGTCC  28 1918 1064008 N/A N/A 10626 10641 GTTGAATAGGGCTCTT  51 1919 1064040 N/A N/A 11312 11327 CAAGGACCATTCTTAC  78 1920 1064072 N/A N/A 11469 11484 ATCCCGAAAGGAAGCT  68 1921 1064106 N/A N/A 11607 11622 TAGCAGGGTCCCTCCC 177 1922 1064138 N/A N/A 11671 11686 CTCGGGCGAATCCACC  74 1923 1064170 N/A N/A 11790 11805 AGTAACTTGCACACCA  81 1924 1064202 N/A N/A 11871 11886 GAGCACCTGACATAAG 215 1925 1064234 N/A N/A 11946 11961 CCCCTACAAGGTGAGT  70 1926 1064266 N/A N/A 12096 12111 CCTGCTTACCCAGCGG   62* 1927 1064298 N/A N/A 12336 12351 TAGGTTTAGGGTCAGA  27 1928 1064330 N/A N/A 12478 12493 TTGGCATAAAGGCTGG  55 1929 1064362 N/A N/A 12683 12698 GGTGAGGTTCAGGTTT  82 1930 1064394 N/A N/A 12868 12883 AGGATGAGGTTAGTTG 199 1931 1064426 N/A N/A 13044 13059 GGCCAACTTAAGGGTC  98 1932 1064458 N/A N/A 13334 13349 AGGGACAGGACTAGAT 109 1933

TABLE 30 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT 162   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  55   65 1062026   61   76   461   476 AAAACCACGCTGTACG  70 1934 1062058  246  261  6784  6799 TGGGCGAGGCTCCTGG  70 1935 1062090  342  357  6880  6895 AGGCATGGGCCCCGCC  53 1936 1062122  501  516  7664  7679 CCACCGTTGAGAGCTG 140 1937 1062154  702  717  8279  8294 GTGCACTGGGATTTGG  82 1938 1062186  826  841 N/A N/A CAGTGCTTGAGGAAGT  51 1939 1062218 1007 1022 11163 11178 GCCCTTGTCGGATGAT  92 1940 1062250 1162 1177 12032 12047 TAGTCCATGTTGTGGA   49* 1941 1062282 1377 1392 13787 13802 TCTCGCTCTCCACCCG  71 1942 1062314 1520 1535 13930 13945 TCCCACCAGTTTGGCC 104 1943 1062346 1797 1812 14207 14222 AATCTGTGCGAGCAGC  59 1944 1062378 1919 1934 14329 14344 GATGCAGCTTTGAGGT  19 1945 1062410 2115 2130 14525 14540 TGAATTCTAACAGGCC  40 1946 1062442 2318 2333 N/A N/A GCCTTGGATCCCAAAT  57 1947 1062474 N/A N/A 13562 13577 CAGAGGAGCTCACCTT 131 1948 1062506 N/A N/A 13658 13673 CATCCCGTTCCTCCCC  64 1949 1062538 N/A N/A   670   685 CACGGTAGCTGGGTAC 108 1950 1062570 N/A N/A   788   803 CGTATCAATTGATGAA  17 1951 1062602 N/A N/A  1014  1029 ACAGACAGATGGCGGG  59 1952 1062634 N/A N/A  1214  1229 TACTATTATTAAACGC  79 1953 1062666 N/A N/A  1316  1331 AGTTAAGTGCTCAGCT  52 1954 1062699 N/A N/A  1411  1426 AGGTCCACACAGCTAA  42 1955 1062731 N/A N/A  1687  1702 ATGTGAGGACAGTCTT 117 1956 1062763 N/A N/A  1830  1845 TTAAAAATGCACGCCC  95 1957 1062795 N/A N/A  2014  2029 GCCAATGAATAGTAAA 110 1958 1062827 N/A N/A  2125  2140 TCCAAATAAAGAGCTG  97 1959 1062859 N/A N/A  2347  2362 AGCCAACATAGGTGAA 147 1960 1062891 N/A N/A  2512  2527 CAGTACATATGAGGAA  19 1961 1062923 N/A N/A  2672  2687 CATATACCCTAAAATG 220 1962 1062955 N/A N/A  2809  2824 TTTCAAACTGGAGGAC  70 1963 1062987 N/A N/A  3029  3044 TCTCTGGCTGGTTCAA  44 1964 1063019 N/A N/A  3186  3201 AGAGATAGGGATACAT 134 1965 1063051 N/A N/A  3324  3339 CAATTTGCCCTTCTAC 151 1966 1063083 N/A N/A  3611  3626 GACCTATGGAGTCCGG 139 1967 1063115 N/A N/A  3759  3774 GCCTTCGCCAATACAG  54 1968 1063147 N/A N/A  4032  4047 TCCCAAAGTCTCAGTA 100 1969 1063179 N/A N/A  4192  4207 CCCAGGTTTGAAGCTC 117 1970 1063211 N/A N/A  4374  4389 AGAAGAGGGCAGATAC 157 1971 1063242 N/A N/A  4462  4477 TGTCACAGCCCCCGAC  86 1972 1063274 N/A N/A  4683  4698 GTGGGATGGCCTGACT 148 1973 1063306 N/A N/A  4811  4826 AACTAATACCGATTTC 129 1974 1063338 N/A N/A  5170  5185 CCAGGTATTAAGTTCT  49 1975 1063370 N/A N/A  5430  5445 CCATAGTGACTTGAGA 213 1976 1063402 N/A N/A  5619  5634 CTCACCTTGAAAGCCC  85 1977 1063434 N/A N/A  5833  5848 ATCATGCACGGATCCA 154 1978 1063466 N/A N/A  5957  5972 TGCAAAAGTGCAGGTG  55 1979 1063498 N/A N/A  6104  6119 TCTGAAGCTGGATCAG 151 1980 1063530 N/A N/A  6255  6270 TGACTAGGCATGGACT 173 1981 1063562 N/A N/A  6407  6422 CCTCTATGAGGGCAAT 237 1982 1063594 N/A N/A  6643  6658 ATGAGATACTCGACCA  60 1983 1063626 N/A N/A  7069  7084 CTGCATAAGTCACAGA  83 1984 1063658 N/A N/A  7356  7371 ATGCTATGATCATCCC  26 1985 1063690 N/A N/A  7568  7583 ATTCACCGTCCATACC  68 1986 1063722 N/A N/A  7910  7925 GAGACCTGACACCTTT  57 1987 1063754 N/A N/A  8034  8049 GCCATTCGCAGGTGCT  55 1988 1063785 N/A N/A  8471  8486 CTCACTTGAGGAAGTC 101 1989 1063817 N/A N/A  8705  8720 AATAACAGCACAAACG  71 1990 1063849 N/A N/A  8901  8916 AGGAGCTAGAACTTTG 133 1991 1063881 N/A N/A  9380  9395 CCACGACAGGCCTGGT  72 1992 1063913 N/A N/A  9557  9572 GTGGACAGAAGGTTTT  44 1993 1063945 N/A N/A  9870  9885 TGAGGTTAGGTTCCCT  73 1994 1063977 N/A N/A 10381 10396 GCAGGTTACATAGCTG  57 1995 1064009 N/A N/A 10662 10677 CGTATGTGGCCACTGA  56 1996 1064041 N/A N/A 11313 11328 GCAAGGACCATTCTTA  86 1997 1064073 N/A N/A 11476 11491 CACGGACATCCCGAAA  74 1998 1064107 N/A N/A 11608 11623 TTAGCAGGGTCCCTCC  59 1999 1064139 N/A N/A 11672 11687 GCTCGGGCGAATCCAC 117 2000 1064171 N/A N/A 11792 11807 GGAGTAACTTGCACAC  89 2001 1064203 N/A N/A 11883 11898 GTACTGTTTGCTGAGC  31 2002 1064235 N/A N/A 11966 11981 AGCTAGCTCCCTGTCC  50 2003 1064267 N/A N/A 12097 12112 CCCTGCTTACCCAGCG   71* 2004 1064299 N/A N/A 12358 12373 GAGGTGGACATCTGGA  52 2005 1064331 N/A N/A 12483 12498 TTGGGTTGGCATAAAG  69 2006 1064363 N/A N/A 12698 12713 CTGGTATCATGTAGGG  53 2007 1064395 N/A N/A 12869 12884 AAGGATGAGGTTAGTT  74 2008 1064427 N/A N/A 13045 13060 AGGCCAACTTAAGGGT  74 2009 1064459 N/A N/A 13337 13352 ATCAGGGACAGGACTA 177 2010

TABLE 31 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  34   65  911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG  16  306 1062027   70   85   470   485 CCGAGAAGAAAAACCA  69 2011 1062059  247  262  6785  6800 CTGGGCGAGGCTCCTG 129 2012 1062091  343  358  6881  6896 GAGGCATGGGCCCCGC 104 2013 1062123  502  517  7665  7680 TCCACCGTTGAGAGCT  85 2014 1062155  710  725  8287  8302 CTTCCTGGGTGCACTG 101 2015 1062187  833  848 N/A N/A CGCCTGGCAGTGCTTG 112 2016 1062219 1009 1024 11165 11180 GAGCCCTTGTCGGATG 129 2017 1062251 1164 1179 12034 12049 AGTAGTCCATGTTGTG   45* 2018 1062283 1379 1394 13789 13804 CTTCTCGCTCTCCACC 104 2019 1062315 1523 1538 13933 13948 GCCTCCCACCAGTTTG  61 2020 1062347 1798 1813 14208 14223 TAATCTGTGCGAGCAG  37 2021 1062379 1920 1935 14330 14345 TGATGCAGCTTTGAGG  32 2022 1062411 2128 2143 14538 14553 TGAGATACACAGGTGA  63 2023 1062443 2319 2334 N/A N/A GGCCTTGGATCCCAAA 121 2024 1062475 N/A N/A 13563 13578 TCAGAGGAGCTCACCT 138 2025 1062507 N/A N/A 13659 13674 ACATCCCGTTCCTCCC  77 2026 1062539 N/A N/A   671   686 TCACGGTAGCTGGGTA  79 2027 1062571 N/A N/A   802   817 ATCCTATCCATCTACG 110 2028 1062603 N/A N/A  1023  1038 AGTGTAGCGACAGACA 129 2029 1062635 N/A N/A  1215  1230 TTACTATTATTAAACG 128 2030 1062667 N/A N/A  1317  1332 CAGTTAAGTGCTCAGC  39 2031 1062700 N/A N/A  1415  1430 GGGTAGGTCCACACAG  40 2032 1062732 N/A N/A  1688  1703 GATGTGAGGACAGTCT 116 2033 1062764 N/A N/A  1831  1846 TTTAAAAATGCACGCC  73 2034 1062796 N/A N/A  2015  2030 GGCCAATGAATAGTAA 101 2035 1062828 N/A N/A  2138  2153 GGTTAATAACCATTCC  90 2036 1062860 N/A N/A  2348  2363 AAGCCAACATAGGTGA  64 2037 1062892 N/A N/A  2523  2538 TATAACCATTGCAGTA  58 2038 1062924 N/A N/A  2678  2693 CATCATCATATACCCT 113 2039 1062956 N/A N/A  2813  2828 GGCATTTCAAACTGGA  97 2040 1062988 N/A N/A  3040  3055 ACATTTGCTGGTCTCT  45 2041 1063020 N/A N/A  3189  3204 CTGAGAGATAGGGATA  79 2042 1063052 N/A N/A  3342  3357 CCTGAGATCTCTGGTC  63 2043 1063084 N/A N/A  3614  3629 CCTGACCTATGGAGTC 100 2044 1063116 N/A N/A  3845  3860 CGCCAGAGATGGCAAC 103 2045 1063148 N/A N/A  4039  4054 TCTACGGTCCCAAAGT  65 2046 1063180 N/A N/A  4193  4208 ACCCAGGTTTGAAGCT  55 2047 1063212 N/A N/A  4387  4402 ACCACGGAGGAAGAGA  94 2048 1063243 N/A N/A  4467  4482 CCTGTTGTCACAGCCC  64 2049 1063275 N/A N/A  4685  4700 ATGTGGGATGGCCTGA 123 2050 1063307 N/A N/A  4813  4828 CAAACTAATACCGATT  96 2051 1063339 N/A N/A  5171  5186 TCCAGGTATTAAGTTC  56 2052 1063371 N/A N/A  5431  5446 CCCATAGTGACTTGAG  83 2053 1063403 N/A N/A  5626  5641 TATTGTCCTCACCTTG  77 2054 1063435 N/A N/A  5834  5849 GATCATGCACGGATCC  73 2055 1063467 N/A N/A  5958  5973 GTGCAAAAGTGCAGGT 117 2056 1063499 N/A N/A  6105  6120 ATCTGAAGCTGGATCA  99 2057 1063531 N/A N/A  6257  6272 AGTGACTAGGCATGGA  47 2058 1063563 N/A N/A  6408  6423 TCCTCTATGAGGGCAA 120 2059 1063595 N/A N/A  6644  6659 TATGAGATACTCGACC 129 2060 1063627 N/A N/A  7075  7090 CAACATCTGCATAAGT  93 2061 1063659 N/A N/A  7357  7372 GATGCTATGATCATCC 114 2062 1063691 N/A N/A  7570  7585 CCATTCACCGTCCATA 110 2063 1063723 N/A N/A  7911  7926 TGAGACCTGACACCTT  78 2064 1063755 N/A N/A  8035  8050 GGCCATTCGCAGGTGC  98 2065 1063786 N/A N/A  8472  8487 ACTCACTTGAGGAAGT 152 2066 1063818 N/A N/A  8760  8775 GATCAAGACACTTAAC  30 2067 1063850 N/A N/A  8902  8917 GAGGAGCTAGAACTTT  88 2068 1063882 N/A N/A  9381  9396 ACCACGACAGGCCTGG  87 2069 1063914 N/A N/A  9560  9575 ATGGTGGACAGAAGGT  47 2070 1063946 N/A N/A  9871  9886 GTGAGGTTAGGTTCCC  14 2071 1063978 N/A N/A 10383 10398 CTGCAGGTTACATAGC 116 2072 1064010 N/A N/A 10683 10698 TTAGAGCACAGGTGCG 115 2073 1064042 N/A N/A 11314 11329 TGCAAGGACCATTCTT 110 2074 1064074 N/A N/A 11478 11493 GCCACGGACATCCCGA  98 2075 1064108 N/A N/A 11609 11624 CTTAGCAGGGTCCCTC  45 2076 1064140 N/A N/A 11673 11688 AGCTCGGGCGAATCCA 102 2077 1064172 N/A N/A 11793 11808 CGGAGTAACTTGCACA  52 2078 1064204 N/A N/A 11887 11902 ACAGGTACTGTTTGCT  50 2079 1064236 N/A N/A 11967 11982 TAGCTAGCTCCCTGTC 100 2080 1064268 N/A N/A 12153 12168 TTGGGAGGCAGGTCCC  85 2081 1064300 N/A N/A 12359 12374 TGAGGTGGACATCTGG  47 2082 1064332 N/A N/A 12484 12499 GTTGGGTTGGCATAAA  78 2083 1064364 N/A N/A 12699 12714 TCTGGTATCATGTAGG  70 2084 1064396 N/A N/A 12870 12885 CAAGGATGAGGTTAGT 148 2085 1064428 N/A N/A 13113 13128 GACATTTCAGGGTTGG  71 2086 1064460 N/A N/A 13338 13353 AATCAGGGACAGGACT 123 2087

TABLE 32 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  53   65  911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG  16  306 1062028   81   96   481   496 TTGCTTTTATACCGAG   8 2088 1062060  248  263  6786  6801 GCTGGGCGAGGCTCCT  53 2089 1062092  346  361  6884  6899 GAGGAGGCATGGGCCC  74 2090 1062124  503  518  7666  7681 ATCCACCGTTGAGAGC 118 2091 1062156  723  738 N/A N/A AAAGGGTGCTGTCCTT  77 2092 1062188  835  850 N/A N/A TCCGCCTGGCAGTGCT  83 2093 1062220 1012 1027 11168 11183 CAGGAGCCCTTGTCGG 109 2094 1062252 1165 1180 12035 12050 AAGTAGTCCATGTTGT   44* 2095 1062284 1386 1401 13796 13811 CAGCCCCCTTCTCGCT 126 2096 1062316 1551 1566 13961 13976 GCCTATCATCCCTGCC 153 2097 1062348 1801 1816 14211 14226 AAGTAATCTGTGCGAG  36 2098 1062380 1921 1936 14331 14346 ATGATGCAGCTTTGAG  43 2099 1062412 2129 2144 14539 14554 GTGAGATACACAGGTG  45 2100 1062444 2337 2352 N/A N/A ACGGTACTGTGGGTTG  36 2101 1062476 N/A N/A 13569 13584 GCCACCTCAGAGGAGC 141 2102 1062508 N/A N/A 13665 13680 CAACCCACATCCCGTT  74 2103 1062540 N/A N/A   672   687 ATCACGGTAGCTGGGT  95 2104 1062572 N/A N/A   803   818 AATCCTATCCATCTAC 161 2105 1062604 N/A N/A  1033  1048 AGAGAGTCTGAGTGTA 121 2106 1062636 N/A N/A  1220  1235 CGACATTACTATTATT  78 2107 1062668 N/A N/A  1318  1333 TCAGTTAAGTGCTCAG  25 2108 1062701 N/A N/A  1442  1457 GACTCTGGTCACACAC  88 2109 1062733 N/A N/A  1701  1716 CAAAGTTCATGCTGAT  58 2110 1062765 N/A N/A  1842  1857 GGGTCATAAACTTTAA  43 2111 1062797 N/A N/A  2025  2040 AAGCATGAATGGCCAA  34 2112 1062829 N/A N/A  2139  2154 AGGTTAATAACCATTC  40 2113 1062861 N/A N/A  2350  2365 AGAAGCCAACATAGGT  28 2114 1062893 N/A N/A  2524  2539 TTATAACCATTGCAGT  54 2115 1062925 N/A N/A  2694  2709 CAGTTTGAAATGTCAC 128 2116 1062957 N/A N/A  2815  2830 GTGGCATTTCAAACTG 116 2117 1062989 N/A N/A  3041  3056 AACATTTGCTGGTCTC  23 2118 1063021 N/A N/A  3193  3208 CTGGCTGAGAGATAGG  52 2119 1063053 N/A N/A  3355  3370 ATTTCGGTGAGGCCCT  49 2120 1063085 N/A N/A  3624  3639 AACTAGGCCTCCTGAC  64 2121 1063117 N/A N/A  3847  3862 TCCGCCAGAGATGGCA 115 2122 1063149 N/A N/A  4068  4083 CTAGAATCTCAAAACC 133 2123 1063181 N/A N/A  4196  4211 AGGACCCAGGTTTGAA 105 2124 1063213 N/A N/A  4388  4403 CACCACGGAGGAAGAG 139 2125 1063244 N/A N/A  4469  4484 GCCCTGTTGTCACAGC  63 2126 1063276 N/A N/A  4686  4701 CATGTGGGATGGCCTG  73 2127 1063308 N/A N/A  4814  4829 ACAAACTAATACCGAT 106 2128 1063340 N/A N/A  5174  5189 GAATCCAGGTATTAAG  72 2129 1063372 N/A N/A  5432  5447 TCCCATAGTGACTTGA  53 2130 1063404 N/A N/A  5627  5642 CTATTGTCCTCACCTT  42 2131 1063436 N/A N/A  5837  5852 TGTGATCATGCACGGA  35 2132 1063468 N/A N/A  5999  6014 ACATTACCTGAGATGG 130 2133 1063500 N/A N/A  6107  6122 TAATCTGAAGCTGGAT 168 2134 1063532 N/A N/A  6261  6276 CCCCAGTGACTAGGCA  78 2135 1063564 N/A N/A  6413  6428 ATGTGTCCTCTATGAG 129 2136 1063596 N/A N/A  6649  6664 GGCGGTATGAGATACT  97 2137 1063628 N/A N/A  7081  7096 GCCCTGCAACATCTGC  70 2138 1063660 N/A N/A  7360  7375 GTAGATGCTATGATCA  36 2139 1063692 N/A N/A  7571  7586 CCCATTCACCGTCCAT  36 2140 1063724 N/A N/A  7912  7927 CTGAGACCTGACACCT  71 2141 1063756 N/A N/A  8036  8051 CGGCCATTCGCAGGTG  71 2142 1063787 N/A N/A  8474  8489 CCACTCACTTGAGGAA  90 2143 1063819 N/A N/A  8765  8780 ATTTTGATCAAGACAC  52 2144 1063851 N/A N/A  8904  8919 TAGAGGAGCTAGAACT  90 2145 1063883 N/A N/A  9396  9411 GATTCCATGCAGGTGA 135 2146 1063915 N/A N/A  9564  9579 GCACATGGTGGACAGA  20 2147 1063947 N/A N/A  9872  9887 TGTGAGGTTAGGTTCC  10 2148 1063979 N/A N/A 10411 10426 CGCCATCTTGAAATCT  45 2149 1064011 N/A N/A 10684 10699 ATTAGAGCACAGGTGC  82 2150 1064043 N/A N/A 11315 11330 GTGCAAGGACCATTCT 130 2151 1064075 N/A N/A 11505 11520 ACTCGAGACCATATGG 111 2152 1064109 N/A N/A 11610 11625 ACTTAGCAGGGTCCCT 108 2153 1064141 N/A N/A 11674 11689 GAGCTCGGGCGAATCC 109 2154 1064173 N/A N/A 11794 11809 GCGGAGTAACTTGCAC  49 2155 1064205 N/A N/A 11888 11903 CACAGGTACTGTTTGC  51 2156 1064237 N/A N/A 11968 11983 CTAGCTAGCTCCCTGT 134 2157 1064269 N/A N/A 12190 12205 GAACCCACTCTGAGGG 134 2158 1064301 N/A N/A 12360 12375 CTGAGGTGGACATCTG  47 2159 1064333 N/A N/A 12529 12544 TGTATTGACATACTGG 133 2160 1064365 N/A N/A 12704 12719 GAATATCTGGTATCAT 141 2161 1064397 N/A N/A 12871 12886 GCAAGGATGAGGTTAG 107 2162 1064429 N/A N/A 13152 13167 GTCTGGGATGGAGTTG  64 2163 1064461 N/A N/A 13339 13354 TAATCAGGGACAGGAC  68 2164

TABLE 33 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  35   65  911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG  23  306 1062029   82   97   482   497 TTTGCTTTTATACCGA   7 2165 1062061  249  264  6787  6802 AGCTGGGCGAGGCTCC 185 2166 1062093  347  362  6885  6900 AGAGGAGGCATGGGCC  36 2167 1062125  505  520  7668  7683 GCATCCACCGTTGAGA  29 2168 1062157  724  739 N/A N/A GAAAGGGTGCTGTCCT 266 2169 1062189  842  857  9432  9447 AAGATGGTCCGCCTGG  76 2170 1062221 1014 1029 11170 11185 AGCAGGAGCCCTTGTC 188 2171 1062253 1166 1181 12036 12051 GAAGTAGTCCATGTTG   76* 2172 1062285 1395 1410 13805 13820 CGGTCCACACAGCCCC  99 2173 1062317 1553 1568 13963 13978 GGGCCTATCATCCCTG 103 2174 1062349 1803 1818 14213 14228 TGAAGTAATCTGTGCG  29 2175 1062381 1923 1938 14333 14348 TGATGATGCAGCTTTG  56 2176 1062413 2130 2145 14540 14555 CGTGAGATACACAGGT  11 2177 1062445 2338 2353 N/A N/A GACGGTACTGTGGGTT  94 2178 1062477 N/A N/A 13572 13587 ACCGCCACCTCAGAGG  81 2179 1062509 N/A N/A 13666 13681 ACAACCCACATCCCGT  43 2180 1062541 N/A N/A   673   688 AATCACGGTAGCTGGG  72 2181 1062573 N/A N/A   825   840 CTGGCAGCTGACATAT 148 2182 1062605 N/A N/A  1034  1049 AAGAGAGTCTGAGTGT  43 2183 1062637 N/A N/A  1223  1238 CGGCGACATTACTATT  87 2184 1062669 N/A N/A  1319  1334 TTCAGTTAAGTGCTCA   9 2185 1062702 N/A N/A  1445  1460 ATGGACTCTGGTCACA  74 2186 1062734 N/A N/A  1702  1717 TCAAAGTTCATGCTGA  42 2187 1062766 N/A N/A  1845  1860 AGAGGGTCATAAACTT  71 2188 1062798 N/A N/A  2055  2070 GACCAGACAACCAAAA 212 2189 1062830 N/A N/A  2143  2158 TGAAAGGTTAATAACC  36 2190 1062862 N/A N/A  2351  2366 TAGAAGCCAACATAGG  34 2191 1062894 N/A N/A  2525  2540 ATTATAACCATTGCAG  15 2192 1062926 N/A N/A  2696  2711 CCCAGTTTGAAATGTC 110 2193 1062958 N/A N/A  2826  2841 TTGTGATGAATGTGGC 159 2194 1062990 N/A N/A  3042  3057 GAACATTTGCTGGTCT  62 2195 1063022 N/A N/A  3196  3211 GGACTGGCTGAGAGAT 113 2196 1063054 N/A N/A  3356  3371 CATTTCGGTGAGGCCC  18 2197 1063086 N/A N/A  3625  3640 CAACTAGGCCTCCTGA 110 2198 1063118 N/A N/A  3848  3863 CTCCGCCAGAGATGGC 153 2199 1063150 N/A N/A  4072  4087 GATCCTAGAATCTCAA  38 2200 1063182 N/A N/A  4197  4212 GAGGACCCAGGTTTGA  78 2201 1063214 N/A N/A  4390  4405 GACACCACGGAGGAAG  45 2202 1063245 N/A N/A  4473  4488 CTGGGCCCTGTTGTCA  78 2203 1063277 N/A N/A  4689  4704 ACACATGTGGGATGGC  87 2204 1063309 N/A N/A  4847  4862 ACTCAGTTGTGGTACT 143 2205 1063341 N/A N/A  5176  5191 GAGAATCCAGGTATTA  93 2206 1063373 N/A N/A  5433  5448 GTCCCATAGTGACTTG 145 2207 1063405 N/A N/A  5628  5643 TCTATTGTCCTCACCT 114 2208 1063437 N/A N/A  5838  5853 GTGTGATCATGCACGG  31 2209 1063469 N/A N/A  6000  6015 GACATTACCTGAGATG  98 2210 1063501 N/A N/A  6110  6125 ACTTAATCTGAAGCTG  61 2211 1063533 N/A N/A  6264  6279 TTGCCCCAGTGACTAG 104 2212 1063565 N/A N/A  6424  6439 CCCTGGTGTGGATGTG  85 2213 1063597 N/A N/A  6650  6665 GGGCGGTATGAGATAC  92 2214 1063629 N/A N/A  7090  7105 ATTTTCTTGGCCCTGC 105 2215 1063661 N/A N/A  7362  7377 TGGTAGATGCTATGAT  40 2216 1063693 N/A N/A  7641  7656 CATGTGGGCTGTGGTT  40 2217 1063725 N/A N/A  7916  7931 GCCTCTGAGACCTGAC  57 2218 1063757 N/A N/A  8037  8052 ACGGCCATTCGCAGGT  24 2219 1063788 N/A N/A  8475  8490 GCCACTCACTTGAGGA 150 2220 1063820 N/A N/A  8766  8781 GATTTTGATCAAGACA 118 2221 1063852 N/A N/A  8905  8920 CTAGAGGAGCTAGAAC  72 2222 1063884 N/A N/A  9397  9412 AGATTCCATGCAGGTG 128 2223 1063916 N/A N/A  9578  9593 GAACTTGGTTTCTGGC  53 2224 1063948 N/A N/A  9873  9888 ATGTGAGGTTAGGTTC  20 2225 1063980 N/A N/A 10416 10431 GTGGTCGCCATCTTGA  12 2226 1064012 N/A N/A 10685 10700 TATTAGAGCACAGGTG  31 2227 1064044 N/A N/A 11316 11331 AGTGCAAGGACCATTC  79 2228 1064076 N/A N/A 11506 11521 CACTCGAGACCATATG 104 2229 1064110 N/A N/A 11612 11627 TTACTTAGCAGGGTCC  84 2230 1064142 N/A N/A 11675 11690 TGAGCTCGGGCGAATC 107 2231 1064174 N/A N/A 11795 11810 AGCGGAGTAACTTGCA  33 2232 1064206 N/A N/A 11889 11904 GCACAGGTACTGTTTG  83 2233 1064238 N/A N/A 11969 11984 CCTAGCTAGCTCCCTG  32 2234 1064270 N/A N/A 12191 12206 GGAACCCACTCTGAGG 106 2235 1064302 N/A N/A 12361 12376 GCTGAGGTGGACATCT 106 2236 1064334 N/A N/A 12531 12546 GGTGTATTGACATACT  52 2237 1064366 N/A N/A 12732 12747 TCAGGGTTTCAGTTCA  57 2238 1064398 N/A N/A 12872 12887 GGCAAGGATGAGGTTA 120 2239 1064430 N/A N/A 13158 13173 TGAAAGGTCTGGGATG 121 2240 1064462 N/A N/A 13342 13357 AGGTAATCAGGGACAG 105 2241

TABLE 34 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 Compound SEQ ID NO: 1 SEQ ID NO: 1 SEQ ID NO: 2 SEQ ID NO: 2 Sequence FOXP3 SEQ Number Start Site Stop Site Start Site Stop Site (5′ to 3′) (% UTC) ID NO  910950 1434 1449 13844 13859 GCCTCTGGCTCCGTTT  15   94  911144 N/A N/A  7355  7370 TGCTATGATCATCCCC  23   65 1062030   83   98   483   498 CTTTGCTTTTATACCG   3 2242 1062062  251  266  6789  6804 CCAGCTGGGCGAGGCT 107 2243 1062094  348  363  6886  6901 AAGAGGAGGCATGGGC  26 2244 1062126  556  571  7719  7734 ATGGCTGGGCTCTCCA  36 2245 1062158  728  743  8374  8389 AGCCGAAAGGGTGCTG 103 2246 1062190  843  858  9433  9448 GAAGATGGTCCGCCTG  59 2247 1062222 1015 1030 11171 11186 CAGCAGGAGCCCTTGT 104 2248 1062254 1167 1182 12037 12052 TGAAGTAGTCCATGTT   57* 2249 1062286 1397 1412 13807 13822 CACGGTCCACACAGCC  76 2250 1062318 1554 1569 13964 13979 AGGGCCTATCATCCCT  74 2251 1062350 1804 1819 14214 14229 CTGAAGTAATCTGTGC  33 2252 1062382 1924 1939 14334 14349 GTGATGATGCAGCTTT  16 2253 1062414 2169 2184 14579 14594 ACTCAAGAGACCCACT  39 2254 1062446 2339 2354 N/A N/A GGACGGTACTGTGGGT  20 2255 1062478 N/A N/A 13573 13588 CACCGCCACCTCAGAG  67 2256 1062510 N/A N/A 13667 13682 AACAACCCACATCCCG 109 2257 1062542 N/A N/A   674   689 GAATCACGGTAGCTGG  14 2258 1062574 N/A N/A   828   843 AGACTGGCAGCTGACA  56 2259 1062606 N/A N/A  1052  1067 CCAGGAGAGATGCGGG  85 2260 1062638 N/A N/A  1224  1239 TCGGCGACATTACTAT  29 2261 1062670 N/A N/A  1324  1339 CAAAGTTCAGTTAAGT  24 2262 1062703 N/A N/A  1448  1463 AATATGGACTCTGGTC  50 2263 1062735 N/A N/A  1703  1718 ATCAAAGTTCATGCTG  53 2264 1062767 N/A N/A  1847  1862 AGAGAGGGTCATAAAC  45 2265 1062799 N/A N/A  2065  2080 GTAAGGACATGACCAG  27 2266 1062831 N/A N/A  2148  2163 GCTGATGAAAGGTTAA  31 2267 1062863 N/A N/A  2352  2367 CTAGAAGCCAACATAG  75 2268 1062895 N/A N/A  2526  2541 TATTATAACCATTGCA  32 2269 1062927 N/A N/A  2716  2731 ATCCCAACAACCCCTC  50 2270 1062959 N/A N/A  2846  2861 ACATATGGAGAGAACT  56 2271 1062991 N/A N/A  3043  3058 AGAACATTTGCTGGTC   9 2272 1063023 N/A N/A  3211  3226 GCCCCTCTATCCAGGG  76 2273 1063055 N/A N/A  3359  3374 CTGCATTTCGGTGAGG  22 2274 1063087 N/A N/A  3626  3641 CCAACTAGGCCTCCTG  81 2275 1063119 N/A N/A  3850  3865 CACTCCGCCAGAGATG  31 2276 1063151 N/A N/A  4073  4088 GGATCCTAGAATCTCA  60 2277 1063183 N/A N/A  4198  4213 AGAGGACCCAGGTTTG  55 2278 1063215 N/A N/A  4391  4406 CGACACCACGGAGGAA  68 2279 1063246 N/A N/A  4477  4492 GCATCTGGGCCCTGTT  57 2280 1063278 N/A N/A  4692  4707 CAAACACATGTGGGAT  87 2281 1063310 N/A N/A  4870  4885 GATCAATTTCTGTTGC  11 2282 1063342 N/A N/A  5177  5192 TGAGAATCCAGGTATT  38 2283 1063374 N/A N/A  5435  5450 TAGTCCCATAGTGACT 104 2284 1063406 N/A N/A  5630  5645 CTTCTATTGTCCTCAC  31 2285 1063438 N/A N/A  5839  5854 AGTGTGATCATGCACG  96 2286 1063470 N/A N/A  6001  6016 TGACATTACCTGAGAT  30 2287 1063502 N/A N/A  6112  6127 AGACTTAATCTGAAGC  29 2288 1063534 N/A N/A  6267  6282 ATTTTGCCCCAGTGAC  66 2289 1063566 N/A N/A  6425  6440 GCCCTGGTGTGGATGT  79 2290 1063598 N/A N/A  6651  6666 AGGGCGGTATGAGATA  30 2291 1063630 N/A N/A  7118  7133 TCCAATCTCTGAGGCC  45 2292 1063662 N/A N/A  7363  7378 ATGGTAGATGCTATGA  57 2293 1063694 N/A N/A  7662  7677 ACCGTTGAGAGCTGGG  35 2294 1063726 N/A N/A  7928  7943 TGGAGTTTCCAAGCCT  67 2295 1063758 N/A N/A  8038  8053 GACGGCCATTCGCAGG  54 2296 1063789 N/A N/A  8497  8512 CGGTAGACTGGCACAG  58 2297 1063821 N/A N/A  8773  8788 ACTGGGAGATTTTGAT 104 2298 1063853 N/A N/A  8906  8921 TCTAGAGGAGCTAGAA  38 2299 1063885 N/A N/A  9405  9420 TAGGGAGAAGATTCCA  83 2300 1063917 N/A N/A  9582  9597 AGGTGAACTTGGTTTC  20 2301 1063949 N/A N/A  9879  9894 ACCTGAATGTGAGGTT  42 2302 1063981 N/A N/A 10418 10433 CTGTGGTCGCCATCTT   4 2303 1064013 N/A N/A 10694 10709 AGCCGTATTTATTAGA  29 2304 1064045 N/A N/A 11317 11332 TAGTGCAAGGACCATT  33 2305 1064077 N/A N/A 11507 11522 ACACTCGAGACCATAT  93 2306 1064111 N/A N/A 11613 11628 ATTACTTAGCAGGGTC  22 2307 1064143 N/A N/A 11677 11692 GGTGAGCTCGGGCGAA  36 2308 1064175 N/A N/A 11796 11811 AAGCGGAGTAACTTGC  50 2309 1064207 N/A N/A 11891 11906 GGGCACAGGTACTGTT  60 2310 1064239 N/A N/A 11970 11985 TCCTAGCTAGCTCCCT  35 2311 1064271 N/A N/A 12192 12207 AGGAACCCACTCTGAG  49 2312 1064303 N/A N/A 12362 12377 GGCTGAGGTGGACATC  23 2313 1064335 N/A N/A 12553 12568 TTGGGAATGGTGCCCA  35 2314 1064367 N/A N/A 12738 12753 GCTAGGTCAGGGTTTC  68 2315 1064399 N/A N/A 12884 12899 GGTTAGGCTCAGGGCA  71 2316 1064431 N/A N/A 13159 13174 GTGAAAGGTCTGGGAT  89 2317 1064463 N/A N/A 13344 13359 GCAGGTAATCAGGGAC  86 2318

TABLE 35 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO 911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 42 65 911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG 19 306 1062031 97 112 497 512 CGTATCAAAAACAACT 98 2319 1062063 268 283 6806 6821 GCTTTGGGTGCAGCCC 104  2320 1062095 375 390 6913 6928 GCGATGGTGGCATGGG 67 2321 1062127 559 574 7722 7737 ATCATGGCTGGGCTCT 57 2322 1062159 729 744 8375 8390 CAGCCGAAAGGGTGCT 136  2323 1062191 844 859 9434 9449 AGAAGATGGTCCGCCT 48 2324 1062223 1023 1038 11179 11194 CTACGATGCAGCAGGA 65 2325 1062255 1170 1185 12040 12055 ACTTGAAGTAGTCCAT  56* 2326 1062287 1413 1428 13823 13838 GGAACTCCAGCTCATC 85 2327 1062319 1555 1570 13965 13980 CAGGGCCTATCATCCC 103  2328 1062351 1805 1820 14215 14230 CCTGAAGTAATCTGTG 102  2329 1062383 1925 1940 14335 14350 TGTGATGATGCAGCTT 14 2330 1062415 2173 2188 14583 14598 CGGGACTCAAGAGACC 93 2331 1062447 2357 2372 N/A N/A TCGGCTGCAGTTTATT 36 2332 1062479 N/A N/A 13576 13591 AGTCACCGCCACCTCA 53 2333 1062511 N/A N/A 13668 13683 CAACAACCCACATCCC 97 2334 1062543 N/A N/A 675 690 GGAATCACGGTAGCTG 31 2335 1062575 N/A N/A 829 844 AAGACTGGCAGCTGAC 56 2336 1062607 N/A N/A 1053 1068 GCCAGGAGAGATGCGG 124  2337 1062639 N/A N/A 1225 1240 CTCGGCGACATTACTA 41 2338 1062671 N/A N/A 1325 1340 GCAAAGTTCAGTTAAG 53 2339 1062704 N/A N/A 1449 1464 GAATATGGACTCTGGT 74 2340 1062736 N/A N/A 1705 1720 CAATCAAAGTTCATGC 63 2341 1062768 N/A N/A 1848 1863 CAGAGAGGGTCATAAA 72 2342 1062800 N/A N/A 2066 2081 AGTAAGGACATGACCA 66 2343 1062832 N/A N/A 2149 2164 GGCTGATGAAAGGTTA 11 2344 1062864 N/A N/A 2353 2368 ACTAGAAGCCAACATA 110  2345 1062896 N/A N/A 2527 2542 CTATTATAACCATTGC 44 2346 1062928 N/A N/A 2718 2733 TTATCCCAACAACCCC 58 2347 1062960 N/A N/A 2847 2862 CACATATGGAGAGAAC 84 2348 1062992 N/A N/A 3058 3073 GGATTGCCTCAAATAA 69 2349 1063024 N/A N/A 3216 3231 CAATTGCCCCTCTATC 85 2350 1063056 N/A N/A 3368 3383 ACTCTGCCGCTGCATT 69 2351 1063088 N/A N/A 3627 3642 GCCAACTAGGCCTCCT 112  2352 1063120 N/A N/A 3853 3868 GGCCACTCCGCCAGAG 127  2353 1063152 N/A N/A 4075 4090 AAGGATCCTAGAATCT 70 2354 1063184 N/A N/A 4199 4214 GAGAGGACCCAGGTTT 83 2355 1063216 N/A N/A 4393 4408 ATCGACACCACGGAGG 74 2356 1063247 N/A N/A 4497 4512 ATGTTTTCATATCGGG 39 2357 1063279 N/A N/A 4693 4708 CCAAACACATGTGGGA 113  2358 1063311 N/A N/A 4943 4958 CCTTATGGCCCCCAGA 99 2359 1063343 N/A N/A 5178 5193 GTGAGAATCCAGGTAT 55 2360 1063375 N/A N/A 5440 5455 TTCCGTAGTCCCATAG 103  2361 1063407 N/A N/A 5633 5648 GCTCTTCTATTGTCCT 64 2362 1063439 N/A N/A 5845 5860 TCCAGGAGTGTGATCA 106  2363 1063471 N/A N/A 6003 6018 GCTGACATTACCTGAG 83 2364 1063503 N/A N/A 6116 6131 TCTGAGACTTAATCTG 95 2365 1063535 N/A N/A 6269 6284 CTATTTTGCCCCAGTG 92 2366 1063567 N/A N/A 6426 6441 AGCCCTGGTGTGGATG 125  2367 1063599 N/A N/A 6654 6669 GCTAGGGCGGTATGAG 127  2368 1063631 N/A N/A 7119 7134 CTCCAATCTCTGAGGC 99 2369 1063663 N/A N/A 7364 7379 CATGGTAGATGCTATG 110  2370 1063695 N/A N/A 7793 7808 TACCAGGTGGGAGGCC 106  2371 1063727 N/A N/A 7959 7974 TAAGGTTCTGCACCTG 123  2372 1063759 N/A N/A 8039 8054 AGACGGCCATTCGCAG 70 2373 1063790 N/A N/A 8499 8514 GCCGGTAGACTGGCAC 88 2374 1063822 N/A N/A 8776 8791 GGAACTGGGAGATTTT 39 2375 1063854 N/A N/A 8907 8922 ATCTAGAGGAGCTAGA 117  2376 1063886 N/A N/A 9406 9421 GTAGGGAGAAGATTCC 120  2377 1063918 N/A N/A 9584 9599 CCAGGTGAACTTGGTT 99 2378 1063950 N/A N/A 9893 9908 CCCTAGCTCTCAGGAC 152  2379 1063982 N/A N/A 10419 10434 TCTGTGGTCGCCATCT 31 2380 1064014 N/A N/A 10698 10713 CATGAGCCGTATTTAT 56 2381 1064046 N/A N/A 11318 11333 GTAGTGCAAGGACCAT 73 2382 1064078 N/A N/A 11509 11524 CGACACTCGAGACCAT 128  2383 1064112 N/A N/A 11614 11629 AATTACTTAGCAGGGT 90 2384 1064144 N/A N/A 11681 11696 GATAGGTGAGCTCGGG 52 2385 1064176 N/A N/A 11797 11812 GAAGCGGAGTAACTTG 102  2386 1064208 N/A N/A 11893 11908 ACGGGCACAGGTACTG 89 2387 1064240 N/A N/A 11971 11986 CTCCTAGCTAGCTCCC 75 2388 1064272 N/A N/A 12193 12208 GAGGAACCCACTCTGA 91 2389 1064304 N/A N/A 12378 12393 AGAGGGTTAGGTATGG 97 2390 1064336 N/A N/A 12559 12574 GAAAGGTTGGGAATGG 88 2391 1064368 N/A N/A 12762 12777 AGTGAGGCTATCAGTC 84 2392 1064400 N/A N/A 12891 12906 GTTAGGTGGTTAGGCT 64 2393 1064432 N/A N/A 13160 13175 GGTGAAAGGTCTGGGA 79 2394 1064464 N/A N/A 13375 13390 AGCCATCTGACATGGG 144  2395

TABLE 36 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO 911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 23 65 911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG 20 306 1062032 111 126 511 526 GTGGGAAACTGTCACG 51 2396 1062064 270 285 6808 6823 AGGCTTTGGGTGCAGC 247  2397 1062096 377 392 6915 6930 CTGCGATGGTGGCATG 236  2398 1062128 563 578 7726 7741 GCTGATCATGGCTGGG 94 2399 1062160 730 745 8376 8391 ACAGCCGAAAGGGTGC 306  2400 1062192 845 860 9435 9450 CAGAAGATGGTCCGCC 245  2401 1062224 1025 1040 11181 11196 AGCTACGATGCAGCAG 124  2402 1062256 1171 1186 12041 12056 AACTTGAAGTAGTCCA  44* 2403 1062288 1414 1429 13824 13839 CGGAACTCCAGCTCAT 224  2404 1062320 1556 1571 13966 13981 CCAGGGCCTATCATCC 62 2405 1062352 1806 1821 14216 14231 CCCTGAAGTAATCTGT 75 2406 1062384 1926 1941 14336 14351 GTGTGATGATGCAGCT 38 2407 1062416 2174 2189 14584 14599 ACGGGACTCAAGAGAC 118  2408 1062448 2358 2373 N/A N/A CTCGGCTGCAGTTTAT 24 2409 1062480 N/A N/A 13579 13594 CCCAGTCACCGCCACC 51 2410 1062512 N/A N/A 13669 13684 CCAACAACCCACATCC 249  2411 1062544 N/A N/A 676 691 TGGAATCACGGTAGCT 72 2412 1062576 N/A N/A 833 848 CATAAAGACTGGCAGC 77 2413 1062608 N/A N/A 1054 1069 GGCCAGGAGAGATGCG 121  2414 1062640 N/A N/A 1227 1242 TCCTCGGCGACATTAC 163  2415 1062672 N/A N/A 1332 1347 GATACAAGCAAAGTTC 177  2416 1062705 N/A N/A 1451 1466 CTGAATATGGACTCTG 88 2417 1062737 N/A N/A 1706 1721 TCAATCAAAGTTCATG 24 2418 1062769 N/A N/A 1849 1864 GCAGAGAGGGTCATAA 76 2419 1062801 N/A N/A 2067 2082 GAGTAAGGACATGACC 110  2420 1062833 N/A N/A 2151 2166 ATGGCTGATGAAAGGT 24 2421 1062865 N/A N/A 2354 2369 GACTAGAAGCCAACAT 163  2422 1062897 N/A N/A 2542 2557 CTCCTGAGGAAGGTAC 61 2423 1062929 N/A N/A 2720 2735 CATTATCCCAACAACC 80 2424 1062961 N/A N/A 2850 2865 ACCCACATATGGAGAG 218  2425 1062993 N/A N/A 3060 3075 GAGGATTGCCTCAAAT 130  2426 1063025 N/A N/A 3227 3242 CTTCAAGTTGACAATT 61 2427 1063057 N/A N/A 3375 3390 GATTTCAACTCTGCCG 38 2428 1063089 N/A N/A 3628 3643 GGCCAACTAGGCCTCC 202  2429 1063121 N/A N/A 3855 3870 ATGGCCACTCCGCCAG 254  2430 1063153 N/A N/A 4076 4091 AAAGGATCCTAGAATC 277  2431 1063185 N/A N/A 4200 4215 GGAGAGGACCCAGGTT 53 2432 1063217 N/A N/A 4394 4409 CATCGACACCACGGAG 73 2433 1063248 N/A N/A 4498 4513 TATGTTTTCATATCGG 20 2434 1063280 N/A N/A 4694 4709 CCCAAACACATGTGGG 206  2435 1063312 N/A N/A 4944 4959 CCCTTATGGCCCCCAG 57 2436 1063344 N/A N/A 5180 5195 GTGTGAGAATCCAGGT 86 2437 1063376 N/A N/A 5446 5461 GCCGAGTTCCGTAGTC 70 2438 1063408 N/A N/A 5644 5659 ACGCAAGACCTGCTCT 198  2439 1063440 N/A N/A 5846 5861 GTCCAGGAGTGTGATC 71 2440 1063472 N/A N/A 6004 6019 AGCTGACATTACCTGA 63 2441 1063504 N/A N/A 6119 6134 GATTCTGAGACTTAAT 62 2442 1063536 N/A N/A 6270 6285 CCTATTTTGCCCCAGT 89 2443 1063568 N/A N/A 6427 6442 CAGCCCTGGTGTGGAT 59 2444 1063600 N/A N/A 6656 6671 GTGCTAGGGCGGTATG 76 2445 1063632 N/A N/A 7121 7136 GCCTCCAATCTCTGAG 228  2446 1063664 N/A N/A 7368 7383 CCCACATGGTAGATGC 222  2447 1063696 N/A N/A 7795 7810 GTTACCAGGTGGGAGG 51 2448 1063728 N/A N/A 7960 7975 TTAAGGTTCTGCACCT 92 2449 1063760 N/A N/A 8040 8055 AAGACGGCCATTCGCA 61 2450 1063791 N/A N/A 8501 8516 GGGCCGGTAGACTGGC 102  2451 1063823 N/A N/A 8787 8802 TCTGTCACTCAGGAAC 104  2452 1063855 N/A N/A 8908 8923 CATCTAGAGGAGCTAG 88 2453 1063887 N/A N/A 9407 9422 AGTAGGGAGAAGATTC 82 2454 1063919 N/A N/A 9585 9600 CCCAGGTGAACTTGGT 71 2455 1063951 N/A N/A 9918 9933 CATGTTTGGAGCTGGG 76 2456 1063983 N/A N/A 10448 10463 TATGTGGCACCCTGTG 100  2457 1064015 N/A N/A 10706 10721 CAAAACAGCATGAGCC 93 2458 1064047 N/A N/A 11342 11357 GGATTAGGAGCTTGGG 26 2459 1064079 N/A N/A 11511 11526 CCCGACACTCGAGACC 50 2460 1064113 N/A N/A 11616 11631 GGAATTACTTAGCAGG 30 2461 1064145 N/A N/A 11682 11697 GGATAGGTGAGCTCGG 27 2462 1064177 N/A N/A 11798 11813 AGAAGCGGAGTAACTT 94 2463 1064209 N/A N/A 11894 11909 CACGGGCACAGGTACT 69 2464 1064241 N/A N/A 11972 11987 CCTCCTAGCTAGCTCC 123  2465 1064273 N/A N/A 12194 12209 GGAGGAACCCACTCTG 97 2466 1064305 N/A N/A 12379 12394 GAGAGGGTTAGGTATG 162  2467 1064337 N/A N/A 12565 12580 TACAAGGAAAGGTTGG 87 2468 1064369 N/A N/A 12775 12790 CGATGATGATTGCAGT 70 2469 1064401 N/A N/A 12892 12907 GGTTAGGTGGTTAGGC 75 2470 1064433 N/A N/A 13162 13177 GAGGTGAAAGGTCTGG 36 2471 1064465 N/A N/A 13379 13394 CCCGAGCCATCTGACA 88 2472

TABLE 37 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO 911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 35 65 911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG 15 306 1062033 113 128 513 528 TTGTGGGAAACTGTCA 51 2473 1062065 280 295 6818 6833 AGCAGGTCTGAGGCTT 101  2474 1062097 378 393 6916 6931 GCTGCGATGGTGGCAT 81 2475 1062129 566 581 7729 7744 GAGGCTGATCATGGCT 47 2476 1062161 732 747 8378 8393 GCACAGCCGAAAGGGT 72 2477 1062193 846 861 9436 9451 CCAGAAGATGGTCCGC 71 2478 1062225 1026 1041 11182 11197 CAGCTACGATGCAGCA 108  2479 1062257 1172 1187 12042 12057 GAACTTGAAGTAGTCC  80* 2480 1062289 1415 1430 13825 13840 GCGGAACTCCAGCTCA 95 2481 1062321 1558 1573 13968 13983 ATCCAGGGCCTATCAT 74 2482 1062353 1807 1822 14217 14232 GCCCTGAAGTAATCTG 65 2483 1062385 1927 1942 14337 14352 TGTGTGATGATGCAGC 32 2484 1062417 2175 2190 14585 14600 CACGGGACTCAAGAGA 54 2485 1062449 2361 2376 N/A N/A GAGCTCGGCTGCAGTT 88 2486 1062481 N/A N/A 13580 13595 TCCCAGTCACCGCCAC 40 2487 1062513 N/A N/A 13671 13686 CACCAACAACCCACAT 68 2488 1062545 N/A N/A 677 692 CTGGAATCACGGTAGC 36 2489 1062577 N/A N/A 836 851 ATCCATAAAGACTGGC 53 2490 1062609 N/A N/A 1092 1107 TCAAGATGGAGGAGAC 109  2491 1062641 N/A N/A 1233 1248 TAAAGGTCCTCGGCGA 30 2492 1062673 N/A N/A 1333 1348 CGATACAAGCAAAGTT 79 2493 1062706 N/A N/A 1452 1467 CCTGAATATGGACTCT 61 2494 1062738 N/A N/A 1712 1727 GTCAAATCAATCAAAG 65 2495 1062770 N/A N/A 1854 1869 AATTAGCAGAGAGGGT 75 2496 1062802 N/A N/A 2069 2084 AGGAGTAAGGACATGA 18 2497 1062834 N/A N/A 2154 2169 GTAATGGCTGATGAAA 39 2498 1062866 N/A N/A 2355 2370 AGACTAGAAGCCAACA 83 2499 1062898 N/A N/A 2543 2558 ACTCCTGAGGAAGGTA 76 2500 1062930 N/A N/A 2721 2736 CCATTATCCCAACAAC 79 2501 1062962 N/A N/A 2860 2875 TTGGACATGGACCCAC 89 2502 1062994 N/A N/A 3061 3076 GGAGGATTGCCTCAAA 115  2503 1063026 N/A N/A 3231 3246 AGGGCTTCAAGTTGAC 71 2504 1063058 N/A N/A 3376 3391 GGATTTCAACTCTGCC 24 2505 1063090 N/A N/A 3634 3649 CGCTCTGGCCAACTAG 59 2506 1063122 N/A N/A 3859 3874 ATACATGGCCACTCCG 93 2507 1063154 N/A N/A 4077 4092 TAAAGGATCCTAGAAT 83 2508 1063186 N/A N/A 4210 4225 CTTGGGTTGTGGAGAG 58 2509 1063218 N/A N/A 4395 4410 TCATCGACACCACGGA 77 2510 1063249 N/A N/A 4499 4514 TTATGTTTTCATATCG 50 2511 1063281 N/A N/A 4695 4710 CCCCAAACACATGTGG 135  2512 1063313 N/A N/A 5000 5015 TAACAAAGATTGCCAG 75 2513 1063345 N/A N/A 5185 5200 GATGAGTGTGAGAATC 81 2514 1063377 N/A N/A 5448 5463 ATGCCGAGTTCCGTAG 46 2515 1063409 N/A N/A 5645 5660 CACGCAAGACCTGCTC 81 2516 1063441 N/A N/A 5850 5865 GCGAGTCCAGGAGTGT 46 2517 1063473 N/A N/A 6008 6023 ACCGAGCTGACATTAC 79 2518 1063505 N/A N/A 6122 6137 GTAGATTCTGAGACTT 74 2519 1063537 N/A N/A 6272 6287 GTCCTATTTTGCCCCA 40 2520 1063569 N/A N/A 6435 6450 CGCTAGCACAGCCCTG 102  2521 1063601 N/A N/A 6673 6688 GGAAAGGAGTCACACG 117  2522 1063633 N/A N/A 7126 7141 GGAGAGCCTCCAATCT 95 2523 1063665 N/A N/A 7369 7384 GCCCACATGGTAGATG 76 2524 1063697 N/A N/A 7796 7811 TGTTACCAGGTGGGAG 107  2525 1063729 N/A N/A 7961 7976 TTTAAGGTTCTGCACC 106  2526 1063761 N/A N/A 8041 8056 AAAGACGGCCATTCGC 51 2527 1063792 N/A N/A 8511 8526 CCACAAGCCAGGGCCG 88 2528 1063824 N/A N/A 8820 8835 CTAGAGCCTGGCTACA 70 2529 1063856 N/A N/A 8909 8924 CCATCTAGAGGAGCTA 79 2530 1063888 N/A N/A 9409 9424 TAAGTAGGGAGAAGAT 94 2531 1063920 N/A N/A 9586 9601 TCCCAGGTGAACTTGG 88 2532 1063952 N/A N/A 9922 9937 TGGGCATGTTTGGAGC 59 2533 1063984 N/A N/A 10450 10465 GTTATGTGGCACCCTG 36 2534 1064016 N/A N/A 10717 10732 GTGGAATCCCACAAAA 103  2535 1064048 N/A N/A 11344 11359 CAGGATTAGGAGCTTG 80 2536 1064080 N/A N/A 11512 11527 GCCCGACACTCGAGAC 64 2537 1064114 N/A N/A 11618 11633 CTGGAATTACTTAGCA 57 2538 1064146 N/A N/A 11685 11700 AGTGGATAGGTGAGCT 63 2539 1064178 N/A N/A 11799 11814 AAGAAGCGGAGTAACT 99 2540 1064210 N/A N/A 11895 11910 CCACGGGCACAGGTAC 96 2541 1064242 N/A N/A 11973 11988 ACCTCCTAGCTAGCTC 93 2542 1064274 N/A N/A 12195 12210 TGGAGGAACCCACTCT 87 2543 1064306 N/A N/A 12380 12395 GGAGAGGGTTAGGTAT N.D. 2544 1064338 N/A N/A 12566 12581 TTACAAGGAAAGGTTG 112  2545 1064370 N/A N/A 12776 12791 GCGATGATGATTGCAG 109  2546 1064402 N/A N/A 12920 12935 TATCGAGTATCTTACG 68 2547 1064434 N/A N/A 13164 13179 GTGAGGTGAAAGGTCT 91 2548 1064466 N/A N/A 13381 13396 ACCCCGAGCCATCTGA N.D. 2549

TABLE 38 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO 911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 38 65 911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG 24 306 1062034 114 129 514 529 CTTGTGGGAAACTGTC 23 2550 1062066 289 304 6827 6842 CGGGCCCCCAGCAGGT 87 2551 1062098 379 394 6917 6932 AGCTGCGATGGTGGCA 89 2552 1062130 569 584 7732 7747 TGTGAGGCTGATCATG 65 2553 1062162 734 749 8380 8395 GGGCACAGCCGAAAGG 83 2554 1062194 847 862 9437 9452 TCCAGAAGATGGTCCG 73 2555 1062226 1027 1042 11183 11198 GCAGCTACGATGCAGC 116  2556 1062258 1173 1188 12043 12058 GGAACTTGAAGTAGTC  40* 2557 1062290 1417 1432 13827 13842 TTGCGGAACTCCAGCT 112  2558 1062322 1569 1584 13979 13994 CCTGTGGGCACATCCA 33 2559 1062354 1808 1823 14218 14233 AGCCCTGAAGTAATCT 62 2560 1062386 1934 1949 14344 14359 GTGTGATTGTGTGATG 32 2561 1062418 2176 2191 14586 14601 GCACGGGACTCAAGAG 50 2562 1062450 2362 2377 N/A N/A GGAGCTCGGCTGCAGT 86 2563 1062482 N/A N/A 13583 13598 CCATCCCAGTCACCGC 62 2564 1062514 N/A N/A 13695 13710 TCAACCTCTGAGGCCA 78 2565 1062546 N/A N/A 678 693 GCTGGAATCACGGTAG 41 2566 1062578 N/A N/A 856 871 AAGTTGTTCAAAGCTC 40 2567 1062610 N/A N/A 1093 1108 GTCAAGATGGAGGAGA 78 2568 1062642 N/A N/A 1234 1249 GTAAAGGTCCTCGGCG 37 2569 1062674 N/A N/A 1334 1349 GCGATACAAGCAAAGT 56 2570 1062707 N/A N/A 1453 1468 TCCTGAATATGGACTC 55 2571 1062739 N/A N/A 1713 1728 GGTCAAATCAATCAAA 31 2572 1062771 N/A N/A 1855 1870 GAATTAGCAGAGAGGG 30 2573 1062803 N/A N/A 2070 2085 TAGGAGTAAGGACATG N.D. 2574 1062835 N/A N/A 2156 2171 ATGTAATGGCTGATGA 17 2575 1062867 N/A N/A 2356 2371 GAGACTAGAAGCCAAC 80 2576 1062899 N/A N/A 2544 2559 GACTCCTGAGGAAGGT 63 2577 1062931 N/A N/A 2723 2738 GTCCATTATCCCAACA 45 2578 1062963 N/A N/A 2861 2876 CTTGGACATGGACCCA 87 2579 1062995 N/A N/A 3063 3078 GAGGAGGATTGCCTCA 99 2580 1063027 N/A N/A 3232 3247 CAGGGCTTCAAGTTGA 67 2581 1063059 N/A N/A 3386 3401 ATCTAGGCTTGGATTT 97 2582 1063091 N/A N/A 3636 3651 CACGCTCTGGCCAACT 67 2583 1063123 N/A N/A 3860 3875 AATACATGGCCACTCC 86 2584 1063155 N/A N/A 4080 4095 ATTTAAAGGATCCTAG 118  2585 1063187 N/A N/A 4213 4228 CTTCTTGGGTTGTGGA 37 2586 1063219 N/A N/A 4396 4411 TTCATCGACACCACGG 34 2587 1063250 N/A N/A 4535 4550 TCAGAAGCTGAATGGG 36 2588 1063282 N/A N/A 4707 4722 GCTAAGAATTCTCCCC 57 2589 1063314 N/A N/A 5072 5087 GCACTGGTGAGATGAG N.D. 2590 1063346 N/A N/A 5192 5207 TGAGGGAGATGAGTGT 73 2591 1063378 N/A N/A 5453 5468 CTCAGATGCCGAGTTC 51 2592 1063410 N/A N/A 5646 5661 CCACGCAAGACCTGCT N.D. 2593 1063442 N/A N/A 5852 5867 AGGCGAGTCCAGGAGT 80 2594 1063474 N/A N/A 6009 6024 GACCGAGCTGACATTA 76 2595 1063506 N/A N/A 6123 6138 GGTAGATTCTGAGACT 54 2596 1063538 N/A N/A 6273 6288 AGTCCTATTTTGCCCC 29 2597 1063570 N/A N/A 6437 6452 CACGCTAGCACAGCCC 97 2598 1063602 N/A N/A 6674 6689 GGGAAAGGAGTCACAC 84 2599 1063634 N/A N/A 7151 7166 CCTGAGACAGGGATTG 55 2600 1063666 N/A N/A 7371 7386 AAGCCCACATGGTAGA 65 2601 1063698 N/A N/A 7798 7813 GGTGTTACCAGGTGGG 35 2602 1063730 N/A N/A 7962 7977 CTTTAAGGTTCTGCAC 110  2603 1063762 N/A N/A 8042 8057 TAAAGACGGCCATTCG 53 2604 1063793 N/A N/A 8526 8541 ACCCTAGACCTCTCCC 44 2605 1063825 N/A N/A 8823 8838 ATTCTAGAGCCTGGCT 92 2606 1063857 N/A N/A 8910 8925 GCCATCTAGAGGAGCT 109  2607 1063889 N/A N/A 9410 9425 CTAAGTAGGGAGAAGA 117  2608 1063921 N/A N/A 9605 9620 TCCTTTATACCAGCCC 25 2609 1063953 N/A N/A 9923 9938 CTGGGCATGTTTGGAG 60 2610 1063985 N/A N/A 10452 10467 TGGTTATGTGGCACCC 39 2611 1064017 N/A N/A 10723 10738 TCTGAGGTGGAATCCC 21 2612 1064049 N/A N/A 11345 11360 TCAGGATTAGGAGCTT 47 2613 1064081 N/A N/A 11535 11550 CCCCAAGGGAGTCAGG 73 2614 1064115 N/A N/A 11619 11634 CCTGGAATTACTTAGC 57 2615 1064147 N/A N/A 11686 11701 CAGTGGATAGGTGAGC 25 2616 1064179 N/A N/A 11800 11815 AAAGAAGCGGAGTAAC 88 2617 1064211 N/A N/A 11896 11911 TCCACGGGCACAGGTA 86 2618 1064243 N/A N/A 11975 11990 GGACCTCCTAGCTAGC 54 2619 1064275 N/A N/A 12196 12211 ATGGAGGAACCCACTC 87 2620 1064307 N/A N/A 12381 12396 AGGAGAGGGTTAGGTA 68 2621 1064339 N/A N/A 12569 12584 GTGTTACAAGGAAAGG 68 2622 1064371 N/A N/A 12778 12793 CAGCGATGATGATTGC 60 2623 1064403 N/A N/A 12921 12936 TTATCGAGTATCTTAC 101  2624 1064435 N/A N/A 13165 13180 AGTGAGGTGAAAGGTC 72 2625 1064467 N/A N/A 13384 13399 CCTACCCCGAGCCATC 69 2626

TABLE 39 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 23 65  911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG 17 306 1062035 115 130 515 530 GCTTGTGGGAAACTGT 29 2627 1062067 302 317 6840 6855 TCCCCCTGGGCCCCGG 1 2628 1062099 412 427 7477 7492 GCCACCATGACTAGGG 154  2629 1062131 582 597 7745 7760 CGGTGGTGGGTGGTGT 106  2630 1062163 750 765 8396 8411 GTGGGTAGGAGCTCTG 58 2631 1062195 848 863 9438 9453 ATCCAGAAGATGGTCC 81 2632 1062227 1029 1044 11185 11200 CAGCAGCTACGATGCA 178  2633 1062259 1175 1190 12045 12060 GTGGAACTTGAAGTAG   8* 2634 1062291 1418 1433 13828 13843 CTTGCGGAACTCCAGC 265  2635 1062323 1570 1585 13980 13995 CCCTGTGGGCACATCC 66 2636 1062355 1809 1824 14219 14234 CAGCCCTGAAGTAATC 190  2637 1062387 2019 2034 14429 14444 CCTGTGTTGACAGTGC 90 2638 1062419 2177 2192 14587 14602 TGCACGGGACTCAAGA 104  2639 1062483 N/A N/A 13592 13607 CACTTGAGGCCATCCC 123  2640 1062515 N/A N/A 13696 13711 GTCAACCTCTGAGGCC 123  2641 1062547 N/A N/A 680 695 TGGCTGGAATCACGGT 134  2642 1062579 N/A N/A 857 872 CAAGTTGTTCAAAGCT 91 2643 1062611 N/A N/A 1094 1109 GGTCAAGATGGAGGAG 77 2644 1062643 N/A N/A 1235 1250 TGTAAAGGTCCTCGGC 53 2645 1062676 N/A N/A 1335 1350 AGCGATACAAGCAAAG 51 2646 1062708 N/A N/A 1469 1484 GAACAACCTGTTTGCT 65 2647 1062740 N/A N/A 1718 1733 CACTTGGTCAAATCAA 72 2648 1062772 N/A N/A 1857 1872 GAGAATTAGCAGAGAG 37 2649 1062804 N/A N/A 2072 2087 ATTAGGAGTAAGGACA 86 2650 1062836 N/A N/A 2157 2172 TATGTAATGGCTGATG 53 2651 1062868 N/A N/A 2364 2379 CCATAAAAGAGACTAG 93 2652 1062900 N/A N/A 2548 2563 CAAAGACTCCTGAGGA 124  2653 1062932 N/A N/A 2724 2739 AGTCCATTATCCCAAC 80 2654 1062964 N/A N/A 2863 2878 AGCTTGGACATGGACC 162  2655 1062996 N/A N/A 3064 3079 AGAGGAGGATTGCCTC 90 2656 1063028 N/A N/A 3234 3249 TGCAGGGCTTCAAGTT 52 2657 1063060 N/A N/A 3387 3402 GATCTAGGCTTGGATT 174  2658 1063092 N/A N/A 3637 3652 CCACGCTCTGGCCAAC 113  2659 1063124 N/A N/A 3861 3876 AAATACATGGCCACTC 93 2660 1063156 N/A N/A 4081 4096 GATTTAAAGGATCCTA 70 2661 1063188 N/A N/A 4215 4230 CCCTTCTTGGGTTGTG 77 2662 1063220 N/A N/A 4397 4412 CTTCATCGACACCACG 92 2663 1063251 N/A N/A 4548 4563 CTGACTGGGTTTCTCA 35 2664 1063283 N/A N/A 4708 4723 AGCTAAGAATTCTCCC 67 2665 1063315 N/A N/A 5073 5088 AGCACTGGTGAGATGA 43 2666 1063347 N/A N/A 5255 5270 GAGCAGTTGCTCCTTC 174  2667 1063379 N/A N/A 5454 5469 GCTCAGATGCCGAGTT 112  2668 1063411 N/A N/A 5648 5663 AGCCACGCAAGACCTG 106  2669 1063443 N/A N/A 5853 5868 GAGGCGAGTCCAGGAG 36 2670 1063475 N/A N/A 6010 6025 GGACCGAGCTGACATT 68 2671 1063507 N/A N/A 6127 6142 AGTGGGTAGATTCTGA 44 2672 1063539 N/A N/A 6274 6289 GAGTCCTATTTTGCCC 68 2673 1063571 N/A N/A 6438 6453 CCACGCTAGCACAGCC 222  2674 1063603 N/A N/A 6964 6979 GGTACCCCACCCTGCC 86 2675 1063635 N/A N/A 7169 7184 AATACGGCCTCCTCCT 217  2676 1063667 N/A N/A 7372 7387 CAAGCCCACATGGTAG 61 2677 1063699 N/A N/A 7799 7814 AGGTGTTACCAGGTGG 23 2678 1063731 N/A N/A 7966 7981 GCATCTTTAAGGTTCT  6 2679 1063763 N/A N/A 8043 8058 TTAAAGACGGCCATTC 266  2680 1063794 N/A N/A 8557 8572 TTATTGGGATGAAGCC 21 2681 1063826 N/A N/A 8842 8857 GGGCAAAGCAGGAGTG 126  2682 1063858 N/A N/A 8911 8926 AGCCATCTAGAGGAGC 101  2683 1063890 N/A N/A 9411 9426 CCTAAGTAGGGAGAAG 421  2684 1063922 N/A N/A 9633 9648 TTCCCTGGGAGTGCCC 37 2685 1063954 N/A N/A 9927 9942 AGGTCTGGGCATGTTT 27 2686 1063986 N/A N/A 10453 10468 GTGGTTATGTGGCACC 61 2687 1064018 N/A N/A 10742 10757 GCCCTCTTCTAAATTC 40 2688 1064050 N/A N/A 11347 11362 TGTCAGGATTAGGAGC 67 2689 1064082 N/A N/A 11541 11556 CCCAATCCCCAAGGGA 118  2690 1064116 N/A N/A 11620 11635 TCCTGGAATTACTTAG 212  2691 1064148 N/A N/A 11687 11702 GCAGTGGATAGGTGAG 20 2692 1064180 N/A N/A 11801 11816 AAAAGAAGCGGAGTAA 270  2693 1064212 N/A N/A 11897 11912 GTCCACGGGCACAGGT 124  2694 1064244 N/A N/A 11976 11991 AGGACCTCCTAGCTAG 169  2695 1064276 N/A N/A 12197 12212 AATGGAGGAACCCACT 118  2696 1064308 N/A N/A 12382 12397 CAGGAGAGGGTTAGGT 79 2697 1064340 N/A N/A 12576 12591 CAAATGGGTGTTACAA 234  2698 1064372 N/A N/A 12779 12794 TCAGCGATGATGATTG 84 2699 1064404 N/A N/A 12922 12937 ATTATCGAGTATCTTA 74 2700 1064436 N/A N/A 13176 13191 GCTAGGGCTGAAGTGA 101  2701 1064468 N/A N/A 13389 13404 TATGACCTACCCCGAG 131  2702

TABLE 40 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 30 65  911179 N/A N/A 10316 10331 GCTTTAACAACTCAGG 21 306 1062036 117 132 517 532 TGGCTTGTGGGAAACT 36 2703 1062068 309 324 6847 6862 GGAAGGTTCCCCCTGG 44 2704 1062100 420 435 7485 7500 CGGAGGGTGCCACCAT 14 2705 1062132 591 606 7754 7769 CCCCAGTGGCGGTGGT 47 2706 1062164 751 766 8397 8412 AGTGGGTAGGAGCTCT 81 2707 1062196 857 872 9447 9462 GCCCTTCTCATCCAGA 52 2708 1062228 1047 1062 11203 11218 CGACAGGGCCTTGGCT 280  2709 1062260 1176 1191 12046 12061 TGTGGAACTTGAAGTA  33* 2710 1062292 1421 1436 13831 13846 TTTCTTGCGGAACTCC 141  2711 1062324 1584 1599 13994 14009 CCTCACTTCTTGGTCC 51 2712 1062356 1847 1862 14257 14272 ACAGGATTGTGACATT 83 2713 1062388 2025 2040 14435 14450 CACACCCCTGTGTTGA 81 2714 1062420 2178 2193 14588 14603 CTGCACGGGACTCAAG 67 2715 1062484 N/A N/A 13593 13608 GCACTTGAGGCCATCC 106  2716 1062516 N/A N/A 13730 13745 TCTGTGGAAGGCCGGG 95 2717 1062548 N/A N/A 681 696 CTGGCTGGAATCACGG 141  2718 1062580 N/A N/A 863 878 GCATTTCAAGTTGTTC  5 2719 1062612 N/A N/A 1107 1122 ATCGATGGAGTGTGGT 63 2720 1062644 N/A N/A 1236 1251 ATGTAAAGGTCCTCGG 23 2721 1062677 N/A N/A 1336 1351 AAGCGATACAAGCAAA 58 2722 1062709 N/A N/A 1471 1486 CTGAACAACCTGTTTG 95 2723 1062741 N/A N/A 1719 1734 GCACTTGGTCAAATCA 24 2724 1062773 N/A N/A 1874 1889 GGACAACCTTTTGGAA 105  2725 1062805 N/A N/A 2073 2088 TATTAGGAGTAAGGAC 70 2726 1062837 N/A N/A 2158 2173 ATATGTAATGGCTGAT 18 2727 1062869 N/A N/A 2365 2380 GCCATAAAAGAGACTA 58 2728 1062901 N/A N/A 2554 2569 TCTAAACAAAGACTCC 81 2729 1062933 N/A N/A 2729 2744 TAGTCAGTCCATTATC 42 2730 1062965 N/A N/A 2864 2879 AAGCTTGGACATGGAC 70 2731 1062997 N/A N/A 3066 3081 CGAGAGGAGGATTGCC 94 2732 1063029 N/A N/A 3235 3250 CTGCAGGGCTTCAAGT 77 2733 1063061 N/A N/A 3388 3403 AGATCTAGGCTTGGAT 142  2734 1063093 N/A N/A 3639 3654 CACCACGCTCTGGCCA 96 2735 1063125 N/A N/A 3862 3877 CAAATACATGGCCACT 87 2736 1063157 N/A N/A 4084 4099 TTAGATTTAAAGGATC 78 2737 1063189 N/A N/A 4218 4233 TGGCCCTTCTTGGGTT 99 2738 1063221 N/A N/A 4401 4416 CGGGCTTCATCGACAC 36 2739 1063252 N/A N/A 4553 4568 CCTTTCTGACTGGGTT 77 2740 1063284 N/A N/A 4709 4724 GAGCTAAGAATTCTCC 97 2741 1063316 N/A N/A 5074 5089 GAGCACTGGTGAGATG 43 2742 1063348 N/A N/A 5273 5288 TATAGAAGGGTTCTGG 32 2743 1063380 N/A N/A 5481 5496 AGCCAACCCCATTATA 116  2744 1063412 N/A N/A 5653 5668 GTCCAAGCCACGCAAG 114  2745 1063444 N/A N/A 5854 5869 GGAGGCGAGTCCAGGA 91 2746 1063476 N/A N/A 6011 6026 AGGACCGAGCTGACAT 68 2747 1063508 N/A N/A 6132 6147 CGAGAAGTGGGTAGAT 52 2748 1063540 N/A N/A 6278 6293 CTCGGAGTCCTATTTT 100  2749 1063572 N/A N/A 6440 6455 GCCCACGCTAGCACAG 69 2750 1063604 N/A N/A 6965 6980 AGGTACCCCACCCTGC 96 2751 1063636 N/A N/A 7170 7185 CAATACGGCCTCCTCC 83 2752 1063668 N/A N/A 7374 7389 TGCAAGCCCACATGGT 148  2753 1063700 N/A N/A 7800 7815 GAGGTGTTACCAGGTG 97 2754 1063732 N/A N/A 7967 7982 TGCATCTTTAAGGTTC 28 2755 1063764 N/A N/A 8044 8059 CTTAAAGACGGCCATT 206  2756 1063795 N/A N/A 8558 8573 CTTATTGGGATGAAGC 221  2757 1063827 N/A N/A 8847 8862 TAGCAGGGCAAAGCAG 107  2758 1063859 N/A N/A 8915 8930 CAGCAGCCATCTAGAG 83 2759 1063891 N/A N/A 9412 9427 GCCTAAGTAGGGAGAA 155  2760 1063923 N/A N/A 9642 9657 GCTACGGTCTTCCCTG 61 2761 1063955 N/A N/A 9938 9953 GACAGATTTCCAGGTC 94 2762 1063987 N/A N/A 10460 10475 GACCTATGTGGTTATG 242  2763 1064019 N/A N/A 10744 10759 ACGCCCTCTTCTAAAT 34 2764 1064051 N/A N/A 11374 11389 GCTCCTTTGCACCCTC 55 2765 1064083 N/A N/A 11546 11561 ATGGCCCCAATCCCCA 200  2766 1064117 N/A N/A 11621 11636 CTCCTGGAATTACTTA 80 2767 1064149 N/A N/A 11688 11703 AGCAGTGGATAGGTGA 62 2768 1064181 N/A N/A 11802 11817 GAAAAGAAGCGGAGTA 53 2769 1064213 N/A N/A 11907 11922 CAACACCCGTGTCCAC 93 2770 1064245 N/A N/A 11977 11992 CAGGACCTCCTAGCTA 147  2771 1064277 N/A N/A 12198 12213 GAATGGAGGAACCCAC 321  2772 1064309 N/A N/A 12383 12398 CCAGGAGAGGGTTAGG 165  2773 1064341 N/A N/A 12577 12592 TCAAATGGGTGTTACA 91 2774 1064373 N/A N/A 12780 12795 GTCAGCGATGATGATT 306  2775 1064405 N/A N/A 12923 12938 AATTATCGAGTATCTT 261  2776 1064437 N/A N/A 13177 13192 GGCTAGGGCTGAAGTG 66 2777 1064469 N/A N/A 13390 13405 CTATGACCTACCCCGA 214  2778

TABLE 41 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  678925 N/A N/A 12902 12917 TCAGGGACATGGTTAG 75 2779  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 33 65 1154721 84 99 484 499 ACTTTGCTTTTATACC 20 2780 1154727 336 351 6874 6889 GGGCCCCGCCTCGAAG 99 2781 1154733 1147 1162 N/A N/A AGGAACTCTGGGAATG 53 2782 1154739 1154 1169 12024 12039 GTTGTGGAGGAACTCT 54 2783 1154745 1255 1270 13485 13500 TTGAGTGTCCGCTGCT  16* 2784 1154751 1914 1929 14324 14339 AGCTTTGAGGTTGTTT 30 2785 1154757 1931 1946 14341 14356 TGATTGTGTGATGATG 64 2786 1154763 2125 2140 14535 14550 GATACACAGGTGAATT 83 2787 1154769 2247 2262 14657 14672 GGGAGTGAGGTGAGTG 51 2788 1154775 N/A N/A 621 636 GCCGTGCCTACCTCCC 40 2789 1154781 N/A N/A 628 643 CCCCCCCGCCGTGCCT 66 2790 1154787 N/A N/A 679 694 GGCTGGAATCACGGTA 64 2791 1154793 N/A N/A 859 874 TTCAAGTTGTTCAAAG 47 2792 1154799 N/A N/A 1106 1121 TCGATGGAGTGTGGTC 63 2793 1154805 N/A N/A 1291 1306 ACCTTGCAATCCTCCT 43 2794 1154811 N/A N/A 1379 1394 GTGTGAAGTGCTCCCT 31 2795 1154817 N/A N/A 1572 1587 ATTCTAATTTGGTTAC 46 2796 1154823 N/A N/A 1580 1595 ATAGCATGATTCTAAT 89 2797 1154829 N/A N/A 1710 1725 CAAATCAATCAAAGTT 112  2798 1154835 N/A N/A 1820 1835 ACGCCCCCTTTGCCCC 51 2799 1154841 N/A N/A 1853 1868 ATTAGCAGAGAGGGTC 51 2800 1154847 N/A N/A 2023 2038 GCATGAATGGCCAATG 73 2801 1154853 N/A N/A 2155 2170 TGTAATGGCTGATGAA 28 2802 1154859 N/A N/A 2511 2526 AGTACATATGAGGAAA 31 2803 1154865 N/A N/A 2519 2534 ACCATTGCAGTACATA 17 2804 1154871 N/A N/A 2622 2637 AATGCTGATCTTGGGT 59 2805 1154877 N/A N/A 2800 2815 GGAGGACCATGGAGTA 101  2806 1154883 N/A N/A 3037 3052 TTTGCTGGTCTCTGGC 34 2807 1154889 N/A N/A 3218 3233 GACAATTGCCCCTCTA 54 2808 1154895 N/A N/A 3266 3281 TTCTACGCTGTCTGGT 63 2809 1154901 N/A N/A 3354 3369 TTTCGGTGAGGCCCTG 47 2810 1154907 N/A N/A 3377 3392 TGGATTTCAACTCTGC 50 2811 1154913 N/A N/A 3492 3507 GGAATGGTAGCCCAGG 54 2812 1154919 N/A N/A 3657 3672 CTGACATGCCTCCATC 72 2813 1154925 N/A N/A 3715 3730 CCCACAATCAAGGTTT 89 2814 1154931 N/A N/A 4022 4037 TCAGTATGTGTAGGCC 29 2815 1154937 N/A N/A 4247 4262 ACTATGACAAGCCCCT 63 2816 1154943 N/A N/A 4453 4468 CCCCGACTTGCCCAGA 47 2817 1154949 N/A N/A 4652 4667 ACATTCTCAGACAGGG 72 2818 1154955 N/A N/A 4758 4773 CATGTGGCTGGCCTGT 92 2819 1154961 N/A N/A 5158 5173 TTCTTAGTCTCCTGGG 40 2820 1154967 N/A N/A 5539 5554 CTTTTCAGGATCCTAT 92 2821 1154973 N/A N/A 5699 5714 TGCTACACCCCCTGCC 109  2822 1154979 N/A N/A 5970 5985 GAGTTGGATTGGGTGC 52 2823 1154985 N/A N/A 6043 6058 AAGTGACATGGGTTTT 58 2824 1154991 N/A N/A 6070 6085 GGATGTAGTGGGCAAG 27 2825 1154997 N/A N/A 6276 6291 CGGAGTCCTATTTTGC 90 2826 1155003 N/A N/A 6562 6577 CATAGTTGCACCCCAG 202  2827 1155009 N/A N/A 6648 6663 GCGGTATGAGATACTC 126  2828 1155015 N/A N/A 7006 7021 TCCCGCCCAGTGCCAC 84 2829 1155021 N/A N/A 7178 7193 TGGGACTACAATACGG 46 2830 1155027 N/A N/A 7239 7254 CCTACTTGGCCCCAGT 61 2831 1155033 N/A N/A 7315 7330 CTCATGGAGATCGAGT 92 2832 1155039 N/A N/A 7398 7413 GTGTCTAATTCAAATA 97 2833 1155045 N/A N/A 7903 7918 GACACCTTTGACCCCC 55 2834 1155051 N/A N/A 7971 7986 ATTCTGCATCTTTAAG 68 2835 1155057 N/A N/A 8002 8017 TTGTAAAGCTCTGTGG 27 2836 1155063 N/A N/A 8050 8065 GAGAAGCTTAAAGACG 92 2837 1155069 N/A N/A 8556 8571 TATTGGGATGAAGCCT 79 2838 1155075 N/A N/A 8813 8828 CTGGCTACATGGGTTC 106  2839 1155081 N/A N/A 9160 9175 TGAGTTGAGAATGGGC 76 2840 1155087 N/A N/A 9420 9435 CTGGCAGTGCCTAAGT 106  2841 1155093 N/A N/A 9602 9617 TTTATACCAGCCCTCG 82 2842 1155099 N/A N/A 9875 9890 GAATGTGAGGTTAGGT 15 2843 1155105 N/A N/A 10282 10297 CTTAGAGTCAGAGGGT 34 2844 1155111 N/A N/A 10309 10324 CAACTCAGGATCACAG 32 2845 1155117 N/A N/A 10415 10430 TGGTCGCCATCTTGAA 36 2846 1155123 N/A N/A 10462 10477 GTGACCTATGTGGTTA 119  2847 1155129 N/A N/A 10702 10717 ACAGCATGAGCCGTAT 93 2848 1155135 N/A N/A 11570 11585 GCTGGAGTCCAGAGTG 81 2849 1155141 N/A N/A 11808 11823 GAGGTTGAAAAGAAGC 53 2850 1155147 N/A N/A 12338 12353 GGTAGGTTTAGGGTCA 80 2851 1155153 N/A N/A 12568 12583 TGTTACAAGGAAAGGT 102  2852 1155159 N/A N/A 12703 12718 AATATCTGGTATCATG 109  2853 1155165 N/A N/A 12805 12820 TTGGATTCAGGAATGG 80 2854 1155176 N/A N/A 13341 13356 GGTAATCAGGGACAGG 50 2855

TABLE 42 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 26 65 1154723 112 127 512 527 TGTGGGAAACTGTCAC 84 2856 1154729 837 852 9427 9442 GGTCCGCCTGGCAGTG 41 2857 1154735 1149 1164 N/A N/A GGAGGAACTCTGGGAA 75 2858 1154741 1249 1264 13479 13494 GTCCGCTGCTTCTCTG   1* 2859 1154747 1908 1923 14318 14333 GAGGTTGTTTGAGTGT 17 2860 1154753 1918 1933 14328 14343 ATGCAGCTTTGAGGTT N.D. 2861 1154759 1933 1948 14343 14358 TGTGATTGTGTGATGA 27 2862 1154765 2127 2142 14537 14552 GAGATACACAGGTGAA 14 2863 1154771 2249 2264 14659 14674 ATGGGAGTGAGGTGAG 44 2864 1154777 N/A N/A 623 638 CCGCCGTGCCTACCTC 63 2865 1154783 N/A N/A 650 665 CACTGTACCAGAGGGC 72 2866 1154789 N/A N/A 784 799 TCAATTGATGAATTCA 44 2867 1154795 N/A N/A 862 877 CATTTCAAGTTGTTCA 30 2868 1154801 N/A N/A 1193 1208 GTGTACAAAGCTCTAG 38 2869 1154807 N/A N/A 1320 1335 GTTCAGTTAAGTGCTC 32 2870 1154813 N/A N/A 1403 1418 ACAGCTAAACTACGGT 69 2871 1154819 N/A N/A 1574 1589 TGATTCTAATTTGGTT 53 2872 1154825 N/A N/A 1704 1719 AATCAAAGTTCATGCT 75 2873 1154831 N/A N/A 1816 1831 CCCCTTTGCCCCAGCA 85 2874 1154837 N/A N/A 1823 1838 TGCACGCCCCCTTTGC 103  2875 1154843 N/A N/A 1876 1891 TAGGACAACCTTTTGG 39 2876 1154849 N/A N/A 2071 2086 TTAGGAGTAAGGACAT 50 2877 1154855 N/A N/A 2164 2179 TGCTATATATGTAATG 60 2878 1154861 N/A N/A 2514 2529 TGCAGTACATATGAGG 24 2879 1154867 N/A N/A 2614 2629 TCTTGGGTTTATTGTG 36 2880 1154873 N/A N/A 2676 2691 TCATCATATACCCTAA 86 2881 1154879 N/A N/A 2849 2864 CCCACATATGGAGAGA 75 2882 1154885 N/A N/A 3039 3054 CATTTGCTGGTCTCTG 34 2883 1154891 N/A N/A 3242 3257 TAGGTGTCTGCAGGGC 15 2884 1154897 N/A N/A 3290 3305 TGGAGTAGACAAGGGC 36 2885 1154903 N/A N/A 3371 3386 TCAACTCTGCCGCTGC 28 2886 1154909 N/A N/A 3404 3419 CCCACCTAGAGTCCTG 72 2887 1154915 N/A N/A 3653 3668 CATGCCTCCATCATCA 78 2888 1154921 N/A N/A 3660 3675 TGACTGACATGCCTCC 65 2889 1154927 N/A N/A 3800 3815 CCTTTGGTCTGGGCCT 37 2890 1154933 N/A N/A 4035 4050 CGGTCCCAAAGTCTCA 43 2891 1154939 N/A N/A 4269 4284 GGTAGGTGATGTCCAT 46 2892 1154945 N/A N/A 4459 4474 CACAGCCCCCGACTTG 60 2893 1154951 N/A N/A 4657 4672 TAGATACATTCTCAGA 58 2894 1154957 N/A N/A 5096 5111 GGCTCCGAACAAGGGC 85 2895 1154963 N/A N/A 5437 5452 CGTAGTCCCATAGTGA 74 2896 1154969 N/A N/A 5600 5615 ACAATGGCTCCGGGCC 86 2897 1154975 N/A N/A 5766 5781 TGTAGAAGCTTCTCTA 83 2898 1154981 N/A N/A 6035 6050 TGGGTTTTAGCTTGAG 18 2899 1154987 N/A N/A 6049 6064 GAGTCAAAGTGACATG 57 2900 1154993 N/A N/A 6145 6160 GCAGTGGAGAAGGCGA 74 2901 1154999 N/A N/A 6292 6307 TCTCGGACTTTCTCCT 63 2902 1155005 N/A N/A 6617 6632 GTGGACACTCCTCTGG 85 2903 1155011 N/A N/A 7001 7016 CCCAGTGCCACAGTAA 82 2904 1155017 N/A N/A 7008 7023 CCTCCCGCCCAGTGCC 64 2905 1155023 N/A N/A 7189 7204 AGCTATGCTCATGGGA 46 2906 1155029 N/A N/A 7243 7258 CTCACCTACTTGGCCC 67 2907 1155035 N/A N/A 7351 7366 ATGATCATCCCCCTTT 66 2908 1155041 N/A N/A 7810 7825 GGTACGGGCTGAGGTG 50 2909 1155047 N/A N/A 7942 7957 CGTTTTTTGGAGGGTG 13 2910 1155053 N/A N/A 7996 8011 AGCTCTGTGGTTTTGT 31 2911 1155059 N/A N/A 8004 8019 CTTTGTAAAGCTCTGT 32 2912 1155065 N/A N/A 8052 8067 CAGAGAAGCTTAAAGA 96 2913 1155071 N/A N/A 8663 8678 GAGGTCGAGAGAAGCT 95 2914 1155077 N/A N/A 8880 8895 AGTGGAATAAGGCTGG 105  2915 1155083 N/A N/A 9326 9341 TGGGAGTTCTCTCCTC 91 2916 1155089 N/A N/A 9422 9437 GCCTGGCAGTGCCTAA 103  2917 1155095 N/A N/A 9607 9622 CTTCCTTTATACCAGC 44 2918 1155101 N/A N/A 9881 9896 GGACCTGAATGTGAGG 71 2919 1155107 N/A N/A 10302 10317 GGATCACAGTGTTTGG  4 2920 1155113 N/A N/A 10380 10395 CAGGTTACATAGCTGG 54 2921 1155119 N/A N/A 10420 10435 CTCTGTGGTCGCCATC 15 2922 1155125 N/A N/A 10550 10565 TCTGTACATTCGCATC 23 2923 1155131 N/A N/A 11156 11171 TCGGATGATGCCTGGG 85 2924 1155137 N/A N/A 11572 11587 TAGCTGGAGTCCAGAG 74 2925 1155143 N/A N/A 11915 11930 CTCACCGTCAACACCC 97 2926 1155149 N/A N/A 12400 12415 TAGGCTATTTTATGGG 85 2927 1155155 N/A N/A 12580 12595 GGATCAAATGGGTGTT 67 2928 1155161 N/A N/A 12731 12746 CAGGGTTTCAGTTCAG 46 2929 1155167 N/A N/A 12888 12903 AGGTGGTTAGGCTCAG 66 2930 1155172 N/A N/A 12959 12974 TGACTTGGCTTTAGGT 96 2931 1155178 N/A N/A 13388 13403 ATGACCTACCCCGAGC 104  2932

TABLE 43 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 24 65 1154724 144 159 544 559 AAGTGGACTGACAGAA 73 2933 1154730 838 853 9428 9443 TGGTCCGCCTGGCAGT 46 2934 1154736 1150 1165 N/A N/A TGGAGGAACTCTGGGA 85 2935 1154742 1250 1265 13480 13495 TGTCCGCTGCTTCTCT   8* 2936 1154748 1909 1924 14319 14334 TGAGGTTGTTTGAGTG 35 2937 1154754 1928 1943 14338 14353 TTGTGTGATGATGCAG  4 2938 1154760 1935 1950 14345 14360 TGTGTGATTGTGTGAT 57 2939 1154766 2243 2258 14653 14668 GTGAGGTGAGTGGCAG 49 2940 1154772 2267 2282 N/A N/A TGGATCAGGGCTCAGG 34 2941 1154778 N/A N/A 625 640 CCCCGCCGTGCCTACC 26 2942 1154784 N/A N/A 656 671 ACATCCCACTGTACCA 78 2943 1154790 N/A N/A 786 801 TATCAATTGATGAATT 134  2944 1154796 N/A N/A 864 879 AGCATTTCAAGTTGTT 47 2945 1154802 N/A N/A 1270 1285 TAGGGTGAACAGAACT 79 2946 1154808 N/A N/A 1321 1336 AGTTCAGTTAAGTGCT 63 2947 1154814 N/A N/A 1470 1485 TGAACAACCTGTTTGC 104  2948 1154820 N/A N/A 1575 1590 ATGATTCTAATTTGGT 41 2949 1154826 N/A N/A 1707 1722 ATCAATCAAAGTTCAT 47 2950 1154832 N/A N/A 1817 1832 CCCCCTTTGCCCCAGC 47 2951 1154838 N/A N/A 1824 1839 ATGCACGCCCCCTTTG 108  2952 1154844 N/A N/A 1902 1917 TTAGCTTAAGTAGAGG 43 2953 1154850 N/A N/A 2150 2165 TGGCTGATGAAAGGTT 48 2954 1154856 N/A N/A 2165 2180 TTGCTATATATGTAAT 104  2955 1154862 N/A N/A 2515 2530 TTGCAGTACATATGAG 77 2956 1154868 N/A N/A 2617 2632 TGATCTTGGGTTTATT 58 2957 1154874 N/A N/A 2789 2804 GAGTATGGTTTAACAA 63 2958 1154880 N/A N/A 2906 2921 CCCTGGTATAAGAACA 112  2959 1154886 N/A N/A 3044 3059 AAGAACATTTGCTGGT 44 2960 1154892 N/A N/A 3243 3258 TTAGGTGTCTGCAGGG 69 2961 1154898 N/A N/A 3291 3306 GTGGAGTAGACAAGGG 21 2962 1154904 N/A N/A 3372 3387 TTCAACTCTGCCGCTG 48 2963 1154910 N/A N/A 3411 3426 CCAGGGTCCCACCTAG 115  2964 1154916 N/A N/A 3654 3669 ACATGCCTCCATCATC 70 2965 1154922 N/A N/A 3661 3676 CTGACTGACATGCCTC 56 2966 1154928 N/A N/A 4017 4032 ATGTGTAGGCCAGTGT 31 2967 1154934 N/A N/A 4037 4052 TACGGTCCCAAAGTCT 97 2968 1154940 N/A N/A 4270 4285 TGGTAGGTGATGTCCA 96 2969 1154946 N/A N/A 4508 4523 GGACACAGATTATGTT 90 2970 1154952 N/A N/A 4658 4673 ATAGATACATTCTCAG 50 2971 1154958 N/A N/A 5097 5112 AGGCTCCGAACAAGGG 75 2972 1154964 N/A N/A 5531 5546 GATCCTATAATCCTGG 96 2973 1154970 N/A N/A 5601 5616 CACAATGGCTCCGGGC 74 2974 1154976 N/A N/A 5914 5929 AATATGTGAGTGGAGG 68 2975 1154982 N/A N/A 6038 6053 ACATGGGTTTTAGCTT 62 2976 1154988 N/A N/A 6051 6066 GAGAGTCAAAGTGACA 74 2977 1154994 N/A N/A 6189 6204 AACAGTCCTGGCAAGT 129  2978 1155000 N/A N/A 6308 6323 ATCTTGCCGGAGCTGG 68 2979 1155006 N/A N/A 6618 6633 CGTGGACACTCCTCTG 93 2980 1155012 N/A N/A 7002 7017 GCCCAGTGCCACAGTA 104  2981 1155018 N/A N/A 7009 7024 CCCTCCCGCCCAGTGC 67 2982 1155024 N/A N/A 7190 7205 TAGCTATGCTCATGGG 47 2983 1155030 N/A N/A 7304 7319 CGAGTAACTTTTTAAA 103  2984 1155036 N/A N/A 7353 7368 CTATGATCATCCCCCT 64 2985 1155042 N/A N/A 7885 7900 AGTACTGCAATTCAGA 57 2986 1155048 N/A N/A 7965 7980 CATCTTTAAGGTTCTG 16 2987 1155054 N/A N/A 7997 8012 AAGCTCTGTGGTTTTG 49 2988 1155060 N/A N/A 8014 8029 TTTTGACTAGCTTTGT 45 2989 1155066 N/A N/A 8053 8068 GCAGAGAAGCTTAAAG 79 2990 1155072 N/A N/A 8664 8679 TGAGGTCGAGAGAAGC 121  2991 1155078 N/A N/A 8883 8898 AACAGTGGAATAAGGC 65 2992 1155084 N/A N/A 9329 9344 CTCTGGGAGTTCTCTC 85 2993 1155090 N/A N/A 9423 9438 CGCCTGGCAGTGCCTA 89 2994 1155096 N/A N/A 9608 9623 CCTTCCTTTATACCAG 102  2995 1155102 N/A N/A 9954 9969 TTTGTAAGTAGAAGGG 32 2996 1155108 N/A N/A 10303 10318 AGGATCACAGTGTTTG 18 2997 1155114 N/A N/A 10412 10427 TCGCCATCTTGAAATC 57 2998 1155120 N/A N/A 10421 10436 GCTCTGTGGTCGCCAT 34 2999 1155126 N/A N/A 10584 10599 GTCACCTAAACCCCCC 54 3000 1155132 N/A N/A 11322 11337 CCGTGTAGTGCAAGGA 106  3001 1155138 N/A N/A 11574 11589 AGTAGCTGGAGTCCAG 42 3002 1155144 N/A N/A 12285 12300 TTGGATTTGCGGACAG 57 3003 1155150 N/A N/A 12550 12565 GGAATGGTGCCCAGTT 105  3004 1155156 N/A N/A 12700 12715 ATCTGGTATCATGTAG 80 3005 1155162 N/A N/A 12758 12773 AGGCTATCAGTCAGGA 74 3006 1155168 N/A N/A 12894 12909 ATGGTTAGGTGGTTAG 92 3007 1155173 N/A N/A 12966 12981 GATGGGATGACTTGGC 76 3008 1155179 N/A N/A 13391 13406 GCTATGACCTACCCCG 96 3009

TABLE 44 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 30 65 1154725 152 167 N/A N/A GCTTGGTGAAGTGGAC 48 3010 1154731 839 854 9429 9444 ATGGTCCGCCTGGCAG 48 3011 1154737 1152 1167 N/A N/A TGTGGAGGAACTCTGG 74 3012 1154743 1252 1267 13482 13497 AGTGTCCGCTGCTTCT   7* 3013 1154749 1911 1926 14321 14336 TTTGAGGTTGTTTGAG 40 3014 1154755 1929 1944 14339 14354 ATTGTGTGATGATGCA 38 3015 1154761 2066 2081 14476 14491 ATCCTGAGGGTACTGA 75 3016 1154767 2244 2259 14654 14669 AGTGAGGTGAGTGGCA 33 3017 1154773 N/A N/A 619 634 CGTGCCTACCTCCCTG 48 3018 1154779 N/A N/A 626 641 CCCCCGCCGTGCCTAC 33 3019 1154785 N/A N/A 660 675 GGGTACATCCCACTGT 83 3020 1154791 N/A N/A 787 802 GTATCAATTGATGAAT 100  3021 1154797 N/A N/A 865 880 CAGCATTTCAAGTTGT 71 3022 1154803 N/A N/A 1277 1292 CTGCTACTAGGGTGAA 22 3023 1154809 N/A N/A 1322 1337 AAGTTCAGTTAAGTGC 38 3024 1154815 N/A N/A 1523 1538 TACTTTGTGCCAAACG 62 3025 1154821 N/A N/A 1578 1593 AGCATGATTCTAATTT 28 3026 1154827 N/A N/A 1708 1723 AATCAATCAAAGTTCA 76 3027 1154833 N/A N/A 1818 1833 GCCCCCTTTGCCCCAG 26 3028 1154839 N/A N/A 1825 1840 AATGCACGCCCCCTTT 108  3029 1154845 N/A N/A 1906 1921 AGGGTTAGCTTAAGTA 40 3030 1154851 N/A N/A 2152 2167 AATGGCTGATGAAAGG 39 3031 1154857 N/A N/A 2190 2205 GCAAATGATGAATTGG 34 3032 1154863 N/A N/A 2516 2531 ATTGCAGTACATATGA 52 3033 1154869 N/A N/A 2620 2635 TGCTGATCTTGGGTTT 33 3034 1154875 N/A N/A 2792 2807 ATGGAGTATGGTTTAA 23 3035 1154881 N/A N/A 2968 2983 AGGGACACCCATGGCT 87 3036 1154887 N/A N/A 3045 3060 TAAGAACATTTGCTGG 33 3037 1154893 N/A N/A 3250 3265 TAAGTCATTAGGTGTC 21 3038 1154899 N/A N/A 3314 3329 TTCTACACTGAGCACG 49 3039 1154905 N/A N/A 3373 3388 TTTCAACTCTGCCGCT 79 3040 1154911 N/A N/A 3412 3427 ACCAGGGTCCCACCTA 112  3041 1154917 N/A N/A 3655 3670 GACATGCCTCCATCAT 51 3042 1154923 N/A N/A 3662 3677 ACTGACTGACATGCCT 55 3043 1154929 N/A N/A 4018 4033 TATGTGTAGGCCAGTG 11 3044 1154935 N/A N/A 4226 4241 TGAAGACCTGGCCCTT 90 3045 1154941 N/A N/A 4273 4288 ATGTGGTAGGTGATGT 45 3046 1154947 N/A N/A 4609 4624 AGGACCTAGAGGGCCG 122  3047 1154953 N/A N/A 4663 4678 AAAGCATAGATACATT 69 3048 1154959 N/A N/A 5098 5113 GAGGCTCCGAACAAGG 57 3049 1154965 N/A N/A 5532 5547 GGATCCTATAATCCTG 114  3050 1154971 N/A N/A 5603 5618 TCCACAATGGCTCCGG 72 3051 1154977 N/A N/A 5944 5959 GTGTAGATAGACATGA 91 3052 1154983 N/A N/A 6039 6054 GACATGGGTTTTAGCT 63 3053 1154989 N/A N/A 6052 6067 GGAGAGTCAAAGTGAC 81 3054 1154995 N/A N/A 6268 6283 TATTTTGCCCCAGTGA 60 3055 1155001 N/A N/A 6396 6411 GCAATGGTTGTTTCCC 38 3056 1155007 N/A N/A 6641 6656 GAGATACTCGACCACC 59 3057 1155013 N/A N/A 7003 7018 CGCCCAGTGCCACAGT 78 3058 1155019 N/A N/A 7092 7107 GGATTTTCTTGGCCCT 94 3059 1155025 N/A N/A 7192 7207 CATAGCTATGCTCATG 99 3060 1155031 N/A N/A 7313 7328 CATGGAGATCGAGTAA 25 3061 1155037 N/A N/A 7358 7373 AGATGCTATGATCATC 114  3062 1155043 N/A N/A 7900 7915 ACCTTTGACCCCCAGA 61 3063 1155049 N/A N/A 7969 7984 TCTGCATCTTTAAGGT 89 3064 1155055 N/A N/A 7998 8013 AAAGCTCTGTGGTTTT 57 3065 1155061 N/A N/A 8016 8031 CATTTTGACTAGCTTT 48 3066 1155067 N/A N/A 8192 8207 ACAGGGCACCTATGGA 85 3067 1155073 N/A N/A 8691 8706 CGTTTCTTATTATACA 75 3068 1155079 N/A N/A 8890 8905 CTTTGGGAACAGTGGA 83 3069 1155085 N/A N/A 9331 9346 CCCTCTGGGAGTTCTC 99 3070 1155091 N/A N/A 9424 9439 CCGCCTGGCAGTGCCT 41 3071 1155097 N/A N/A 9609 9624 TCCTTCCTTTATACCA 71 3072 1155103 N/A N/A 9959 9974 GAGGGTTTGTAAGTAG 94 3073 1155109 N/A N/A 10304 10319 CAGGATCACAGTGTTT 12 3074 1155115 N/A N/A 10413 10428 GTCGCCATCTTGAAAT 54 3075 1155121 N/A N/A 10422 10437 TGCTCTGTGGTCGCCA 27 3076 1155127 N/A N/A 10609 10624 ACCACCCAACTGTGAC 88 3077 1155133 N/A N/A 11424 11439 TGAGTGGCGGCAGCTG 91 3078 1155139 N/A N/A 11576 11591 ATAGTAGCTGGAGTCC 35 3079 1155145 N/A N/A 12298 12313 TGGTGGTTTAGGTTTG 68 3080 1155151 N/A N/A 12564 12579 ACAAGGAAAGGTTGGG 84 3081 1155157 N/A N/A 12701 12716 TATCTGGTATCATGTA 110  3082 1155163 N/A N/A 12759 12774 GAGGCTATCAGTCAGG 62 3083 1155169 N/A N/A 12896 12911 ACATGGTTAGGTGGTT 93 3084 1155174 N/A N/A 13278 13293 GGTGAAGTGTCGGGTT 58 3085 1155180 N/A N/A 13392 13407 GGCTATGACCTACCCC N.D. 3086

TABLE 45 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 25 65 1154726 335 350 6873 6888 GGCCCCGCCTCGAAGA 62 3087 1154732 1146 1161 N/A N/A GGAACTCTGGGAATGT 40 3088 1154738 1153 1168 12023 12038 TTGTGGAGGAACTCTG 71 3089 1154744 1254 1269 13484 13499 TGAGTGTCCGCTGCTT  24* 3090 1154750 1912 1927 14322 14337 CTTTGAGGTTGTTTGA 37 3091 1154756 1930 1945 14340 14355 GATTGTGTGATGATGC 25 3092 1154762 2067 2082 14477 14492 GATCCTGAGGGTACTG 55 3093 1154768 2246 2261 14656 14671 GGAGTGAGGTGAGTGG 41 3094 1154774 N/A N/A 620 635 CCGTGCCTACCTCCCT 39 3095 1154780 N/A N/A 627 642 CCCCCCGCCGTGCCTA 54 3096 1154786 N/A N/A 662 677 CTGGGTACATCCCACT 98 3097 1154792 N/A N/A 858 873 TCAAGTTGTTCAAAGC 37 3098 1154798 N/A N/A 968 983 GCAAGACAGGGTGAGC 91 3099 1154804 N/A N/A 1288 1303 TTGCAATCCTCCTGCT 95 3100 1154810 N/A N/A 1323 1338 AAAGTTCAGTTAAGTG 60 3101 1154816 N/A N/A 1562 1577 GGTTACAGAAATACTA 84 3102 1154822 N/A N/A 1579 1594 TAGCATGATTCTAATT 66 3103 1154828 N/A N/A 1709 1724 AAATCAATCAAAGTTC N.D. 3104 1154834 N/A N/A 1819 1834 CGCCCCCTTTGCCCCA 45 3105 1154840 N/A N/A 1844 1859 GAGGGTCATAAACTTT 66 3106 1154846 N/A N/A 1913 1928 CTCACCTAGGGTTAGC 76 3107 1154852 N/A N/A 2153 2168 TAATGGCTGATGAAAG 80 3108 1154858 N/A N/A 2247 2262 GACTGTATAAAACCAT 20 3109 1154864 N/A N/A 2518 2533 CCATTGCAGTACATAT 27 3110 1154870 N/A N/A 2621 2636 ATGCTGATCTTGGGTT 45 3111 1154876 N/A N/A 2795 2810 ACCATGGAGTATGGTT 102  3112 1154882 N/A N/A 3036 3051 TTGCTGGTCTCTGGCT 74 3113 1154888 N/A N/A 3094 3109 ATGCATGGAGAGCCAG 91 3114 1154894 N/A N/A 3263 3278 TACGCTGTCTGGTTAA 60 3115 1154900 N/A N/A 3353 3368 TTCGGTGAGGCCCTGA 70 3116 1154906 N/A N/A 3374 3389 ATTTCAACTCTGCCGC 46 3117 1154912 N/A N/A 3490 3505 AATGGTAGCCCAGGTT 63 3118 1154918 N/A N/A 3656 3671 TGACATGCCTCCATCA 75 3119 1154924 N/A N/A 3712 3727 ACAATCAAGGTTTTCG 21 3120 1154930 N/A N/A 4021 4036 CAGTATGTGTAGGCCA 11 3121 1154936 N/A N/A 4231 4246 AGCTCTGAAGACCTGG 62 3122 1154942 N/A N/A 4451 4466 CCGACTTGCCCAGATT 68 3123 1154948 N/A N/A 4638 4653 GGACATGGAGATGATC 78 3124 1154954 N/A N/A 4664 4679 CAAAGCATAGATACAT 66 3125 1154960 N/A N/A 5104 5119 TCTGTGGAGGCTCCGA 72 3126 1154966 N/A N/A 5535 5550 TCAGGATCCTATAATC 84 3127 1154972 N/A N/A 5604 5619 CTCCACAATGGCTCCG 68 3128 1154978 N/A N/A 5946 5961 AGGTGTAGATAGACAT 45 3129 1154984 N/A N/A 6040 6055 TGACATGGGTTTTAGC 48 3130 1154990 N/A N/A 6069 6084 GATGTAGTGGGCAAGA 55 3131 1154996 N/A N/A 6275 6290 GGAGTCCTATTTTGCC 67 3132 1155002 N/A N/A 6499 6514 AGGTACATGTACATAC 74 3133 1155008 N/A N/A 6647 6662 CGGTATGAGATACTCG 79 3134 1155014 N/A N/A 7004 7019 CCGCCCAGTGCCACAG 73 3135 1155020 N/A N/A 7177 7192 GGGACTACAATACGGC 32 3136 1155026 N/A N/A 7194 7209 CACATAGCTATGCTCA 38 3137 1155032 N/A N/A 7314 7329 TCATGGAGATCGAGTA 16 3138 1155038 N/A N/A 7359 7374 TAGATGCTATGATCAT 58 3139 1155044 N/A N/A 7901 7916 CACCTTTGACCCCCAG 40 3140 1155050 N/A N/A 7970 7985 TTCTGCATCTTTAAGG 59 3141 1155056 N/A N/A 7999 8014 TAAAGCTCTGTGGTTT 86 3142 1155062 N/A N/A 8022 8037 TGCTGACATTTTGACT 74 3143 1155068 N/A N/A 8498 8513 CCGGTAGACTGGCACA 94 3144 1155074 N/A N/A 8811 8826 GGCTACATGGGTTCAA 89 3145 1155080 N/A N/A 9124 9139 AAGCATTCTGGGTGGA 53 3146 1155086 N/A N/A 9389 9404 TGCAGGTGACCACGAC 74 3147 1155092 N/A N/A 9552 9567 CAGAAGGTTTTGCGCA 50 3148 1155098 N/A N/A 9874 9889 AATGTGAGGTTAGGTT 40 3149 1155104 N/A N/A 10281 10296 TTAGAGTCAGAGGGTT 28 3150 1155110 N/A N/A 10308 10323 AACTCAGGATCACAGT 79 3151 1155116 N/A N/A 10414 10429 GGTCGCCATCTTGAAA 37 3152 1155122 N/A N/A 10459 10474 ACCTATGTGGTTATGT 80 3153 1155128 N/A N/A 10653 10668 CCACTGATGCTGGGAC 88 3154 1155134 N/A N/A 11508 11523 GACACTCGAGACCATA 66 3155 1155140 N/A N/A 11789 11804 GTAACTTGCACACCAA 62 3156 1155146 N/A N/A 12304 12319 CCTGGATGGTGGTTTA 64 3157 1155152 N/A N/A 12567 12582 GTTACAAGGAAAGGTT 103  3158 1155158 N/A N/A 12702 12717 ATATCTGGTATCATGT 82 3159 1155164 N/A N/A 12769 12784 TGATTGCAGTGAGGCT 102  3160 1155170 N/A N/A 12900 12915 AGGGACATGGTTAGGT 66 3161 1155175 N/A N/A 13340 13355 GTAATCAGGGACAGGA 107  3162 1155181 N/A N/A 13421 13436 GCACATTCCCCAAACT 107  3163

TABLE 46 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.: 1, and 2 SEQ ID SEQ ID SEQ ID SEQ ID NO: 1 NO: 1 NO: 2 NO: 2 FOXP3 SEQ Compound Start Stop Start Stop (% ID Number Site Site Site Site Sequence (5′ to 3′) UTC) NO  911144 N/A N/A 7355 7370 TGCTATGATCATCCCC 27 65 1154722 85 100 485 500 AACTTTGCTTTTATAC N.D. 3164 1154728 836 851 9426 9441 GTCCGCCTGGCAGTGC 51 3165 1154734 1148 1163 N/A N/A GAGGAACTCTGGGAAT 65 3166 1154740 1155 1170 12025 12040 TGTTGTGGAGGAACTC 83 3167 1154746 1905 1920 14315 14330 GTTGTTTGAGTGTACT 67 3168 1154752 1916 1931 14326 14341 GCAGCTTTGAGGTTGT 49 3169 1154758 1932 1947 14342 14357 GTGATTGTGTGATGAT 20 3170 1154764 2126 2141 14536 14551 AGATACACAGGTGAAT 48 3171 1154770 2248 2263 14658 14673 TGGGAGTGAGGTGAGT 57 3172 1154776 N/A N/A 622 637 CGCCGTGCCTACCTCC 43 3173 1154782 N/A N/A 649 664 ACTGTACCAGAGGGCC 77 3174 1154788 N/A N/A 783 798 CAATTGATGAATTCAT 86 3175 1154794 N/A N/A 861 876 ATTTCAAGTTGTTCAA 55 3176 1154800 N/A N/A 1192 1207 TGTACAAAGCTCTAGG 32 3177 1154806 N/A N/A 1313 1328 TAAGTGCTCAGCTTGC 71 3178 1154812 N/A N/A 1385 1400 ACAATGGTGTGAAGTG 42 3179 1154818 N/A N/A 1573 1588 GATTCTAATTTGGTTA 41 3180 1154824 N/A N/A 1581 1596 TATAGCATGATTCTAA 67 3181 1154830 N/A N/A 1729 1744 CCAACAATCGGCACTT 49 3182 1154836 N/A N/A 1822 1837 GCACGCCCCCTTTGCC 46 3183 1154842 N/A N/A 1872 1887 ACAACCTTTTGGAAGG 85 3184 1154848 N/A N/A 2027 2042 AAAAGCATGAATGGCC 72 3185 1154854 N/A N/A 2161 2176 TATATATGTAATGGCT 40 3186 1154860 N/A N/A 2513 2528 GCAGTACATATGAGGA 21 3187 1154866 N/A N/A 2531 2546 GGTACTATTATAACCA 97 3188 1154872 N/A N/A 2637 2652 TAAGTTTTAACACCTA 69 3189 1154878 N/A N/A 2837 2852 GAGAACTGAATTTGTG 22 3190 1154884 N/A N/A 3038 3053 ATTTGCTGGTCTCTGG 8 3191 1154890 N/A N/A 3225 3240 TCAAGTTGACAATTGC 54 3192 1154896 N/A N/A 3289 3304 GGAGTAGACAAGGGCC 14 3193 1154902 N/A N/A 3363 3378 GCCGCTGCATTTCGGT 74 3194 1154908 N/A N/A 3378 3393 TTGGATTTCAACTCTG 44 3195 1154914 N/A N/A 3613 3628 CTGACCTATGGAGTCC 73 3196 1154920 N/A N/A 3659 3674 GACTGACATGCCTCCA 42 3197 1154926 N/A N/A 3717 3732 GCCCCACAATCAAGGT 91 3198 1154932 N/A N/A 4031 4046 CCCAAAGTCTCAGTAT 92 3199 1154938 N/A N/A 4250 4265 GCCACTATGACAAGCC 71 3200 1154944 N/A N/A 4458 4473 ACAGCCCCCGACTTGC 123 3201 1154950 N/A N/A 4656 4671 AGATACATTCTCAGAC 49 3202 1154956 N/A N/A 4785 4800 GATGTTTTCCACCACT 15 3203 1154962 N/A N/A 5216 5231 GGGTGGTTGTCAGAGC 17 3204 1154968 N/A N/A 5554 5569 TGAGGGAAGCACTGGC 42 3205 1154974 N/A N/A 5700 5715 ATGCTACACCCCCTGC 74 3206 1154980 N/A N/A 5971 5986 GGAGTTGGATTGGGTG 33 3207 1154986 N/A N/A 6047 6062 GTCAAAGTGACATGGG 39 3208 1154992 N/A N/A 6092 6107 TCAGGAGCAGTGCTAG 79 3209 1154998 N/A N/A 6277 6292 TCGGAGTCCTATTTTG 63 3210 1155004 N/A N/A 6607 6622 CTCTGGTCAAAGCAGG 74 3211 1155010 N/A N/A 7000 7015 CCAGTGCCACAGTAAA 66 3212 1155016 N/A N/A 7007 7022 CTCCCGCCCAGTGCCA 51 3213 1155022 N/A N/A 7179 7194 ATGGGACTACAATACG 25 3214 1155028 N/A N/A 7242 7257 TCACCTACTTGGCCCC 68 3215 1155034 N/A N/A 7350 7365 TGATCATCCCCCTTTT 70 3216 1155040 N/A N/A 7633 7648 CTGTGGTTCAGCCTGA 64 3217 1155046 N/A N/A 7929 7944 GTGGAGTTTCCAAGCC 40 3218 1155052 N/A N/A 7995 8010 GCTCTGTGGTTTTGTG 19 3219 1155058 N/A N/A 8003 8018 TTTGTAAAGCTCTGTG 22 3220 1155064 N/A N/A 8051 8066 AGAGAAGCTTAAAGAC 73 3221 1155070 N/A N/A 8569 8584 GCATCTTACTACTTAT 24 3222 1155076 N/A N/A 8827 8842 GCAGATTCTAGAGCCT 57 3223 1155082 N/A N/A 9175 9190 ATGTTGGAAGTGTGGT 69 3224 1155088 N/A N/A 9421 9436 CCTGGCAGTGCCTAAG 79 3225 1155094 N/A N/A 9606 9621 TTCCTTTATACCAGCC 62 3226 1155100 N/A N/A 9876 9891 TGAATGTGAGGTTAGG 6 3227 1155106 N/A N/A 10286 10301 GGATCTTAGAGTCAGA 20 3228 1155112 N/A N/A 10372 10387 ATAGCTGGTCCTGCTG 105 3229 1155118 N/A N/A 10417 10432 TGTGGTCGCCATCTTG 23 3230 1155124 N/A N/A 10549 10564 CTGTACATTCGCATCA 35 3231 1155130 N/A N/A 10720 10735 GAGGTGGAATCCCACA 83 3232 1155136 N/A N/A 11571 11586 AGCTGGAGTCCAGAGT 45 3233 1155142 N/A N/A 11839 11854 TTGCACCACTTCTGCC 83 3234 1155148 N/A N/A 12397 12412 GCTATTTTATGGGTCC 19 3235 1155154 N/A N/A 12574 12589 AATGGGTGTTACAAGG 57 3236 1155160 N/A N/A 12705 12720 GGAATATCTGGTATCA 70 3237 1155166 N/A N/A 12886 12901 GTGGTTAGGCTCAGGG 51 3238 1155171 N/A N/A 12930 12945 TGGTTTGAATTATCGA 37 3239 1155177 N/A N/A 13345 13360 GGCAGGTAATCAGGGA 51 3240

TABLE 47 Inhibition of Foxp3 mRNA by 3-10-3 cEt gapmers targeting SEQ ID NO.:3, 4 and 5 SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID NO: 3 NO: 3 NO: 4 NO: 4 NO: 5 NO: 5 FOXP3 SEQ Compound Start Stop Start Stop Start Stop (% ID Number Site Site Site Site Site Site Sequence (5′ to 3′) UTC) NO 1062517 N/A N/A N/A N/A  11  26 GGCGAGGCTCCT 92  626 GAGA  911066 395 410 N/A N/A 162 177 CACCGTTGAGA 54 3241 GCTGC 1062518 N/A N/A N/A N/A  12  27 GGGCGAGGCTC 75 3242 CTGAG 1063075 N/A N/A 11215 11230 N/A N/A TAAACTGAGGC 74 3243 CTGCA 1062451 393 408 N/A N/A 160 175 CCGTTGAGAGCT 53 3244 GCAG 1062452 394 409 N/A N/A 161 176 ACCGTTGAGAG 82 3245 CTGCA 1062519 N/A N/A N/A N/A  13  28 TGGGCGAGGCT 98 3246 CCTGA

Example 3: Dose-Dependent Inhibition of Human Foxp3 in LNCaP Cells by cEt Gapmers

Modified oligonucleotides described in the studies above were tested at various doses in LNCaP cells. Cultured LNCaP cells at a density of 30,000 cells per well were transfected using electroporation with modified oligonucleotides diluted to concentrations of 8,000 nM, 4,000 nM, 500 nM and 125 nM for 24 hours. After 24 hours, Foxp3 mRNA levels were measured as previously described using the Human Foxp3 primer-probe set RTS35925. Foxp3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to untreated control cells (% UTC). IC50s were calculated using a linear regression on a log/linear plot of the data in excel.

TABLE 48 Dose-dependent inhibition of human Foxp3 mRNA expression by modified oligonucleotides in LNCaP cells % UTC ION 125 500 2000 8000 IC₅₀ NO. nM nM nM nM (μM) 911180 87 45 15 2 0.5 911032 74 63 28 9 0.7 910969 91 75 24 11 0.9 911120 73 57 19 15 0.5 911152 99 70 29 15 0.9 910965 112 70 34 22 1.1 911144 56 47 23 8 0.3 911028 99 67 36 22 1.1 911012 85 53 17 5 0.5 910926 75 58 32 14 0.7 910958 98 66 35 18 1.0 911093 83 76 33 16 1.1 911105 100 72 39 16 1.3 911133 75 41 27 10 0.4 911101 100 48 26 16 0.7 910930 89 58 25 4 0.7 910962 90 47 35 24 0.7 910997 105 52 27 19 0.7 911110 101 54 23 10 0.7

TABLE 49 Dose-dependent inhibition of human Foxp3 mRNA expression by modified oligonucleotides in LNCaP cells % UTC ION 125 500 2000 8000 IC₅₀ NO. nM nM nM nM (μM) 911098 80 53 24 8 0.6 911118 73 53 28 3 0.5 911014 104 53 26 16 0.7 911162 94 66 17 11 0.7 911182 103 70 27 10 0.9 910959 94 52 20 9 0.6 910955 59 64 39 13 0.9 911194 79 44 19 5 0.4 911023 92 69 30 14 0.9 910956 74 47 19 6 0.4 911179 106 55 21 8 0.7 911171 76 59 21 11 0.6 911011 116 58 30 11 0.9 910924 88 66 30 12 0.9 911019 76 52 24 6 0.5 911051 99 75 33 14 1.1 910980 67 41 33 10 0.4 911183 113 75 43 23 1.5 911180 105 46 30 7 0.7

Example 4: Dose-Dependent Inhibition of Human Foxp3 in SUP-M2 Cells by cEt Gapmers

Modified oligonucleotides described in the studies above were tested at various doses in SUP-M2 cells. ION No. 141923 (5-10-5 MOE gapmer, CCTTCCCTGAAGGTTCCTCC, designated herein as SEQ ID NO: 3247), a control modified oligonucleotide that does not target Foxp3, has been included in each experiment as a negative control.

Cultured SUP-M2 cells at a density of 60,000 cells per well were treated using free uptake with modified oligonucleotides diluted to concentrations of 7,000 nM, 1,750 nM, 437.5 nM and 109.375 nM for 24 hours. After 24 hours, Foxp3 mRNA levels were measured as previously described using the Human Foxp3 primer-probe set RTS35925. Foxp3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to untreated control cells (% UTC). IC50s were calculated using a linear regression on a log/linear plot of the data in excel. The modified oligonucleotides with percent control values marked with an asterisk (*) target the amplicon region of the primer probe set. Additional assays may be used to measure the potency and efficacy of the modified oligonucleotides targeting the amplicon region.

TABLE 50 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 910956 82 73 39 26 1.2 911144 74 81 47 11 1.1 911179 75 44 19 10 0.4 1062005 121 75 19 6 1.1 1062006 97 65 41 15 1.1 1062166 99 127 109 94 >7.0 1062422 114 104 75 51 >7.0 1062645 148 93 49 17 2.0 1062838 137 88 28 11 1.4 1062839 72 82 54 20 1.5 1062903 108 47 9 7 0.7 1063062 123 78 36 18 1.5 1063063 98 63 21 14 0.8 1063094 150 126 78 60 >7.0 1063158 138 97 66 43 4.3 1063159 71 90 66 23 2.4 1063542 103 107 101 88 >7.0 1063734 73 45 11 5 0.3 1063988 130 119 60 26 3.1

TABLE 51 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144 112 68 42 12 1.3 1062008 69 30 10 3 0.2 1062009 80 40 18 5 0.4 1062393 71 42 42 14 0.5 1062425 58 23 5 2 <0.1 1062937 75 44 37 18 0.5 1062938 62 41 21 5 0.2 1063033 64 48 24 15 0.3 1063097 79 43 23 12 0.5 1063320 67 46 22 14 0.3 1063353 81 52 54 52 >7.0 1063736 83 60 41 15 0.9 1063768 65 64 20 19 0.5 1063769 66 24 5 1 0.2 1063895 74 44 34 11 0.5 1063959 114 93 49 23 2.1 1063960 73 35 19 9 0.3 1064121 78 51 34 14 0.6 1064122 82 61 41 13 0.8

TABLE 52 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144  44  43  36  11 <0.1 1062010  64  28  10  3 0.2 1062268  13*  19*    9*    3* <0.1* 1062299 112 140 148 103 >7.0 1062331 138  93 113  59 >7.0 1062395  80  41  16  4 0.4 1062426 101  57  27  13 0.8 1062427 139 133  54  13 2.5 1062907 103  57  17  6 0.7 1062908 142  75  43  13 1.6 1063035  86  50  27  9 0.6 1063036 160 102  46  8 1.9 1063037  40  27  35  19 <0.1 1063067 118  84  37  21 1.6 1063099  70  67  49  23 1.1 1063163 117  62  35  13 1.2 1063164 129 112  68  25 3.2 1063962 153 129  69  33 4.0 1064091  36  37  51  27 <0.1

TABLE 53 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144  61 48 29 12 0.3 1062007 102 35 25  6 0.6 1062044  53 37 21 13 0.1 1062263  113*  72*  30*  6* 1.1* 1062396  47 44 34 23 <0.1 1062428  59 37 19 14 0.2 1062712  67 78 42 18 0.9 1062840 102 41 37  7 0.7 1062904  60 86 32 26 0.9 1062909  47 44 22 13 <0.1 1063032  85 41 11  3 0.4 1063101  49 35 22  8 <0.1 1063197  51 47 31 14 0.2 1063319  47 42 62 54 0.6 1063324  86 43 26 13 0.6 1063511  89 53 50 14 0.9 1063735  86 27 34 12 0.4 1063963  49 33 18  7 <0.1 1064312  56 42 50 33 0.3

TABLE 54 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144 80 51 41 14 0.7 1062015 76 66 41 39 1.6 1062047 86 68 46 16 1.1 1062206 88 87 92 87 >7.0 1062335 86 68 63 28 2.1 1062336 91 73 36 18 1.1 1062367 90 61 36 11 0.9 1062368 68 29 9 7 0.2 1062431 66 54 45 30 0.7 1062560 97 63 40 21 1.2 1062753 77 71 41 39 1.7 1063648 115 69 29 11 1.1 1063649 71 35 14 1 0.3 1063743 110 81 43 17 1.5 1063744 82 47 10 4 0.4 1063967 90 90 88 80 >7.0 1064094 71 59 37 21 0.7 1064095 94 78 40 12 1.2 1064161 80 71 67 36 3.4

TABLE 55 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144 39 22 21 7 <0.1 1062372 83 51 23 11 0.6 1062596 44 44 63 42 4.3 1062660 43 31 62 58 1.1 1062724 51 19 7 2 <0.1 1062725 101 80 31 14 1.2 1062885 93 41 48 15 0.8 1062979 116 39 25 14 0.8 1063203 95 54 25 20 0.8 1063234 71 78 27 17 0.8 1063268 55 36 22 7 0.1 1063331 52 23 10 3 <0.1 1063332 104 75 34 16 1.2 1063394 86 69 38 22 1.1 1063491 49 18 9 4 <0.1 1063587 88 87 59 40 3.9 1063619 39 20 17 9 <0.1 1063651 101 71 38 18 1.2 1063652 75 61 25 12 0.6

TABLE 56 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144 81 54 35 9 0.6 1062087 51 30 23 8 <0.1 1062247 66 52 27 21 0.4 1062375 51 26 14 5 <0.1 1062376 102 67 39 15 1.1 1062439 103 48 26 18 0.8 1062504 188 173 105 57 >7.0 1062536 100 97 81 19 3.2 1062760 59 29 17 18 0.1 1062761 136 103 39 49 3.4 1062857 57 65 37 24 0.6 1063049 134 117 57 24 2.8 1063145 141 103 28 21 1.8 1063399 93 109 33 21 1.7 1063400 106 54 77 22 2.1 1063912 75 48 40 26 0.7 1063975 110 100 39 18 1.7 1063976 51 33 16 6 <0.1 1064103 72 48 24 22 0.4

TABLE 57 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144 86 55 26 8 0.6 1062030 110 45 12 3 0.7 1062125 156 149 93 67 >7.0 1062349 154 91 41 21 2.0 1062382 72 57 20 10 0.5 1062446 120 106 100 48 >7.0 1062542 94 98 79 28 4.3 1062670 115 68 42 45 2.5 1062991 108 41 40 18 1.0 1063055 98 83 57 39 3.3 1063310 116 100 51 25 2.4 1063437 188 147 88 85 >7.0 1063757 121 114 62 74 >7.0 1063917 109 87 30 20 1.4 1063948 111 97 36 11 1.5 1063981 122 57 22 4 0.9 1064012 184 159 122 82 >7.0 1064111 115 140 86 52 >7.0 1064303 114 98 74 48 >7.0

TABLE 58 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144 114 70 22 9 1.0 1062094 36 71 65 50 <0.1 1062383 76 71 54 23 1.4 1062384 57 45 23 9 0.2 1062447 85 96 62 35 3.8 1062448 99 91 33 15 1.4 1062543 64 57 23 9 0.4 1062737 93 56 24 11 0.7 1062802 92 48 21 8 0.6 1062832 79 84 43 11 1.1 1062833 93 75 30 12 1.0 1063058 82 35 25 5 0.4 1063247 70 55 40 11 0.6 1063248 59 39 26 5 0.2 1063822 78 77 80 57 >7.0 1063982 90 81 37 16 1.2 1064047 112 86 51 20 1.9 1064113 57 74 31 15 0.5 1064145 100 73 43 13 1.2

TABLE 59 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM) 911144 76 69 34 14 0.8 1062035 91 57 32 18 0.9 1062067 71 36 15 9 0.3 1062100 120 132 106 69 >7.0 1062132 109 68 83 68 >7.0 1062580 96 35 9 0 0.5 1062644 140 77 35 5 1.4 1062741 109 71 35 11 1.2 1062837 128 65 41 14 1.4 1062933 109 75 46 26 1.8 1063348 97 86 41 15 1.4 1063410 86 88 58 49 6.3 1063699 89 66 44 15 1.0 1063731 70 27 8 3 0.2 1063732 75 45 29 7 0.4 1063794 88 116 122 93 >7.0 1063954 90 64 19 4 0.7 1064019 74 73 45 31 1.4 1064148 102 54 31 15 0.9

TABLE 60 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM)  911144 88 71 29 11 0.9 1062078 123 118 110 88 >7.0 1062334 93 68 40 12 1.0 1062365 60 26 9 2 0.1 1062366 98 60 22 6 0.7 1062397 70 46 25 9 0.4 1062783 83 72 34 13 0.9 1063038 77 34 17 5 0.3 1063039 96 76 55 35 2.6 1063326 114 89 48 21 1.9 1063646 93 75 59 39 3.2 1063774 87 86 61 37 3.6 1063804 79 58 37 15 0.7 1063901 125 92 81 55 >7.0 1063964 83 92 49 21 1.8 1064060 117 85 55 35 2.8 1064120 85 85 58 46 5.0 1064184 96 72 33 19 1.1 1064191 85 79 52 20 1.5

TABLE 61 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM)  911144 100 62 25 5 0.8 1062017 96 82 48 27 1.9 1062305 67 57 36 16 0.5 1062369 92 52 29 10 0.7 1062529 33 14 13 9 <0.1 1062561 98 85 71 37 4.4 1062562 139 94 45 22 2.1 1062722 90 60 29 8 0.7 1062723 104 103 48 16 1.9 1062754 88 78 77 38 5.5 1063074 83 74 60 22 1.8 1063329 77 31 12 4 0.3 1063330 60 37 15 4 0.2 1063553 75 64 39 19 0.8 1063650 119 40 10 2 0.7 1063745 73 46 14 3 0.4 1063905 109 89 31 6 1.2 1064064 75 79 35 21 1.0 1064096 65 35 9 3 0.2

TABLE 62 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM)  911144 108 91 31 12 1.3 1062021 60 47 29 12 0.3 1062086 64 40 20 11 0.2 1062310 84 54 24 11 0.6 1062373 52 37 4 2 0.1 1062407 93 52 25 13 0.7 1062437 89 64 48 18 1.2 1062470 93 78 37 2 1.0 1062566 86 58 22 7 0.6 1062823 114 98 76 35 4.6 1063207 83 77 32 6 0.9 1063237 32 22 18 11 <0.1 1063238 33 25 16 9 <0.1 1063333 71 44 23 10 0.4 1063429 78 63 48 28 1.2 1063653 79 36 15 4 0.3 1063654 88 61 60 12 1.2 1063655 99 60 29 8 0.8 1063910 93 57 18 6 0.6

TABLE 63 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM)  911144 100 80 29 7 1.0 1062377 95 101 51 23 2.2 1062378 65 45 24 6 0.3 1062410 117 80 50 53 4.1 1062441 90 71 60 48 5.2 1062570 79 50 26 9 0.5 1062633 104 77 67 42 4.2 1062699 106 70 37 19 1.3 1062890 81 64 47 30 1.4 1062891 68 35 15 6 0.2 1063082 83 101 73 63 >7.0 1063146 89 77 50 52 4.7 1063178 79 71 43 15 1.0 1063529 98 90 76 50 >7.0 1063658 96 61 30 12 0.9 1063721 74 77 53 28 1.7 1063946 91 37 10 3 0.4 1064008 84 68 34 18 0.9 1064203 97 85 37 21 1.5

TABLE 64 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM)  911144 94 53 24 5 0.7 1062028 34 26 3 1 <0.1 1062029 46 26 3 0 <0.1 1062347 95 137 107 82 >7.0 1062348 66 51 35 13 0.4 1062379 88 56 23 6 0.6 1062413 74 24 19 4 0.2 1062667 76 65 24 8 0.6 1062668 93 29 11 3 0.4 1062669 81 45 14 3 0.4 1062700 69 50 32 12 0.5 1062861 76 77 44 31 1.6 1062894 94 57 31 11 0.8 1062989 82 44 11 3 0.4 1063054 106 90 55 15 1.8 1063818 110 112 99 109 >7.0 1063915 94 73 33 10 1.0 1063947 66 36 5 3 0.2 1063980 71 35 9 1 0.3

TABLE 65 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 109.375 437.5 1750.0 7000.0 IC₅₀ No. nM nM nM nM (μM)  911144 98 58 12 22 0.8 1062034 75 56 20 8 0.5 1062322 107 73 29 13 1.1 1062385 93 56 18 5 0.6 1062386 74 51 22 14 0.5 1062481 56 67 42 27 0.7 1062545 99 90 49 14 1.6 1062641 96 59 27 7 0.8 1062739 92 59 28 7 0.7 1062771 73 57 27 6 0.5 1062803 92 59 33 16 0.9 1062834 117 55 14 7 0.8 1062835 80 53 18 12 0.5 1063314 141 56 18 5 1.0 1063538 38 29 15 5 <0.1 1063921 77 41 19 5 0.4 1063984 78 35 21 5 0.3 1064017 96 61 31 12 0.9 1064147 99 74 38 11 1.1

Example 5: Dose-Dependent Inhibition of Human Foxp3 in SUP-M2 Cells by cEt Gapmers

Modified oligonucleotides described in the studies above were tested at various doses in SUP-M2 cells. Cultured SUP-M2 cells at a density of 60,000 cells per well were treated using free uptake with modified oligonucleotides diluted to concentrations of 6,000 nM, 1,500 nM, 375.0 nM and 93.75 nM for 24 hours. After 24 hours, Foxp3 mRNA levels were measured as previously described using the Human Foxp3 primer-probe set RTS35925. Foxp3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to untreated control cells (% UTC). IC50s were calculated using a linear regression on a log/linear plot of the data in excel. The modified oligonucleotides with percent control values marked with an asterisk (*) target the amplicon region of the primer probe set. Additional assays may be used to measure the potency and efficacy of the modified oligonucleotides targeting the amplicon region.

TABLE 66 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 93.75 375.0 1500.0 6000.0 IC₅₀ No. nM nM nM nM (μM)  911144 69 81 61 30 2.1 1154721 149 89 49 18 1.7 1154747 198 140 106 39 5.1 1154751 170 107 60 32 2.7 1154754 77 91 81 46 >6.0 1154765 151 98 88 33 3.8 1154853 205 149 57 23 2.7 1154861 81 86 69 40 5.0 1154865 143 77 44 13 1.4 1154891 197 188 111 32 5.5 1154931 150 118 52 24 2.3 1154981 106 122 113 37 >6.0 1154991 218 154 63 37 3.3 1155047 90 72 28 13 0.8 1155057 273 110 75 29 2.8 1155099 73 57 22 6 0.4 1155107 47 41 20 8 <0.1 1155119 198 182 87 45 5.3 1155125 91 130 56 29 3.1

TABLE 67 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 93.75 375.0 1500.0 6000.0 IC₅₀ No. nM nM nM nM (μM)  911144 66 54 35 25 0.5 1154778 139 130 68 40 4.1 1154803 61 52 23 13 0.3 1154821 98 83 79 20 2.4 1154833 115 100 101 72 >6.0 1154858 55 62 64 30 1.3 1154875 75 83 41 19 1.0 1154893 30 39 23 5 <0.1 1154898 123 98 54 19 1.9 1154924 53 89 49 31 1.5 1154928 162 72 44 22 1.6 1154929 96 78 33 9 0.9 1154930 84 99 28 12 1.0 1155031 95 82 77 44 >6.0 1155032 44 52 19 11 0.1 1155048 65 51 24 5 0.3 1155108 100 60 24 9 0.7 1155109 95 86 39 12 1.1 1155121 129 143 125 34 >6.0

TABLE 68 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in SUP-M2 cells % UTC ION 93.75 375.0 1500.0 6000.0 IC₅₀ No. nM nM nM nM (μM)  911144 74 71 56 31 1.6 1154722 77 83 81 67 >6.0 1154756 92 77 61 28 2.0 1154758 109 95 69 49 6.0 1154860 135 102 88 41 5.1 1154864 114 81 60 35 2.5 1154878 131 132 145 95 >6.0 1154884 119 81 37 15 1.2 1154896 107 90 59 27 2.1 1154956 110 85 39 20 1.4 1154962 98 90 50 5 1.2 1155022 79 92 64 61 >6.0 1155052 92 69 36 17 0.9 1155058 112 125 110 57 >6.0 1155070 71 63 53 23 0.9 1155100 125 65 32 8 1.0 1155104 149 92 60 29 2.4 1155106 108 99 64 31 2.8 1155118 85 80 42 27 1.3

Example 6: Dose-Dependent Inhibition of Human Foxp3 in CD4 T-Cells by cEt Gapmers

Modified oligonucleotides described in the studies above were tested at various doses in primary PBMC-derived CD4 T-cells. Total human CD4 T-cells were purified from human peripheral blood leukapheresis sample (Leukopak, Stemcell Technologies) using Easysep human CD4 T-cell isolation kit (Stemcell Technologies). Purified human CD4 cells were cultured in Immunocult-XT T-cell expansion media (Stemcell Technologies) supplemented with 30 ng/mL of human recombinant IL-2 (Stemcell Technologies). Cultured CD4 T-cells at a density of 50,000 cells per well were treated using free uptake with modified oligonucleotides diluted to concentrations specified in the tables below. After a 48 hour incubation, Foxp3 mRNA levels were measured as previously described using the Human Foxp3 primer-probe set RTS35925. Foxp3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to untreated control cells (% UTC).

TABLE 69 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in CD4 T-cells % UTC ION 109.4 437.5 1750.0 7000.0 No. nM nM nM nM  141923 128 104 85 89  911144 88 63 61 56 1062008 63 94 104 107 1062010 107 93 96 80 1062086 128 111 120 120 1062413 62 63 58 59 1062425 70 47 54 39 1062428 77 72 71 63 1062529 111 125 125 125 1062760 94 111 109 134 1062891 108 104 101 84 1062938 81 62 59 46 1063101 117 81 89 85 1063237 98 121 121 106 1063238 122 118 149 120 1063268 71 51 46 40 1063619 103 109 127 127 1063963 84 80 83 81 1063976 89 84 79 50 1064313 80 79 64 52

TABLE 70 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in CD4 T-cells % UTC 109.4 437.5 1750.0 7000.0 ION No. nM nM nM nM  141923 109 114 84 71  911144 80 59 62 51 1062247 79 84 109 86 1062397 100 87 89 93 1062580 103 103 98 101 1062668 73 38 52 41 1062669 83 75 92 82 1062835 111 100 82 85 1062937 75 76 57 46 1063032 84 88 100 76 1063038 100 93 107 111 1063058 90 93 96 103 1063320 96 108 97 124 1063649 82 87 74 60 1063734 58 48 43 32 1063735 95 86 81 89 1063744 102 90 94 108 1063921 95 73 87 91 1063946 79 62 86 56 1064096 74 73 59 62

TABLE 71 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in CD4 T-cells % UTC 109.4 437.5 1750.0 7000.0 ION No. nM nM nM nM  141923 113 101 111 110  582468 106 115 83 107  911144 68 78 51 67  911179 115 72 79 71 1062007 107 103 113 106 1062044 102 142 98 130 1062375 121 102 94 102 1062641 90 88 66 103 1062712 84 126 55 142 1062802 99 122 110 98 1062834 101 108 111 97 1062840 112 107 129 142 1062857 124 162 114 169 1063035 137 141 137 78 1063037 78 109 101 114 1063097 175 122 122 109 1063650 95 175 99 160 1063655 65 71 59 46 1063895 33 10 7 5 1063910 93 116 105 93

Example 7: Dose-Dependent Inhibition of Human Foxp3 in Regulatory T-Cells (T-Reg) by cEt Gapmers

Modified oligonucleotides described in the studies above were tested at various doses in in vitro differentiated regulatory T-cells. T-regs were differentiated for 2 weeks from naïve human CD4 cells (purified from frozen PBMCs (Stemcell technologies) using EasySep human naïve CD4 T-cell isolation kit (Stemcell technologies)) in Immunocult-XT T-cell expansion media (Stemcell Technologies) supplemented with ImmunoCult Human Treg Differentiation Supplement and ImmunoCult Human CD3/CD28 T-cell Activator (Stemcell Technologies). Cultured T-reg cells at a density of 20,000 cells per well were treated using free uptake with modified oligonucleotides diluted to concentrations specified in the tables below. After a 48 hour incubation, Foxp3 mRNA levels were measured as previously described using the Human Foxp3 primer-probe set RTS35925. Foxp3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to untreated control cells (% UTC).

TABLE 72 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in T-reg cells % UTC 370.4 1111.1 3333.3 10000.0 ION No. nM nM nM nM 1062010 99 107 98 118 1062835 89 92 102 87 1062247 97 110 120 113 1062840 94 84 83 83 1062413 94 85 74 75 1062857 103 97 94 98 1062428 108 111 105 100 1062891 90 87 72 61 1062641 107 116 114 110 1062937 88 69 63 59 1063101 112 107 106 87 1062669 94 95 86 72 1062938 93 80 65 50  911179 98 95 76 57 1062712 113 95 104 107 1063035 99 96 103 86 1062802 106 105 106 99 1063037 104 90 91 67

TABLE 73 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in T-reg cells % UTC 370.4 1111.1 3333.3 10000.0 ION No. nM nM nM nM 1063238 102 99 99 94 1063734 75 64 54 35 1063248 92 113 100 107 1064096 85 81 74 72 1063268 97 100 105 88 1064313 97 92 92 81 1063320 113 119 125 129 1063619 108 111 120 115  911179 97 77 65 54 1063649 96 98 109 96  911144 104 104 89 61 1063650 96 89 82 61 1063655 95 91 87 80

TABLE 74 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in T-reg cells % UTC 370.4 1111.1 3333.3 10000.0 ION No. nM nM nM nM 1062010 93 111 103 115 1062835 90 100 102 81 1062247 86 90 99 96 1062840 97 84 86 75 1062413 73 77 61 58 1062857 118 94 81 87 1062428 74 86 77 83 1062891 79 67 70 47 1062641 77 84 91 71 1062937 66 66 58 41 1063101 97 80 74 59 1062669 64 66 62 56 1062938 58 48 41 32  911179 88 66 62 47 1062712 66 64 68 64 1063035 59 60 61 46 1062802 55 65 75 71 1063037 58 58 47 41

TABLE 75 Dose-dependent inhibition of human Foxp3 mRNA expression by free uptake of modified oligonucleotides in T-reg cells % UTC ION 370.4 1111.1 3333.3 10000.0 No. nM nM nM nM 1063238 111 108 81 70 1063734 90 80 56 40 1063248 97 105 102 102 1064096 85 88 75 69 1063268 94 92 94 87 1064313 95 89 71 61 1063320 79 80 82 88 1063619 86 91 84 92 911179 59 56 54 40 1063649 65 69 64 69 911144 81 66 58 47 1063650 56 50 47 34 1063655 70 67 61 57

Example 8: Tolerability of Modified Oligonucleotides Targeting Human Foxp3 in Balb/c Mice

Balb/c mice were treated with modified oligonucleotides selected from studies described above and evaluated for changes in the levels of various plasma chemistry markers.

Treatment

Groups of female Balb/c mice (obtained from Charles River) were injected subcutaneously twice a week for three weeks (for a total of 7 treatments) with 50 mg/kg of modified oligonucleotides. One group of female Balb/c mice was injected with PBS. Mice were euthanized on day 21 post start of treatment (24 hours following the final administration).

Plasma Chemistry Markers

To evaluate the effect of modified oligonucleotides on liver function, plasma levels of blood urea nitrogen (BUN), albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and albumin (ALB) were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, N.Y.). The results are presented in the Table below. Modified oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 76 Plasma chemistry markers in female Balb/c mice Plasma clinical chemistry ION ALB ALT AST TBIL BUN No. (g/dL) (U/L) (U/L) (mg/dL) (mg/dL) PBS 2.6 86 108 0.3 19 549148 2.8 30 48 0.2 20 910956 2.7 992 1040 0.2 15 910959 3.2 1311 869 1.3 15 911019 3.6 1118 893 0.3 19 911101 2.8 1709 1506 0.7 13 911118 2.8 968 524 4.9 15 911144 2.7 1138 843 0.3 22 L0911171 3.1 1144 1120 0.6 21 911179 2.9 453 353 0.2 20 911180 2.5 170 143 0.2 16

Body and Organ Weights

Body weights of Balb/c mice were measured on day 22, and the average body weight for each group is presented in the table below. Kidney, spleen, and liver weights were measured at the end of the study and are presented in the table below. Modified oligonucleotides that caused any changes in organ weights outside the expected range for modified oligonucleotides were excluded from further studies.

TABLE 77 Body and organ weights (in grams) body ION weight Liver Kidney Spleen No. (g) (g) (g) (g) PBS 22 1.08 0.28 0.12 549148 21 1.16 0.29 0.12 910956 21 1.36 0.27 0.12 910959 22 1.38 0.35 0.12 911019 23 1.61 0.32 0.12 911101 18 1.48 0.26 0.13 911118 16 1.01 0.25 0.09 911144 22 1.49 0.26 0.15 911171 19 1.30 0.28 0.17 911179 20 1.26 0.25 0.14 911180 21 1.22 0.26 0.14

Example 9: Tolerability of Modified Oligonucleotides Targeting Human Foxp3 in CD-1 Mice

CD-1 mice were treated with modified oligonucleotides selected from studies described above and evaluated for changes in the levels of various plasma chemistry markers.

Treatment

Groups of male CD-1 mice (obtained from Charles River) were injected subcutaneously once a week for six weeks (for a total of 7 treatments) with 50 mg/kg of modified oligonucleotides. One group of male CD-1 mice was injected with PBS. Mice were euthanized on day 39 post start of treatment (24 hours following the final administration).

Plasma Chemistry Markers

To evaluate the effect of modified oligonucleotides on liver function, plasma levels of blood urea nitrogen (BUN), albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and albumin (ALB) were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, N.Y.). The results are presented in the table below. Modified oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 78 Plasma chemistry markers in male CD-1 mice Plasma clinical chemistry ION ALB ALT AST TBIL BUN No. (g/dL) (U/L) (U/L) (mg/dL) (mg/dL) PBS 2.8 27 48 0.2 19 1062008 2.2 836 1125 9.1 24 1062010 2.2 105 139 0.2 18 1062385 2.4 3206 3112 0.7 20 1062425 2.5 612 490 7.1 19 1062545 2.3 74 70 0.2 21 1062641 2.3 86 95 0.1 21 1062838 2.4 178 232 0.3 18 1062903 2.5 220 408 0.3 18 1062907 3.2 2055 1321 2.4 21 1062937 2.6 100 97 0.2 22 1063038 2.8 480 279 0.2 19 1063158 2.6 37 56 0.2 21 1063414 3.0 2316 1649 0.3 21 1063734 2.7 63 76 0.2 18 1063984 3.0 1382 767 6.3 26 1064060 3.4 3034 1927 0.8 21 1064313 2.3 107 109 0.2 17

Body and Organ Weights

Body weights of CD-1 mice were measured on the day the mice were sacrificed, and the average body weight for each group is presented in the Table below. Kidney, spleen, and liver weights were measured at the end of the study and are presented in the Table below. Modified oligonucleotides that caused any changes in organ weights outside the expected range for modified oligonucleotides were excluded from further studies.

TABLE 79 Body and organ weights (in grams) body ION weight Liver Kidney Spleen No. (g) (g) (g) (g) PBS 38 1.88 0.58 0.12 1062008 34 2.65 0.49 0.84 1062010 40 2.21 0.57 0.18 1062385 37 2.65 0.60 0.19 1062425 33 3.13 0.46 0.18 1062545 36 2.09 0.56 0.12 1062641 40 2.31 0.54 0.20 1062838 39 2.04 0.53 0.14 1062903 33 2.04 0.55 0.16 1062907 37 3.85 0.54 0.19 1062937 38 2.23 0.63 0.13 1063038 39 2.56 0.65 0.27 1063158 39 1.96 0.62 0.13 1063414 35 2.75 0.67 0.17 1063734 39 2.05 0.59 0.14 1063984 28 2.09 0.38 0.07 1064060 36 2.64 0.58 0.08 1064313 39 2.04 0.62 0.14

Hematology Assays

Blood obtained from mouse groups at day 40 were sent to IDEXX BioResearch for measurement of blood cell counts. Counts taken include red blood cell (RBC) count, white blood cell (WBC) count, hemoglobin (HGB), hematocrit (HCT), Mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and individual white blood cell counts, such as that of monocytes (MON), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS), basophils (BAS), reticulocytes (RETIC) and platelets (PLT). The results are presented in the tables below. N.D refers to samples where data is not available. Ionis oligonucleotides that caused changes in the blood cell count outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 80 Blood Cell Count in CD-1 mice ION RBC Retic HCT HGB MCV MCH MCHC No. (M/uL) (K/uL) (%) (g/dL) (fL) (pg) (g/dL) PBS 8 312 40 13 47 16 33 1062008 5 1308 36 9 72 18 26 1062010 10 310 43 15 45 15 34 1062385 8 339 37 12 45 15 32 1062425 8 272 36 11 47 15 32 1062545 9 267 41 14 45 15 33 1062641 8 332 38 13 45 15 33 1062838 8 299 40 12 48 15 31 1062903 8 431 39 12 50 16 32 1062907 9 410 42 13 46 14 31 1062937 11 346 52 17 47 15 33 1063038 8 279 40 12 50 15 30 1063158 11 376 50 16 47 15 31 1063414 8 154 36 11 48 15 31 1063734 10 328 48 14 47 14 30 1063984 8 381 38 11 50 15 31 1064060 8 303 35 11 45 14 31 1064313 10 350 49 15 47 15 31

TABLE 81 Blood Cell Count in CD-1 mice ION WBC LYM MON NEU EOS PLT No. (K/uL) (/uL) (/uL) (/uL) (/uL) (K/uL) PBS 4 2817 63 597 124 988 1062008 40 30502 1399 7366 379 208 1062010 6 3961 449 1159 181 775 1062385 21 12537 957 6621 572 1118 1062425 11 6560 1030 2608 692 963 1062545 4 3226 204 721 175 1182 1062641 3 2506 307 475 109 779 1062838 7 3961 539 1793 275 896 1062903 19 14165 1005 3595 451 595 1062907 8 5351 909 1635 193 885 1062937 4 2287 414 769 118 958 1063038 8 5063 1512 936 103 943 1063158 3 2145 210 707 108 1141 1063414 13 7724 1404 3786 270 1924 1063734 5 3822 795 644 92 1044 1063984 12 6263 1057 4238 232 1169 1064060 7 4110 1044 1459 94 1093 1064313 5 3475 515 1026 96 936

Example 10: Tolerability of Modified Oligonucleotides Targeting Human Foxp3 in CD-1 Mice

CD-1 mice were treated with modified oligonucleotides selected from studies described above and evaluated for changes in the levels of various plasma chemistry markers.

Treatment

Groups of male CD-1 mice (obtained from Charles River) were injected subcutaneously once a week for six weeks (for a total of 7 treatments) with 50 mg/kg of modified oligonucleotides. One group of male CD-1 mice was injected with PBS. Mice were euthanized on day 40 post start of treatment (24 hours following the final administration). In addition, 6 additional groups of mice (treated with ION Nos. 1062413, 1062669, 1062712, 1062835, 1063655, and 1063946) were treated subcutaneously once a week for 5 weeks (a total of 6 treatments) with 50 mg/kg of modified oligonucleotides. Mice were euthanized on day 33 post start of treatment (24 hrs post following the final administration).

Plasma Chemistry Markers

To evaluate the effect of modified oligonucleotides on liver function, plasma levels of blood urea nitrogen (BUN), albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and albumin (ALB) were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, N.Y.). The results are presented in the Table below. Modified oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 82 Plasma chemistry markers in male CD-1 mice Plasma clinical chemistry ION ALB ALT AST TBIL BUN No. (g/dL) (U/L) (U/L) (mg/dL) (mg/dL) PBS 2.8 23 42 0.2 28 1062007 2.1 1051 1244 1.1 31 1062413 2.5 95 68 0.2 27 1062580 2.4 220 154 0.2 23 1062669 2.4 61 82 0.1 21 1062712 2.3 101 107 0.2 20 1062724 2.6 999 694 0.2 25 1062802 2.7 153 101 0.2 23 1062835 2.3 120 104 0.1 24 1062857 2.6 66 73 0.2 24 1062891 2.5 64 81 0.1 25 1063032 2.5 452 282 0.2 25 1063238 2.7 71 74 0.2 26 1063248 2.1 103 171 0.1 25 1063650 2.8 59 76 0.2 25 1063655 2.3 52 93 0.1 20 1063744 2.4 308 212 0.2 22 1063910 2.5 371 296 0.1 24 1063946 3.0 1136 696 0.5 24 1063981 3.3 767 909 3.0 27

Body and Organ Weights

Body weights of CD-1 mice were measured on the day the mice were sacrificed, and the average body weight for each group is presented in the Table below. Kidney, spleen, and liver weights were measured at the end of the study and are presented in the Table below. Modified oligonucleotides that caused any changes in organ weights outside the expected range for modified oligonucleotides were excluded from further studies.

TABLE 83 Body and organ weights (in grams) body ION weight Liver Kidney Spleen No. (g) (g) (g) (g) PBS 40 2.08 0.61 0.11 1062007 34 2.76 0.52 0.65 1062413 38 2.20 0.55 0.11 1062580 38 2.47 0.58 0.18 1062669 39 2.47 0.54 0.15 1062712 35 2.01 0.61 0.17 1062724 34 2.92 0.54 0.22 1062802 37 1.97 0.58 0.12 1062835 36 2.27 0.59 0.16 1062857 41 2.42 0.66 0.13 1062891 40 2.36 0.65 0.19 1063032 39 2.87 0.80 0.23 1063238 39 2.44 0.61 0.11 1063248 39 2.42 0.54 0.16 1063650 37 2.28 0.58 0.12 1063655 38 1.96 0.59 0.15 1063744 44 2.73 0.78 0.20 1063910 49 3.64 0.66 0.19 1063946 37 2.88 0.64 0.21 1063981 35 4.08 0.49 0.14

Hematology Assays

Blood obtained from mouse groups at day 40 were sent to IDEXX BioResearch for measurement of blood cell counts. Counts taken include red blood cell (RBC) count, white blood cell (WBC) count, hemoglobin (HGB), hematocrit (HCT), Mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and individual white blood cell counts, such as that of monocytes (MON), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS), basophils (BAS), reticulocytes (RETIC) and platelets (PLT). The results are presented in the tables below. Ionis oligonucleotides that caused changes in the blood cell count outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 84 Blood Cell Count in CD-1 mice ION RBC Retic HCT HGB MCV MCH MCHC No. (M/uL) (K/uL) (%) (g/dL) (fL) (pg) (g/dL) PBS 700 4 262 8 12 3395 37 1062007 29943 65 1018 4 8 19758 32 1062413 892 6 267 8 12 4416 38 1062580 1585 18 258 8 12 15847 36 1062669 732 6 292 9 13 4748 40 1062712 661 6 287 9 14 4716 42 1062724 3723 21 521 8 12 15787 37 1062802 1088 8 235 7 10 6087 30 1062835 1172 6 302 10 15 4172 44 1062857 730 6 325 10 15 4736 43 1062891 988 7 284 8 13 5892 38 1063032 1678 12 434 10 15 9049 44 1063238 986 7 304 10 15 5537 43 1063248 1246 10 293 9 14 8042 42 1063650 542 6 266 9 13 4770 41 1063655 883 6 337 9 14 4277 41 1063744 1218 9 388 10 16 7135 49 1063910 1171 12 246 8 12 9552 37 1063946 2081 17 369 9 14 12975 41 1063981 3304 20 297 9 14 14916 43

TABLE 85 Blood Cell Count in CD-1 mice ION WBC LYM MON NEU EOS PLT No. (K/uL) (/uL) (/uL) (/uL) (/uL) (K/uL) PBS 210 70 47 15 33 458 1062007 5231 1215 75 20 26 148 1062413 277 235 47 15 33 1215 1062580 584 341 45 15 34 1186 1062669 401 194 47 15 33 1076 1062712 349 195 46 15 34 984 1062724 1454 253 44 14 32 1186 1062802 372 301 46 15 33 1289 1062835 249 158 46 16 34 979 1062857 233 198 45 15 34 1072 1062891 397 196 46 15 33 909 1063032 583 261 46 15 33 837 1063238 241 133 46 15 34 963 1063248 725 247 47 16 33 728 1063650 222 213 46 15 33 950 1063655 228 159 46 16 34 892 1063744 468 261 49 16 33 708 1063910 857 259 47 15 32 847 1063946 918 520 44 15 34 797 1063981 1230 362 48 15 32 899

Example 11: Tolerability of Modified Oligonucleotides Targeting Human Foxp3 in CD-1 Mice

CD-1 mice were treated with modified oligonucleotides selected from studies described above and evaluated for changes in the levels of various plasma chemistry markers.

Treatment

Groups of male CD-1 mice (obtained from Charles River) were injected subcutaneously once a week for six weeks (for a total of 7 treatments) with 50 mg/kg of modified oligonucleotides. One group of male CD-1 mice was injected with PBS. Mice were euthanized on day 41 post start of treatment (24 hours following the final administration). In addition, 4 additional groups of mice (treated with ION Nos. 1062247, 1063619, 1063653, and 1064096) were treated subcutaneously once a week for 5 weeks (a total of 6 treatments) with 50 mg/kg of modified oligonucleotides. Mice were euthanized on day 38 post start of treatment (5 days following the final administration).

Plasma Chemistry Markers

To evaluate the effect of modified oligonucleotides on liver function, plasma levels of blood urea nitrogen (BUN), albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and albumin (ALB) were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, N.Y.). The results are presented in the table below. Modified oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 86 Plasma chemistry markers in male CD-1 mice Plasma clinical chemistry ION ALB ALT AST TBIL BUN No. (g/dL) (U/L) (U/L) (mg/dL) (mg/dL) PBS 3.4 27 44 0.18 33 1062034 3.7 623 401 0.19 28 1062044 3.7 2279 1471 3.13 33 1062086 3.6 271 167 0.22 26 1062247 3.0 123 150 0.28 22 1062397 2.9 1455 1777 3.11 26 1062428 2.8 132 110 0.26 23 1062529 2.7 991 612 0.17 25 1062668 2.6 537 448 0.17 21 1062760 2.6 1086 603 0.24 20 1062840 2.6 38 52 0.17 25 1063035 2.3 97 110 0.14 23 1063037 2.5 99 89 0.15 21 1063058 2.4 1173 1307 0.24 26 1063097 3.0 1239 1219 0.99 27 1063101 2.7 48 62 0.21 25 1063237 3.1 1108 736 0.27 21 1063268 3.0 60 76 0.21 26 1063320 3.4 69 72 0.25 23 1063619 3.1 99 126 0.26 26 1063649 3.0 67 85 0.18 20 1063653 3.7 3499 2440 1.11 31 1063735 2.7 1440 1224 0.36 22 1063895 3.1 1533 1261 0.63 24 1063921 1.3 674 1603 2.70 29 1063963 3.1 2918 2985 0.98 24 1064096 3.0 31 103 0.22 23

Body and Organ Weights

Body weights of CD-1 mice were measured on the day the mice were sacrificed, and the average body weight for each group is presented in the table below. Kidney, spleen, and liver weights were measured at the end of the study and are presented in the table below. Modified oligonucleotides that caused any changes in organ weights outside the expected range for modified oligonucleotides were excluded from further studies.

TABLE 87 Body and organ weights (in grams) body ION weight Liver Kidney Spleen No. (g) (g) (g) (g) PBS 37 1.97 0.58 0.10 1062034 41 2.64 0.66 0.16 1062044 35 3.50 0.54 0.15 1062086 37 2.52 0.53 0.15 1062247 37 2.13 0.57 0.14 1062397 36 2.52 0.54 0.13 1062428 36 2.31 0.51 0.14 1062529 41 3.63 0.73 0.27 1062668 35 2.37 0.56 0.17 1062760 37 2.58 0.58 0.15 1062840 41 2.43 0.68 0.20 1063035 42 2.52 0.61 0.18 1063037 43 2.76 0.63 0.21 1063058 36 2.75 0.57 0.20 1063097 35 2.67 0.52 0.19 1063101 42 2.42 0.67 0.16 1063237 38 2.74 0.51 0.15 1063268 40 2.19 0.51 0.12 1063320 42 2.64 0.62 0.18 1063619 37 36.75 2.10 0.56 1063649 37 2.18 0.55 0.17 1063653 35 3.54 0.57 0.13 1063735 41 2.39 0.56 0.18 1063895 40 3.29 0.66 0.20 1063921 35 1.19 0.35 0.06 1063963 30 3.14 0.46 0.09 1064096 41 2.14 0.58 0.18

Hematology Assays

Blood obtained from mouse groups at day 40 were sent to IDEXX BioResearch for measurement of blood cell counts. Counts taken include red blood cell (RBC) count, white blood cell (WBC) count, hemoglobin (HGB), hematocrit (HCT), Mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and individual white blood cell counts, such as that of monocytes (MON), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS), basophils (BAS), reticulocytes (RETIC) and platelets (PLT). The results are presented in the tables below. N/A below refers to samples where data is not available due to insufficient blood volume. Ionis oligonucleotides that caused changes in the blood cell count outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 88 Blood Cell Count in CD-1 mice ION RBC Retic HCT HGB MCV MCH MCHC No. (M/uL) (K/uL) (%) (g/dL) (fL) (pg) (g/dL) PBS 9 306 40 14 45 15 33 1062034 8 230 35 11 44 14 33 1062044 9 303 40 13 46 15 33 1062086 8 223 34 11 45 15 33 1062247 9 334 41 14 48 16 33 1062397 7 280 31 10 46 15 33 1062428 10 319 43 14 45 15 33 1062529 9 246 39 13 42 15 34 1062668 9 331 42 14 44 15 33 1062760 9 266 41 14 45 15 34 1062840 9 274 41 13 46 15 33 1063035 9 232 39 13 46 15 33 1063037 7 260 33 11 48 15 32 1063058 9 313 41 13 47 15 33 1063097 10 329 48 15 48 15 32 1063101 10 273 49 15 50 15 31 1063237 9 213 39 13 44 15 33 1063268 11 297 51 16 48 15 31 1063320 10 271 46 15 46 15 32 1063619 8 269 39 13 47 15 33 1063649 10 255 44 14 46 15 32 1063653 8 421 35 11 46 15 32 1063735 9 325 44 14 47 15 32 1063895 10 314 44 14 45 14 33 1063921 N/A N/A N/A N/A N/A N/A N/A 1063963 9 394 44 14 48 15 32 1064096 8 316 37 12 46 15 33

TABLE 89 Blood Cell Count in CD-1 mice ION WBC LYM MON NEU EOS PLT No. (K/uL) (/uL) (/uL) (/uL) (/uL) (K/uL) PBS 6 4358 234 1097 133 1251 1062034 12 9581 718 1333 384 951 1062044 23 11726 1569 2757 521 1370 1062086 9 7082 743 1371 201 1066 1062247 6 4230 517 1447 75 971 1062397 21 15205 1188 4188 236 547 1062428 9 6947 526 875 222 1002 1062529 6 3214 461 2504 103 887 1062668 14 10018 1248 2217 378 1048 1062760 7 4690 517 1352 200 851 1062840 5 4274 506 594 102 772 1063035 11 8936 533 1402 294 1097 1063037 5 3493 69 1467 13 461 1063058 22 16671 1649 3215 324 942 1063097 15 10425 2326 1692 314 880 1063101 6 4212 503 953 124 990 1063237 5 3996 536 760 172 1242 1063268 5 4341 365 616 86 1082 1063320 7 5701 367 700 124 1129 1063619 6 4783 622 832 185 1198 1063649 7 5429 430 902 161 1116 1063653 18 9995 2571 4439 1228 1465 1063735 6 4547 630 1016 70 819 1063895 11 7987 965 1877 113 1223 1063921 N/A N/A N/A N/A N/A N/A 1063963 25 15990 2336 5937 940 1443 1064096 10 8031 661 858 195 986

Example 12: Tolerability of Modified Oligonucleotides Targeting Human Foxp3 in Sprague-Dawley Rats

Sprague-Dawley rats are a multipurpose model used for safety and efficacy evaluations. The rats were treated with Ionis modified oligonucleotides from the studies described in the Examples above and evaluated for changes in the levels of various plasma chemistry markers.

Treatment

Male Sprague-Dawley rats were maintained on a 12-hour light/dark cycle and fed ad libitum with Purina normal rat chow. Groups of 4 Sprague-Dawley rats each were weekly injected subcutaneously with 50 mg/kg of Ionis oligonucleotide for 6 weeks (total 7 doses). In addition, a group of 3 Sprague-Dawley rats was injected subcutaneously with saline for the same time period. Forty-eight hours after the last dose, the rats were euthanized; and organs, urine and plasma were harvested for further analysis.

Plasma Chemistry Markers

To evaluate the effect of Ionis oligonucleotides on hepatic function, plasma levels of transaminases were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, N.Y.). Plasma levels of ALT (alanine transaminase) and AST (aspartate transaminase) were measured and the results are presented in the Table below expressed in IU/L. Plasma levels of total bilirubin (TBIL), albumin (ALB), and blood urea nitrogen (BUN) were also measured using the same clinical chemistry analyzer and the results are also presented in the Table below. Ionis modified oligonucleotides that caused changes in the levels of any markers of liver function outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 90 Plasma chemistry markers in Sprague-Dawley rats ION ALB ALT AST TBIL BUN NO. (g/dL) (IU/L) (IU/L) (mg/dL) (mg/dL) Saline 3.7 66 105 0.15 18 1062428 4.2 146 149 0.23 26 1062641 3.2 75 155 0.12 20 1062835 1.9 45 70 0.12 64 1062937 3.1 129 164 0.16 23 1063268 3.5 79 121 0.13 20 1063649 3.6 141 207 0.20 20 1063655 3.2 89 170 0.17 24 1063734 3.4 62 121 0.15 20 1064096 3.1 74 163 0.17 28 1064313 2.8 117 186 0.16 27

Hematology Assays

Blood obtained from mouse groups at week 6 were sent to IDEXX BioResearch for measurement of blood cell counts. Counts taken include red blood cell (RBC) count, white blood cell (WBC) count, hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and individual white blood cell counts, such as that of monocytes (MON), neutrophils (NEU), lymphocytes (LYM), eosinophils (EOS), reticulocytes (RETIC) and platelets (PLT). The results are presented in the tables below. Ionis oligonucleotides that caused changes in the blood cell count outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 91 Blood Cell Count in Sprague-Dawley Rats ION RBC WBC HGB HCT MCV MCH MCHC No. (M/uL) (K/uL) (g/dL) (%) (fL) (pg) (g/dL) Saline 8 14 15 47 57 19 33 1062428 7 20 14 42 61 20 32 1062641 7 22 14 41 57 19 33 1062835 9 15 16 47 54 18 33 1062937 8 17 13 41 53 17 33 1063268 7 15 13 39 55 18 32 1063649 7 12 13 41 54 18 33 1063655 8 12 14 43 55 18 33 1063734 8 18 15 45 55 18 33 1064096 7 21 13 40 56 18 33 1064313 8 15 14 42 54 18 33

TABLE 92 Blood Cell Count in Sprague-Dawley Rats ION MON NEU LYM EOS RETIC PLT No. (/uL) (/uL) (/uL) (/uL) (K/uL) (K/uL) Saline 670 1296 11523 130 328 737 1062428 2742 602 16053 68 373 457 1062641 2344 1951 17379 56 194 567 1062835 1598 2239 10485 200 289 939 1062937 1856 1390 13361 48 244 604 1063268 821 1203 12352 88 132 611 1063649 1013 1048 9398 68 218 663 1063655 1113 1635 9214 115 207 728 1063734 1785 899 15240 42 276 702 1064096 1754 1126 17788 158 259 620 1064313 1268 638 12587 69 231 428

Kidney Function

To evaluate the effect of Ionis oligonucleotides on kidney function, urinary levels of total protein and creatinine were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, N.Y.). The ratios of total protein to creatinine (P/C ratio) are presented in the Table below. Ionis oligonucleotides that caused changes in the levels of the ratio outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 93 Total protein to creatinine ratio in Sprague-Dawley rats URINE ION P/C NO. ratio Saline 1.0 1062428 5.5 1062641 7.4 1062835 11.1 1062937 7.4 1063268 4.4 1063649 3.8 1063655 7.7 1063734 5.4 1064096 5.6 1064313 9.1

Body and Organ Weights

Liver, heart, spleen and kidney weights were measured at the end of the study and are presented in the table below. Terminal body weight was measured prior to necropsy. Ionis oligonucleotides that caused any changes in organ weights outside the expected range for modified oligonucleotides were excluded from further studies.

TABLE 94 Body and Organ weights Body ION Weight Liver Kidney Spleen No. (g) (g) (g) (g) Saline 467 19 3.4 0.9 1062428 348 15 2.6 1.1 1062641 352 18 3.0 2.4 1062835 379 17 3.4 1.4 1062937 360 15 3.3 1.4 1063268 418 18 3.0 1.1 1063649 385 19 3.6 1.7 1063655 398 21 4.0 2.5 1063734 341 17 2.9 1.5 1064096 397 20 4.2 3.7 1064313 381 20 4.4 2.8

Example 13: Effect of Modified Oligonucleotides on Human FOXP3 Expression in a Humanized PBMC Mouse Model

Humanized PBMC mice obtained from Jackson Laboratory (hu-PBMC-NSG). NOD.Cg-Prkdcscid Il2rgtm1Wj1/SzJ mice were engrafted with human PBMCs to generate the hu-PBMC-NSG model. Mice were treated with modified oligonucleotides selected from studies described above and evaluated for changes in the levels of various plasma chemistry markers as well as mRNA.

Treatment

Groups of 4 female hu-PBMC-NSG mice (obtained from Jackson Laboratory) were injected subcutaneously daily (for a total of 4 treatments) with 25 mg/kg of modified oligonucleotides. Mice were treated with modified oligonucleotide in groups of 4. One additional group of 8 female huPBMC mice was injected with PBS. Mice were euthanized on day 4 post start of treatment (24 hours following the final administration).

Plasma Chemistry Markers

To evaluate the effect of modified oligonucleotides on liver function, plasma levels of blood urea nitrogen (BUN), albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and albumin (ALB) were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400c, Melville, N.Y.). The results are presented in the Table below. Modified oligonucleotides that caused changes in the levels of any of the liver or kidney function markers outside the expected range for modified oligonucleotides were excluded in further studies.

TABLE 95 Plasma chemistry markers in female huPBMC mice ION Albumin ALT AST TBIL BUN NO. (g/dL) (U/L) (U/L) (mg/dL) (mg/dL) PBS 3.1 26 73 0.24 22 549148 3.1 36 78 0.19 21 1062413 3.0 58 115 0.20 24 1062428 3.0 80 118 0.22 19 1062641 2.9 68 163 0.27 21 1063268 3.1 40 85 0.45 20 1063649 3.1 29 63 0.23 20 1063734 3.0 131 257 0.23 19 1064096 3.0 31 122 0.19 23

Body Weights

Body weights of hu-PBMC-NSG mice were measured on the day the mice were sacrificed, and the average body weight for each group is presented in the Table below. Modified oligonucleotides that caused any changes in organ weights outside the expected range for modified oligonucleotides were excluded from further studies.

TABLE 96 Body and organ weights (in grams) Body ION Weight NO. (g) PBS 21 549148 21 1062413 22 1062428 21 1062641 22 1063268 23 1063649 22 1063734 22 1064096 20

RNA Analysis

Splenocytes and lymph nodes were extracted for RNA analysis. Splenocytes were isolated from the spleens by mechanical disruption in tissue dissociation tubes (Mitelnyi) on gentleMACS dissociator (Mitelnyi). Primer probe sets RTS35925 described above and RTS35988 (forward sequence, CAAATGGTGTCTGCAAGTGG, designated herein as SEQ ID NO: 3248; reverse sequence, CTCTGGAGGAGACATGTGC, designated herein as SEQ ID NO: 3249; probe sequence, CCTGGCAGTGCITGAGGAAGTCC, designated herein as SEQ ID NO: 3250) were used to measure human Foxp3 RNA levels in separate PCRs. Results are presented as percent change of RNA, relative to PBS control, normalized to either human GAPDH and human CD4. Human GAPDH was amplified using primer probe set RTS 104 (forward sequence, GAAGGTGAAGGTCGGAGTC, designated herein as SEQ ID NO: 3251; reverse sequence, GAAGATGGTGATGGGATITC, designated herein as SEQ ID NO: 3252; probe sequence, CAAGCTCCCGTCTCAGCC, designated herein as SEQ ID NO: 3253). Human CD4 was amplified using ABI primer probe set Hs01058407_m 1.

As presented in the table below, treatment with Ionis modified oligonucleotides resulted in reduction of Foxp3 RNA in comparison to the PBS control. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to PBS control (% control).

TABLE 97 Modified oligonucleotide mediated inhibition of human Foxp3 RNA expression in huPBMC model Splenocytes Lymph Node Normalized to GAPDH Normalized to CD4 Normalized to GAPDH Normalized to CD4 Foxp3 Foxp3 Foxp3 Foxp3 Foxp3 Foxp3 Foxp3 Foxp3 Levels Levels Levels Levels Levels Levels Levels Levels ION (RTS35925) (RTS35988) (RTS35925) (RTS35988) (RTS35925) (RTS35988) (RTS35925) (RTS35988) No. % control % control % control % control % control % control % control % control PBS 100 100 100 100 100 100 100 100 549148 79 87 84 93 91 91 107 102 1062413 34 42 55 69 86 82 91 89 1062428 65 73 80 96 60 58 89 89 1062641 31 39 52 64 36 38 70 70 1063268 61 75 56 70 60 55 97 89 1063649 55 68 64 80 58 60 97 97 1063734 34 43 55 66 82 74 106 94 1064096 65 79 63 77 83 79 107 93

Flow Cytometry

Foxp3 protein levels were measured in regulatory T-cells using flow cytometry. After incubation with modified oligonucleotides, CD4⁺ T-cells were stained with fluorescently-labeled CD3, CD4, Helios and FOXP3 antibodies (Biolegend) using TrueNuclear Transcription Factor Buffer Set (Biolegend). Regulatory T-cells were gated as CD3⁺CD4⁺Helios⁺ cells and Foxp3 protein levels were quantified using median fluorescent intensity of Foxp3 antibody stain.

TABLE 98 Modified oligonucleotide mediated inhibition of human Foxp3 protein levels in huPBMC model % control ION Foxp3 NO. protein PBS 100 549148 74 1062413 63 1062428 59 1062641 48 1063268 53 1063649 22 1063734 33 1064096 54

Example 14: Dose-Dependent Inhibition of Human Foxp3 mRNA and Protein Levels in CD4 T-Cells Derived from Hu-PBMC-NSG Mice by Modified Oligonucleotide

Human CD4⁺ T-cells were isolated from splenocytes of humanized PBMC mice (hu-PBMC-NSG, Jackson Laboratory) through a combination of initial purification using the Human Easysep CD4 T-cell purification kit (Stemcell Technologies), followed by a negative selection using the Mouse Easysep CD4 T-cell purification kit (Stemcell Technologies) to enrich the human population only. Purified human CD4⁺ T-cells were cultured in Immunocult-XT T-cell expansion media (Stemcell Technologies) supplemented with 30 ng/mL of human recombinant IL-2 (Stemcell Technologies). CD4⁺ T-cells were treated ex-vivo with modified oligonucleotides by free uptake in a dose response study for 72 hours. Cells were activated for 24h in the presence of Imunocult human CD3/CD28/CD2 T-cell activator (Stemcell Technologies). Cells were harvested and evaluated for changes in the levels of Foxp3 mRNA.

Primer probe set RTS35988 was used to measure human Foxp3 RNA levels. Foxp3 RNA levels are normalized to either human GAPDH or to human CD4. Human GAPDH was amplified using primer probe set RTS104. Human CD4 was amplified using ABI primer probe set Hs01058407_m1. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to PBS control (%/control).

Foxp3 protein levels were measured in regulatory T-cells using flow cytometry. After incubation with modified oligonucleotides, CD4⁺ T-cells were stained with fluorescently-labeled CD3, CD4, Helios and FOXP3 antibodies (Biolegend) using TrueNuclear Transcription Factor Buffer Set (Biolegend). Regulatory T-cells were gated as CD3⁺CD4⁺Helios⁺ cells and Foxp3 protein levels were quantified using median fluorescent intensity of Foxp3 antibody stain.

TABLE 99 Modified oligonucleotide mediated inhibition of human Foxp3 RNA expression in CD4 T-cells from huPBMC model (normalized to GAPDH) % control - RTS35925 normalized to GAPDH ION 10 2.5 0.63 0.16 0.04 IC50 No. μM μM μM μM μM (μM) 1062428 47 48 48 75 85 2.6 1062641 57 65 71 75 99 16.9 1062835 59 65 70 85 80 46.3 1062937 39 46 61 62 80 1.8 1063268 38 46 60 66 86 1.9 1063649 50 68 77 91 113 8.7 1063655 33 35 60 80 103 1.5 1063734 13 24 34 54 86 0.3 1064096 54 52 72 79 91 8.4 1064313 61 70 77 84 102 24.7 792169 138 87 87 71 81 >10

TABLE 100 Modified oligonucleotide mediated inhibition of human Foxp3 RNA expression in CD4 T-cells from huPBMC model (normalized to CD4) % control - RTS35925 normalized to CD4 ION 10 2.5 0.63 0.16 0.04 IC50 No. μM μM μM μM μM (μM) 1062428 48 47 46 70 90 2.3 1062641 50 60 64 70 86 8.5 1062835 59 62 66 79 79 40.6 1062937 41 44 55 61 74 1.5 1063268 41 45 61 66 82 2.2 1063649 55 62 75 87 110 9.9 1063655 34 37 60 75 97 1.5 1063734 13 23 33 51 82 0.2 1064096 46 49 65 75 90 3.8 1064313 59 65 73 79 97 20.6 792169 139 90 87 73 80 >10

TABLE 101 Dose-dependent inhibition of human Foxp3 protein expression by modified oligonucleotides in regulatory T-cells % control ION 10 2.5 0.63 0.16 0.04 IC₅₀ No. μM μM μM μM μM (μM) 1062428 32 45 53 73 93 1.4 1062641 54 65 74 91 102 11.0 1062835 60 69 77 89 100 20.9 1062937 44 46 59 72 88 2.6 1063268 46 57 69 87 100 5.5 1063649 33 43 58 81 101 1.8 1063655 26 31 49 72 90 0.8 1063734 12 16 28 50 80 0.2 1064096 31 40 58 78 92 1.5 1064313 50 57 68 84 98 6.5 792169 105 94 97 106 107 >10

Example 15: Dose-Dependent Inhibition of Human Foxp3 in SUP-M2 Cells by Modified Oligonucleotide

Modified oligonucleotides were tested for their effect on Foxp3 mRNA level in vitro in SUP-M2 cells. Cultured SUP-M2 cells at a density of 35,000 cells per mL, were transfected using electroporation with modified oligonucleotides diluted to concentrations of 10 μM, 2.5 μM, 0.63 μM, 0.16 μM and 0.04 μM. After a treatment period of approximately 48 hours, RNA was isolated from the cells and Foxp3 mRNA levels were measured by quantitative real-time RTPCR. Human primer probe sets RTS35925 and RTS35988 were both used to measure mRNA levels in separate RTPCR reactions. Foxp3 mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®, as well as adjusted to GAPDH levels measured by human primer-probe set RTS 104. Results are presented in the tables below as percent control of the amount of Foxp3 mRNA relative to untreated control cells (% UTC).

TABLE 102 Dose-dependent inhibition of human Foxp3 mRNA expression by modified oligonucleotides in SUP-M2 cells % UTC - RTS35925 normalized to GAPDH ION 10 2.5 0.63 0.16 0.04 IC₅₀ No. μM μM μM μM μM (μM) 1062428 7 18 48 84 95 0.6 1062641 10 30 61 92 101 0.9 1062835 17 42 77 94 126 >10 1062937 24 60 112 144 134 1.6 1063268 9 24 52 71 84 0.9 937101 43 50 58 64 69 1.8 549144 52 45 56 74 82 0.3 1063649 3 11 26 85 102 0.3 1063655 10 24 61 98 119 0.5 1063734 2 12 33 74 124 0.1 1064096 4 19 48 95 110 0.5 1064313 20 44 83 90 112 2.7 937101 49 70 69 72 83 >10 549144 52 66 79 83 94 >10

TABLE 103 Dose-dependent inhibition of human Foxp3 mRNA expression by modified oligonucleotides in SUP-M2 cells % UTC - RTS35925 normalized to Ribogreen ION 10 2.5 0.63 0.16 0.04 IC₅₀ No. μM μM μM μM μM (μM) 1062428 9 22 47 81 91 0.7 1062641 15 42 71 94 108 >10 1062835 25 49 89 102 125 2.8 1062937 19 45 72 95 97 >10 1063268 14 35 70 85 110 >10 937101 67 83 95 110 120 >10 549144 68 57 69 81 91 >10 1063649 4 13 30 82 88 0.4 1063655 13 29 68 102 111 0.2 1063734 3 16 39 80 129 0.4 1064096 6 21 51 92 99 0.8 1064313 25 53 91 93 115 >10 937101 80 113 107 111 121 1.7 549144 69 91 101 99 106 >10

TABLE 104 Dose-dependent inhibition of human Foxp3 mRNA expression by modified oligonucleotides in SUP-M2 cells % UTC - RTS35988 normalized to GAPDH ION 10 2.5 0.63 0.16 0.04 IC₅₀ No. μM μM μM μM μM (μM) 1062428 8 18 56 82 94 0.7 1062641 11 30 60 80 97 1.1 1062835 18 47 72 99 114 2.4 1062937 24 71 102 150 144 2.2 1063268 9 33 47 70 82 >10 937101 49 57 54 62 62 >10 549144 52 64 73 77 91 >10 1063649 3 10 38 76 112 0.2 1063655 9 21 46 76 115 0 1063734 4 12 29 72 93 0.3 1064096 8 22 53 82 104 0.5 1064313 25 49 74 92 104 2.3 937101 56 59 69 74 72 1.2 549144 69 71 77 88 93 0.4

TABLE 105 Dose-dependent inhibition of human Foxp3 mRNA expression by modified oligonucleotides in SUP-M2 cells % UTC - RTS35988 normalized to Ribogreen ION 10 2.5 0.63 0.16 0.04 IC₅₀ No. μM μM μM μM μM (μM) 1062428 10 23 53 78 91 0.7 1062641 17 42 67 82 101 1.8 1062835 26 55 84 104 116 1.8 1062937 20 54 65 98 106 1.8 1063268 14 48 64 90 108 2.3 937101 77 96 90 109 111 4.9 549144 67 84 93 90 102 >10 1063649 4 12 43 76 97 0.2 1063655 12 26 51 81 110 0 1063734 5 16 35 78 97 0.3 1064096 10 26 58 82 98 0.5 1064313 32 60 82 96 107 2.3 937101 93 98 109 116 108 1.2 549144 93 99 100 106 106 0.4 

1-8. (canceled)
 9. A compound comprising a modified oligonucleotide consisting of 16 to 30 linked nucleosides and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, and
 2575. 10. The compound of claim 9, comprising a modified oligonucleotide having a nucleobase sequence consisting of the nucleobase sequence of any one of SEQ ID NOs: 449, 501, 544, 794, 1293, 1307, 1511, 1755, 2492, and
 2575. 11. The compound of claim 9, wherein at least one internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage, at least one sugar moiety of the modified oligonucleotide is a modified sugar moiety, or at least one nucleobase of the modified oligonucleotide is a modified nucleobase.
 12. The compound of claim 11, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.
 13. The compound of claim 111, wherein the modified sugar moiety is a bicyclic sugar moiety.
 14. The compound of claim 13, wherein the bicyclic sugar moiety is selected from the group consisting of: 4′-(CH2)-O-2′ (LNA); 4′-(CH2)2-O-2′ (ENA); and 4′-CH(CH3)-O-2′ (cEt).
 15. The compound of claim 111, wherein the modified sugar moiety is 2′-O-methoxyethyl.
 16. The compound of claim 11, wherein the modified nucleobase is a 5-methylcytosine.
 17. The compound of claim 9, wherein the modified oligonucleotide comprises: a gap segment consisting of linked deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides; wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
 18. (canceled)
 19. The compound of claim 9, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides; a 5′ wing segment consisting of three linked nucleosides; and a 3′ wing segment consisting of three linked nucleosides; wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein each nucleoside of each wing segment comprises a cEt nucleoside; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.
 20. The compound of claim 19, wherein the nucleobase sequence of the modified oligonucleotide comprises the nucleobase sequence recited in SEQ ID NO:
 449. 21. The compound of claim 9, wherein the modified oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of SEQ ID NOs: 1-5.
 22. The compound of claim 9, wherein the compound is single-stranded.
 23. The compound of claim 9, wherein the compound is double-stranded.
 24. The compound of claim 9, wherein the compound comprises ribonucleotides.
 25. The compound of claim 9, wherein the compound comprises deoxyribonucleotides.
 26. The compound of claim 9, wherein the modified oligonucleotide consists of 16 to 30 linked nucleosides.
 27. The compound of claim 9, wherein the compound consists of the modified oligonucleotide.
 28. A compound consisting of a pharmaceutically acceptable salt of the compound of claim
 9. 29. The compound of claim 28, wherein the pharmaceutically acceptable salt is a sodium salt.
 30. The compound of claim 28, wherein the pharmaceutically acceptable salt is a potassium salt.
 31. A compound having the formula:

or a salt thereof.
 32. A compound having the formula:


33. A composition comprising the compound of claim 31 and a pharmaceutically acceptable carrier.
 34. A composition comprising the compound of claim 32 and a pharmaceutically acceptable carrier.
 35. A method of treating or ameliorating cancer in an individual comprising administering to the individual a compound targeted to FOXP3, thereby treating or ameliorating the cancer, wherein the compound targeted to FOXP3 is the compound of claim
 31. 36. A method of treating or ameliorating cancer in an individual comprising administering to the individual a compound targeted to FOXP3, thereby treating or ameliorating the cancer, wherein the compound targeted to FOXP3 is the compound of claim
 32. 37. The method of claim 36, wherein the cancer is a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas, chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL).
 38. The method of claim 36, wherein administering the compound (1) inhibits or reduces immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis; or (2) induces or activates anticancer or antitumor immunity, anticancer or antitumor immune response, immune cell activation or infiltration, inflammatory cell activation or infiltration, effector immune cell activation or infiltration, T cell activation or infiltration, CD8 T cell activation or infiltration, NK cell activation or infiltration, macrophage and dendritic cell activation or infiltration, inflammation, or inflammatory cytokine or chemokine expression, or both.
 39. A method of inhibiting expression of FOXP3 in a cell, comprising contacting the cell with a compound targeted to FOXP3, thereby inhibiting expression of FOXP3 in the cell, wherein the compound targeted to FOXP3 is the compound of claim
 32. 40. The method of claim 39, wherein the cell is a cancer cell.
 41. The method of claim 40, wherein the cancer is a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas, chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL).
 42. A method of reducing or inhibiting immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis in an individual having cancer, comprising administering a compound targeted to FOXP3 to the individual, thereby reducing or inhibiting immunosuppression, Treg immunosuppressive activity, cancer cell proliferation, tumor growth, or metastasis in the individual, wherein the compound targeted to FOXP3 is the compound of claim
 32. 43. A method of inducing or activating anticancer or antitumor immunity; anticancer or antitumor immune response; immune cell activation or infiltration; inflammatory cell activation or infiltration; effector immune cell activation or infiltration; T cell activation or infiltration; CD8 T cell activation or infiltration; NK cell activation or infiltration; macrophage and dendritic cell activation or infiltration; inflammation; or inflammatory cytokine or chemokine expression in an individual having cancer, comprising administering a compound targeted to FOXP3 to the individual, wherein the compound targeted to FOXP3 is the compound of claim
 32. 44. The method of claim 43, wherein the individual has a cancer having FOXP3 positive (FOXP3+) Tregs in the microenvironment or stroma or tumor draining lymph nodes, lung cancer, non-small cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), squamous cell carcinoma (SCC), head and neck cancer, head and neck squamous cell carcinoma (HNSCC), gastrointestinal cancer, large intestinal cancer, small intestinal cancer, stomach cancer, colon cancer, colorectal cancer, bladder cancer, liver cancer, hepatocellular carcinoma (HCC), esophageal cancer, pancreatic cancer, biliary tract cancer, gastric cancer, urothelial cancer, breast cancer, triple-negative breast cancer (TNBC), ovarian cancer, endometrial cancer, cervical cancer, prostate cancer, mesothelioma, sarcomas, chordoma, renal cancer, renal cell carcinoma (RCC), brain cancer, neuroblastoma, glioblastoma, skin cancer, melanoma, basal cell carcinoma, merkel cell carcinoma, blood cancer, hematopoetic cancer, myeloma, multiple myeloma (MM), B cell malignancies, lymphoma, B cell lymphoma, Hodgkin lymphoma, T cell lymphoma, leukemia, or acute lymphocytic leukemia (ALL).
 45. (canceled)
 46. (canceled)
 47. The method of claim 36, wherein the compound is administered parenterally. 48-59. (canceled) 